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Abstract: Research in the field of sexuality has shown growing scientific development in recent
years, although there’s a lack of well-trained professionals who could contribute to increasing its
benefits. Sexuality continues to be a taboo with different interpretations and difficult delimitation of
either normal or pathological behavior. More resources are needed for the understanding of new
emerging pathologies, and to increase the research in new models of sexual behavior. All psychiatric
diseases include symptoms affecting sexual life, such as impaired desire, arousal, or sexual satisfaction
that need to be properly addressed. Health providers and prescribers must detect and prevent
iatrogenic sexual dysfunction that can highly deteriorate a patient’s sexual life and satisfaction,
leading to frequent drop-outs of medication. Approaching and researching aspects of sexual intimacy,
life desires, frustrations, and fears undoubtedly constitutes the best mental health care.
Keywords: sexuality; mental health; research; sexual dysfunction
Sexuality, understood as a drive and an inherent need for human beings, has unquestionably been
part of the occupations and concerns of psychiatrists from the beginning of the century. Not in vain,
psychoanalysts theorized about the importance of sexual repression as the origin of a great number
of mental diseases. Sexual drive, originally called libido, seemed to be the nucleus of life and its
repression or deficiencies a way towards mental suffering. The concept obviously must be extended
towards eroticism in a broader sense, not always necessarily coital, and to satisfaction of physical
pleasure and intimacy. Over the years, following growth in scientific research, it has become essential
to invest increasing interest and more research resources to contribute to the theoretical maxims that
could empirically explain the secrets of such important drives.
Fortunately, research in the field of sexuality has shown growing scientific development, leading
to the greater interest of researchers [1–8]. The emergence of an increasing number of specific journals
focusing on some either large or small sexual issues are symptomatic of our contemporary society’s
concerns. The great and unexpected role of sexual abuse in the origin or development of some mental
illnesses and the boundaries between normal and pathological sexuality, without having so far found
satisfactory agreement in this sense, have constituted some of the areas of greatest interest.
However, one of the biggest limitations for the generalization of adequate sexual health is the lack
of well-trained professionals who could contribute to increasing its benefits. The training of mental
health providers focusing in sexology has not developed accordingly to accompany the population’s
needs. Sexuality continues to be a taboo, and professionals dealing with its research and treatment
remain scarce, even with a large heterogeneous background. The widespread access to continuous,
multiple, and often unhealthy sexual content without any ethical filter or prior preparation in our
young people has been a new challenge in addressing their understanding. The different interpretations
of such a variable concept leads to an extremely difficult delimitation of either normal or pathological
sexuality. The easy to use and generalized online access has popularized sexual performance so much
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that some new unexpected phenomena have recently emerged, such as online shared group rapes or the
increased number of “unlinked sexual seekers” looking for some new variate, intense, and prolonged
sexual experiences, as well as some novel shocking sensations such as chemsex. More resources are
needed to cope with the appearance of these new emerging pathologies, and to increase the research
in these new models of sexual behavior. Unfortunately, in most parts of the world, basic training in
sexology has not been sufficiently developed as a fundamental part of the scientific growth of our
mental health professionals. Sexuality is commonly interpreted as a minor discipline that unfortunately
is not included as a part of the basic training to provide adequate support for normal subjects and
mental health patients.
It is well known that all psychiatric diseases include some variations in sexual symptoms and
difficulties with highly different individual sexual meanings and concerns. Depression, bipolar disorder,
anxiety disorders, or even psychosis include symptoms affecting sexual life, such as impaired desire,
arousal, or sexual satisfaction that inevitably need to be properly identified and addressed. There are no
sexless human beings, and neither are our patients sexless, even if they do not carry out an active sex life.
As a main classification instrument today, the Diagnostic and Statistical Manual of Mental
Disorders DSM-5 recognizes certain sexual conditions to which it grants diagnostic criteria, although
not without some controversy. It would be very unfortunate if this would be the only approach
to bringing the average professional closer to the sexual life and intimacy needs of their patients.
These days, hypoactive sexual desire or even aversion to sex (paradoxically frequently iatrogenic
after the prescription of a chronic use of serotonergic antidepressants) have reached almost epidemic
proportions that remain unnoticed and understudied. Additionally, there is a lack of economic resource
investment in their research by the pharmaceutical companies themselves or by public health systems.
Generally, a great number of antidepressant prescribers are poorly motivated to detect and prevent
iatrogenic sexual dysfunction that can highly deteriorate the patient’s sexual life and satisfaction,
leading to subsequent emotional deprivation of all those who must endure it in the medium and long
term, as serotonergic antidepressants (SSRIs) remain the most prescribed in the Western world.
Taking into account the patients with psychosis, there may be some clinicians who consider that
it would be better not to investigate the sexual life of their patients, as this could worsen psychotic
symptoms, or simply interpret that the information obtained would be unreliable. Many others may avoid
it, because in this way they are not forced to face the side effects of some prescribed antipsychotics that
intensely block the dopamine activity and deteriorate sexual functioning. Let us remember that sexuality
includes the creation of links and intimacy with another person, which helps patients to fight against
the negative symptoms of the disease. Perhaps some clinicians consider that sexual relationships in
psychiatric female patients with chronic psychosis mainly involves a risk of pregnancy and the appearance
of sexually transmitted diseases. Therefore, implicitly, the absence of any interview about their sexual
life and interpersonal relationships, including the needs of intimacy and maternity plans, promotes a
silent sterilization. That is, the prescription of an antipsychotic that increases prolactin blood levels is
inevitably linked to anovulation and sterility. Can patients then decide on their motherhood? Obviously
not, because often those who prescribe these antipsychotics have inappropriately decided for their patients
without exchanging a single comment or adequate reflection about their family life project. On the other
hand, some HIV-positive patients are severely mentally ill and use prostitution as the only means of
obtaining sexual pleasure and intimacy. Most of these patients have limited stable sexual relationships or
sex partners, and many of them have none except masturbation, duplicating the general population rates
of prostitution and the consequent increased risks of HIV and sexually transmitted diseases. Perhaps
some may think that these are issues outside the mental health professional’s goal and that they would be
much better addressed by other health providers; however, unfortunately, these patients go to a general
practitioner infrequently, and rarely establish lasting and close relationships with them. In addition,
frequent drop-outs of medication have been reported due to iatrogenic sexual dysfunction associated
with the use of hyperprolactinemic antipsychotics, which remains widely underestimated by psychiatrists
despite its striking clinical implications in the short, medium, and long term. The abrupt or progressive
2
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decline in desire, excitatory, and/or orgasmic function compromises the compliance and makes long-term
treatment uncertain in some specific groups, such as young male patients. The emphatic approach to
this adverse event by clinicians, through adequate sensitization and training, would prevent catastrophic
consequences compromising the clinical evolution of patients with psychosis and, moreover, improve
the doctor–patient relationship. Approaching the aspects of intimacy, life desires, frustrations, and fears
undoubtedly constitutes real mental health care. As a sample of this, in a recent survey on sexual health
in Spain [9] a large number of people were interviewed about their motivation for sexual intercourse.
Surprisingly, only a few of them selected sexual pleasure as a fundamental reason (mostly males) or
procreation (mostly women). The vast majority pointed out that the main reason was the search for
emotional intimacy or to satisfy the need to love and be loved. However, sexual pleasure is once again
only a small part of love.
For many of us, it is never too late to regain the study and approach to sexuality and its concerns
as something enriching in mental health, and of course in the global existence of our patients. We may
not need to be sexologists but recovering sexuality as a basic aspect of mental health must become
one of our most current aims. The way forward must be through the incorporation of sexuality as an
inseparable part of the human being and its research as an essential instrument in the holistic vision of
the existence of our patients.
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Abstract: Objective: To assess patient satisfaction with surgical outcome, body related self-perceptions,
self-attitudes of sexuality, and health related quality of life after penile surgery with small intestinal
submucosa (SIS) grafting for the treatment of severe Peyronie’s disease (PD). Material and methods:
This retrospective study included 82 patients, who were treated with SIS grafting for severe PD
between 2009 and 2013 at the University Medical Center Hamburg-Eppendorf. Patients were asked
to complete standardized questionnaires including the International Index of Erectile Function
Erectile Function domain (IIEF-EF), Short-Form (SF)-8 Health Survey, and Frankfurt Body Concept
Scale-Sexuality (FKKS-SEX). Results: Follow-up was available in 58 (69.9%) patients. SIS grafting
resulted in subjective straightening of the penis in 53 (91.3%) patients. After a mean follow-up
of 28.9 ± 16.5 months, 24 (41.4%) patients were satisfied or very satisfied with surgical outcome.
Postoperatively, the mean FKKS-SEX was 23.5 ± 5.9. In total, 36 (62.1%), 18 (31%), and four (6.9%)
patients had FKKS-SEX scores corresponding to positive, neutral, and negative self-perception and
self-attitude of sexuality, respectively. The mean postoperative SF-8 was 15.2 ± 6.4. Compared to the
mean for German controls, patients achieved lower mean scores in the domains social functioning
(50.4 ± 7.1), mental health (49.5 ± 9.2), and emotional roles (48.5 ± 6.8). Subjective shortening of the
penis (Odds ratio (OR): 2.0), negative body related self-perceptions, and self-attitudes of sexuality
(OR: 3.6) as well as IIEF-EF score (OR: 0.9) were risk factors for patient dissatisfaction (p-values ≤ 0.02).
Conclusion: A relevant number of patients is not satisfied with surgical outcome after SIS grafting for
the treatment of severe PD. Subjective shortening of the penis, negative body related self-perceptions,
and self-attitudes of sexuality as well as IIEF-EF score were risk factors for patient dissatisfaction.
Keywords: peyronie’s disease; penile induration; sexuality; patient satisfaction
1. Introduction
Peyronie’s disease (PD) is a chronic connective tissue disorder of the tunica albuginea of the
corpora cavernosa of the penis, and may cause relevant penile pain, penile plaque formation, and
loss of penile length, as well as deformity and curvature of the penis [1]. As a consequence, PD may
severely impair sexual activity and emotional wellbeing [2]. Up to 54% and 48% of PD patients present
J. Clin. Med. 2019, 8, 1121; doi:10.3390/jcm8081121 www.mdpi.com/journal/jcm5
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with erectile dysfunction (ED) [3] and depression [4], respectively, emphasizing the complexity of
symptoms which patients may be affected by.
Surgical treatment is performed to correct penile deformity and penile curvature, with the aim to
enable patients to have sexual intercourse. This represents the standard therapy in the stable phase
of severe PD [5]. Various surgical procedures have been described, including tunical plication and
grafting techniques [6,7]. Currently, xenogenic small intestinal submucosa (SIS) represents one of the
most commonly used and widely established grafts for penile surgery in PD patients [5,7]. To date,
there have been few published studies on SIS grafting for PD, and these studies have primarily focused
on surgical outcome and complications [8–11], whereas patient reported treatment satisfaction has
been considered in the minority of studies [12–16]. In addition, patient self-perceptions and attitudes
of sexuality following SIS grafting have not been investigated so far.
Thus, the aim of the present study was to analyze body related self-perceptions and self-attitudes
of sexuality as well as health-related quality of life following penile surgery with SIS grafting for severe
PD, and to identify risk factors for patient dissatisfaction.
2. Patients and Methods
2.1. Patients
We retrospectively collected data of 82 patients with severe PD, who were treated with SIS grafting
between 2009 and 2013 at the University Medical Center Hamburg-Eppendorf. Preoperative evaluation
included an in-depth history of onset and duration of PD-specific symptoms, prior PD-specific treatment
and general medical history. Auto-photographic documentation determined degree, direction, shape,
and severity of penile curvature, as described in detail previously [17]. Physical examination and
penile ultra-sonography determined location, number, and size of plaques of the tunica albuginea of
the penis. Penile length was measured from suprapubic skin to distal glans in the stretched flaccid
penis, as described previously [18]. Color duplex Doppler ultra-sonography (CDDU) of the penis
combined with intracavernous injection of 20 μg Prostavasin was performed preoperatively according
to established standard operating procedures [19].
2.2. Patient Reported Outcome Measure
Patient reported outcomes were assessed using a standardized questionnaire. Firstly, we employed
several validated patient reported outcome measures. The validated International Index of Erectile
Function Erectile Function domain (IIEF-EF) evaluated erectile function. No ED corresponded to an
IIEF-EF score of 26–30, mild ED to a score of 22–25, mild to moderate ED to a score of 17–21, moderate
ED to a score of 11–16, and severe ED to a score of 6–10. Health related quality of life was assessed
with the validated Short-Form (SF)-8 Health Survey, consisting of eight dimensions including social
functioning, mental health, emotional roles, role physical, bodily pain, general health, vitality, and
physical functioning [20]. SF-8 physical component score and SF-8 mental component score were
calculated weighting each SF-8 item using the norm-based scoring method as described previously [21].
The mean scores in the 8 dimensions were compared to the mean for German controls [22]. A score of 50
is the mean for the German general population, a higher score indicates increased quality of life. Body
related self-perceptions and self-attitudes of sexuality were assessed with the Frankfurt Body Concept
Scale-Subscale Sexuality (FKKS-SEX), consisting of eight items with six answering options, respectively.
The subscale is intended to measure how satisfied patients are with their sexuality, how attractive
they consider themselves to potential sexual partners, and how they deal with sexual intimacy. The
maximum FKKS-SEX score is 36, the minimum six; a score of 6–18, 19–23 and 24–36 is indicating a
negative, neutral, and positive self-perception and self-attitude of sexuality, respectively [23]. Secondly,
we included non-validated questions on patient satisfaction, penile paresthesia, and sexual activity.
Non-validated questions were assessed using a five-point Likert-scale.
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2.3. Follow-Up
Patients were seen at various time points after surgery at the outpatient clinic of our institution and
received the standardized questionnaire. In addition, physical examination, penile ultra-sonography,
penile length measurement, and CDDU of the penis were performed. There was no preoperative
evaluation of health-related quality of life and no preoperative evaluation of self-perception and
self-attitude of sexuality. Missing baseline data is denoted in the respective tables of the results section
of the manuscript.
2.4. Surgical Procedure and Postoperative Management
Generally, SIS grafting was performed under general anesthesia as described in detail previously [5].
In brief, a circumcision was performed, followed by complete de-gloving of the penis and careful
exposure of the dorsal neurovascular bundle. Then, an artificial erection was achieved with
intracavernous injection of sodium chloride to identify the maximum convexity of the penile curvature.
A transverse incision of the tunica and/or the plaque was performed at the maximum convexity, and
the lateral margins of the incision were extended in a Y-formed shape. The length of the Y-shape was
chosen depending on the degree of the lateral penile curvature. The size of the SIS graft was chosen
depending on the size of the resulting defect of the tunica albuginea of the corpora cavernosa. The
Biodesign® four-layer SIS (Cook Medical LLC, Bloomington, IN, USA) was transplanted to the defect
and fixed to the tunica albuginea with 3-0 monofil continuous sutures. Then, an artificial erection
was provoked again to control for complete straightening of the penis. In cases of remaining slight
curvature, a tunical plication was performed according to Yachia’s technique [24] at the discretion
of the surgeon. After closure of Buck’s fascia and skin, a suprapubic catheter was placed, and a
compression bandage was put on the penis. Roland Dahlem, Margit Fisch, and Oliver Engel performed
all surgical procedures.
Generally, the compression bandage and suprapubic catheter were removed on postoperative
day five, and patients were discharged. Patients were advised to perform penile rehabilitation with
daily stretching of the penis using a vacuum device plus daily intake of phosphodiesterase-5 inhibitors.
Patients were not allowed to have sexual intercourse for six weeks postoperatively.
2.5. Statistical Analysis
All analyses were performed with SPSS 20 (SPSS Inc., IBM Corp., Armonk, NY, USA). All tests were
two-sided and a p < 0.05 was set to be statistically significant. Differences between continuous variables
in one group were assessed using the T-test. Differences between categorical variables were assessed
with the Chi square test. Uni-variable binary logistic regression analysis was employed to identify risk
factors for patient dissatisfaction. For uni-variable binary logistic regression analysis, patients were
grouped as “satisfied” (patients, who responded that they were “satisfied” or “very satisfied” with
surgical outcome) and “dissatisfied” (patients, who responded “undecided”, “dissatisfied”, or “very
dissatisfied” with surgical outcome).
3. Results
3.1. Patient Characteristics
Table 1 presents clinical features of the patients. Hypertension, Morbus Dupuytren, and prostatic
hyperplasia were the most common comorbidities in 25 (30.5%), 15 (18.3%), and nine (11%) patients,
respectively. In total, 11 (13.4%) patients reported previous penile trauma. The mean degree of penile
curvature was 65◦, and the majority of patients reported dorsal and lateral-left curvature in 51 (62.2%)
and 11 (13.4%) patients, respectively.
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Table 1. Clinical characteristics of 82 patients treated with small intestinal submucosa grafting for
Peyronie’s disease.
All (n = 82)
Age (years; mean (95% CI)) 56.9 (55.5–58.5)
Body mass index (mean (95% CI))





Morbus Dupuytren 15 (18.3)
Morbus Ledderhose 1 (1.2)
Prostatic hyperplasia 9 (11.0)
Penile trauma 11 (13.4)




Penile curvature (degree; mean, (95% CI))
18 (22%) patients missing 64.8 (59.1–70.5)
Direction of penile curvature (n; %)
Ventral 3 (3.7)
Dorsal 51 (62.2)
Lateral left 11 (13.4)
Lateral right 6 (7.3)
Plaque size (cm; mean, (95% CI))
44 (53.7%) patients missing 2.9 (1.7–4.2)
Duration of PD-specific symptoms (days; mean (95% CI))
1 (1.2%) patient missing 343.8 (217.7–469.8)
Previous PD-specific treatments (n; %)
Potaba 26 (41.3)







Preoperative Resistance index as measured by CDDU (mean (95% CI))
29 (35.4%) patients missing 0.87 (0.82–0.93)
Abbreviations: CDDU = Color duplex Doppler ultra-sonography; CI = Confidence interval; ESWT = extracorporal
shock wave therapy; PD = Peyronie’s disease.
3.2. Patient Reported Outcomes
Follow-up was available in 58 (69.9%) patients. After a mean follow-up of 28.9 ± 16.5 months,
complete straightening of the penis was achieved in 53 (91.3%) patients, while five (8.7%) patients
reported insufficient straightening. Overall, 41 (70.7%) patients reported paresthesia of the penis,
corresponding to hypoesthesia and hyperesthesia in 34 (82.9%) and seven (17.1%) patients, respectively.
Penile paresthesia was not bothering in 23 (56.1%) patients. In total, 56 (96.6%) patients reported
subjective shortening of the penis. There was no significant difference in measured penile length
preoperatively and postoperatively (p = 0.9). Postoperatively, 36 (62.1%) patients reported subjective
deterioration of erectile function. According to the IIEF-EF score, postoperatively, 22 (37.9%) and
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13 (22.4%) patients had severe and moderate ED, respectively, compared to 11 (19.0%) and seven
(12.1%) patients with severe and moderate ED preoperatively (p = 0.041; Table 2).
Table 2. Change in preoperative and postoperative erectile function in 58 patients treated with small
intestinal submucosa grafting for Peyronie’s disease.
Preoperative Postoperative Difference p-Value
IIEF-EF score (mean (95% CI)) 12.2 (8.4–15.9)29 (50%) patients missing 14.5 (12.2–16.9) 2.0 (−4.5–8.5) 0.13 *
Erectile dysfunction
according to IIEF-EF (n; %)
0.041 #
Severe 11 (19.0) 22 (37.9)
Moderate 7 (12.1) 13 (22.4)
Mild to moderate 4 (6.9) 6 (10.3)
Mild 3 (5.2) 7 (12.1)
No 2 (3.4) 10 (17.2)
Missing 29 (50.0) 0 (0)
* Paired samples T-test. # Chi square test. Abbreviations: CI = Confidence interval; IIEF-EF = international index of
erectile function erectile function domain.
The mean postoperative FKKS-SEX was 23.5 ± 5.9, which corresponds to neutral to positive
self-perception and self-attitude of sexuality. In total, 36 (62.1%), 18 (31%), and four (6.9%) patients had
FKKS-SEX scores corresponding to positive, neutral, and negative self-perception and self-attitude
of sexuality, respectively. The mean postoperative SF-8 was 15.2 ± 6.4. Compared to the mean for
German controls, patients achieved lower mean scores in the domains social functioning (50.4 ± 7.1),
mental health (49.5 ± 9.2), and emotional roles (48.5 ± 6.8); higher mean scores in the domains role
physical (50.0 ± 6.8), bodily pain (54.5 ± 9.1), general health (51.5 ± 7.2), and vitality (51.5 ± 8.1); and
equivalent mean scores in the domain physical functioning (49.0 ± 8.2).
3.3. Patient Satisfaction
In total, 24 (41.4%) patients were satisfied or very satisfied with surgical outcome, while 26 (44.8%)
patients were dissatisfied or very dissatisfied. Altogether, eight (13.8%) patients were undecided
regarding satisfaction with surgical outcome.
In total, 26 (44.8%) of 58 patients with postoperative subjective shortening of the penis were
dissatisfied or very dissatisfied with surgical outcome. Overall, 17 (77.3%) patients of 22 patients with
severe postoperative ED were dissatisfied or very dissatisfied with surgical outcome. In total, four
(100%) patients with low body related self-perceptions and self-attitudes of sexuality were dissatisfied
or very dissatisfied with surgical outcome. Of the 26 patients, who were dissatisfied or very dissatisfied
with surgical outcome, 19 (73.1%), 19 (73.1%), and four (15.4%) patients had subjective shortening
of the penis, subjective deterioration of erectile function, and low body related self-perceptions and
self-attitudes of sexuality, respectively.
In uni-variable logistic regression analysis, subjective shortening of the penis, negative body
related self-perceptions and self-attitudes of sexuality as well as IIEF-EF score were risk factors for
patient dissatisfaction (p-values ≤ 0.02; Table 3).
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Table 3. Uni-variable logistic regression of subjective penile shortening, subjective reduced erectile
function, negative body related self-perceptions and self-attitudes of sexuality, International Index of
Erectile Function Erectile Function domain (IIEF-EF) and Short-Form (SF)-8 score predicting patient
dissatisfaction with surgical outcome in 58 patients treated with small intestinal submucosa grafting
for Peyronie’s disease.
Odds Ratio 95% CI p-Value
Subjective loss of penile length 2.026 1.152–3.563 0.014
Subjective reduced erectile function 2.154 0.507–9.147 0.298
Negative body related self-perceptions and self-attitudes of sexuality 3.632 1.231–10.718 0.020
IIEF-EF score 0.870 0.805–0.940 <0.001
SF-8 physical component score 0.963 0.898–1.034 0.299
SF-8 mental component score 0.971 0.920–1.026 0.298
Abbreviations: CI = Confidence interval; IIEF-EF = International index of erectile function erectile function domain;
SF-8 = Short-Form-8 Health Survey.
4. Discussion
We found that 41% of patients were satisfied, whereas almost 45% of patients were not satisfied
with outcome following surgery, although SIS grafting resulted in complete straightening of the
penis in more than 90% of patients. Previously, others have reported inconsistent findings on patient
satisfaction with surgical outcome following SIS grafting. Some studies found high satisfaction rates of
82–89% [13–16], while Chung et al. reported that more than 65% of patients were not satisfied with
surgical outcome [12]. Variable findings among studies regarding patient satisfaction with surgical
outcome may be due to differences in patient characteristics, follow-up, study design, and methods.
For example, the prospective study by Sayedahmed et al. included 43 patients, who were recruited
from two centers over a time period of eight years. Kovac et al. and Chung et al. included 36
and 46 patients, respectively, who were recruited over a time period of six years and also received
dermal and synthetic grafts [12] or dermal and cadaveric pericardial grafts [13], which may render
comparison of results difficult. Morgado et al. focused on patient satisfaction with sex life after
surgery [16]. Other studies reported less subjective penile shortening in 5–71% of patients [12–16],
compared to almost 97% of patients in the present study. Importantly, we could demonstrate that
subjective shortening of the penis was a risk factor for patient dissatisfaction, which therefore could be
a reason for the observed differences in patient satisfaction. In addition, the present study included
a higher proportion of patients with moderate and severe preoperative ED, compared to 7–10%
preoperative ED in previous studies [14,15]. It is well established that ED may deteriorate after SIS
grafting [5]. We could demonstrate that subjective worsening of erectile function was not a risk factor
for patient dissatisfaction. However, higher IIEF-EF postoperative scores significantly reduced the
risk of dissatisfaction. Moreover, other studies evaluated patient satisfaction with 5-point scales [12],
4-answering possibilities [15], 3-answering possibilities [13], a modified Erectile Dysfunction Inventory
of Treatment Satisfaction [16], or did not report in detail on how patient satisfaction was measured [14],
which may contribute to variable results. Finally, we found a higher proportion of patients with
penile paresthesia following SIS grafting, compared to previous reports [12–16]. These differences may
rely on variable evaluation of penile sensibility among different studies. In addition, circumcision
was performed in all patients in the present study and might have contributed to penile paresthesia.
Moreover, the type of graft may play a role, although Kovac et al. did not report relevant differences in
penile hypoesthesia among patients, who received SIS grafts, dermal grafts or Tutoplast grafts [13].
Finally, the dissection of the dorsal pedicle may also influence sensory changes. The majority of
patients in the present study reported that penile paresthesia was not bothering. However, we cannot
exclude that this may have contributed to overall dissatisfaction. In the present study, circumcision
was performed in all patients during penile surgery, although a case series questioned its need in
patients undergoing penile surgery for PD [25]. Although circumcision is in general considered
a safe procedure, it may have adverse effects, e.g., hypoesthesia of the glans, as well as negative
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psychological consequences [26]. Thus, we cannot exclude that circumcision may have added to
patient dissatisfaction.
For the first time, the present study incorporated patients’ body related self-perceptions and
self-attitudes of sexuality, which was assessed with validated FKKS-SEX. Thus far, FKKS-SEX was
primarily used in patients with psychiatric disorders, e.g., depression and addiction [23]. We found
that the majority of patients had a positive or neutral self-perception and self-attitude of sexuality.
Importantly, negative self-perception and self-attitude of sexuality was a risk factor for patient
dissatisfaction. Thus, FKKS-SEX may represent a promising tool to preoperatively identify patients,
who are at risk for dissatisfaction. At best, it may be helpful in detecting patients with relevant
underlying psychological conditions prior surgery. Then, these patients may benefit from rigorous
sexological evaluation, support, or intervention in the preoperative and postoperative setting. We
used the validated SF-8 to assess health related quality of life, and found that patients had lower social
functioning, mental health, and emotional roles compared to the mean for German controls, although
neither SF-8 physical component score nor SF-8 mental component score were risk factors for patient
dissatisfaction with surgical outcome. Thus far, SF-8 has mainly been used to evaluate patients with
other chronic illness, e.g., migraine, depression, and diabetes [20]. Our findings indicate that this
questionnaire may be useful in PD patients treated with SIS grafting. However, further prospective
studies are needed to confirm the potential of FKKS-SEX and SF-8 in outcome measurement in these
patients; and to analyze the possibility of identifying patients with underlying psychological conditions,
who may benefit from sexological support or intervention.
We found considerable discrepancy between patients’ complaints and objective outcome. First of
all, almost 97% of patients reported loss of penile length, whereas measurement revealed no significant
change between preoperative and postoperative penile length. This corresponds to findings of other
authors, who found that 71% of patients reported subjective loss of penile length, whereas measurement
revealed penile shortening in 14% of patients [15]. These findings highlight the importance of thorough
preoperative counseling, with the aim to lower patients’ unrealistic expectations of SIS grafting, such
as restoration of penile length as it was prior disease onset. Second, 62% of patients reported subjective
worsening of erectile function. Indeed, postoperatively, more patients reported severe and moderate
ED. This corresponds to findings of other authors, who found that 32% of patients reported decreased
rigidity, whereas only 18% of patients had IIEF scores corresponding to moderate and severe ED [15].
Compared to the present study, others have previously reported better [13–15] or worse postoperative
erectile function [12]. Inconsistent findings regarding postoperative erectile function may be due to
differences in methods, follow-up and patient characteristics. For example, other studies used IIEF-5
questionnaire [12–16], had longer [12,14,16] or shorter [13,15] follow-up or did not report on relevant
comorbidities [14], which may be associated with ED. Importantly, with longer time from penile surgery,
other factors like age and comorbidities may occur and have additional negative impact on erectile
function. For example, increasing age is a well-established risk factor for erectile dysfunction [27].
The present study has important limitations, which are first and foremost inherent to the
retrospective study design. The number of patients is low, and follow-up was not available in 30% of
patients. Therefore, selection bias could have influenced the results both at baseline and at follow-up.
In addition, preoperative or postoperative data, e.g., penile length measurement, was not available
in a relevant number of patients. Particularly, this may have introduced relevant reporting bias. In
addition to validated instruments, the questionnaire included non-validated questions, which renders
comparability with results of other studies difficult. Neither FKKS-SEX nor SF-8 have been validated
for the use in patients with PD. Moreover, patients did receive the questionnaire at different time
points following SIS grafting, which might cause relevant heterogeneity of results. The effect of SIS
grafting on health-related quality of life as well as self-perception and self-attitude of sexuality remains
uncertain, since preoperative data on SF-8 and FKKS-SEX was not available. The incision of the tunica
albuginea of the corpora cavernosa may also have an impact on outcome, especially erectile function,
but was not assessed in the present study. Data on treatment of ED after SIS grafting was missing.
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Multivariable analysis to identify independent predictors for patient dissatisfaction was not possible,
since the number of events was too low. Nevertheless, our data suggest that patient related features as
subjective shortening of the penis, negative body related self-perceptions and self-attitudes of sexuality
as well as IIEF-EF score were risk factors for patient dissatisfaction. Thus, validation of our results in
prospective studies with larger patient cohorts is warranted.
5. Conclusions
A relevant number of patients with severe PD are not satisfied with surgical outcome after SIS
grafting. The majority of patients have positive and neutral self-perception and self-attitudes of
sexuality. Following SIS grafting, patients have lower social functioning, mental, and emotional health
compared to controls. Subjective shortening of the penis, negative body related self-perceptions, and
self-attitudes of sexuality as well as IIEF-EF score are risk factors for patient dissatisfaction. Further
prospective studies with larger patient cohorts are necessary to validate these findings.
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Abstract: High prevalence of child sexual offending stand in contradiction to low conviction rates
(one-tenth at most) of child sexual offenders (CSOs). Little is known about possible differences
between convicted and non-convicted pedophilic CSOs and why only some become known to the
judicial system. This investigation takes a closer look at the two sides of “child sexual offending” by
focusing on clinical and neurobiological characteristics of convicted and non-convicted pedophilic
CSOs as presented in the Neural Mechanisms Underlying Pedophilia and sexual offending against
children (NeMUP)*-study. Seventy-nine male pedophilic CSOs were examined, 48 of them convicted.
All participants received a thorough clinical examination including the structured clinical interview
(SCID), intelligence, empathy, impulsivity, and criminal history. Sixty-one participants (38 convicted)
underwent an inhibition performance task (Go/No-go paradigm) combined with functional magnetic
resonance imaging (fMRI). Convicted and non-convicted pedophilic CSOs revealed similar clinical
characteristics, inhibition performances, and neuronal activation. However, convicted subjects’ age
preference was lower (i.e., higher interest in prepubescent children) and they had committed a
significantly higher number of sexual offenses against children compared to non-convicted subjects.
In conclusion, sexual age preference may represent one of the major driving forces for elevated rates
of sexual offenses against children in this sample, and careful clinical assessment thereof should be
incorporated in every preventive approach.
Keywords: NeMUP; child sexual offending; child sexual abuse; pedophilia; fMRI; SCID
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1. Introduction
With a prevalence of 12.7%, child sexual offenses occur across most ethnic, religious and
socioeconomic groups all over the world [1]. This is especially devastating since the effects on
children’s wellbeing and development are tremendous and might persist until adulthood [2–4]. The
high prevalence in comparison to the low conviction rate of child sexual offenders (CSOs) [2] suggests
that the majority of CSOs may never get caught. The reasons for the low conviction rate remain
unclear but could originate from three different circumstances: (1) Characteristics of the victim (e.g.,
age), (2) characteristics of the offender (e.g., being better at hiding the crime due to intelligence),
and (3) circumstances of the crime (e.g., abuse by an intimate person). One of the most frequently
described risk-factors concerning child sexual offending is a pedophilic preference which has been
described in about 50% of convicted CSOs [5,6]. The International Classification of Diseases, tenth
edition (ICD-10) [7] defines diagnostic criteria of pedophilia as a sexual preference for children—boys
or girls or both—usually of prepubertal or early pubertal age including the following criteria: “(A) The
general criteria for F65 disorders of sexual preference must be met (G1. Recurrent intense sexual urges
and fantasies involving unusual objects or activities. G2. Acts on the urges or is markedly distressed by
them. G3. The preference has been present for at least six months). (B) A persistent or a predominant
preference for sexual activity with a prepubescent child or children. (C) The person is at least 16 years
old and at least five years older than the child or children” [7].
Pedophilia has often been linked to higher psychiatric comorbidities [8–10] as well as
neurobiological and neuropsychological alterations (e.g., [11]). These results correspond to Krueger and
Schiffer [12], who showed that convicted pedophiles serving prison sentences in a forensic treatment
facility performed lower on all subtests of a shortened IQ test than a control group except for completing
images. Multiple studies showed coherence between pedophilic CSOs and impairment in behavioral
inhibition [13–15]. Nevertheless, Gerwinn et al. [10] were one of the first revealing an effect of offender
status but not of pedophilia on intelligence and other measures in their subgroups. Furthermore,
it was shown that essential alterations of brain structure and function—which were assumed to be
pedophilia-specific—were predominantly associated with child sexual offending rather than with
the pedophilic preference [16–19]. Most importantly, Kärgel et al. [17] even found non-offending
pedophiles to perform significantly better in a behavioral inhibition task (go/nogo paradigm). This
leads to the hypothesis that behavioral inhibition potentially secures non-offending pedophiles from
acting upon their urges in comparison to sexually offending pedophiles.
Alternatively, there may be effects such as the number of the victims and age of the offender
that can lead to imprisonment. Neutze et al. [20] found an age difference between detected and
undetected pedophilic CSOs with the detected CSOs being older. Hence, it might be possible that
being convicted is just a matter of time. The authors [20] conclude that two sets of factors are associated
with detection status: (1) “preceding” ones that might influence whether an individual is detected
(e.g., age or education) and (2) “resulting” ones which may either be a response to detection (e.g.,
emotion-oriented coping, childhood sexual victimization) or reflect a bias in self-report measures (e.g.,
sexual self-regulation problems, paraphilic interests) in order to avoid negative consequences (e.g.,
severe punishment) [20].
In the last years, research on neurobiological underpinnings of pedophilia has gained some
attention. Unfortunately, the majority of the few studies focusing on child sexual offending and
pedophilia mainly examined convicted CSOs. Some studies did not even take sexual preference into
consideration at all when comparing groups of offenders and non-offenders. For that reason, results
cannot be seen as representative for pedophilia in general, and findings are restricted to the particular
group of convicted CSOs [15]. Subsequently, it must be considered that there could be an offender effect
rather than an effect of pedophilia itself. Hence, when investigating characteristics due to a pedophilic
preference, it is crucial to distinguish between convicted pedophiles, non-convicted pedophiles, and
convicted CSOs who are not pedophilic.
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Throughout the last years, the research consortium NeMUP, which is the acronym for “neural
mechanisms underlying pedophilia and sexual offending against children”, discriminated between
pedophilia and child sexual offending by using a two by two factorial design (offender status/pedophilia).
Results of the NeMUP consortium showed increased levels of psychiatric comorbidities, sexual
dysfunctions, and adverse childhood experiences among pedophiles as well as child sexual
offenders [10]. Additionally, regression analyses were more powerful in segregating offender status
than sexual preference (mean classification accuracy: 76% versus 68%). In summary, results of
the NeMUP consortium showed that executive dysfunctions in CSOs are rather small and may be
independent of pedophilic preferences. Neurobiological assessment showed changes in brain structure,
metabolism [21] and function, which were particularly associated with the offending status but not
with pedophilic preference [16–19].
Regarding the characteristics of victims that might differentiate between convicted and
non-convicted CSOs, it is important to acknowledge that the authors have no intention to blame
victims of sexual offenses. Nevertheless, some victim related factors might decrease the likelihood of
incarceration of the offenders. It has been shown that children who were older, came from incestuous
families, felt greater responsibility for the abuse, and feared negative consequences of disclosure took
longer to disclose a crime [22]. Additionally, the sex of the victim could possibly discriminate between
convicted and non-convicted CSOs. Since it could be shown that reports of female victims are twice as
frequent as of male victims [1] it is also possible that males are victimized equally often but report
sexual offenses less frequently [23]. This might be caused by more intense feelings of shame and
guilt [24]. Finally, another factor that might differentiate between convicted and non-convicted CSOs
may be the quality of the relationship between offender and victim. Whereas it is more probable that
sexual offenses against children are committed by a relative or a good friend of the family [25,26] this
could also lead to a dilemma concerning a complaint to the police.
While the current investigation did not put an emphasis on victims’ characteristics, it was
designed to carefully analyze clinical, neuropsychological and neurobiological features of convicted
and non-convicted CSOs in order to unravel possible factors that might increase or decrease the
probability to be convicted.
2. Method
2.1. Participants
Participants of the study were recruited by research associates and practicing psychotherapists
as part of the multi-site research project “Neural Mechanisms Underlying Pedophilia and Sexual
Offending against Children” (NeMUP, www.nemup.de) which includes five collaborative research
sites from (forensic) psychiatry or sexual medicine located in Berlin, Bochum/Essen, Hanover, Kiel
and Magdeburg. Most sites of the project were involved in the prevention project “Don’t offend”
(www.dont-offend.org) for self-identified pedophiles seeking therapy [27]. Additionally, some subjects
were recruited in prisons or during fulfilment of a suspended sentence. Moreover, the official
“NeMUP”-website (www.nemup.de) as well as various German internet forums were used to inform
self-identified pedophilic men and child sex offenders without pedophilia about the study [10]. For a
detailed description of recruitment and collection of the whole NeMUP data, the reader is kindly
asked to take a look at Gerwin et al. [10]. The present study only included the NeMUP sample of
pedophiles who committed child sexual offenses in the analysis. This group (CSO) contains men
who fulfill the criteria of being pedophile/hebephile and have committed at least one “hands-on” [10]
delict against children under the age of 14. All participants provided written informed consent before
participating, and all local ethics committees located in Berlin, Bochum/Essen, Hanover, Kiel, and
Magdeburg approved the study (approval code 6048).
While pedophilia is a sexual preference for prepubescent children and teleiophilia is a sexual
responsiveness to adults [10], hebephilia is defined as a sexual preference for children in early pubertal
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stages. The hebephilic group was subsumed under the label of pedophilia according to ICD-10 that
defines pedophilia as a “sexual preference for children . . . of pre-pubertal or early pubertal stage”
(ICD 10).
“Hands-on” delicts were defined as sexual acts that involved touching or manipulating the
child’s naked body or genitals (manually or orally) by the offender with the intention of sexually
stimulating himself, penetrating the child (anally or vaginally) or forcing the child to (anally or vaginally)
penetrate or touch/manipulate the offenders’ genitals [10]. Pedophiles who had not committed such a
“hands-on” offense and/or who were currently or historically consumers of material that shows the
sexual exploitation of children or so-called indicative pictures (e.g., fully clothed children in erotic
poses) were not assigned into this group. This procedure does in no way indicate to degrade such
behavior as “non-criminal”, it was used to differentiate between pedophiles who were or were not able
to refrain from direct sexual behavior towards children.
In the present study, the group of CSOs was divided into two different subgroups. The first
subgroup (non-convicted CSOs) contained men who had not been convicted for their sexual offenses
against children, hence pedophiles in the so-called “dark field”. The other group (convicted CSOs)
included men that had been convicted for their crimes. Men belonging to the non-convicted CSOs
were mainly recruited within the “Don’t Offend” project in Germany [27] and various German internet
forums. Participants who were categorized into the subgroup of convicted CSOs were recruited in
prisons or during fulfillment of suspended sentences. Exclusion criteria were acute psychiatric or
neurological disorders others than pedophilia, acute episodes of alcohol or drug abuse as well as past
dependencies and current medication related to sexual functioning. Overall, 31 non-convicted CSOs
and 48 convicted CSOs were incorporated into data analysis.
2.2. Procedure
Data were collected in two different sessions over two days. The first session included the survey
of interviews and diagnostic data, whereas during the second session the magnetic resonance imaging
(MRI) assessment was performed.
Structured clinical interview for DSM (SCID) [28] enabled to screen for DSM Axis I and
Axis II disorders.
Semi-structured interview was performed in order to gain information about the participants’
sexual interaction interest(s), child pornography consumption, history of offenses in general and
biographical information (e.g., age of first coitus, psychiatric disorders in family, own children).
Sexual gender and age orientation was measured by a modification of the Kinsey Scale [29] where
participants were asked to indicate range and peak for the age and sex of their preferred sexual partner
using the Tanner stages I to V [10]. In case of uncertainty concerning the age preference legal information
(if available) and individual case conferences were utilized to ensure a valid clinical diagnosis.
Intelligence was estimated by the German version of the Wechsler Adult Intelligence Scale
(WAIS-IV) [30]. Global intelligence was assessed by means of four subtests (“Similarities”, “Vocabulary”,
“Block Design”, and “Matrix Reasoning”) [30]. All assessments were carried out by experienced
research associates, trained to use these instruments.
Childhood trauma questionnaire (CTQ) [31] was given to the participants to estimate the burden
of self-experienced abuse and neglect. The questionnaire screens for a history of five different types
of maltreatment (sexual abuse, physical abuse, emotional abuse, physical neglect and emotional
neglect). Moreover, an assessment of psychiatric and criminal history of both parents was included
in the semi-structured interview for assessing other relevant clinical variables. In the current paper,
the difference between the five different types of maltreatment for each group was used to describe
differences in experienced childhood trauma. Thresholds for severe childhood trauma can be found at
Glaesmer et al. [32].
Empathy was measured using the multifaceted empathy test (MET) [33]. The MET consists of
26 photographs, mostly depicting people in emotionally charged situations. The test assesses cognitive
18
J. Clin. Med. 2019, 8, 947
empathy by requiring subjects to deduce mental states of the individuals shown in the photographs.
In order to address emotional empathy participants also rate their own emotional reaction in response
to the pictures. Unfortunately, no cut-off values for the MET can be found in the literature. However,
since the paper focuses on the differentiation between two groups the differences between both groups
were used to describe differences in empathy.
Barratt impulsiveness scale (BIS-11) [34] was used to measure self-reported impulsiveness. The
questionnaire consists of 30 items and is designed to assess three facets of impulsiveness: (1) attentional
impulsiveness, defined as the (in-)ability to concentrate or focus attention, (2) motor impulsiveness,
the propensity to act without thinking, and (3) non-planning impulsiveness, or the lack of planning the
future and forethought. In the current paper, the difference between the total score for each group was
used to describe differences in impulsiveness. For an overview of different clinical scores of BIS-11 the
reader is kindly asked to look at Stanford et al. [35].
2.3. Imaging Parameters and Processing
Since not all participants fulfilled the criteria to be examined with MRI (e.g., because of
claustrophobia or having a pacemaker) only subgroups of the sample were included in the
measurements. Therefore, the analysis of the Go/No-go paradigm included 23 non-convicted CSOs and
38 CSOs convicted participants instead of the overall 31 non-convicted CSOs and 48 convicted CSOs.
The MRI images were acquired at five separate 3T MRI scanners that were equipped with
32 channel head coils: 2× Siemens Skyra, 2× Siemens Trio and 1× Phillips Achiva. T1 images were
created by means of MPRAGE sequence (slices = 192, FoV = 256 mm, voxel size = 1 × 1 × 1 mm,
TR = 2.500 ms, TE = 4.37 ms, flip angle = 7, distance factor = 50%). T2 weighted images were gained
using an echo planar imaging (EPI) sequence (slices = 38, field of view = 240 mm, voxel size = 2.3
× 2.3 × 3 mm, time of repetition = 2.400 ms, echo time 30 ms, flip angle = 80, distance factor = 10%).
MRI phantom stability measures [36] were accompanied to prevent signal fluctuations across all sites.
For functional imaging analysis, the Statistical Parametric Mapping Software (SPM 12) [37] was used.
The first five images were discarded to account for T1 relaxation effects. Before statistical analysis,
functional volumes were (1) slice time corrected using the middle slice as reference, (2) realigned
and unwarped, (3) co-registered to the according T1 image, (4) spatially normalized into Montreal
Neurological Institute (MNI) space utilizing the individual T1 image and (5) smoothed with an isotropic
Gaussian kernel (full width half maximum of 8 mm).
Go/nogo task: As a measure of impulse control and behavioral inhibition participants performed
an event-related go/nogo task preceded by an alertness task of go-trials. The alertness task was applied
to allow the participant to familiarize with the MRI environment as well as to provide a baseline
measure for reaction time to a simple target stimulus. The projection screen was localized either in front
(Hanover) or behind the magnet bore (Berlin, Essen, Kiel). At first, an instruction was presented which
informed the participants to respond as fast as possible to any presented stimulus indicated by “X”.
Afterwards, the stimulus presentation of 50 alertness trials was initiated. Next, a second instruction
screen followed introducing the go/nogo condition containing 150 trials. Participants were asked to
respond as fast as possible to frequently presented go-trials (80% indicated by “X”) and withhold the
response to infrequently presented no-go trials (20% indicated by “+”). Stimuli were presented using
Presentation Software package (Neurobehavioral Systems, Berkeley, CA, USA) and were shown in
a pseudo-randomized order, precluding the occurrence of two repeatedly presented no-go stimuli.
Stimuli were presented 200 ms with an inter-stimulus-interval (ISI) of 1500–2500 ms. Before scanning,
participants were instructed to respond with the right forefinger to the response box. The number
of commission errors of no-go trials as well as the reaction times of alertness were used for further
statistical analysis to provide a behavioral measure of response inhibition. Outliers differing more than
threefold from the distance between the 25% and 75% percentile of the distribution were excluded
from analysis. Visual impairments were corrected by a goggle system that was compatible with MR.
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2.4. Statistical Analysis
Behavioral analysis: SPSS version 24 [38] was used for statistical analysis. To distinguish effects
between non-convicted CSOs and convicted CSOs with respect to intelligence, clinical characteristics,
empathy, impulsiveness, childhood trauma, victim characteristics, and biographical information,
t-tests were used for interval data and Chi2 tests for dichotomous data. Since the study is part of the
NeMUP project there was no specialized sample size calculation for this particular paper. However,
the sample size for the whole NeMUP research was calculated for each of the four groups that were
included in research (pedophiles with child sexual abuse, pedophiles without child sexual abuse. child
sexual abusers without pedophilia and controls). For group one which was included in the current
paper, there was a sample size calculation of 60 participants to ensure MRI results were measurable.
Concerning non-convicted pedophiles, there are only to papers known by the authors that integrated
non-convicted pedophiles into their research. Beier et al. [27] included 53 pedophiles and 22 control
participants in his design. Engel et al. [28] included 35 treated pedophiles and 51 treatment refusers in
his analysis. For that reason, the sample size of the current paper stands in line with other research
published on this topic.
In order to correct for multiple testing, Bonferroni–Holm correction was implemented for different
subgroups. Subgroups were: Characteristics of the offender, clinical information, experienced childhood
trauma, characteristics of the victims, delict specifics, history of delicts (except hands-on delicts) as well
as sexual problems and paraphilias. In order to determine if the number of delicts could be associated
with other (sexual) characteristics of the offender, correlations between sexual age preference, sexual
gender preference, and quantity of sexual child offenses were included in the analysis. In Table 1
subgroups are described in more detail as well as their descriptive statistic parameters.
For behavioral data of go/nogo paradigm, reaction time, error rate and error quote were analyzed
using two sample t-tests.
Table 1. Characteristics of non-convicted and convicted child sexual offenders (CSOs).
Non-Convicted CSOs (n = 31) Convicted CSOs (n = 43)
T
M SD Minimum Maximum M SD Minimum Maximum
Offender characteristics
Age 40.4 10.8 20 59 39.8 9.0 24 62 0.27
Intelligence (WAIS)
Estimated general IQ 100.26 18.51 62 140 98.27 18.95 66 166 0.46
Estimated verbal IQ 95.00 21.52 54 137 92.14 17.45 57 129 0.65
Estimated performance IQ 106.87 19.41 78.00 143.0 103.31 17.29 63.00 149.00 0.85
Empathy (MET)
Emotional 5.11 1.25 2.65 7.44 5.33 1.74 1.44 8.11 −0.57
Cognitive 6.98 1.02 4.63 9.00 7.10 1.04 3.88 8.50 −0.49
Impulsiveness (BIS-11) 64.46 9.86 47.00 81.00 63.49 8.59 46.00 88.00 0.44
Family background
Experienced childhood trauma (CTQ)
Emotional abuse 11.20 4.90 5.00 23.00 10.24 5.41 5.00 25.00 0.79
Sexual abuse 7.00 2.45 5.00 14.00 9.48 6.34 5.00 25.00 −2.40
Physical abuse 7.70 3.37 5.00 20.00 8.43 4.71 5.00 22.00 −0.74
Emotional neglect 13.20 4.91 5.00 25.00 12.37 4.57 5.00 25.00 0.75
Physical neglect 7.60 2.90 5.00 17.00 7.85 3.05 5.00 20.00 −0.35
Information about the victims
Age (mean)
Female victim 10.50 3.19 5.0 15.5 8.68 2.31 5.0 13.0 2.15
Male victim 11.28 2.59 6.0 15.0 10.18 2.48 3.0 14.5 −0.25
History of Delicts (except hands-on Delicts)
Quantity of violent offense 0.13 0.43 0 2 0.66 1.23 0 2 0.125
Quantity of other offenses 0.83 1.23 0 5 0.55 1.23 0 7 −0.28
Delict specifics
Quantity of child sexual offenses 1.94 1.41 1 7 4.53 3.91 1 17 −4.23 ***
Number of victims 2.35 2.53 1 11 5.08 8.71 1 60 0.39
Number of female victims 1.58 2.59 0 11 1.33 2.13 0 10 0.48
Number of male victims 0.77 1.43 0 7 3.76 8.81 0 60 −2.32
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Table 1. Cont.
Non-Convicted CSOs (n = 31) Convicted CSOs (n = 43)
T
M SD Minimum Maximum M SD Minimum Maximum
n a n a χ2
Clinical diagnoses
SCID I disorders
Affective disorders 13 16 0.40
Anxiety disorders 8 9 0.63
Sexual disorders 0 0 1.60
Obsessive compulsive disorders 1 1 0.11
Substance disorders 6 12 0.29
Eating disorders 0 1 0.64
ADHD 1 0 1.60
SCID II disorders 0.91
Cluster A 2 3 0.00
Cluster B 11 10 2.22
Cluster C 6 12 0.29
Sexual age orientation 14.00 *
Hebephile 1 3
Pedophile 5 19
Mixed pedophile and teleiophile 5 11
Mixed hebephile and teleiophile 11 3
Mixed pedophile and hebephile 5 5
Mixed pedophile, hebephile and teleiophile 4 8




Intrafamilial (incest) delicts 7 6 1.49
Extrafamilial delicts 24 43 1.49
M: Mean, SD: standard deviation, a number of participants fulfilling the criteria, * p ≤ 0.05, *** p ≤ 0.001.
fMRI analysis: SPM12 was used to analyze functional volumes. For first-level analysis the
following events were included as regressors in the design matrix: (1) alertness, (2) hits to go-trials,
(3) false responses to no-go trials, (4) false responses to no-go trials (commission errors), (5) movement
as regressors of no interest. Event-related responses were convolved with the canonical hemodynamic
response (HRF), and separate linear contrast images (vectors for each condition) were built. For
assessing group differences, contrast images were analyzed using two-sided t-tests (non-convicted
CSOs vs. convicted CSOs) between groups for the different regressors of interest: (1) alertness,
(2) go-trials, (3) successfully inhibited no-go trials and (4) false responses to no-go trials (commission
errors). Groups neither differed in age nor IQ so these variables were of no interest for further
analysis. The threshold for all analyses was set to p = 0.05, familywise error (FWE) corrected for
multiple comparisons.
3. Results
3.1. Characteristics of the Offender
As shown in Table 1, no significant differences could be found which distinguished between
the two offender groups concerning age or intelligence (neither in relation to general, verbal nor
performance intelligence). Moreover, measurements for empathy or impulsiveness did not separate
between non-convicted and convicted CSOs. No correlation between sexual age preference, sexual
gender preference, and quantity of sexual child offenses was seen.
3.2. Sexuality
Non-convicted and convicted CSOs differed in sexual age orientation χ2 (1, n = 79) = 14.00,
p = 0.03. Convicted CSOs were more often pedophilic (n = 19 convicted, n = 5 non-convicted) or mixed
pedophilic/teleiophilic (n = 11 convicted, n = 5 non-convicted), whereas non-convicted CSOs showed
an age preference more often than mixed hebephilic/teleiophilic (n = 3 convicted, n = 11 non-convicted).
There was no difference in sexual gender orientation χ2 (1, n = 79) = 4.01, p = 0.135).
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3.3. Experienced Childhood Trauma
There were no significant differences in self-experienced childhood traumatization as assessed by
the CTQ questionnaire between non-convicted and convicted CSOs. A more detailed overview of the
data can be found in Table 1.
3.4. Clinical Information
As can be seen in Table 1, no significant difference was found between the two groups concerning
any clinical features.
3.5. Delinquency
CSO delicts: Non-convicted CSOs and convicted CSOs differed in the quantity of their sexual child
offenses (t (78)=−4.23, p< 0.001), but not in the number of victims or in the number of victims by gender.
A marginal significance for a difference in the number of male victims was evident (t (78) = −2.32,
p = 0.06). There was neither a correlation between sexual age preference and quantity of sexual child
offenses nor between sexual gender preference and quantity of sexual child offenses.
Non-CSO delicts: As can be seen in Table 1, the two groups did not differ concerning delicts other
than child sexual offending.
3.6. Victims’ Characteristics
The groups showed a marginal significance in the difference of age of female victims (t (78) = −2.51,
p = 0.06).
3.7. Go/No-Go Task
Non-convicted and convicted CSOs did not significantly differ in this task, neither in post-error
slowing nor in reaction times to commission errors. For detailed information see Table 2.
Table 2. Inhibited response to no-go trials for both groups.
Non-Convicted CSOs (n = 31) Convicted CSOs (n = 49) Statistics (t-Value)
RT Alertness in ms, M (SD) 263.009 (58.269) 273.540 (47.545) t (78) = −0.74; p = 0.46
RT Go in ms, M (SD) 388.062 (43.298) 400.053 (54.644) t (78) = −0.85; p = 0.40
Global Error Rate, M (SD) 0.0598 (0.043) 0.0532 (0.0394) t (78) = 0.61; p = 0.54
Global Error Quote, M (SD) 11.455 (8.830) 10.632 (7.875) t (78) = 0.37; p = 0.71
Coordinates are denoted by x, y, z in mm according to the MNI-space (Montreal Neurological Institute).
3.8. fMRI Analysis
Successful response-inhibition activated clusters in the anterior cingulate cortex, supplemental
motor cortex, insula and middle temporal gyrus (FWE corrected on voxel level, see Table 3) for both
groups. No differences were found between both groups.
Table 3. Go/No-Go task performance.
Location (AAL) Hemisphere x y z Size t-Value
Inhibited response to no-go trials for both groups, FWE peak level
Insula L −22 24 8 18 6.28
ACC L −4 34 22 76 6.15
Middle temporal gyrus R 46 −42 −8 28 6.03
Middle temporal gyrus L −54 −22 −14 16 5.99
Supplemental motor area R 2 24 46 12 5.43
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4. Discussion
Overall, only subtle differences between non-convicted and convicted CSOs were identified.
Thus, most of the initial hypotheses of the authors concerning differences between convicted and
non-convicted pedophilic offenders could not be supported. Data shows that non-convicted CSOs
were neither more intelligent nor less impulsive nor suffered less from psychiatric disorders than
convicted CSOs in this study. Additionally, no differences could be found concerning their age, the
number of victims or the level of empathy. Interestingly, convicted CSOs committed more delicts
than non-convicted CSOs. Furthermore, non-convicted and convicted CSOs differed in sexual age
orientation. Moreover, all hypotheses except age and gender preference concerning characteristics
of victims could not be supported in the present study. However, there was a marginal significance
concerning the number of male victims and the age of female victims.
Our data shows that the risk of being caught increases with the number of victims. First, it is
likely that with an increasing number of delicts it becomes more probable that one victim is able to
identify the offender or to confide in another person about the crime. Second, more frequent delicts of
child sexual offending may increase hubris of the offender and lead to carelessness concerning the
crime scene, which may finally lead to the offender’s incarceration.
Since convicted CSOs were more often exclusively pedophilic or mixed pedophilic/teleiophilic it is
possible that harming a child might lead more often to incarceration than harming an adolescent. This
might be due to the social perspective that harming adolescents might be less harmful. Additionally,
there is an ongoing debate about whether or not hebephilia is relevant for psychopathology [39]. This
debate has been consistent with the evolutionary psychology position that emphasizing the adaptive
partner-preference is for fecund females (although females are actually subfecund for one to two years
after menarche) [39,40]. Hence it is possible, that mixed hebephilic/teleiphilic preference—which has
been shown more often in the group of non-convicted CSOs—will be longer “below radar level” than
pedophilic preference. However, since the following data is cross-sectional no causal connections
are possible.
The present data suggest that incarceration effects are not as prominent as often stated in criticisms
about research with convicted subjects. The general criticism that it is difficult or even impossible
to interpret data gained by imprisoned groups exclusively can subsequently be put into another
perspective. Nonetheless, it is important to keep incarceration effects, environmental effects, and the
effect of critical life events such as being convicted in mind.
Relating to the aim of the study to find differences between both groups which might help to
decrease the number of CSOs and—more importantly—undetected CSOs, the difference in the number
of delicts between non-convicted CSOs and convicted CSOs actually is of high relevance. However, it
is important not to interpret the results as a causal relationship between the number of delicts that
would lead to incarceration or not.
The presented data is in line with findings from Neutze et al. [20], showing more group similarities
than differences between detected and undetected offenders altogether.
Additionally, the present study compared ‘resulting’ factors of convicted CSOs and non-convicted
CSOs. “Preceding” factors are defined as the ones that might influence whether an individual is
detected (e.g., age or education) whereas (2) “resulting” ones may either be a response to detection (e.g.,
emotion-oriented coping, childhood sexual victimization) or reflect a bias in self-report measures (e.g.,
sexual self-regulation problems, paraphilic interests) in order to avoid negative consequences (e.g.,
severe punishment). Differences which have been described between convicted and non-convicted CSOs
concerning age and education in the study of Neutze et al. [20] (non-convicted CSOs were younger) [20],
were not replicated in the present study. Furthermore, the report of suffering more from own childhood
victimization in the group of convicted CSO [20] was observable as a marginal significance in the
present study. Therefore, the two different sets of factors, proposed by Neutze et al. [20], that are
associated with detection status were not observed in the present study. Overall, future research should
address these factors.
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The consequences of child sexual offending are, as already mentioned, fatal and costly for society
(the estimated lifetime economic burden of CSO is approximately $9.3 billion in the US [20]) as well as
for children’s wellbeing and development [2–4]. Additionally, the devastating effect may persist until
adulthood. Thus, emphasis should be laid on preventing offenses. Due to a lack of confidentiality
regulations in many countries, offering therapy is only possible after incarceration, i.e., after the crime
has not to be concealed anymore. Since therapy may decrease the risk of committing another crime by
focusing on dynamic risk factors of offending [27], offering a therapeutic concept to non-convicted
CSOs may not only decrease the number of delicts, but it may also reduce the socioeconomic burden
and increase the well-being of children. Future research should focus on how preventive approaches
may help to reduce the number of offenses.
However, to go one step further offering therapy to non-convicted CSOs might raise the concern
that treating this group could lead to better “skills” in hiding crimes and criminal behavior. By working
on topics such as behavioral control, social skills, and empathy, non-convicted CSOs might not only
learn how to hide a crime better, they may also be able to get better in contacting children and—if
so—therapy of non-convicted CSOs might theoretically actively exaggerate the risk of (re)offending.
Furthermore, there is a wide discussion in society whether or not offender treatment does more harm
than good [41,42]. However, since it is shown in the present study that non-convicted CSOs and
convicted CSOs seem to suffer from comparable psychiatric burdens and difficulties, it is unlikely that
they will learn skills which may increase their risk of offending. Regarding the fact that detected and
undetected CSOs do not differ in clinical characteristics, there is no reason for withholding therapy from
undetected CSOs. Moreover, Beier et al. [27] showed that therapy in the German “Dunkelfeld” (dark
field) project altered dynamic risk factors for child sexual offending and reduced related behaviors.
This knowledge is fundamental to ensure the protection and wellbeing of children and to uncover
child sexual abuse as early as possible.
5. Limitations
First of all, participants were recruited as part of the multi-site research project NeMUP, which
includes five collaborative research sites from (forensic) psychiatry or sexual medicine located in Berlin,
Bochum/Essen, Hanover, Kiel and Magdeburg and did not only include convicted and non-convicted
CSOs but also healthy controls and “hands-off” pedophiles who have not committed a crime yet.
There were several exclusion criteria which were important for other investigations in the NeMUP
consortium but might limit generalizing the results of this study. Those were an intellectual disability,
psychotic disorder, current severe major depressive disorder (score greater than 15 on the Hamilton
Depression Scale) or anxiety disorder (score greater than 25 in the Hamilton Anxiety Scale), clinically
predominant substance misuse or dependence and any psychotropic medication. Subsequently, it is
possible that differences between CSOs and non-convicted CSOs vanished not because differences
did not exist but because of the early exclusion of offenders with a high psychiatric burden. Future
research should include participants with current mental disorders and a high psychiatric burden to
ensure differences are not disappearing due to strict inclusion and exclusion criteria. Additionally,
the questions asked on recruitment might lead to possible bias such as not detecting pedophiles who
are ashamed of “coming out” with their sexual preference or not integrating participants with a high
psychiatric burden due to exclusion criteria. Since a large number of participants has been recruited
within the “Don’t offend”-network this might represent another bias because these subjects are all
motivated to undergo psychotherapy.
Another difficulty in the study is the missing detailed data about the crime itself and the crime
scene. Due to our quantitative approach, we were not able to include this data as well. However, it is
indeed possible that circumstances of the crime and the crime scene are a certain factor for leading
to conviction or non-conviction. Circumstances such as sadism or threatening the victim were not
included in the analysis. These factors may be important not only for the likelihood of reporting the
crime but also for the effort of engaged third parties such as social workers and/or the police. The topic
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of circumstances of the crime should be taken into consideration for future research. The following
paper focuses on the characteristics of the offenders and only a few characteristics of the victims.
Since each and every crime has its own characteristics and specifics, it is difficult to investigate the
circumstances of a crime by using quantitative research. Concerning alterations in the characteristics
of convicted in comparison to non-convicted CSOs, the study only included pedophilic CSOs who are
either known by the judicial system, and therefore, convicted or are in the so-called “dark field”.
Moreover, the reliance on self-report concerning detection status of non-convicted CSOs might
be a problem for analysis. Future research has to find a way of limiting the risk of false-negative
responses by the participants due to the possible withholding of information in virtue of shame for
being detected. Another limitation is the confinement of the study sample to individuals who applied
voluntarily. For that reason, it is possible that differences or similarities between help-seeking offenders
and those not seeking help—independent of detection status—may not have been targeted.
Nevertheless, the study design is cross-sectional, and causal connections are therefore prohibited.
Finally, including measurements for socially desirable responding to the procedure of collecting
data would be appreciated.
6. Concluding Remark
The study shows effects on a marginally significant level for the number of victims, number
of male victims, age of female victims, and self-reported sexual abuse. Additionally, a significant
effect for the number of sexual offenses was shown. Hence, convicted CSOs may represent a specific
subsample with higher risk and a greater burden of adverse life events though differences appear
to be smaller than commonly perceived. The main strength of this study is that it is one of the first
focusing on differences between detected and undetected CSOs. Until now, there is only one other
study [20] known by the authors that tried to understand which factors may play an important role in
the incarceration of CSOs. Because of its design, the study was able to examine differences between
those groups.
Author Contributions: Conceptualization, C.G., C.S. and T.H.C.K.; Methodology, C.G., C.S.; Software, C.S.;
Validation, C.S., K.M.B., H.W., K.S., J.P., M.W., B.S. and T.H.C.K.; Formal Analysis, C.G., C.S.; Investigation, J.K.,
T.A., S.M., H.G., A.P., C.F., I.R., C.K., C.M.; Resources, C.G., J.K., T.A., S.M., H.G., A.P., C.F., I.R., C.K., C.M., C.S.,
K.M.B., H.W., K.S., J.P., M.W., B.S. and T.H.C.K.; Data Curation, C.G.; Writing-Original Draft Preparation, C.G.;
Writing-Review & Editing, C.G., C.S., J.K., T.A., S.M., H.G., A.P., C.F., I.R., C.K., C.M., K.M.B., H.W., K.S., J.P., M.W.,
B.S. and T.H.C.K.; Visualization, C.G. and C.S.; Supervision, C.S., K.M.B., H.W., K.S., J.P., M.W., B.S. and T.H.C.K.;
Project Administration, K.M.B., H.W., K.S., J.P., M.W., B.S. and T.H.C.K.; Funding Acquisition, K.M.B., H.W., K.S.,
J.P., M.W., B.S. and T.H.C.K.
Funding: This research was funded by the Federal Ministry of Education and Research (BMBF). Grant number
01KR1205 to B.S., M.W., K.M.B., H.W., J.P. and T.H.C.K. Parts of the study were also funded by the German
Research Foundation (DFG): Schi 1034/3-1 to B.S.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Stoltenborgh, M.; Van Ijzendoorn, M.H.; Euser, E.M.; Bakermans-Kranenburg, M.J. A global perspective
on child sexual abuse: Meta-analysis of prevalence around the world. Child. Maltreat. 2011, 16, 79–101.
[CrossRef]
2. Kessler, R.C.; McLaughlin, K.A.; Green, J.G.; Gruber, M.J.; Sampson, N.A.; Zaslavsky, A.M.; Benjet, C.
Childhood adversities and adult psychopathology in the WHO world mental health surveys. Br. J. Psychiatry.
2010, 197, 378–385. [CrossRef]
3. Tomoda, M.H.; Navalata, A.; Polcary, C.P.; Sadato, A.; Teicher, N. Childhood sexual abuse is associated with
reduced gray matter volume in visual cortex of young women. Biol. Psychiatry 2009, 66, 642–648. [CrossRef]
4. Heim, C.M.; Mayberg, H.S.; Mletzko, T.; Nemeroff, C.B.; Pruessner, J.C. Decreased cortical representation of
genital somatosensory field after childhood sexual abuse. Am. J. Psychiatry 2013, 170, 616–623. [CrossRef]
25
J. Clin. Med. 2019, 8, 947
5. Seto, M.M. Pedophilia and Sexual Offending Against Children: Theory, Assessment, and Intervention; American
Psychological Association: Washington, DC, USA, 2008.
6. Whitaker, D.J.; Le, B.; Hanson, R.K.; Baker, C.K.; McMahon, P.M.; Ryan, G.; Rice, D.D. Child abuse neglect
risk factors for the perpetration of child sexual abuse: A review and meta-analysis. Child. Abuse Negl. 2008,
32, 529–548. [CrossRef]
7. World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions
and Diagnostic Guidelines; World Health Organization: Geneva, Switzerland, 1992.
8. Dunsieth, N.W., Jr.; Nelson, E.B.; Brusman-Lovins, L.A.; Holcomb, J.L.; Beckman, D.; Welge, J.A.; McElroy, S.L.
Psychiatric and legal features of 113 men convicted of sexual offenses. J. Clin. Psychiatry 2010, 65, 293–300.
[CrossRef]
9. Eher, R.; Neuwirth, W.; Fruehwald, S.; Frottier, P. Sexualization and lifestyle impulsivity: Clinically valid
discriminators in sexual offenders. Int. J. Offender Ther. Comp. Criminol. 2003, 47, 452–467. [CrossRef]
10. Gerwinn, H.; Weiß, S.; Tenbergen, G.; Amelung, T.; Födisch, C.; Pohl, A.; Wittfoth, M. Clinical characteristics
associated with paedophilia and child sex offending–Differentiating sexual preference from offence status.
Eur. Psychiatry 2018, 51, 74–85. [CrossRef]
11. Cantor, J.M.; Lafaille, S.; Soh, D.W.; Moayedi, M.; Mikulis, D.J.; Girard, T.A. Diffusion tensor imaging of
pedophilia. Arch. Sex. Behav. 2015, 44, 2161–2172. [CrossRef]
12. Kruger, T.H.; Schiffer, B. Neurocognitive and personality factors in homo- and heterosexual pedophiles and
controls. J. Sex. Med. 2011, 8, 1650–1659. [CrossRef]
13. Schiffer, B.; Vonlaufen, C. Executive dysfunctions in pedophilic and nonpedophilic child molesters. J. Sex.
Med. 2011, 8, 1975–1984. [CrossRef]
14. Suchy, Y.; Eastvold, A.D.; Strassberg, D.S.; Franchow, E.I. Understanding processing speed weaknesses
among pedophilic child molesters: Response style vs. neuropathology. J. Abnorm. Psychol. 2014, 123, 273–285.
[CrossRef]
15. Mohnke, S.; Mueller, S.; Amelung, T.; Krueger, T.H.; Ponseti, J.; Schiffer, B.; Walter, H. Brain alterations in
paedophilia: A critical review. Prog. Neurobiol. 2014, 122, 1–23. [CrossRef]
16. Kärgel, C.; Massau, C.; Weiß, S.; Walter, M.; Kruger, T.H.; Schiffer, B. Diminished functional connectivity on
the road to child sexual abuse in pedophilia. J. Sex. Med. 2015, 12, 783–795. [CrossRef]
17. Kärgel, C.; Massau, C.; Weiß, S.; Walter, M.; Borchardt, V.; Krueger, T.H.; Gerwinn, H. Evidence for superior
neurobiological and behavioral inhibitory control abilities in non-offending as compared to offending
pedophiles. Hum. Brain Mapp. 2017, 38, 1092–1104. [CrossRef]
18. Massau, C.; Tenbergen, G.; Kärgel, C.; Weiß, S.; Gerwinn, H.; Pohl, A.; Ristow, I. Executive functioning in
pedophilia and child sexual offending. J. Int. Neuropsychol. Soc. 2017, 23, 460–470. [CrossRef]
19. Schiffer, B.; Amelung, T.; Pohl, A.; Kaergel, C.; Tenbergen, G.; Gerwinn, H.; Marr, V. Gray matter anomalies in
pedophiles with and without a history of child sexual offending. Transl. Psychiatry 2017, 7, e1129. [CrossRef]
20. Neutze, J.; Grundmann, D.; Scherner, G.; Beier, K.M. Undetected and detected child sexual. Int. J. Law
Psychiatry 2012, 35, 168–175. [CrossRef]
21. Kruger, T.H.; Sinke, C.; Kneer, J.; Tenbergen, G.; Khan, A.Q.; Burkert, A.; Pohl, A. Child sexual offenders
show prenatal and epigenetic alterations of the androgen system. Transl. Psychiatry 2019, 9, 28. [CrossRef]
22. Goodman-Brown, T.B.; Edelstein, R.S.; Goodman, G.S.; Jones, D.P.; Gordon, D.S. Why children tell: A model
of children’s disclosure of sexual abuse. Child. Abuse Negl. 2003, 27, 525–540. [CrossRef]
23. Holmes, G.R.; Offen, L.; Waller, G. See no evil, hear no evil, speak no evil: Why do relatively few male
victims of childhood sexual abuse receive help for abuse-related issues in adulthood? Clin. Psychol. Rev.
1997, 17, 69–88. [CrossRef]
24. University of Michigan. Male Survivors of Sexual Assault; Sexual Assault Prevention and Awareness Center:
Ann Arbor, MI, USA, 2018.
25. Wetzels, P. Gewalterfahrungen in der Kindheit: Sexueller Missbrauch, Körperliche Misshandlung und Deren
langfristige Konsequenzen; Verlagsgesellschaft: Baden-Baden, Germany, 1997.
26. Stadler, L.; Bieneck, S.; Pfeiffer, C. Repräsentativbefragung Sexueller Missbrauch 2011; Kriminologisches
Forschungsinstitut: Hannover, Germany, 2012.
27. Beier, K.M.; Grundmann, D.; Kuhle, L.F.; Scherner, G.; Konrad, A.; Amelung, T. The German dunkelfeld
project: A pilot study to prevent child sexual abuse and the use of child abusive images. J. Sex. Med. 2015,
12, 529–542. [CrossRef]
26
J. Clin. Med. 2019, 8, 947
28. Wittchen, H.-U.; Zaudig, M.; Fydrich, T. SKID. Strukturiertes Klinisches Interview für DSM-IV. Achse I und II.
Handanweisung; Hogrefe Publishing Group: Göttingen, Germany, 1997; p. 3.
29. Martin, N.G.; Kirk, K.; Dunne, M.P.; Bailey, J.M. Measurement models for sexual orientation in a large
Australian twin sample. Behav. Genet. 1998, 28, 475–476.
30. Wechsler, D. Wechsler Adult Intelligence Scale–Fourth Edition (WAIS–IV); The Psychological Corporation:
San Antonio, TX, USA, 2008.
31. Wingenfeld, K.; Spitzer, C.; Mensebach, C.; Grabe, H.J.; Hill, A.; Gast, U.; Driessen, M. Die deutsche version
des childhood trauma questionnaire (CTQ): Erste befunde zu den psychometrischen Kennwerten. Psychother.
Psychosom. Medizinische Psychol. 2010, 60, 442–450. [CrossRef]
32. Glaesmer, H.; Schulz, A.; Häuser, W.; Freyberger, H.J.; Brähler, E.; Grabe, H.J. Der childhood trauma screener
(CTS)-Entwicklung und validierung von Schwellenwerten zur Klassifikation. Psychiatr. Prax. 2013, 40,
220–226. [CrossRef]
33. Dziobek, I.; Rogers, K.; Fleck, S.; Bahnemann, M.; Heekeren, H.R.; Wolf, O.T.; Convit, A. Dissociation of
cognitive and emotional empathy in adults with asperger syndrome using the multifaceted empathy test
(MET). J. Autism Dev. Disord. 2008, 38, 464–473. [CrossRef]
34. Patton, J.H.; Stanford, M.S.; Barratt, E.S. Factor structure of the barratt impulsiveness scale. J. Clin. Psychol.
1995, 51, 768–774. [CrossRef]
35. Stanford, M.S.; Mathias, C.W.; Dougherty, D.M.; Lake, S.L.; Anderson, N.E.; Patton, J.H. Fifty years of the
barratt impulsiveness scale: An update and review. Pers. Individ. Dif. 2009, 47, 385–395. [CrossRef]
36. Hellerbach, A. Phantomentwicklung und Einführung einer systematischen Qualitätssicherung bei multizentrischen
Magnetresonanztomographie-Untersuchungen; Philipps-Universität: Marburg, Germany, 2013.
37. Ashburner, J.; Barnes, G.; Chen, C.; Daunizeau, J.; Flandin, G.; Friston, K.; Penny, W. SPM12 Manual; The FIL
Methods Group: London, UK, 2013.
38. IBM Corp. IBM SPSS Statistics for Windows, Version 24.0; IBM Corp.: Armonk, NY, USA, 2016.
39. Blanchard, R.; Lykins, A.D.; Wherrett, D.; Kuban, M.E.; Cantor, J.M.; Blak, T.; Klassen, P.E. Pedophilia,
Hebephilia, and the DSM-V. Arch. Sex. Behav. 2009, 38, 335–350. [CrossRef]
40. Wood, J.W. Dynamics of Human Reproduction, 1st ed.; Routledge: New York, NY, USA, 1994.
41. Wolf, C. Was bringt die Therapie von Sexualstraftätern? Spektrum. 2018. Available online: https://www.
spektrum.de/news/was-bringt-die-therapie-von-sexualstraftaetern/1605646 (accessed on 13 February 2019).
42. Friedrichsen, G. Strafjustiz: Noch gefährlicher durch Therapie. Der Spiegel. 2002. Available online:
http://www.spiegel.de/spiegel/print/d-25554388.html (accessed on 13 February 2019).
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution






Frequency of Sexual Dysfunction in Patients Treated
with Desvenlafaxine: A Prospective
Naturalistic Study
Angel L. Montejo 1,2,*, Joemir Becker 2, Gloria Bueno 3, Raquel Fernández-Ovejero 4,
María T. Gallego 2, Nerea González 5, Adrián Juanes 6, Laura Montejo 7,
Antonio Pérez-Urdániz 2,3, Nieves Prieto 2,3 and José L. Villegas 2
1 Nursing School E.U.E.F., University of Salamanca, 37004 Salamanca, Spain
2 Instituto de Investigación Biomédica de Salamanca, Servicio de Psiquiatría, Hospital Universitario de
Salamanca, 37007 IBSAL, Spain; jbecker@saludcastillayleon.es (J.B.);
mtgallego@saludcastillayleon.es (M.T.G.); perurdan@ono.com (A.P.-U.);
nprietom@saludcastillayleon.es (N.P.); jlvillegas@saludcastillayleon.es (J.L.V.)
3 Departamento de Psiquiatría, Universidad de Salamanca, 37004 Salamanca, Spain; gloriabueno@usal.es
4 Servicio Navarro de Salud, 31008 Osasunbidea, Spain; rqfo25@gmail.com
5 Departamento de Estadística, Universidad de Salamanca, 37004 Salamanca, Spain;
nerea_gonzalez_garcia@usal.es
6 Atención Primaria de Salamanca, 37900 SACYL, Spain; ajuanesd@yahoo.es
7 Barcelona Bipolar and Depressive Disorders Program, Institute of Neurosciences, University of Barcelona,
IDIBAPS, CIBERSAM, Hospital Clinic of Barcelona, 08401 Catalonia, Spain; laumonteg@gmail.com
* Correspondence: amontejo@usal.es; Tel.: +34-639-754-620
Received: 29 March 2019; Accepted: 16 May 2019; Published: 21 May 2019
Abstract: Despite being clinically underestimated, sexual dysfunction (SD) is one of the most frequent
and lasting adverse effects associated with antidepressants. Desvenlafaxine is an antidepressant (AD)
with noradrenergic and serotonergic action that can cause a lower SD than other serotonergic ADs
although there are still few studies on this subject. Objective: To check the frequency of SD in two
groups of depressive patients: one group was desvenlafaxine-naïve; the other was made up of patients
switched to desvenlafaxine from another AD due to iatrogenic sexual dysfunction. A naturalistic,
multicenter, and prospective study of patients receiving desvenlafaxine (50–100 mg/day) was carried
out on 72 patients who met the inclusion criteria (>18 years old and sexually active), who had received
desvenlafaxine for the first time (n = 27) or had switched to desvenlafaxine due to SD with another
AD (n = 45). Patients with previous SD, receiving either drugs or presenting a concomitant pathology
that interfered with their sexual life and/or patients who abused alcohol and/or drugs were excluded.
We used the validated Psychotropic-Related Sexual Dysfunction Questionnaire (PRSexDQ-SALSEX)
to measure AD-related sexual dysfunction and the Clinical Global Impression Scale for psychiatric
disease (CGI-S) and for sexual dysfunction (CGI-SD) at two points in time: baseline and three months
after the commencement of desvenlafaxine treatment. Results: In desvenlafaxine-naïve patients,
59.2% of the sample showed moderate/severe sexual dysfunction at baseline, which was reduced to
44% at follow-up. The PSexDQ-SALSEX questionnaire total score showed a significant improvement
in sexual desire and sexual arousal without changes in orgasmic function at follow-up (p < 0.01). In
the group switched to desvenlafaxine, the frequency of moderate/severe SD at baseline (93.3%) was
reduced to 75.6% at follow-up visit. Additionally, SD significantly improved in three out of four items
of the SALSEX: low desire, delayed orgasm, and anorgasmia at follow-up (p < 0.01), but there was
no significant improvement in arousal difficulties. The frequency of severe SD was reduced from
73% at baseline to 35% at follow-up. The CGI for psychiatric disease and for sexual dysfunction
improved significantly in both groups (p < 0.01). There was a poor tolerability with risk of treatment
noncompliance in 26.7% of patients with sexual dysfunction due to another AD, this significantly
reduced to 11.1% in those who switched to desvenlafaxine (p = 0.004). Conclusion: Sexual dysfunction
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improved significantly in depressed patients who initiated treatment with desvenlafaxine and in
those who switched from another AD to desvenlafaxine, despite this, desvenlafaxine treatment is
not completely devoid of sexual adverse effects. This switching strategy could be highly relevant
in clinical practice due to the significant improvement in moderate/severe and poorly tolerated SD,
while maintaining the AD efficacy.
Keywords: desvenlafaxine; sexual dysfunction; antidepressant; treatment; prsexdq-salsex
questionnaire; switching strategy
1. Introduction
Sexual dysfunction (SD) is one of the most frequent and lasting adverse effects caused by
serotonergic antidepressants (ADs). However, unfortunately, it is underestimated in the data elaborated
by pharmaceutical companies in post-registration studies, where frequencies of 2–16% are reflected [1,2],
much lower than those found in specific case series studies [3–5], systematic reviews [6,7], and
meta-analyses [8]. The reasons for this underestimation could be that the frequency of SD is obtained
from clinical trials designed to find efficacy; these are usually unreliable short-term studies because
they can include either sexually inactive patients or lack specific sexual dysfunction questionnaires,
counting only spontaneous communications of sexual adverse events.
The real prevalence of SD secondary to treatment with ADs calculated in clinical practice
is much higher, as has been demonstrated in studies including long series of patients [9,10].
Using specific questionnaires such as the Psychotropic-Related Sexual Dysfunction Questionnaire
(PRSexDQ-SALSEX) [11,12] or the Changes in Sexual Function Questionnaire (CSFQ) [13], a prevalence
of SD secondary to Selective Serotonin Reuptake Inhibitors (SSRI) of between 50–79% in sexually active
patients has been shown [14–17], increasing to more than 80% in healthy volunteers who received SSRI
for at least eight weeks [18,19].
In a recent study using the PRSexDQ-SALSEX to evaluate the frequency and tolerance of
sexual dysfunction in the majority of ADs approved for the treatment of depression, such as SSRI,
serotonin-noradrenaline reuptake inhibitors (SNRIs), clomipramine, agomelatine, bupropion, and
mirtazapine, 79% patients showed sexual dysfunction, as indicated by a total score ≥3 on the
PRSexDQ-SALSEX; 64% showed moderate-severe sexual dysfunction, with no differences between
men and women on these outcomes [5]. Sexual dysfunction is extremely common in patients
receiving ADs, especially serotonergic ones, with a significantly lower frequency of SD associated with
non-serotonergic ADs such as mirtazapine, agomelatine, and bupropion. The consequences of this
adverse side effect range from the deterioration of the quality of life to quitting treatment due to the
sexual dysfunction which occurs in 20–35% of patients [15,20], with the consequent risk of relapse and
other negative repercussions related to depression [21,22].
The most common symptoms of SD are a decrease in desire and a delay in achieving orgasm.
Erectile dysfunction is less common, although paroxetine, citalopram, and venlafaxine produce it in
about 30–40% of patients at usual therapeutic doses [1,5,13,20]. Anorgasmia or lack of ejaculation is
the worst side effect tolerated by patients [15]. Unfortunately, SDs are rarely examined routinely by
physicians and only 15–40% of patients report it spontaneously, despite the high frequency observed
in those treated with AD [1,5,13,15] and with antipsychotics [23,24]. Therefore, it is necessary to use
specific questionnaires to detect SDs and its influence on the quality of life of the patient and his/her
partner in the short, medium, and long term. This feature of sexual tolerability should be considered
carefully in the selection of an AD [25].
Other ADs, with non-serotonergic mechanisms of action (agomelatine, mirtazapine, bupropion)
have been shown to produce little deterioration in the sexuality of patients in controlled studies
compared to serotonergic ADs in medium- and long-term case series [26–29]. However, it might be
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possible that the clinical effect of non-serotonergic compounds was insufficient in some groups of
patients in need for a serotonergic effect to deal with symptoms such as obsessive-compulsive behavior
or in severely depressed patients.
Dual SNRIs, mixed inhibitors of the reuptake of serotonin and noradrenaline (duloxetine and
desvenlafaxine), may have a lower frequency of SD, although there are contradictory data regarding
this in several studies with varying designs [15,30]. The evidence for mirtazapine having an advantage
over selective serotonin reuptake inhibitors (SSRIs) is lacking and there are currently not sufficient
data as regards the effects of desvenlafaxine. Usually, sexual function data come from clinical trials on
efficacy which include moderately depressed patients and do not select the trial population according
to inclusion and exclusion criteria in terms of prior activity and sexual satisfaction.
Well-designed comparative studies of present ADs with a direct assessment of sexual side effects
as the primary outcome measure are scarce [31]. On the other hand, ADs can improve sexual function
in depressed patients. There is less frequency of SD in patients who respond better to treatment
compared to those who do not significantly improve in the medium and long term [15]. With respect
to this, the effect of duloxetine on the patient’s sexual life seems to be linked to the AD effect. SD is
more frequent in populations that show a lower response to ADs compared to those that respond
adequately [32]. On the other hand, vortioxetine, with a serotonergic, noradrenergic, and dopaminergic
multimodal mechanism of action, seems to be associated with lower SD according to the data derived
from clinical registration trials [33,34] and a specific study of switching to vortioxetine due to sexual
dysfunction [35]; however, additional data obtained with naturalistic designs in real clinical practice
are needed to corroborate this.
The SD managing approach includes dose reduction, the addition of an antidote, such as an
inhibitor of phosphodiesterase type 5 (IPD5) if there is erectile dysfunction, AD withdrawal for 24–48 h
before intercourse in the case of anorgasmia, and a change of treatment to another non-serotonergic
AD [5,36–38]. None of these methods are free from risk, which can include relapses or the appearance
of new adverse side effects concomitant to the change of treatment. Therefore, it is necessary to
adequately clarify the role that different ADs play in the appearance of SD and the deterioration of the
quality of life that they can produce in the patient. To start with, drugs that do not have deteriorating
effects on sexual life in sexually active patients should always be taken into account in patients with
depression. On the other hand, given that SD is more frequent with some ADs, it should always be
considered in the investigation of new molecules, seeking better tolerability profiles in the medium
and long term [39].
There are still few studies that specifically analyze the influence of desvenlafaxine on the sexual
function of patients. The risk of SD associated with desvenlafaxine treatment has been studied in a
post-hoc analysis of a clinical trial compared to placebo using the ASEX. After 12 weeks, orgasm delay
was observed at a higher rate than placebo in men, but not in women. Other sexual functions such as
desire and arousal were not affected [40]. In another randomized double-blind study, no differences were
found between desvenlafaxine (50–100 mg) and placebo [41]. The data suggest that there could be higher
SD with 100 mg/day, but these data were not conclusive since no statistically significant differences were
obtained. After an integrated analysis of short-term, randomized, double-blind, placebo-controlled
registration studies for major depressive disorder (50–400 mg/day) with desvenlafaxine vs. placebo for
eight weeks, very few adverse sexual effects were found with desvenlafaxine: erectile dysfunction in
men (7% vs. 1% with placebo) and anorgasmia in women (1% vs. 0%) [42]. This low frequency of SD
data does not seem to be in line with what was expected of a drug with a serotonergic mechanism of
action. This could be due to the fact that these studies were not specifically designed to find differences
in sexual function with samples properly selected using inclusion and exclusion criteria, or because
only spontaneous communications were taken into account over a short period of eight weeks.
Until now, there have been hardly any naturalistic studies specifically designed to evaluate the
SD associated with desvenlafaxine under the conditions of usual clinical practice. The methodology, to
obtain adequate results, should include patients with a previous active sexual life and lack of another
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pathology or concomitant medication that might affect sexual function, in order to determine the
causality that the drug (and not other associated factors) plays in the possible dysfunction of sexual life.
In a recent study with a naturalistic design in patients with depression or anxiety disorder treated
with fluoxetine, mirtazapine, escitalopram, sertraline, and desvenlafaxine, the sexual function of
209 patients was evaluated using the PRSexDQ-SALSEX questionnaire at baseline and at six weeks.
Twenty-one percent showed sexual dysfunction at the beginning of treatment and this increased to
41% in week 6. With regard to individual questionnaire items, by week 6, sexual desire improved, but
erectile and ejaculatory function in men and orgasmic function in women worsened. Fluoxetine and
sertraline were associated with impaired sexual function, whereas mirtazapine was associated with
favorable sexual function. At week 2, mirtazapine and desvenlafaxine were predictors of favorable
sexual outcome. Additionally, sexual dysfunction was more frequent in men than in women [43].
The main goal of this study is to evaluate the frequency of SD in patients treated with desvenlafaxine
under usual clinical practice conditions using two independent groups: the first one with new patients,
desvenlafaxine-naïve, defined as patients who never before received an AD treatment, and the second
group with patients who were changed to desvenlafaxine due to experiencing SD secondary to
another AD.
2. Experimental Section
A naturalistic, multicenter, prospective study was conducted in patients treated with
desvenlafaxine (at a dose as recommended by the data sheet and usual clinical practice of 50–100 mg/day)
or another AD. We included 72 patients who met the inclusion and exclusion criteria into two groups:
group A, desvenlafaxine-naïve, with 27 patients receiving desvenlafaxine for the first time, and group
B, with 45 patients switched to desvenlafaxine for presenting SD caused by another AD.
2.1. Study Population
Inclusion and exclusion criteria were used to guarantee the validity of the sample, avoiding
possible confounding factors. Patients were consecutively included if they fulfilled the following
inclusion criteria for group A (desvenlafaxine-naïve): over 18 years old, sexually active (defined
as at least one sexual activity in the last six months), who started treatment with desvenlafaxine
50–100 mg/day according to usual clinical practice. The following inclusion criteria were used for
group B (switched to desvenlafaxine): over 18 years old, receiving treatment with AD for at least eight
weeks prior, a history of self-reported normal sexual functioning before the prescription of the AD,
excluding a mildly impaired libido (libido impairment is part of the depressive symptoms). Exclusion
criteria: patient receiving more than one AD or requiring concomitant treatment that may influence
sexual activity (antipsychotics, antihypertensives, beta-blockers, sex hormones, opiates), alcohol and/or
drug abuse and serious medical illness that could cause sexual dysfunction. Patients were allowed to
receive treatment with benzodiazepines. In the baseline visit, information on patient demographics,
psychiatric history, and the treatments that the patient was receiving were recorded.
2.2. Measurement Scales
Sexual function was evaluated with the Psychotropic-Related Sexual Dysfunction Questionnaire
(PRSexDQ-SALSEX), which has shown good psychometric properties both in patients with
depression [9] and in patients with schizophrenia [10]. In patients with depression, the
PRSexDQ-SALSEX has shown adequate internal consistency, with a Cronbach’s alpha value of
0.93, and adequate construct validity [9]. As may be expected, the PRSexDQ-SALSEX showed a high
correlation with the Clinical Global Impression Scale for sexual dysfunction (r = 0.79) and a moderate
correlation with Hamilton Depression Rating Scale scores (r = 0.63). The PRSexDQ-SALSEX also
showed good discrimination between naïve and pretreated depressed or dysthymic patients, with
statistically significant differences between those groups of patients. In brief, the PRSexDQ-SALSEX
has seven questions, and is hetero-applied by the evaluator. The first two questions use a yes/no
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format to record whether patients have noticed any change in their sexual function since they initiated
treatment and whether the sexual dysfunction was spontaneously reported. The next four questions
(items 1 to 4) employ a four-point scale, from no problem to severe problem, to assess the presence and
severity of decreased libido, delayed ejaculation/orgasm, lack of ejaculation/orgasm, and difficulties
with having or maintaining erection/lubrication. The last question (item 5) evaluates the tolerability of
the changes in sexual functioning on a four point scale: 0, No sexual dysfunction; 1, Well, no problem
due to this reason; 2, Fair, the dysfunction bothers him or her, although he or she has not considered
discontinuing the treatment for this reason, or it interferes with the couple’s relationship; 3, Poor, the
dysfunction presents an important problem, and he or she has considered discontinuing treatment
because of it, or it seriously interferes with the couple’s relationship. These five latter items (i.e., items
1 to 5) account for the total score of the PRSexDQ-SALSEX, which ranges from 0 to 15. According
to this total score, patients may be categorized as having no sexual dysfunction (a score of 0 or the
item 1 (libido) scoring 1 and the item 5 (tolerability) scoring 1), or having mild (total score of 3–5)
dysfunction, provided that no item scores ≥2 (i.e., provided that the patient does not have moderate
sexual dysfunction in a specific dimension), moderate (total score of 6–10 or an item scoring 2, provided
that no item scores 3 (i.e., provided that the patient does not have severe sexual dysfunction in a
specific dimension)) or severe (total score of 11–15 or an item scoring 3) sexual dysfunction.
The severity of the psychiatric disorder was evaluated at baseline with the 7-point Clinical
Global Impression of Severity Scale (CGI) [44], as well as the CGI of Sexual Dysfunction (CGI-SD),
which is a clinician-rated instrument identical to the CGI used for the assessment of psychopathology.
Additionally, a 7-point CGI of Change scale was used for psychiatric severity (CGI-CS) [44] and for
sexual dysfunction (CGI-CSD) in the follow-up visit, three months after the baseline visit. The research
team consisted of eight researchers previously trained in the application of SALSEX belonging to
the Department of psychiatry of the University Hospital of Salamanca (seven psychiatrists) and the
Primary Care Service of Salamanca (one general practitioner) between June 2015 and June 2016.
2.3. Ethical Aspects
The protocol was favorably evaluated by the Research Ethics Committee of Salamanca (CEIC)
in November 2014. It was classified by the Spanish Agency for Medicines and Healthcare Products
(AEMPS) as a post-authorization study with prospective follow-up (EPA-SP study) and was authorized
later by the General Directorate of Public Health of Castilla y León, dated February 2015, with the code
AMG-DES-2014-01. All patients signed an informed consent following the international norms and
procedures of medical research in humans using the declaration of Helsinki of the World Medical
Association of 1964.
2.4. Sample Size
There are no specific published data so far to estimate the sample size based on the effect size.
There is only a post-hoc analysis of a pivotal clinical trial in which desvenlafaxine did not show any
significant difference vs. placebo in the mean change of ASEX scale at endpoint (12 weeks of treatment),
with a mean reduction in ASEX of −1.13 (SD = 0.47) in the males group and −1.93 (SD = 0.37) in the
females group treated with desvenlafaxine [40]. This is not a study primarily designed to evaluate
sexual functioning and its design presents relevant differences to the design of our study, so the values
needed to calculate sample size are not available. We have therefore considered this as a pilot study to
evaluate the changes in sexual functioning assessed with the PRSexDQ-SALSEX questionnaire, with
mean change global score as the main outcome, estimating a sample size of 50 subjects (25 per group)
to detect differences in sexual functioning after three months of treatment with desvenlafaxine. A
study withdrawal rate of 15% was assumed.
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2.5. Statistical Analysis
Valid data were analyzed from the database which was created ad-hoc. The main variable “mean
change in PRSexDQ-SALSEX global score from baseline to follow-up visit” and secondary variables
“mean change in PRSexDQ-SALSEX global score at follow-up visit”, “mean change in each item of
PRSexDQ-SALSEX score at follow-up visit”, and “mean change in all CGIs” were analyzed. The
distribution of the quantitative variables was examined using the Kolmogorov–Smirnov test. Later,
they were described using mean and standard deviation (mean ± standard deviation (sd)) in the
case of data that followed the normal distribution, otherwise, median and interquartile range (the
first quartile subtracted from the third quartile) (median ± IQR) were used. The differences between
independent groups of quantitative variables were evaluated using the Student’s t-test for data of
normal distribution, or otherwise using the non-parametric Mann–Whitney U test. The differences in
the response to quantitative variables between paired groups were examined using the Student’s t-test
for paired data (for normally distributed variables) or the Wilcoxon test (for non-parametric data).
The descriptive analysis of categorical qualitative variables was carried out through frequencies and
percentages. Chi-square test and Fisher’s exact test were used to analyze the association of qualitative
variables. The statistical package SPSS, version 22.0, (IBM Corporation, Armonk, NY, USA) was
used for the statistical analysis, with strict quality control procedures. The results were considered
significant if p < 0.05.
3. Results
3.1. Study Population
Initially, 109 patients were included, of whom 37 did not attend the follow-up visit (nine in group
A and 28 in group B, 10 men and 27 women), so they were lost for the study. Finally, 72 patients were
included (52 women and 20 men) with a mean age of 43.4 ± 11.8 diagnosed with affective pathology
(major depression, single episode, 47.2%, recurrent major depression, 12.5%, anxious depressive
disorder, 8.3%, dysthymia, 13.9%, adaptive disorder, 8.3% and others, 9.8%). They were diagnosed
following the International Classification of Diseases 10th Revision (ICD-10) criteria [45]. Of the total of
patients who completed the study, 37.5% were from group A (desvenlafaxine-naïve) and the remaining
62.5% were from group B (changed to desvenlafaxine from a different AD). Group A consisted of 27
patients (22 women and 5 men, average age 42.7 ± 10.9) and group B of 45 patients (30 women and 15
men, average age 43.87 ± 12.34). The patients switched to desvenlafaxine coming from other previous
treatments consisted of 16 patients with escitalopram (36%), 10 duloxetine (22%); 6 venlafaxine (13%);
5 sertraline (11%); 4 paroxetine (9%); 4 Fluoxetine (9%). In 52.3% of the cases, a gradual change was
made, and in the rest of the cases, a sudden change was made to clinical criteria without using a
washout period.
3.2. SALSEX Questionnaire
The spontaneous communication of SD (item B of SALSEX) occurred in 27.3% of patients in group
A and in 35% of group B. The overall SALSEX results for group A and B are shown in Table 1.
In group A, an overall global SALSEX score was obtained at the baseline visit of 5.4 ± 4.3 (with 0 =
no SD and 15 =maximum dysfunction), indicating a degree of mild/moderate initial SD in the sample
of desvenlafaxine-naïve patients. The overall score on the SALSEX scale between the baseline (5.4 ± 4.3)
and follow-up visit (3.9 ± 3.6) was reduced in a highly significant way (p = 0.007) (Figure 1), showing a
clinical improvement in the sexual function of patients who started treatment with desvenlafaxine at
follow-up. In the desvenlafaxine-naïve group, the intensity of the SD was reduced by 28%.
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Table 1. Descriptive statistics of SALSEX questionnaire of groups A and B. Baseline vs. follow-up visit.







SALSEX total 5.4 (4.3) 3.9 (3.6) 0.007 ** 9.6 (3.6) 6.8 (3.9) 0.000 **
Libido Decreased 1 (2) 1 (1) 0.039 * 3 (2) 2 (2) 0.000 **
Orgasm delayed 0 (2) 0 (1) 0.429 2 (1) 2 (1) 0.001 **
Anorgasmia 1 (2) 1 (1) 0.206 2 (1.5) 1 (1.5) 0.000 **
Arousal problems 1 (2) 0 (2) 0.004 ** 2 (1) 1 (2) 0.069
Tolerability of SD 1 (2) 1 (2) 0.003 ** 2 (1) 1 (1) 0.002 **
** = highly significant p-value (<0.01); * = significant p-value (<0.05).
Figure 1. Differences in overall sexual function from baseline at three months in patients treated
with desvenlafaxine.
Patients in group B (changed to desvenlafaxine) obtained a global average score on the SALSEX
scale at the baseline visit of 9.6 ± 3.6 and 6.8 ± 3.9 in the follow-up visit, resulting in this highly
significant difference (p = 0.000) (Figure 1). The improvement in overall sexual function measured with
total SALSEX was greater in group B (all patients suffered from SD secondary to previous treatment)
as their initial SD was reduced by 36% in the second visit.
Taking into account the total score of the SALSEX, the severity of the SD was distributed into
several groups: mild (Salsex = 1–5 points); moderate (Salsex = 6–10 or any item = 2); and intense
(Salsex = 11–15 or any item = 3). Desvenlafaxine-naïve patients showed a significant decrease in severe
SD at follow-up (11 patients in baseline vs. 5 patients in the follow-up visit) (p < 0.05) (Figure 2). In
group B of patients changed to desvenlafaxine, there was a decrease in the group of intense SD from
the baseline visit (32 patients in the baseline vs. 17 in the follow-up visit) (p < 0.05).
The overall frequency of baseline SD (defined as SALSEX score ≥3) was 74% of 27 patients in group
A desvenlafaxine-naïve (14.8% mild, 18.5% moderate, and 40.7% intense) and 70.3% at follow-up (mild
25.9%, moderate 25.9%, and intense 18.5%). In desvenlafaxine-naïve patients, 59.2% of the sample
showed clinically relevant (moderate/severe) sexual dysfunction at baseline that was reduced to 44% at
follow-up. A similar global frequency was observed in SD from the beginning but with a significant
decrease in intensity (p = 0.045), reducing the percentage of cases with severe SD. In group B, the overall
frequency of SD was 100% at baseline (6.7% mild, 22.2% moderate, and 71.1% intense), decreasing
to 91.2% at follow-up (15.6% mild, 37.8% moderate, and 37.8% intense). In this group, the frequency
of clinically relevant (moderate/severe) SD at baseline (93.3%) was reduced to 75.6% at follow-up. A
significant reduction in the intensity of SD after switching to desvenlafaxine was observed (p = 0.011).
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Figure 2. Differences in sexual level of severity from baseline at three months in patients treated
with desvenlafaxine.
3.2.1. Gender Differences
Analyzing the differences between men and women, significant improvements were found in the
overall SALSEX scale in both men and women for the two treatment groups (Table 2 and Figure 3).
The overall improvement was more intense in men of both groups (a 38% improvement in group A in
the follow-up visit and 41.3% in group B), although it is necessary to take into account that the sample
of men is much lower in the study and this can influence the results (52 females vs. 20 males).








Male (n = 5) 8 (10.5) 4 (6) 0.000 **
Female (n = 22) 6 (8.25) 3 (7) 0.043 *
Group B
Male (n = 15) 10 (8) 5 (9) 0.000 **
Female (n = 30) 11 (3.25) 8 (5.25) 0.001 **
** = highly significant p-value (<0.01); * = significant p-value (<0.05).
Figure 3. Gender differences in overall sexual function from baseline at three months in patients treated
with desvenlafaxine.
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3.2.2. Differences by Dose
The patients in the study mostly received doses of 50 mg/day and 100 mg/day of desvenlafaxine.
The mean dose of group A was 53.7 ± 13.3 mg/day at the baseline visit and 63.7 ± 24.7 at follow-up.
Patients in group B received doses of 62.5 ± 22.1 mg/day of desvenlafaxine at the baseline visit and
63.44 ± 26.39 mg/day at follow-up. In group A, 92.6% (n = 25) of them received a dose of 50 mg/day
and the remaining 7.4% (n = 2), a dose of 100 mg/day at the baseline visit; while in the follow-up visit
66.7% (n = 18) and 29.6% (n = 8) of them received doses of 50 and 100 mg, respectively. In the case of
patients in group B, at the baseline visit, 75% of patients (n = 18) received a dose of 50 mg/day and the
remaining 25% (n = 6), a dose of 100 mg/day. At follow-up, 60% of patients (n = 27) received a dose of
50 mg/day, while only 28.9% (n = 13) received a dose of 100 mg/day. The possible association between
desvenlafaxine dose and PRSexDQ-SALSEX global score was examined. In this sense, there were no
statistically significant differences in the overall PRSexDQ-SALSEX scale score in the baseline visit or
in the follow-up visit between those who received a dose of 50 mg/day and those who received a dose
of 100 mg/day in any of the two groups of patients. At the descriptive level, overall SALSEX scores
were lower in those patients who received a higher dose of desvenlafaxine, although the percentage
of cases that received a dose of 100 mg/day of desvenlafaxine was very small and conclusive results
cannot be extracted regarding this.
3.2.3. Analysis of the PRSexDQ-SALSEX Dimensions
The analysis of the individual items in the desvenlafaxine-naïve group showed that no worsening
was observed in any of the items in the follow-up visit compared with the baseline visit. On the
contrary, there was a significant improvement in desire (p = 0.039) and in sexual arousal (p = 0.004)
without significant change in orgasm, so we can say that sexual affectation by desvenlafaxine in the
studied sample is scarce (Figure 4).
Figure 4. Group A. Desvenlafaxine-naïve patients. Changes in sexual functioning at follow-up.
In patients that switched to desvenlafaxine, significant improvements in sexual desire, delayed
orgasm, and anorgasmia appear in the follow-up visit (p = 0.001). Regarding the item of arousal
difficulty (erection in males and vaginal lubrication in women), no significant differences were found
(p = 0.69) (Figure 5).
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Figure 5. Group B. Patients switched to desvenlafaxine. Changes in sexual functioning at follow-up.
3.2.4. Tolerability of Sexual Dysfunction
Item 5 of the SALSEX measures the tolerability and patient acceptance of SD by means of an
intensity scale in which “1 = Tolerates the SD well”, “2 = Tolerates the SD with some difficulties
although has not thought of dropping out of the treatment for this reason” and “3 = Tolerates the
SD poorly, with it affecting his/her relationship with partner and/or has considered dropping out of
the treatment for this reason”. Regarding the patients who tolerated the SD poorly and who were at
risk of noncompliance (item 5 = 3) in the two groups, an improvement in the tolerability of the SD
at the baseline visit was observed compared with the follow-up visit (p = 0.002) (18.5% of baseline
poor tolerability vs. 0% in the follow-up visit in desvenlafaxine-naïve group), significantly decreasing
the risk of dropouts for this reason. Similarly, patients switched to desvenlafaxine showed poor
tolerability with a risk of dropout at baseline in 26.7% of cases, which significantly reduced to 11.1% at
the follow-up visit (p = 0.004).
3.3. Clinical Global Impression Scales
In the scale of severity of psychiatric pathology (CGI), significant improvements were observed
in both groups (group A: p = 0.000, group B: p = 0.003). Therefore, it can be considered that patients
treated with desvenlafaxine showed a significant improvement in clinical situation, both when used
as a starting treatment or when switching from another AD. The CGI scale of SD intensity (CGI-SD),
coinciding with the results of PRSexDQ-SALSEX, showed no changes in the desvenlafaxine-naïve
group but a significant improvement in the intensity of SD in patients switched to desvenlafaxine due
to SD (p = 0.000); therefore, it can be deduced that the improvement in SD is also accompanied by
improvements in the clinical situation (Table 3).
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Table 3. Clinical Global Impression of Severity Scale (CGI) scores of groups A and B, comparing
baseline and follow-up visit values.







CGI Depression 4 (1.3) 1 (1) 0.000 ** 3 (1) 2 (2) 0.003 **
CGI Sexual
Dysfunction 3 (3) 3 (2) 0.539 5(1) 3 (1.8) 0.000 **
** = highly significant p-value (<0.01).
4. Discussion
The results of this naturalistic and prospective study show that sexual functioning improved
in both patient groups (desvelafaxine-naïve patients and those switched to desvenlafaxine from
another AD) measured by the overall score of the SALSEX scale. Contrary to what usually occurs
in patients treated with serotonergic drugs who present a high frequency of SD, treatment with
desvenlafaxine, which has a dual serotonergic and noradrenergic mechanism of action, was associated
with a moderate/severe deterioration (clinically significant) in sexual functioning in 44.4% of sexually
active patients who started treatment with desvenlafaxine. It is interesting that in contrast to the figures
obtained in a recent study carried out with the same methodology using the PRSexDQ-SALSEX, the
frequency of moderate/severe SD was higher (66% with SSRI and 75% with SNRIs (venlafaxine, and
duloxetine)) [15]. In this study, desvenlafaxine presents a much more favorable profile associated with
SD in desvenlafaxine-naïve patients (44.4%) despite having a mechanism of mixed serotonergic and
noradrenergic action and so being considered in the group of dual ADs.
This lower deterioration of sexual function compared with other studies on serotonergic ADs that
impair sexual function (as is widely described in the literature [13,19,21]) can be very relevant when
choosing a drug with dual effects but with a lower ability to influence sexual functioning. In contrast to
venlafaxine, which has shown a high frequency of sexual dysfunction in comparative studies including
series of cases measured with the same PRSexDQ-SALSEX questionnaire [13,15], desvenlafaxine,
the primary metabolite of venlafaxine, has a much lower frequency of sexual dysfunction, which
could be due to the fact that desvenlafaxine is also a relatively low potency 5-HT and NE reuptake
inhibitor. The lower pharmacodynamic potency in the reuptake of serotonin compared to venlafaxine
might be linked to the lower effect in the dopaminergic brake, mediated by serotonin, associated
with sexual dysfunction. Recently, it has been shown that paroxetine, a potent inhibitor of serotonin
reuptake, influences the mechanism of AD-related sexual dysfunction through the inhibition of tyrosine
hydroxylase in dopaminergic neurons related to sexual areas such as substantia nigra, pars compacta,
and the ventral tegmental area but not with agomelatine in male rats [46].
In the group of patients switched to desvenlafaxine, with previous SD secondary to treatment with
another AD (SSRI or SNRI), an improvement in the frequency of moderate/severe SD was observed,
going from 93.3% to 75.6%. In this group in which most had severe dysfunction (and taking into
account that desvenlafaxine was not devoid of sexual dysfunction in the follow-up visit), there was a
significant decrease in baseline values, indicating a clinical improvement in these patients. In addition,
a significant decrease was seen in those who initially showed deterioration in desire and orgasmic
dysfunction without there being an improvement in sexual arousal. On the other hand, analyzing a
very important aspect from the clinical point of view, the poor tolerability for patients with previous
sexual dysfunction also improved significantly, decreasing from 26% to 11% in those who tolerate the
SD badly (where it significantly affects the quality of life and/or the couple’s relationship and/or the
patient has thought about dropping out of the treatment).
Some studies that have focused on the relationship between compliance and SD indicate that
between 20–35% of patients receiving AD present a risk of dropout [13,15,19,24]. An observational study
showed that the most frequent adverse effect related to the noncompliance of treatment three months
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after the start of an AD was sexual dysfunction (47%), followed by weight changes, gastrointestinal
discomfort, and insomnia [47]. The improvement in the risk of noncompliance with the switch to
desvenlafaxine could undoubtedly have very relevant implications to the medium- and long-term
results, avoiding relapses and reducing the deterioration in the quality of life.
Regarding the possible differences between men and women, in our study, significant
improvements were found in the overall SALSEX scale in both men and women for the two treatment
groups (p < 0.05), with more evident improvements in males switched to desvenlafaxine. These data
coincide with previous examples with large sample sizes where a higher frequency of SD was observed
in females taking AD [13,15]. There are data on the generalization of SD in the general population
through extensive surveys in different countries, noting that among women between 40 and 80 years
old, there are frequent problems related to desire, anorgasmia, and sexual arousal, while erectile
dysfunction is the most common sexual problem among males, obviously increasing with age [48,49].
Gender differences play a fundamental role in sexual activity, with males generally showing more
interest in sexual activity and staying active for longer. At least 38% of males remain interested in
sexuality when above 75 years old vs. 16% in females [50]. The elderly male population is of great
interest, because a group of them receiving ADs which impair sexual functioning are more likely to
show a worse acceptance than younger males after the appearance of SD [1,13,15].
The spontaneous communication of SD (item B of SALSEX) was found in 27.3% of patients in
group A and in 35% of group B that had previously received AD. Recent findings show the high
frequency of SD after AD use (78% for men and 80% for women) [15], which surpass the figures found
in the general population, contrasting with the scarcity of spontaneous communications. Nevertheless,
spontaneous communication has increased over the years using the SALSEX questionnaire, from
14% in 1997 [1] to 20% in 2001 [13], reaching up to 44% in 2019 [15]. This increase in spontaneous
communication is possibly due to the greater knowledge and sensitivity regarding this problem in
the general population, with psychiatrists, AD prescribers, and general practitioners. One factor that
undoubtedly contributes to this limited communication is related to the low frequency with which
prescribers systematically interview patients about the presence of SD, this seeming to be relevant to
both doctors and nurses [51,52].
In relation to possible differences between the frequency of SD with 50 and 100 mg/day, the
Mann–Whitney U test revealed no statistically significant differences (p > 0.05) in the overall score of
the SALSEX scale at follow-up in any of the groups; this is possibly due to the small number of patients
taking 100 mg/day. The data from this study partially confirm those obtained in pre-registration
clinical trials conducted with desvenlafaxine, which indicated a better profile of sexual tolerability
compared with other serotonergic ADs [42]; however, in our sample, desvenlafaxine is not exempt
from sexual dysfunction at the average doses used of 63.44 mg/day (±26.39). In one of the trials on
placebo-controlled desvenlafaxine using the ASEX at 12 weeks, orgasm retardation was superior to
placebo in males, but not in females, without affecting desire or sexual arousal [38]. There seems to
be a difference in the sexual effects when taking into account the dose used being 50 mg similar to
placebo, although the studies were not carried out considering inclusion and exclusion criteria on
sexual activity and the factors that may influence it. Thus, in another clinical trial designed to measure
functionality, male and female outpatients with major depression were randomly assigned 12 weeks
of double-blind treatment with desvenlafaxine at 50 mg/day or placebo, sexual functioning scores,
measured with the ASEX, were comparable between groups [53]. In another randomized study, no
differences were found in SD with desvenlafaxine at 50 mg/day, 100 mg/day, and placebo but there
were suggestions that there could be higher SD in the 100 mg group although statistical significance
was not achieved [39]. The existing information on the frequency of desvenlafaxine-associated SD
comes from a post-hoc analysis of three double-blind and short-term clinical trials (two months) using
the self-administered ASEX Scale in outpatients with depression using doses of 50–100 mg. The results
indicate that SD rates were 54%, 47%, and 49% for 50 mg/day, 100 mg/day, and placebo, respectively,
with adjusted odds ratios (95% confidence interval) vs. placebo of 1205 (0.928, 1.564) and 1129 (0.795,
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1.604), respectively [54]. These results partially coincide with the SD figures found in our study with
44% of moderate/severe SD at three months in desvenlafaxine-naïve patients; however, the frequency
was much higher (76%) in patients switched to desvenlafaxine due to previous AD-related sexual
dysfunction after following the course for three months.
To our knowledge, this is the first study carried out in patients switched to desvenlafaxine due
to SD secondary to the use of another AD (mainly SSRIs and SRNIs) so it is not possible to compare
the frequency found here with previous studies. Given the characteristics of this group containing
45 patients with previous sexual dysfunction (most of them poorly tolerated) and who met inclusion
and exclusion criteria to avoid the most common confounders (sexual dysfunction prior to taking
the AD, previous active and satisfactory sexual life, and the absence of concomitant treatments and
medical pathologies that could affect sexual function), it is possible that there were other confounding
factors that contributed to the presence of sexual dysfunction, since in 75.6% of patients, SD remained
at three month follow-up visit. However, the improvement in the frequency and intensity of SD was
significant after the change to desvenlafaxine, followed by an improvement of three of four SALSEX
items in the follow-up visit (p < 0.01), such as low desire, delayed orgasm, and anorgasmia, but it was
not significant in arousal difficulties. Additionally, the SD intensity decreased significantly in each of
the items and the frequency of severe SD was reduced from 73% at baseline to 35% at follow-up.
The Clinical Global Impression (CGI) scores for psychiatric disease (CGI-S) and for sexual
dysfunction (CGI-SD) improved significantly in both groups (p < 0.01) at follow-up, indicating
an improvement both in the previous psychiatric pathology (mainly affective disorder) and in the
subjective impression of the patient on the previous SD. The patient’s CGI scales are very relevant in
naturalistic studies because they indicate the subjective perception of the patient independently of
the absolute value of a scale designed to measure an adverse effect. These improvements in the CGI
scales coincide with the improvement in the tolerability of SD in both groups, decreasing the risk of
treatment dropouts and ameliorating the quality of life.
One of the factors that may influence the sexual improvement observed in the patients switched
to desvenlafaxine could well be a subjective effect underlying the patient’s decision to participate in a
study to improve sexual function and compliance with their expectations of improvement, perhaps
increasing sexual frequency. However, other studies with the same methodology using the SALSEX
scale have shown that the change to another serotonergic AD (paroxetine) was not followed by a
significant decrease in the frequency of SD (100% at baseline versus 89% at six months), but a clear
improvement was found after switching to another non-serotonergic AD (amineptine) from 100% at
baseline to 55% at six months. This finding suggests that the effect of the treatment itself is more
powerful than the subjective effect on the patient [55]. Another dual AD with a similar mechanism of
action to desvenlafaxine such as milnacipran [56] has also been shown in a prospective randomized
study to improve the initial SD in parallel with the AD effect in patients from some different cultural
backgrounds, such as Brazil and Europe [57]. Duloxetine, a dual-action AD, has shown lower SD
scores than SSRI (23% vs. 28%), although not significant, associated with greater clinical improvement
in the CGI severity after six months [30,32].
There are few studies of patients who switch to non-serotonergic drugs. One of them with a
similar naturalistic and uncontrolled methodology, designed to change from fluoxetine to bupropion
due to sexual dysfunction, demonstrated an important improvement in sexual function maintaining
the AD response after eight weeks of follow-up [58].
Finally, the clinical improvement in this study of the change to desvenlafaxine group is of great
interest, since no dropouts or relapses were observed due to lack of AD efficacy. In a similar study of
switching to amineptine vs. paroxetine, 7.5% of the amineptine group had depressive relapses during
the following six months of follow-up compared with none in the paroxetine group [52]. This feature is
very relevant for clinical practice because the recommendations for managing AD-related SD include
a change of AD to another one with a different mechanism of action as a first option. However, the
clinical efficacy and risk of noncompliance or relapse related to this have not been discussed in the
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literature [15]. Although possibly useful in some patients receiving serotonergic AD, a reduction in the
dose is not supported by convincing results and is associated with a risk of relapse.
Our study has several limitations. We did not record information on potentially confounding
factors that are considered to be risk factors for the occurrence of sexual dysfunction, such as educational
background, marital status, or employment status. On the other hand, patients were informed of
the objectives of the study including the evaluation of sexual functioning before participating in the
study. It is, therefore, possible that patients who were more motivated to participate in the study,
showed better results after switching to desvenlafaxine. Additionally, since it is a naturalistic design
in real-life clinical practice, there was no control group of patients who continued with the same
treatment as previously, so a comparison of both groups is not possible. Despite the fact that our study
was conducted under clinical practice conditions, the exclusion of some patients limited the external
validity of our results. Finally, some aspects of sexual functioning, such as subjective satisfaction and
sexual pain, were not evaluated, since they are not included in the PRSexDQ-SALSEX Questionnaire,
but could be taken into consideration in further studies [59]. Being a naturalistic study, patients could
take benzodiazepines according to usual clinical practice and these could have some effect on sexual
dysfunction [60,61]; however, the doses used were low and only lasted a short time (3–6 weeks).
5. Conclusions
Sexual dysfunction improved significantly in depressed patients who initiated treatment with
desvenlafaxine and in those that switched from another AD to desvenlafaxine; however, it was not
completely devoid of sexual adverse effects. This switching strategy could be highly relevant in
clinical practice due to the significant improvement of moderate/severe and poorly tolerated sexual
dysfunction accompanied by the maintenance of AD efficacy. The change to desvenlafaxine can
be a useful alternative in AD switching strategies to help fight iatrogenic sexual dysfunction while
maintaining the efficacy of the previous drug and without the risk of dropout or relapse associated
with switching to other non-serotonergic compounds. Additional ADs that do not adversely impact
sexual function are needed as well as further research into how to manage this side effect in men and
women. Finally, as a result of the scarcity of studies conducted in real clinical practice on the usefulness
of different switching methods to combat iatrogenic SD, additional research is needed to generate new
and strong evidence on the management of this important adverse event in daily clinical practice,
which influences compliance, affects medium- and long-term outcomes, and deteriorates the quality of
life of the patients.
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Abstract: The non-consensual sharing of an intimate image is a serious breach of a person’s right
to privacy and can lead to severe psychosocial consequences. However, little research has been
conducted on the reasons for consuming intimate pictures that have been shared non-consensually.
This study aims to investigate how the supposed consensual or non-consensual distribution of sexting
images affects the perception and evaluation of these images. Participants were randomly assigned
to one of two groups. The same intimate images were shown to all participants. However, one group
assumed that the photos were shared voluntarily, whereas the other group were told that the photos
were distributed non-consensually. While the participants completed several tasks such as rating the
sexual attractiveness of the depicted person, their eye-movements were being tracked. The results
from this study show that viewing behavior and the evaluation of sexting images are influenced by the
supposed way of distribution. In line with objectification theory men who assumed that the pictures
were distributed non-consensually spent more time looking at the body of the depicted person.
This so-called ‘objectifying gaze’ was also more pronounced in participants with higher tendencies
to accept myths about sexual aggression or general tendencies to objectify others. In conclusion,
these results suggest that prevention campaigns promoting ‘sexting abstinence’ and thus attributing
responsibility for non-consensual distribution of such images to the depicted persons are insufficient.
Rather, it is necessary to emphasize the illegitimacy of the non-consensual distribution of sexting
images, especially among male consumers of the material.
Keywords: eye tracking; non-consensual image sharing; intimate images; objectification; objectifying
gaze; rape myth acceptance; sexting
1. Introduction
Sexting, the sending of intimate or explicit personal pictures, videos, or texts [1], has become
common practice within different age groups [2–5]. Definitions vary, and the confusion of consensual
and non-consensual sexting proves to be a central conceptual problem. [6,7]. While consensual sexting
refers to the purposeful, active, and often pleasurable sending of one’s own images, the non-consensual
sharing of sexting images happens against the will or without the knowledge of the person depicted [8].
This non-consensual sharing is one of the most frequently discussed risks in the context of sexting [9–18].
If sexting images are forwarded against the will of the person depicted (e.g., in their circle of friends)
or published on the internet, this poses a serious risk to mental health. Situations in which victims are
J. Clin. Med. 2019, 8, 706; doi:10.3390/jcm8050706 www.mdpi.com/journal/jcm47
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exposed to public humiliation and online bullying can lead to grave psychosocial consequences, in
some cases even suicide [3,7].
Not only in the public debate but also in ‘sexting abstinence’ campaigns [19], sexting, in general,
is deemed dangerous [20]. Not differentiating between consensual and non-consensual sexting
can lead to victim blaming if the depicted producers of the images are held responsible for the
unintended dissemination [7]. This mechanism has been criticized in the theoretical context of ‘rape
culture’ [21–23] and linked to the broader concepts of ‘sexual objectification’ [24–27] and ‘rape myth
acceptance’ [26,28,29]. Objectification theory postulates that in western societies women are sexually
objectified, treated as objects and are only considered worthy to the extent that their bodies give
pleasure to others [29] (for reviews [28,30]). Sexual objectification can be seen as a continuum ranging
from acts of violence to subtler acts such as objectifying gazes [30,31]. These gazes, conceptualized
as visually inspecting (sexual) body parts, have been empirically demonstrated using eye-tracking
technology [32]. Additionally, people who sexually objectify others have been shown to be more likely
to accept rape myths [24,25], which serve to normalize sexual violence, e.g., through victim blaming
(for reviews [27,33]). These subtle myths have been conceptualized as cognitive schemes [34] and
demonstrated to influence eye movements [35,36].
Although research has evolved around non-consensual sexting and its correlates [7,9,20], little
effort has been conducted to investigate reasons for consuming such images. The question arises why
people consume non-consensual sexting material when mere comparisons with consensual material do
not reveal apparent differences in image content. Is there a specific attraction in the non-consensuality
itself, at least for some of the consumers? Against this background, we experimentally investigate
the question of how the supposed way of distribution (consensual vs. non-consensual) influences the
perception of sexting images. Thus, the study promises important findings for future prevention efforts.
In accordance with the objectification theory we expect differences in evaluation and perception
of sexting images depending on their supposedly consensual or non-consensual forwarding. In line
with previous research, we argue that increased objectification is associated with higher attractiveness
ratings of the objectified person [37] and a more pronounced objectifying gaze [32]. We further
hypothesize that supposedly non-consensually forwarded images are considered as more intimate and
their further distribution as more unpleasant. Overall tendencies for other objectification and higher
rape-myth acceptance are also expected to increase objectification.
A large part of the scientific literature on sexting focuses on the behavior of adolescents. This
may reflect widespread societal fears, but, in fact, sexting experience is significantly higher among
adults than among adolescents. In a current systematic review [3] the prevalence estimate of studies of
adolescents sending messages containing sexually suggestive texts or photos was found to be 10.2%
(95% CI (1.77–18.63)), while the estimated mean prevalence of studies of adults was 53.31% (95% CI
(49.57–57.07)). Against this background, and also because the present experimental study does not
focus on a representative image of the user population, we have decided to examine a sample of adults.
We assume that the mechanisms shown are comparable in adolescents, but this must be demonstrated
by future research.
2. Materials and Methods
2.1. Participants
A total of 76 participants (57% female, Mage = 31.99, SDage = 10.28) were recruited via university
newsletters. They were informed about the tasks and the stimulus content but were kept naïve to
the full purpose of the experiment. Participants provided written consent to study participation.
No compensation was given. The ethics committee of the state chamber of psychotherapists of
Hamburg (Psychotherapeutenkammer Hamburg) approved the study protocol of the present study
(03/2015-PTK-HH).
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2.2. Stimuli and Apparatus
Volunteers personally known to the authors but unknown to the study participants provided 14
semi-nude sexting images [38]. One additional image per gender was obtained from freely available
internet sources for public presentation purposes, resulting in a set of 16 pictures (50% female).
Stimulus presentation and data collection were conducted on a 22-inch widescreen monitor
(1680 × 1050 pixels) using SensoMotoric Instruments (SMI GmbH, Teltow, Germany) software
ExperimentCenterTM. A remote eye tracker (SMI, RED system) recorded eye movements at 120 Hz
from 50 cm viewing distance using a head-chin rest.
2.3. Questionnaires
Individuals’ objectification of others was assessed using a German translation of the modified
version of the Self-Objectification Questionnaire [39] for other objectification (Other Objectification
Scale, OOS [40]). The scale consists of 10 body attributes, five competence-based (i.e., strength) and five
are appearance-based (i.e., physical attractiveness). Participants were asked to rank how important they
perceive each attribute (10 = “most important”; 1 = “least important”) separately for men and women.
Possible scores range from −25 to 25 with higher scores indicating higher levels of objectification.
Participants further completed an 11-item short version of the German Acceptance of Modern
Myths About Sexual Aggression Scale (AMMSA) [41] which had been used successfully in other eye
tracking studies already [35,36]. Each item was rated on a 7-point scale (1 = “completely disagree”;
7 = “completely agree”).
2.4. Procedure
Participants read an introductory text stating that the study aimed to understand more about
the evaluation of sexting images. Depending on the condition, picture distribution was either
described as voluntary (consensual condition) or as unwanted, against the will of the depicted person
(non-consensual condition). The manipulation was strengthened by asking participants to state three
feelings the image distribution could have evoked in the depicted persons. Following, participants saw
the images three times with different tasks. Pictures were randomized within blocks, starting with the
male images. Pictures were presented individually on full screen for 5 seconds, preceded by a black
fixation cross on the left side shown for 1 second. The first task was to freely view the pictures. Second,
participants rated the sexual attractiveness of the depicted person. For the third task, participants were
asked to evaluate how intimate they considered the image content and how unpleasant further picture
distribution would be for the depicted person (ranging from 1 = “not at all . . . ”; 7 = “very . . . ”). After
completion of the sociodemographic information, and the questionnaires, participants were thanked
and debriefed.
2.5. Data Reduction and Data Analysis
To account for repeated measures made on the same subject, a mixed model approach was
employed. We examined the fixed effects of the independent variables condition (consensual vs.
non-consensual distribution), gender (women vs. men), image gender (female vs. male images),
of their three and two-way interactions and of the OOS score and AMMSA score on the ratings of
(1) sexual attractiveness, (2) intimacy of image content, and (3) perceived unpleasantness of picture
distribution. Random intercepts were assumed for participants. We report the marginal means and
their 95%-confidence intervals. We report the results of the final models after a backward elimination
of the non-significant effects according to Kleinbaum et al. [42]. All statistical tests were two-tailed
(α = 0.05).
The eye tracking data were analyzed using the same model as described above with the objectifying
gaze as the dependent variable. The objectifying gaze was operationalized as the relative time spent
looking at the body compared to the time spent looking at faces [32]. We created two areas of interest
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(AOI) on each image, one containing the head and the other containing all the rest of the body.
The total dwell time for both AOIs, i.e., the overall time viewing the person depicted, was set to 100%.
For the following analysis, we focus on the percentage of that time directed at the body. Accordingly,
an increase in viewing time on the body always results in a decrease of dwell time on the face, since
both values always add up to 100%. So a stronger objectifying gaze refers to relatively longer viewing
time on the body and shorter viewing time on the face.
Computations were done using the GENLINMIXED (Generalized linear mixed model) routine of
SPSS version 22 (IBM Corporation, Armonk, NY, USA) and eye tracking data reduction was realized




Prior to data analysis participants were excluded due to poor recordings (n = 5), non-heterosexual
orientation (n = 3), or due to inadequate responses to the manipulation check (n = 10) as rated by four
independent raters. A total of 58 participants (57% female, Mage = 31.45, SDage = 10.18) remained for
data analysis (see Table 1). Table 1 also shows the means of participants’ AMMSA and OOS scores.
In this context, it is particularly important that the mean values of the two study groups do not differ.
Table 1. Participant characteristics and questionnaire data.
Condition
Consensual a Non-Consensual b
Female (%) 52% 61%
Age (M, SD) 32.20 (11.75) 31.42 (9.16)
Age (Range) 21–68 19–59
AMMSA score (M, SD) 2.96 (1.33) 2.44 (0.90)
OOS score (of Women; M, SD) 4.58 (10.86) c −0.44 (10.16)
OOS score (of Men; M, SD) 0.67 (8.42) −0.94 (9.67)
The means do not significantly differ between conditions (p > 0.08). OOS score = Scores on the Other Objectification
Scale (Strelan and Hargreaves, 2005) separately for the objectification of women and of men; the possible range is
from −25 (low objectification) to 25 (high objectification). AMMSA score = Scores on the 11-item short version of the
Acceptance of Modern Myths About Sexual Aggression scale (Gerger et al., 2007); the possible range is from 1 (low
acceptance) to 7 (high acceptance). a n = 25. b n = 33. c n = 24.
3.2. Ratings
Separate models were conducted for each of the three explicit ratings, namely sexual attractiveness
of the person depicted, perceived intimacy of the image content, and unpleasantness of further
distribution. Only the significant effects of the final models are reported here.
For attractiveness ratings, we did not find that condition (consensual vs. non-consensual
distribution; see Table 2) had any effect. We did, however, find that gender had an effect as well as an
interaction effect between participant gender and image gender. Overall, men rated the images of men
as more attractive (M = 4.17, SE = 0.32) than women did (M = 3.02, SE = 0.31; t(924) = 3.25, p < 0.001).
Women also rated the images of men as less attractive than images of women (M = 4.46, SE = 0.32,
t(924) = 9.36, p < 0.001). No other effects reached significance.
Concerning the intimacy ratings, we found an interaction effect between condition and gender (p =
0.008, see Table 2). Pairwise contrasts revealed that women who assumed non-consensual distribution
regarded the images as more intimate (M = 4.86, SE = 0.25) than women who assumed consensual
distribution (M = 4.56, SE = 0.26; t(924) = 2.58, p = 0.01).
Analyzing influences on how unpleasant further distribution was considered for the depicted
person, we found that condition (consensual vs. non-consensual distribution; p < 0.001) had a highly
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significant effect (see Table 2). Pairwise contrasts revealed that participants assuming non-consensual
sharing considered further distribution as more unpleasant (M = 4.63, SE = 0.28) than participants who
assumed consensual sharing (M = 4.26, SE = 0.28; t(924) = 3.74, p <.001). We also found an interaction
effect between gender and image gender. Women rated the unpleasantness of further distribution lower
for images of men (M = 4.08, SE = 0.40) than male participants did (M = 4.41, SE = 0.40; t(924) = 2.50, p =
0.013). Furthermore, the AMMSA score reached significance (coefficient = −0.13, p = 0.002), indicating
that the higher participants scored on the AMMSA-scale, the less unpleasant they considered picture
distribution for the depicted person.
Table 2. Final models of the influences on ratings of sexual attractiveness, intimacy, and presumed
unpleasantness of further distribution.
Dependent Variable Independent Variable F p Value Coefficient a
95% Confidence Interval
Lower Limit Upper Limit
Sexual Attractiveness
Gender 50.82 <0.001 −1.15 −1.39 −0.91
Image Gender 4.34 0.038 0.38 −0.50 1.26
Gender × Image Gender 36.89 <0.001 1.06 0.72 1.40
Intimacy
Condition 0.610 0.435 0.16 −0.09 0.42
Gender 0.025 0.874 0.22 −0.01 0.45
Group × Gender 7.029 0.008 −0.46 −0.80 −0.12
Unpleasantness
Condition 14.02 <0.001 −0.37 −0.56 −0.18
Gender 1.47 0.225 −0.34 −0.60 −0.07
Image Gender 0.52 0.473 0.18 −0.93 1.28
Gender × Image Gender 5.41 0.020 0.44 0.07 0.82
AMMSA score 9.48 0.002 −0.13 −0.22 −0.049
Fixed effects (df 1 = 1, df 2 = 924). AMMSA score = Scores on the 11-item short version of the Acceptance of Modern
Myths About Sexual Aggression scale (Gerger et al., 2007). a The coefficient value indicates the increase of the rating
per score-increase of 1 (e.g., unpleasantness rating decrease of −0.13 per AMMSA score increase of 1).
3.3. Eye Tracking Analysis
Regarding eye movements, we were interested in the objectifying gaze, operationalized as the
relative time viewing the body. We found a significant interaction of condition and gender (F(1,834) =
8.36, p < 0.001). Men in the non-consensual condition demonstrated a stronger objectifying gaze as
they looked significantly longer at bodies (M = 54.37, SE = 8.99) than men in the consensual condition
(M = 46.52, SE = 9.01; t(834) = 4.25, p < 0.001) (see Figure 1). Within the non-consensual condition, men
also demonstrated the objectifying gaze more than women did, spending more time looking at bodies
than women did (M = 49.53, SE = 8.97; t(834) = 3.07, p = 0.002). Notably, there was no such gender
difference within the consensual condition (p > 0.05).
Figure 1. Estimates of the mean proportion (and standard error) of dwell time spent on the body by
condition and gender. *** p < 0.001; ** p < 0.01.
The effects of the OOS score and the AMMSA score were significant (p < 0.001), indicating
that relative dwell time on the body increases for higher scores. In other words, this reveals a
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more pronounced objectifying gaze for higher tendencies to objectify and accept myths about sexual
aggression (see Table 3).
Table 3. Influences on the proportion of dwell time spent looking at the body.
Independent Variable F p Value Coefficient a
95% Confidence Interval
Lower Limit Upper Limit
Condition 12.45 <0.001 −7.85 −11.48 −4.22
Gender 1.34 0.247 −4.84 −7.94 −1.74
Gender × Condition 8.36 0.004 6.92 2.22 11.61
OOS score 23.90 <0.001 0.30 0.18 0.42
AMMSA score 31.06 <0.001 2.96 1.92 4.00
Fixed effects (df 1 = 1, df 2 = 834). OOS score = Scores on the Other-Objectification questionnaire (Strelan and
Hargreaves, 2005). AMMSA score = Scores on the 11-item short version of the Acceptance of Modern Myths About
Sexual Aggression scale (Gerger et al., 2007). a The coefficient value indicates the increase of dwell time on the body
per score-increase of 1 (e.g., dwell time increase of 2.96 per AMMSA score increase of 1).
4. Discussion
We demonstrate that not only explicit ratings but also the implicit viewing behavior are influenced
by the assumed consensual or non-consensual distribution of sexting images.
4.1. Image Evaluations
Participants who assumed the non-consensual distribution of a sexting image, namely the sharing
against the will of the person depicted, rated the further distribution of the images as more unpleasant.
This finding demonstrates that not only the picture content itself or personal feelings about sexting
but also the surrounding information is considered when estimating the unpleasantness of further
picture distribution. Interestingly, women rated the unpleasantness of distribution lower for images
of men than male participants did. Seeing images of other men, the risk saliency of becoming a
victim and having one’s images shared non-consensually might have increased for men, leading to
higher ratings of unpleasantness. Due to the common stories of non-consensual sexting involving
women, female participants might be aware of personal risks at any time independent of the condition.
As the potential consequences of forwarding are more severe for women [43,44], female participants
might consider further forwarding as less unpleasant because of the less severe consequences for men.
However, it is important to note that the images of men and women should not be compared directly
with each other in this study as picture compositions varied. Men were usually posing less sexually
than women, which is due to the naturalistic creation of the images, but likely influences the ratings
of unpleasantness.
Overall, higher general rape myth acceptance led to lower ratings of perceived unpleasantness of
further distribution in both conditions. Higher endorsement of rape myths is indicative of a higher
likelihood of victim blaming, which is in line with the common risk discourses on sexting [7,12,22,45].
Accordingly, considering non-consensual sharing a risk inherent in sexting allows minimizing the
expected level of unpleasantness of further distribution. The depicted person is deemed responsible for
having taken the image to begin with and hence either stupid or reckless. In other words, the estimated
unpleasantness decreases when victim blaming increases. This is crucial as this pattern is not only
typical for cases of revenge pornography [46] but also for other forms of sexual harassment [26,47] and
has even found its way into ‘sexting abstinence’ campaigns [20]. Concerning the perceived intimacy
of the images, women assuming non-consensual distribution rated the images as more intimate for
both genders than women assuming consensual sharing. Men, however, did not differ between
the consensual or non-consensual distribution of images of either men or women. This could be
attributed to the fact that women are more likely to be victims of non-consensual sexting [3] and to
be victimized in general in most forms of online gender-based violence [19,48]. Being aware of the
potential personal risk might make women more sensitive to the intentions of the depicted person and
violations of privacy.
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Unlike expected, the assumed way of distribution did not affect how participants rated the sexual
attractiveness. Previous research linking objectification and attractiveness ratings presented women
in casual wear and the same women in bikinis [46]. Such a strong manipulation allows for large
differences between conditions. Using the same semi-nude images in both conditions as done in our
study might not have been a strong enough manipulation to affect explicit attractiveness ratings. The
exhibited interaction effect between gender and image gender, more precisely higher ratings of male
images by men, is likely due to factors inherent in the images and not the context. Therefore, we do
not consider them as relevant for this study.
4.2. The Objectifying Gaze
The objectifying gaze, defined as the relative amount of time looking at the body, was influenced
by condition and participant gender. Men assuming non-consensual distribution displayed the
objectifying gaze more than men assuming voluntary sharing and more than women assuming either
manner of distribution. Hence, we were able to demonstrate for the first time that the supposed way of
distribution influences how participants look at images and how strongly they display the objectifying
gaze. Previous research suggests that especially women are sexually objectified in the media [26,49,50]
and during interpersonal interactions [51,52]. The objectifying gaze has been linked to negative
social perceptions, dehumanization, and self-objectification [53–55]. While an appearance-focus in
women has been linked to negative social perceptions [54,55] and severe mental health problems [55],
no comparable research on men exists.
Although mostly discussed for men, women are thought to have internalized the objectifying gaze
so much that they demonstrate it toward other women as well [56]. However, in our study, only men
assuming non-consensual distribution differed from the other participant groups, albeit unaffected by
the gender of the depicted person. Unlike other studies [57–60], we did not find systematic influences
of image gender on viewing behavior. We suggest that our manipulation might have evoked other task
demands that resulted in viewing patterns different from free viewing conditions, possibly covering
influences of image gender [61]. In line with previous research, higher general tendencies to objectify
others, as well as higher acceptance of rape myths, were related to a more pronounced objectifying
gaze [35]. Numerous gender-specific functions and consequences have been reported for rape myths
acceptance (for a review see [62]). Still, due to cultural changes, rape myths and sexist beliefs have
become increasingly subtle as taken into consideration and measured by the acceptance of modern
myth about sexual aggression scale applied here [63]. This study is the first to consider the influences of
both biases on eye movements and suggests that subtle attitudes indeed affect viewing behavior. These
influences and their implications should be further investigated in the context of sexual aggression.
4.3. Limitations and Future Research
Our study was conducted in the laboratory with well educated, heterosexual participants viewing
images of young, attractive adults who were semi-nude, unlike in most severe cases of non-consensual
image sharing [64]. Accordingly, the generalizability of our results needs further investigation. Future
research has to take intersectional influences (e.g., skin color or age) into account, as these factors
are relevant in the context of objectification [50]. Concerning participants, intersectionality is also
important, as cultural influences regarding eye-movements [65], sexual objectification [66], and sexual
harassment [67,68] have been found. Other reasons for fixating more on bodies (e.g., social comparison)
or avoiding faces (e.g., shame) should be explored as well.
As mentioned above, in this study we have focused on adult participants for two main reasons:
First, the prevalence of sexting among adults is actually higher than among adolescents. Secondly,
we were not interested in a representative image of the user population, but in an experimental
comparison of two equivalent groups. Nevertheless, it is possible that the correlations shown do
not exist among adolescent users. For this reason, a replication of the present study with adolescent
participants would be desirable.
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Although we demonstrated that the supposed manner of distribution affects the perception of
sexting images, qualitative research asking consumers of non-consensual sexting for their motives
seems like an important step to further identify the beliefs behind such behavior, (e.g., the enjoyment
of power) [69]. Another aspect is the perceived agency of the depicted person that might be
decreased by non-consensual forwarding, which in turn could facilitate objectification. This idea needs
further investigation.
Since everyday sexual objectification is common [70], it is crucial to examine and develop
theories regarding possible outcomes and further explore the similarities between sexual assault and
non-consensual pornography, or technology-facilitated violence in general.
As rapid changes of the technological landscape routinely link new types of specific behavior (e.g.,
non-consensual sexting) to existing theory (e.g., on sexual objectification) they can inform the creation
of prevention programs [46,71]. The well-researched theory of ‘sexual double standards’ suggests
that women’s sexuality is often perceived as pure and damageable through active desire, holding
women responsible for protecting themselves from aggressive male sexuality [72,73]. This leads to
the paradoxical position for women of experiencing social and cultural pressure to be sexy while
simultaneously risking negative social consequences when portraying themselves in such manner
online [74,75]. Considering the sexual double standard allows us to understand nonconsensual
sexting as reaffirming stereotypical gender roles that place women under the control of men [53,55].
As girls are more likely to engage in sexualized self-presentations on social network sites and more
attention is paid to their physical appearance than that of boys [76], gendered aspects need to be
considered [17,77]. While arguments have been made to consider sexting as an empowering (social)
media production [78,79] and to frame sexy appearance as a feminist act to counter the negative effects of
objectification [80], this positive reframing carries the potential negative effect of normalizing unwanted
sexual attention, which may outweigh the possible benefits of individual self-preservation [71].
5. Conclusions
In conclusion, we demonstrated that viewing behavior and evaluation of sexting images are
influenced by their supposed consensual or non-consensual distribution. In line with objectification
theory, an ‘objectifying gaze’ was more pronounced in men who assumed non-consensual picture
distribution, meaning they spent a relatively longer time looking at the body of a depicted person. This
‘objectifying gaze’ was also more pronounced for participants with higher tendencies to accept myths
about sexual aggression or general tendencies to objectify others. The results suggest that prevention
campaigns that focus on a general message of sexting abstinence and thus attribute responsibility
for non-consensual distribution of such images to the persons depicted are insufficient. Rather, it is
necessary to emphasize the illegitimacy of the non-consensual distribution of sexting images, especially
among male consumers of the material. This can be done, for example, in the context of school
educational events, but there is also at least one example of an appropriate public prevention campaign:
http://notyourstoshare.scot/. Only with these or comparable measures can the serious psychological
consequences of public humiliation and online bullying be prevented in the long term.
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Abstract: The main goal of this study was to investigate the association between sexual satisfaction and
mental health, and the combined effect of two previously found, statistically significant moderators:
partner status and sexual abstinence. In-person interviews were conducted with 223 participants
(49.327% males and 50.673% females). The effect of sexual satisfaction on mental health and
the interactions of sexual satisfaction × partner status, sexual satisfaction × sexual abstinence,
and sexual satisfaction × partner status × sexual abstinence were examined using simple moderation
and moderated moderation tests after controlling for a set of sociodemographic, penitentiary,
and interpersonal variables. Results revealed a direct relationship between sexual satisfaction and
mental health only for the sexually abstinent group. Partner status was not significant as a moderator.
It seems that the lack of sexual relationships is more powerful as a moderator than the lack of a
romantic relationship. Additionally, the sexually abstinent group showed lower levels of sexual
satisfaction in those with a partner outside or inside prison, and lower mental health independently
of the current romantic status, than sexually active inmates. These findings point to the importance of
sexual satisfaction to mental health in sexual situations of extreme disadvantage.
Keywords: sexual satisfaction; sexual abstinence; partner status; mental health; prison inmates
1. Introduction
More than 10 million people are living in jails and prisons worldwide [1], and considerably larger
numbers of ex-prisoners are living in society [2]. A high prevalence of mental health problems is
present in prison populations [3]. There is also increasing epidemiological evidence that prisoners are
more likely to suffer from mental health problems than the average population [4–7].
In the most representative Spanish study that included 28.8% of the inmate populations in five
different prisons, the lifetime prevalence rate of mental disorders was 84.4%. The prevalence of
any mental disorder in the last month before the time of interview was 41.2% [8]. These results
were confirmed more recently by a study with a smaller sample size (n = 184), obtained from
three prototypical Spanish prisons [9]. A total percentage of 90.2% inmates had suffered a mental
disorder during their lives. Also, 55.2% were suffering a mental disorder at the time. Finally, in this
study, the inmate population was 5.3 times more likely to have a mental health problem than the
general population.
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These mental health problems are risk factors for a range of adverse outcomes in prison and on
release including self-harm [10], suicide [11–16], and violence inside prison [17], and reoffending in
released prisoners [2,18,19].
In sum, most prevalence studies have been conducted in developed countries and consistently
show that a very high proportion of prisoners suffer from poor mental health [3,20]. Despite the high
level of need, these disorders are frequently underdiagnosed and poorly treated [20]. In addition,
a growing literature documents the detrimental consequences of incarceration for mental health [21–24].
For example, early scholars believed being imprisoned is associated with having higher rates of mental
health disorders than inmates would have had if they had remained in the community [25]. Massoglia
found evidence of persisting elevated mental health issues in previously incarcerated individuals [26].
Furthermore, incarceration is negatively associated with finances [27], family ties [28], and physical
health [29] as well as a greater risk for sexual victimization [20].
All this makes the mental health status of current and former prison inmates an important public
health issue [3]. Following the World Health Organization’s definition, this study will consider mental
health as not merely the absence of illness but "a state of well-being in which every individual realizes
his or her own potential, can cope with the normal stresses of life, can work productively and fruitfully,
and is able to make a contribution to her or his community” [30]. Thus, this concept includes mental
illness but also understands mental health as a positive dimension of well-being [31].
One of the possible causes of prison inmates being an at-risk population for poor mental health is
that they encounter difficulties in having a satisfactory sex life [32–35]. Linville found that approximately
75 percent of a sample of 100 male inmates in a minimum-security prison reported emotional problems
due to sexual deprivation [36]. As a result of the sexual deprivation inmates experience, they may seek
relief in alternative, less satisfactory and/or riskier ways [37]. Different studies have demonstrated a
high rate of masturbation [38–40], and the presence of consensual homosexual behavior as alternative
forms of sexual behaviors [41,42]. Such behaviors are sometimes coercive [43–45], and can lead to the
transmission of sexual diseases such as HIV [46]. Conjugal visitations have been suggested as one
possible solution. Consistent with this view, states that permit conjugal visits have lower instances of
reported rape and other sexual offenses in their prisons [47]. Nonetheless, the low frequency of visits,
the lack of good conditions [48], and their being restricted to married or committed partners limits the
efficacy of conjugal visits.
All these experiences are evaluated by prison inmates determining their level of sexual satisfaction.
Sexual satisfaction has been defined as “an affective response arising from one’s subjective evaluation
of the positive and negative dimensions associated with one’s sexual relationship” [49] (p. 258). It is
regarded as a fundamental dimension of the quality of sexual activity. Research on sexual satisfaction
in prison inmates has generally shown very low levels of sexual satisfaction except for those with a
romantic partner inside the same prison and those who did not remain abstinent [48,50,51]. Taken
altogether, sexual needs are not well satisfied in prison.
Arguably, sexual satisfaction can be considered an essential component of general well-being and
mental health. Empirically, higher sexual satisfaction is associated higher mental health and lower
depression [52–54]. The recognition of the need to be loved, appreciated and cared for, and of the
desire for intimate relationships that provide emotional sustenance and empathy, have been considered
important aspects for maintaining mental health in prisons [30].
1.1. The Sexual Satisfaction and Mental Health Relationship Moderated by Partner Status and Sexual Abstinence
Research on the relationship between sexual satisfaction and mental health in prison inmates is in
a fledgling state. Researchers have largely overlooked the part sexual satisfaction can play in inmates’
mental health and well-being. Research involving these variables conducted with other populations is
more extensive.
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1.1.1. Research Conducted Outside Prisons
The consequences of a satisfying sex life are important areas of research that are gaining increasing
attention in the psychological and medical literature, suggesting that sexuality maintains its importance
even in the context of serious health concerns [55]. In this way, higher sexual satisfaction is associated
with low levels of sexual anxiety [56,57], low psychopathological symptoms [57,58], and good mental
health [59,60].
Furthermore, fostering patients’ quality of life and mental health are key aims of health care in
which subjective factors are commonly seen as central [61]. One subjective factor that has received
very little attention is patients’ sexual satisfaction, although Mallis et al.’s results showed that sexual
satisfaction and quality of life are “strongly connected” (p. 447) [62]. Other research has found sexual
dissatisfaction is higher in patients with depression than in those without depressive symptoms [63].
Turning to relationship status and its role in the association between sexual satisfaction and
mental health, in both non-clinical and clinical samples, partnered compared to single individuals
have tended to report higher sexual satisfaction and sexual activity [52,64,65]. Having a partner does
not necessarily mean that couples live together or that they have an active sex life, but it increases the
likelihood that partners do have consistent sexual contact. Furthermore, tight-knit social structures
such as being in a close relationship often, but not always, lead to better mental health outcomes [66].
Consistent with the beneficial view of tight structures, Holt-Lunstad, Birmingham, and Jones [67] and
others (e.g., [68]) have found that being married is associated with better mental and physical health.
Analyses such as this typically lump everyone together and do not examine other predictors of mental
within subgroups.
Although the moderating effect of partner status between sexual satisfaction and mental health
was not specifically investigated in the aforementioned studies of partner status, there is important
evidence that the negative aspects of romantic life (e.g., loneliness and dissatisfaction, two aspects
related to the fact of not having a partner or not having a satisfactory relationship for meeting one’s
emotional needs) predict personal well-being more strongly than the positive aspects (e.g., marital
satisfaction) [69]. Complementing the negative is stronger than the positive, other non-prison studies
have found a strong relationship between sexual satisfaction and general well-being including mental
health for those who had been sexually deprived due to the presence of sexual dysfunctions [70,71],
physical disabilities [72], amputations [73], and having had germ-cell tumor therapy [74].
Other interpersonal variables, a category in which sexuality belongs [75], have a differential
effect on mental health depending on partner status. For example, friendship quality only correlated
significantly with depression among a group of college students without a romantic partner whereas
no association was found in the group in a current romantic relationship [76].
Furthermore, Taleporos and McCabe compared the strength of this relationship for a group
of people with and without sexual difficulty (physical disability vs. no physical disability) [72].
In this case, for both genders, the relationships between sexual satisfaction and indicators of mental
health such as depression and self-esteem were stronger for people with physical disabilities than for
able-bodied people. In other words, sexual satisfaction was a stronger predictor for the mental health
of the group in a less favorable and more restrained condition. This situation might be comparable
with the situation of sexually abstinent prison inmates who have shown much lower levels of sexual
satisfaction than sexually active ones. In this comparison it is the sexually abstinent inmates who are
in a more restrained and difficult situation.
Complementing Taleporos and McCabe’s results, Laumann et al. found that in the cluster of
countries where average levels of sexual satisfaction were low (male-centered regimes; in a worse
situation with a less freedom of choice) there was a stronger relationship between sexual well-being
and happiness, which may be considered as an indirect indicator of positive mental health status, than
in the cluster of countries where average levels of sexual satisfaction were higher (gender-equal sexual
regime; in a better and free situation) [77]. If results in this vein generalize, one would then expect the
association between sexual satisfaction and mental health to be stronger among sexually abstinent
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inmates. Also, based on prisoners’ previously mentioned negative feelings toward abstinence and the
available data, we would expect the sexually abstinent inmates to have low sexual satisfaction.
1.1.2. Research Conducted in Prison Contexts
Sexual satisfaction, mental health and other well-being-related measures have been found to be
significantly correlated in studies conducted in prison settings [48,50,51,78]. The findings revealed
that higher levels of sexual satisfaction were associated with higher levels of mental health and other
well-being related measures.
Typically, in these studies the association between sexual satisfaction and mental health has been
examined without considering the participants’ relationship status. The meaning of sexual experiences
may vary depending on individuals’ romantic situation, especially among prison inmates who have
stringent restrictions imposed on their sexual activities. In fact, research has shown that prison inmates
without a partner or with a partner outside the prison had lower levels of sexual satisfaction and mental
health than those inmates with a partner inside the same prison [48]. In a later study, a moderating
effect of partner status on the relationship between sexual satisfaction and mental health was found.
Lower sexual satisfaction was associated with lower mental health only for those without a partner [50].
These latter findings illustrate a pattern suggested in non-prison studies that the association between
sexual satisfaction and mental health is intensified for those in a less desirable romantic status.
In arguing that a lack of sexual satisfaction can negatively impact prison inmates’ mental health,
most authors [33–35,79] were referring mainly to inmates who had not had heterosexual relationships
during their incarceration. Thus, these investigators were defacto ignoring inmates who were engaging
in sanctioned sexual activities with their partners. Sexual satisfaction reflects a self-evaluation of one’s
current sexual life; sexual abstinence refers to a complete lack of sexual relationships during a period
of time. In reporting their sexual satisfaction, abstinent inmates were reporting on their satisfaction
with not having sanctioned partnered sex whereas partnered inmates were reporting on the partnered
sexual activities they were permitted to have. As has been found, an inmate may have been sexually
abstinent during the last 6 months, yet show reasonable high sexual satisfaction [32]. By contrast,
an individual may have been sexually active and show low sexual satisfaction. Thus in a noteworthy
way, the referent for their judgments of sexual satisfaction is different for abstinent inmates than it is
for partnered inmates.
This opens the possibility that the relationship between inmates’ sexual satisfaction and mental
health may be different for sexual abstainers than for sexually active individuals. An earlier prison
study found such a moderating effect [51]: sexual satisfaction was significantly associated with
psychological health only for the group of inmates who had not had sexual relationships during the
last 6 months, in other words, sexual abstainers.
In sum, previous research findings showed lower levels of sexual satisfaction and mental health
in sexually abstinent inmates [32,51]. More importantly, an association between low sexual satisfaction
and low mental health was only found for those who did not have a partner in the same prison (versus
without a partner) [50] and those who remained sexual abstainers (versus non-abstainers) [32,51].
However, these two interaction effects have not been tested together to study (a) whether both are
significant, (b) whether the proportion of variance for which they account is similar or different,
and (c) whether there is a higher order interaction formed by sexual satisfaction, partner status,
and sexual abstinence.
This study will focus on the new knowledge gained by including both abstinence and partner
status. This current investigation also refines a previous study [50] because it includes three different
partner statuses (no partner, partner outside of prison, and partner inside the same prison) instead of
two (partner vs. no partner). Clearly there is a need of differentiating inmates with a partner inside or
outside because these situations delineate different experiences.
In addition, this study benefits from a larger sample size and the addition of a set of control variables
that have previously been demonstrated to have significant effects on mental health. Namely, poorer
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mental health has been exhibited by inmates who are younger, Caucasian [80], and married [80,81];
who have longer sentences and a longer expected time prior to their release [82]; who report poor
general health [83]; who show higher levels of social and emotional loneliness [32,50,51,78]; and who,
based on non-prison studies [84–86], masturbate more frequently. All these variables will be entered in
the models as covariates.
1.1.3. Research Questions
Flowing from the summary of the aforementioned evidence found, two research questions emerge,
a first and central question and an ancillary second one: (a) Will partner status and sexual activity
level play a moderator role in the relationship between sexual satisfaction and mental health, after
controlling for sociodemographic (sex, age, and nationality), penitentiary (total time in prison and
estimated time to parole), and personal, social, and sexual well-being aspects (self-rated health, social,
family, and romantic loneliness, and frequency of masturbation)? (see Figure 1) and (b) Will partner
status and sexual abstinence be associated with inmates’ sexual satisfaction and mental health, after
controlling for sociodemographic (sex, age, and nationality), penitentiary (total time in prison and
estimated time to parole), and personal, social, and sexual well-being aspects (self-rated health; social,
family, and romantic loneliness; and frequency of masturbation)?
2. Experimental Section
2.1. Participants
Participants for this study were entirely inmates from the medium-security Topas penitentiary,
located in Salamanca (Spain). This prison houses men and women in the same prison but in different
modules. The prison administration decided from which men’s and women’s modules the investigators
could recruit participants. After stratifying by gender, 80% of the participants were randomly selected,
whereas 20% were selected under a “snowball” sampling scheme [36]. Participants were excluded from
this study if they (a) had been in prison for less than 6 months, the time considered necessary to become
adapted to prison life and develop new relationships inside the facility; (b) did not speak Spanish or
English; (c) had been diagnosed with a serious mental disorder; or (d) were not in an optimal condition
to be interviewed (e.g., under the influence of drugs or expressing high levels of anxiety or distrust
toward the interviewer). Only twelve potential participants declined being interviewed. All of the
participants found the interview to be a positive experience.
Due to the difficulties collecting information from this specific population, we retained for analyses
in the present report participants in two of Carcedo et al.’s previous studies [50,51] that had 119
and 173 participants, respectively. For this study, a sample of 223 inmates from 20 to 62 years old
(M = 35.172, SD = 7.823) was used. We selected the increase in sample size to ensure reasonable power
for testing the interaction effects of interest in the current analyses. This increase resulted in successfully
having at least 10 participants per subgroup formed by crossing partner status (inside, outside, no
partner) and sexual abstinence categories (abstinent vs. non-abstinent). Although males and females
in prison are not equal in number, we selected a roughly equal number of male (n = 110) and female
(n = 113) participants in order to explore the possible effect of sex on the results and, consequently,
the results’ interpretation and discussion. Nationality was encoded in two levels: Spanish nationality
(n = 103) and foreign, unspecified origin country (n = 120). Regarding the two moderators in this
study, 76 inmates had no partner (34.080%), 61 had a partner outside the prison (27.354%), and 86 had
a partner inside the prison (38.565%); also, 122 inmates reported having had sex in the last six months
(54.709%) and 101 kept sexually abstinent (45.291%).
In comparison with inmates with a current romantic partner outside the prison, those in a
relationship inside the same prison presented a higher frequency of in-person contact (t (145) = −12.413,
p > 0.001; outside: M = 3.311, SD = 1.679; inside: M = 5.698, SD = 0.510; variable coding: 1 “never”,
2 “more than 6 months”, 3 “3–6 months”, 4 “each 1–2 months”, 5 “each 7–15 days”, and 6 “every day
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or almost every day”, and satisfaction with the current relationship (t (145) = −2.746, p < 0.001; outside:
M = 3.510, SD = 1.678; inside: M = 4.358, SD = 1.326; variable coding: 1 “totally unsatisfied” and
5 “totally satisfied”) and lower duration of the union in months (t (145) = 3.588, p < 0.001; outside:
M = 102.459, SD = 100.593; inside: M = 49.831, SD = 77.172).
All sexually active inmates reported they had engaged in heterosexual behavior at least once in the
last six months. Regarding frequency, 63.934% of sexually active inmates had had sexual relationships
at least once every 15 days, 24.590% every 2 months, and 11.475% every 6 months. Most of these sexual
relationships occurred in conjugal visit rooms (76.471%), but also in other locations inside the prison
(shared areas such as the sociocultural module, prison laundry, kitchen, gym, etc. (19.328%) and family
visit rooms (1.681%)) and during furloughs outside the prison (2.521%). Inmates reported that their
sexual relationships had included vaginal coitus at least once in the last 6 months. It is also important
to mention that three sexually active participants also reported to have had some homosexual contact
in prison. Finally, no sexually active inmate was convicted of sex crimes.
Preliminary analyses did not find any significant effect of sex, in the presence of partner status
and sexual activity level, on sexual satisfaction and mental health nor a moderating effect between
these two variables. Therefore, both sexes were analyzed together and sex was only included as a
control variable in all the analyses.
2.2. Design and Procedure
This study used a short-term longitudinal design. Two interview sessions were carried out
with a difference of a week between them. The main associated variable and control variables were
extracted from the first interview and the outcome (mental health) was taken from the second one.
Each participant was interviewed in a private room located in his or her prison module, separated
from the rest of the inmates. The interviews were kept short (approximately 30 min without counting
the time dedicated to create a good relationship) to ensure that participants did not get tired and to
avoid “interrogation effects”.
All the interviews were conducted by the same interviewer to foster consistency. Before starting
the interview, the interviewer spent a significant amount of time building a trustful relationship with
every inmate (usually about 20–30 min, but depending on the speed of establishing rapport, in some
cases it took up to 2 h). Afterwards, participants were invited to participate and were informed
about the possibility of leaving the study whenever they wished to do so. Participants were informed
about the confidentiality and anonymity of the study and all the participants signed consent forms.
We consider that respecting all of these conditions is extremely important in collecting good-quality
data from this population. Ignoring these conditions can easily increase distrust among the prison
inmates. Finally, it is important to state that this study respected the norms of the Declaration of
Helsinki’s ethical principles for medical research involving human subjects.
2.3. Measures
2.3.1. Sexual Satisfaction
The sexual satisfaction subscale of the Multidimensional Sexual Self-Concept Questionnaire
(MSSCQ) [87] was used to measure the main variable of this study. A total of five items were scored on
a five-point Likert-type scale that ranged from 1 (not at all characteristic of me) to 5 (very characteristic
of me). Cronbach’s alpha for this scale was 0.960.
2.3.2. Moderating Variables: Sexual Activity Level and Partner Status
This variable was recorded as 0 for the inmates who had experienced sexual relationships in the
past 6 months (non-abstinent), and 1 for the inmates who had not (abstinent). Sexual relationships were
understood as any sexual behavior with another person including vaginal or anal intercourse, oral sex,
and mutual masturbation and genital caresses, excluding kisses, hugs, and non-genital caress. Partner
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status was coded to have three categorical levels: no partner (0), partner outside (1), and partner inside
the prison (2). Partner status was defined as a relationship deemed, in the inmate’s mind, as one that
both partners considered serious.
2.3.3. Outcome Variable: Mental Health
This construct was measured with the short Spanish version of the Psychological health subscale
included in the World Health Quality of Life scale (WHOQOL-BREF) [88]. Six items were scored on a
five-point Likert-type scale that ranged, with different labels, from 1 (not at all; very dissatisfied; never)
to 5 (extremely-completely; very satisfied; always). Cronbach’s alpha was 0.709. Sample items include
“To what extent do you feel your life to be meaningful?” and “How often do you have negative feelings
such as blue mood, despair, anxiety, depression?” This scale was selected for multiple reasons: It is
brief; it conceptualizes mental health not only as the absence of illness but also the presence of positive
aspects of mental health; and its concurrent validity as indicated by its high correlation (r = 0.70) with
the widely used SF-36 (36-Item Short-Form Health Survey) mental health subscale [89].
2.3.4. Control Variables: Sociodemographic, Penitentiary, and Personal, Social, and Sexual
Well-Being Variables
Considering sociodemographic variables, sex was codified as 0 for male and 1 for female inmates,
age was asked directly to each inmate and confirmed against inmate penitentiary records for accuracy,
and nationality was dichotomized into Spaniards (0) versus foreigners (1). Regarding penitentiary
variables, total time in prison refers to the total time spent in prison for previous and current offenses.
This information was collected by reviewing inmates’ penitentiary records, and it was recorded in
months. Estimated time to parole was captured by asking the inmates how much time they expected
to be in prison from that moment, based on the information they possessed. This variable was also
computed in months.
With respect to personal, social, and sexual well-being variables, self-rated health was measured
by asking the participants “in general, would you say your health is: excellent (4); very good (3);
good (2); fair (1); or poor (0)?” [90]. The short version of the Social and Emotional Loneliness Scale
for Adults (SELSA-S) [91] was used to measure both types of loneliness. SELSA-S consists of three
subscales labeled (a) social loneliness, (b) family-emotional loneliness, and (c) romantic-emotional
loneliness. Participants rated 15 items (five per scale) on a seven-point Likert-type scale that ranged
from 1 (strongly disagree) to 7 (strongly agree). Cronbach’s alphas were 0.829, 0.898, and 0.840 for social,
family-emotional, and romantic-emotional loneliness, respectively. Finally, masturbation frequency
was codified into six levels based on the frequency inmates reported having masturbated during the
last 6 months: (1) never, (2) less than once a month, (3) once or twice a month, (4) once or twice a week,
(5) once a day, (6) twice a day or more.
Each scale or subscale score was obtained by adding the item scores and dividing them by the
number of items answered. Higher scores represented higher levels in that dimension for all the
variables included in this study.
2.4. Statistical Analysis
A 3 × 2, partner status (no partner, partner outside the prison, and partner inside) by sexual
activity (abstinent vs. non-abstinent inmates) ANCOVA was used to first analyze the differences in
sexual satisfaction and then performed again with mental health as the outcome variable. Each analysis
controlled for sociodemographic, penitentiary, personal, social, and sexual well-being variables. If the
partner status by sexual activity interaction between factors was statistically significant, Bonferroni
post-hoc tests for multiple comparisons were conducted. Statistical significance was defined as p < 0.05.
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The Breuch–Pagan test was conducted to test heteroscedasticity between sexual satisfaction and
mental health. The macro heteroscedasticity test for SPSS [92] was utilized for this purpose. To study
the relationships of sexual satisfaction with mental health and the moderating effects of partner status
and sexual activity level, the PROCESS 3.2. macro for SPSS [93] was utilized. PROCESS’s models
number one and two for two-way interactions (also called simple moderation), and three for the
three-way interaction (also named moderated moderation) were used. Additionally, 95% confidence
intervals were calculated based on 5000 bootstrap samples. The HC3 heteroscedasticity-consistent
standard error estimator was applied [94] due to the violation of homoscedasticity. All the statistical
analyses were conducted using the IBM SPSS 23 package (IBM Corp., Armonk, NY, USA).
3. Results
Descriptive information for the variables considered in this study are included in Table 1. With
sexual satisfaction as the outcome variable, the 3 × 2 partner status by sexual activity level ANCOVA
yielded significant effects for sexual activity level (F (1, 207) = 47.115, p < 0.001, η2p = 0.185) and the
partner status × sexual activity level interaction (F (2, 207) = 14.638, p < 0.001, η2p = 0.124). Bonferroni
post-hoc comparisons revealed lower levels of sexual satisfaction in sexually abstinent inmates in
comparison with non-abstinent for those who had a partner outside (p < 0.001; abstinent: M = 0.838,
SE = 0.237; non-abstinent: M = 2.979, SE = 0.178) or inside the same prison (p < 0.001; abstinent:
M = 1.094, SE = 0.302; non-abstinent: M = 3.006, SE = 0.155). However, no differences in sexual
satisfaction between abstinent and non-abstinent inmates were found for those who were not involved
in a romantic relationship (p > 0.05; abstinent: M = 2.462, SE = 0.197; non-abstinent: M = 2.312,
SE = 0.354).
In the 3 × 2 ANCOVA with mental health as the outcome measure, sexual activity level yielded
a significant effect (F (1, 207) = 10.182, p < 0.01, η2p = 0.047). Those who were sexually abstinent
(M = 3.260, SE = 0.081) presented lower levels of mental health in comparison with non-abstinent
inmates (M = 3.633, SE = 0.080). The effect due to partner status was non-significant.
Regarding associations with mental health, the Breuch–Pagan test yielded a significant result
for heteroscedasticity (LM = 3.883, p < 0.05). Thus the HC3 heteroscedasticity-consistent standard
error estimator was used [42] to run the regression model. The three-way interaction of sexual
satisfaction × partner status × sexual activity level was not significant (ΔR2 = 0.001, F (2, 201) = 0.174,
p > 0.05). By contrast, the two-way sexual satisfaction × sexual activity level interaction was statistically
significant (ΔR2 = 0.016, F (2, 205) = 8.298, p < 0.01), whereas the sexual satisfaction × partner status
interaction was not (ΔR2 = 0.007, F (1, 205) = 1.590, p > 0.05). In the former case, the conditional effects
of sexual satisfaction at the values of the moderators showed lower levels of mental health only for
those who were abstinent during the last six months. This result was found significant across the three
levels of partner status (see Table 2 and Figure 1) and for the whole sample (sexual abstinent group:
B = 0.176, SE = 0.089, t = 1.990, p < 0.05, 95% CI = (−0.346, 0.129)). No significant effect was observed
for sexually active individuals.
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Table 2. Multiple regression analysis on mental health and conditional effects of sexual satisfaction at
values of the moderators (partner status and sexual activity level).
Mental Health
B SE t 95% CI
Sociodemographic and penitentiary variables
Sex −0.043 0.117 −0.366 (−0.273, 0.188)
Age 0.008 0.006 1.252 (−0.005, 0.021)
Nationality 0.359 0.092 3.899 *** (0.178, 0.541)
Total time in prison 0.001 0.001 0.996 (−0.001, 0.003)
Time to parole −0.004 0.002 −2.092 * (−0.008, 0.001)
Personal, social, and sexual well-being variables
Self-rated health 0.133 0.036 3.685 *** (0.062, 0.204)
Social loneliness −0.13 0.028 −4.592 *** (−0.186, −0.074)
Family loneliness −0.002 0.027 −0.072 (−0.056, 0.052)
Romantic loneliness 0.030 0.05 0.597 (−0.069, 0.129)
Masturbation frequency 0.058 0.038 1.515 (−0.017, 0.133)
Conditional effects
Partner outside −0.271 0.324 −0.835 (−0.910, 0.369)
Partner inside −0.180 0.317 −0.566 (−0.805, 0.445)
Sexual activity level −0.628 0.224 −2.800 ** (−1069, −0.186)
Sexual satisfaction −0.108 0.121 −0.899 (−0.346, 0.129)
Two-way interaction model
Sexual satisfaction × Partner status (outside) 0.221 0.124 1.781 (−0.024, 0.467)
Sexual satisfaction × Partner status (inside) 0.175 0.116 1.500 (−0.055, 0.404)
Sexual satisfaction × Sexual activity level 0.285 0.099 2.881 ** (0.090, 0.479)
R2 0.355 ***
Sexual satisfaction at values of the moderators
Non-sexual abstinent—No partner −0.108 0.121 −0.899 (−0.346, 0.129)
Non-sexual abstinent—Partner outside 0.113 0.063 1.791 (−0.011, 0.237)
Non-sexual abstinent—Partner inside 0.066 0.057 1.157 (−0.047, 0.179)
Sexual abstinent—No partner 0.176 0.089 1.990 * (0.002, 0.351)
Sexual abstinent—Partner outside 0.398 0.104 3.835 *** (0.193, 0.602)
Sexual abstinent—Partner inside 0.351 0.098 3.577 *** (0.157, 0.544)
* p < 0.05; ** p < 0.01; *** p < 0.001. B, Unstandardized coefficient; SE, Standard Error.
As clearly can be seen in Figure 1, the interaction effect of sexual satisfaction × sexual activity
presents a similar pattern for the groups of inmates without a partner, and in a current relationship
outside or inside the prison. It is important to highlight that overall a decrease in sexual satisfaction of
the sexually abstinent group is associated with a reduction of mental health levels, and the contrary,
an increase in sexual satisfaction is related to an improvement in mental health.
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Figure 1. Sexual satisfaction × sexual activity level interaction associated with mental health for three
different partner status groups.
4. Discussion
A direct relationship between sexual satisfaction and mental health was only found for the sexually
abstinent group in this study. Partner status did not appear as a significant moderator. However,
among those with a partner outside or inside prison, the sexually abstinent group showed lower levels
of sexual satisfaction and mental health than sexually active inmates.
Again, sexual satisfaction was found to be significantly associated with mental health, as in
other prison studies [36,50,51,78] and non-prison studies [52–54,56–60,63]. In this study, however,
the sexual satisfaction, mental health association was only obtained for those who had remained
sexually abstinent for at least the last six months. Previous research testing just one moderator has
found that higher levels of sexual satisfaction were associated with higher levels of mental health only
for prison inmates without a partner [50] and inmates who were sexually abstinent [51]. The current
study examined the impact of both moderators, partner status and sexual activity level, together on the
sexual satisfaction, mental health association. The results of this analysis showed that only the sexual
satisfaction × sexual activity interaction was statistically significant. Neither the sexual satisfaction
× partner status interaction nor the three-way interaction was significant. Thus a key implication of
this study is that the lack of sexual relationships is more powerful as a moderator than the lack of a
romantic relationship.
An important question here is why the lack of sexual relationships emerged in the regression
analysis as significantly associated with mental health, whereas partner status did not. We speculate
that sexual needs may be more important or basic than the emotional needs associated with
romantic relationships. Sexuality, and more specifically sexual desire, comprises cognitive, emotional,
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and physiological processes and is consubstantial to the fact of being humans. Sexual desire may be a
stimulus that sparks the inmates’ sensitivity to their lack of sexual satisfaction. Lack of sexual contact
in prison has even been named by inmates as “sexual torture” [32]. By contrast, wishing to be in a
romantic relationship in a prison where the pool of eligible partners may not be especially attractive,
may produce either lower levels of reactance and/or lower levels of dissatisfaction with not having a
partner. In addition, intimacy and emotional needs can be solved by other ties, like close friends [75].
This suggests that future research could profitably focus on the role of sexual desire levels as a means
of dealing effectively with inmates’ sexual deprivation and/or the role that non-romantic, personal
relationships contribute to improving their mental health. Hence, the damaging impact of being
exposed to circumstances perceived as negative could be lessened by promoting positive interpersonal
experiences and healthy interactions within inmates’ daily experiences.
Prison settings are an unconventional, yet potentially diagnostic, context in which to study the
sexual satisfaction, mental health association. Similar contexts would be worth considering in other
public health studies. The meaning of sexual satisfaction may be completely different for those who are
sexually inactive or suffering from serious restrictions vis-a-vis sexual activities than for those who are
sexually active. The current results have possible implications for other populations whose freedom to
choose has been reduced or eliminated due to constraining situations or who are involved in more
negative or difficult circumstances. As noted previously, strong associations between sexual satisfaction
and mental health or other well-being related measures have been found in other populations afflicted
by different medical conditions [70–74] or living in a more sexually restrained culture [77].
This study also found significantly lower levels of sexual satisfaction in the abstinent group.
This result is consistent with previous research in prison [32,51]. Furthermore, there were parallel
significant differences in sexual satisfaction between abstinent and sexually active inmates in both the
groups with a partner outside and inside the prison (not all inmates with a partner were sexually active),
but not for those without a partner. Having a partner and not having access to sexual relationships can
generate even more reactance and/or create a worse position than not having a partner and sexual
relationships. Additionally, sexually abstinent inmates showed low mental health. Presumably the
abstinent inmates were in a worse situation and experiencing greater reactance to the loss of freedom
with respect to their sexual lives than the sexually active inmates. All these results are consistent
with previous research developed within prison contexts, highlighting inmates’ difficulties in meeting
their sexual needs [32–35,51] and, as a consequence of this, presenting mental and emotional health
problems [36].
Findings stemming from the two research questions of this study point to the crucial role sexual
abstinence can have for mental health in some circumstances. Low sexual satisfaction (only for
inmates with a partner outside or inside the prison) correlated with poorer mental health and
a significant relationship between sexual satisfaction and mental health was observed in sexual
abstainers. The abstinent group may be increasing their desire for sexual relationships due to their
sexual deprivation [95]. Individuals wish to operate with a freedom to choose behaviors to satisfy
their needs and if their freedom is reduced, threatened, or eliminated, individuals will become
“motivationally aroused” to regain this freedom (see reactance theory [96,97]). Also, as seen in our
results, this group is afflicted by sexual dissatisfaction, possibly the result of a large gap between
their desires and their reality. Negative information and events (e.g., being abandoned by partners,
losing friends, etc.) per se have been shown to have more impact on individuals’ judgments and
well-being than positive ones (e.g., gaining friends, partners, etc.) (see “the bad is stronger than good
approach” [98]), especially in stigmatizing contexts [99]. This association has also been found in
romantic relationships in non-prison studies [69].
The reactance and the bad is stronger than good explanations complement one another but do
differ. The reactance interpretation sees motivation as a triggering factor in the linkage between sexual
abstinence and mental health. The “bad is better than good” interpretation places primary emphasis on
evaluation per se as crucial in the sexual abstinence-mental health association. Future research might
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profitably examine whether the processes implied by one of these explanations is more applicable than
the processes implied by the other and test this current study’s findings in other populations where
individuals are afflicted by sexual deprivation or restriction due to different medical conditions or
social factors.
In sum, this current investigation has found (a) lower levels of both sexual satisfaction and
mental health in the sexually abstinent group, and (b) a stronger sexual satisfaction and mental health
association in that group. Our perspective is that sexual satisfaction has been strongly correlated with
mental health for the abstinent inmates likely because they are in a sexually worse or more deprived
situation, and a similar, strong sexual satisfaction-mental health correlation should be observable in
other comparably compromised situations or populations.
Our findings have important implications. First, inmates, especially those who are not sexually
active, may benefit from prison policies that ease access to romantic and, especially, sexual relationships.
We would note that inmates scoring higher on mental health have lower levels of misconduct [100]
and lower recidivism rate after release [101]. Promoting positive mental health in prison inmates
during incarceration and therefore increasing the likelihood of a successful reentry into society is a
central concern with important consequences for public health, security, and the economy. According
to this, clinical interventions to increase sexual access could be introduced to enhance inmates’ sexual
satisfaction. This in turn should be associated with an increase in their mental health. Such changes,
however, should take into account the risk profile of inmates because it may be an important variable
influencing the choice of interventions.
Assuming inmates will not be able to engage in sexual activities with a partner, other policies
and interventions may also be helpful. A shift in cognitions and/or attitudes might influence inmates’
evaluation of their sexual satisfaction. Cognitive restructuring techniques might be useful in this
regard. Also, helping inmates to focus on other activities, especially ones that they pursue passionately,
may relieve part of the distress associated with abstinence. In his dual theory of passion, Vallerand has
shown that what he calls harmonious engagement in activities leads to psychological well-being [102].
Finally, increasing privacy in prison cells could facilitate masturbation as another way to obtain some
sexual pleasure. Future research should address possible differences in sexual satisfaction between
inmates who do, or do not, share their cells with other inmates. Also, it would be worthwhile to
compare inmates living alone in a cell but in different prisons where inmates have more or less privacy
(e.g., cameras in the rooms, prison officers entering in the cell without asking in advance, etc.).
We also believe that clinicians working with other populations who see their sexual freedom
threatened (e.g., physical disabilities, older adults in nursing homes, etc.) can benefit from considering
the implications of this study. Populations at risk of mental health problems should also be questioned
about the presence or absence of sexual activity in their lives as a means of improving diagnosis and a
more accurate intervention plan. Including sexual satisfaction in any diagnosis of mental health and
its subsequent intervention seems sensible to consider, especially for those who have difficulties in
meeting their sexual needs. Working on external impediments or barriers to having access to sexual
relationships should be addressed too. Finally, clinical strategies aimed at reducing patients’ reactance
and negative evaluations of their sexual deprivation coupled with helping patients discover and
perform new highly motivating activities may help patients overcome part of the distress associated
with their actual sexual situation.
Apropos of the limitations of this work, this study is correlational so causation is difficult
to infer although we used a short-term longitudinal design. Also, a few participants affirmed
engaging in homosexual behavior. Despite our stressing the confidentiality and anonymity of the
study, homosexual contacts might have been underreported by the inmates. The Spanish context is
conservative in character, where heteronormativity (the cultural assumption that heterosexuality is the
only valid social norm) is tied deeply to culture [103]. These values are definitely prone to be found
in prison inmates too [104]. In this context it is not easy to acknowledge engaging in homosexual
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behaviors. However, all the participants pointed out they felt very comfortable during the interview
and disclosed information that they considered sensitive and important.
5. Conclusions
In sum, correctional systems often adopt deprivation as a solution to inmates’ sexual desires
during incarceration. This study offers evidence regarding the importance of sexual satisfaction for
their mental health, especially for abstinent inmates. A clear implication of this work is to urge
prison administrators to find different solutions for inmates’ sexuality that helps them to deal with
their sexual desires. But not only that, this study adds new evidence to highlight the importance of
considering sexual satisfaction as a predictor of mental health especially in those populations whose
freedom to engage in partnered sexual activity has been threatened. From a public health perspective,
the association between sexual satisfaction and mental health can vary depending on an individual’s
sexual activity level, as has been found in this study. Clinicians and health professional should take
into consideration this possibility as part of their patients’ evaluation and intervention.
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Abstract: Hidradenitis suppurativa (HS) is a chronic auto-inflammatory skin disease with a great
impact in quality of life. However, there is little research about the impact of HS on sex life. The aims
of this study are to describe the frequency of sexual distress (SD) in patients with HS and to explore
potentially associated epidemiological and clinical factors. We conducted a cross-sectional study
by means of a crowd-sourced online questionnaire hosted by the Spanish hidradenitis suppurativa
patients’ association (ASENDHI). Sexual distress (SD) was evaluated with a Numeric Rating Scale
(NRS) for HS impact on sex life. A total of 393 participants answered the questionnaire. The mean
NRS for HS impact on sex life was 7.24 (2.77) in women and 6.39 (3.44) in men (p < 0.05). Variables
significantly associated (p < 0.05) with SD in the multiple linear regression model were sex, with a
higher risk in females, the presence of active lesions in the groin and genitals and NRS for pain and
unpleasant odor; being in a stable relationship was an important protector factor. Regarding these
results, it seems that SD in HS patients is due, at least in part, to disease symptoms and active lesions
in specific locations, emphasizing the importance of disease control with a proper treatment according
to management guidelines. Women and single patients are more likely to suffer from sexual distress.
Keywords: sexuality; mental health; mental disorder; sexual dysfunction; hidradenitis suppurativa
1. Introduction
Hidradenitis suppurativa (HS) is a chronic auto-inflammatory skin disease characterized by
recurrent nodules, abscesses and fistulae and which involves hair follicles, predominantly in
intertriginous areas [1]. These lesions cause pain, unpleasant odor, itching and suppuration. When the
disease progresses to advanced stages, there may be a permanent negative effect on body image due
to scarring.
According to recent studies, the reduction in HS patients’ quality of life is one of the most
significant among dermatological patients [2,3] and similar to other non-dermatological illnesses such
as chronic obstructive pulmonary disease, diabetes mellitus, cardiovascular disease and cancer [4].
Some research indicates that pain or pruritus may negatively affect quality of life [5,6].
Sexuality is a basic need and one which cannot be separated from other aspects of human life,
being extremely important for maintaining good mental health [7]. Several studies show a direct
relationship between sexual function and quality of life [8,9]. Sexual functionality can be impaired
by chronic diseases because of factors related to the disease itself, its treatments, or alterations in
body image [10]. Due to the chronic relapsing course of HS and the disease’s characteristics, HS may
affect patients’ sexuality. Numerous publications have associated HS with depression, anxiety, low
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self-esteem, loneliness, stigmatization, suicide risk, or impact on working life [2,3,11–16]. However,
there is little research about the impact of HS on sex life.
The aims of this study are to describe the frequency of sexual distress (SD) in patients with HS
and to explore potentially associated epidemiological and clinical factors.
2. Experimental Section
2.1. Patients and Design
We conducted a cross-sectional study by means of a crowd-sourced online questionnaire.
Participants were recruited from 1 March to 1 April 2018. The Spanish hidradenitis suppurativa
patients’ association (ASENDHI) hosted the questionnaire and invited people with HS to participate in
the study [17].
The selection criterion was self-referred diagnosis of HS. Participants were aware of the
questionnaire’s anonymity and the use of their data for research purposes. The study was approved
on May 2017 by the ethics committee of Hospital Universitario San Cecilio and is in accordance with
the World Health Organization Declaration of Helsinki.
2.2. Questionnaire
The questionnaire was developed with Google® Forms suite. Socio-demographic data, biometric
parameters, use of medication for other comorbidities and several characteristics of the disease, such
as age of onset, time under medical attention and affected areas were collected. Disease severity was
assessed by patients’ self-reported Hurley stage, since patients with HS are capable of self-assessing
their Hurley stage with a good correlation with physician assessment [18].
Disease activity was assessed by Patients’ Global Assessment (PtGA), including five categories
(inactive, very low, low, mild and severe) [19], and intensity of symptoms by Numeric Rating Scales
(NRS) [20]. These scales show the subjective impact of the disease on patients, with equal or greater
importance than objective scales.
SD was evaluated with a NRS for HS impact on sex life, in which participants were asked to
measure from 0 to 10 how much the disease affects their sex life. This scale reflects the subjective
suffering and distress caused by the disease to patients’ sex lives. Its concordance with the Female
Sexual Function Index-6 (FSFI-6) and the International Index of Erectile Function-5 (IIEF-5), two
validated questionnaires that explore female sexual dysfunction and erectile dysfunction respectively,
was also assessed.
2.3. Statistical Analysis
Statistical analyses were performed using JMP version 9.0.1 (SAS institute, Inc., Cary, NC, USA).
When there were missing data in any of the variables of interest, patients were excluded from the study.
When missing data were found in other variables, they were imputed. To explore the characteristics
of the sample, descriptive statistics were used. Continuous variables were expressed as means and
standard deviations. Qualitative variables were expressed as absolute and relative frequencies.
The main outcome of interest was SD, measured by the NRS for HS impact on sex life. To explore
possibly associated factors, simple linear regression was used for continuous variables, Student’s t-test
for dichotomous variables, and one-way analysis of variance for nominal variables with two or more
categories (Levene’s test was used to assess the equality of variances, standardized residual plots to
check independence and Normality was assumed because of the sample size). Significantly associated
variables (p < 0.05) or those showing trends towards statistical significance (p < 0.20) were included in
a multiple linear regression model to assess the factors associated with SD. Statistical significance was
considered if p values were less than 0.05.
The correlation of NRS for HS impact on sex life with FSFI-6 and IIEF-5 was checked with simple
linear regression. Student’s t-test was used to assess differences between NRS for HS impact in sex life
78
J. Clin. Med. 2019, 8, 532
means in participants with and without sexual or erectile dysfunction according to the FSFI-6 or IIEF-5
scores, respectively. The cut-off point for sexual dysfunction using the NRS for HS impact on sex life
was assessed by ROC curve analysis.
3. Results
3.1. Baseline
Three hundred and ninety three participants answered the questionnaire. Seven of them filled
out the questionnaire incompletely, so the final sample consisted of 386 participants (319 (82.6%) from
Spain, 57 (14.8%) from abroad, and 10 (2.6%) did not provide their country of residence). The ratio
of women to men was 3.8:1 (306 (79.27%) women and 80 (20.73%) men). Their socio-demographic
characteristics and comorbidities are shown in Table 1; current smoking was higher among men, body
mass index was 1.5 greater in women, and the prevalence of diabetes mellitus type II and antidepressant
consumption was higher among women, but these differences did not reach statistical significance.
HS baseline characteristics are shown in Table 2. Age of onset was earlier in women (19.09 ± 7.1 vs.
23.57 ± 9.45, p < 0.0001), with a medium diagnosis delay of 11.23 ± 9.55 in women and 8.86 ± 9.13 in
men. The groin was the location most affected in women, either by active lesions (65.7%) or scars
(57.2%). In men, groin was the location more frequently affected by active lesions (53.8%), and axilla by
scars (47.5%). Genitals were affected by active lesions in 111 (36.3%) of women and in 31 (38.8%) of
men, and by scars in 82 (26.8%) of women and in 28 (35%) of men. The presence of active lesions in the
perianal region (35 (43.8%) vs. 50 (16.3%), p < 0.0001) and on the buttocks (35 (43.8%) vs. 95 (31%),
p <0.05) were higher among men, while the breast region was more frequently affected in women
(90 (29.4%) vs. 2 (2.5%), p < 0.0001).
Table 1. Socio-demographic characteristics and comorbidities.
Men (n = 80) Women (n = 306) All (n = 386)
Age 39.21 ± 11.15 37.44 ± 8.69 37.81 ± 9.26
BMI 28.12 ± 5.03 29.67 ± 7.05 29.35 ± 6.71
Current smoker
No 28 (35%) 135 (44.1%) 163 (42.2%)
Yes 52 (65%) 171 (55.9%) 223 (57.8%)
Comorbidities
HBP 4 (5%) 21 (6.9%) 25 (6.5%)
DM2 2 (2.5%) 20 (6.5%) 22 (5.7%)
Dyslipidemia 3 (3.8%) 9 (2.9%) 12 (3.1%)
Antidepressant use 4 (5%) 31 (10.1%) 35 (9.1%)
Benzodiazepine use 4 (5%) 18 (5.9%) 22 (5.7%)
Stable relationship 54 (67.5%) 236 (77.1%) 290 (75.1%)
Continuous variables are expressed as means ± standard deviation and qualitative variables as absolute (relative)
frequencies. BMI: body mass index. HBP: high blood pressure. DM2: diabetes mellitus type 2.
Table 2. Hidradenitis suppurativa (HS) patients’ baseline characteristics.
Men (n = 80) Women (n = 306) All (n = 386)
Time of evolution 15.64 ± 10.53 18.33 ± 9.3 17.77 ± 9.62
Time under medical attention 6.79 ± 7.21 7.1 ± 7.29 7.03 ± 7.27
Number of active regions 2.73 ± 1.79 2.5 ± 1.57 2.55 ± 1.62
Number of regions with scars 2.34 ± 2.29 2.31 ± 2.06 2.31 ± 2.1
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Table 2. Cont.
Men (n = 80) Women (n = 306) All (n = 386)
Hurley state
I 13 (16.3%) 55 (18%) 68 (17.6%)
II 25 (31.3%) 149 (48.7%) 174 (45.1%)
III 42 (52.5%) 102 (33.3%) 144 (37.3%)
PtGA 3.73 ± 1.04 3.65 ± 1.11 3.66 ± 1.09
NRS pain 6.64 ± 2.81 6.52 ± 2.98 6.54 ± 2.95
NRS pruritus 6.24 ± 2.67 6.48 ± 3.03 6.43 ± 2.96
NRS unpleasant odor 6.11 ± 3.05 5.47 ± 3.45 5.6 ± 3.38
NRS suppuration 6.84 ± 3.04 6.39 ± 3.21 6.48 ± 3.18
Continuous variables are expressed as means ± standard deviation and qualitative variables as absolute (relative)
frequencies. PtGA: Patient’s Global Assessment; values range from 1 (inactive disease) to 5 (severe disease). NRS:
Numeric Rating Scale; values range from 0 (no symptoms) to 10 (maximum intensity of symptoms).
3.2. Sexual Distress and Related Factors in Patients with Hidradenitis Suppurativa
The mean NRS for HS impact on sex life was 7.24 (2.77) in women and 6.39 (3.44) in men (p < 0.05).
Results from univariate analysis of factors possibly related to NRS for HS impact on sex life are shown
in Table 3.
Table 3. Univariate analysis of factors associated with sexual distress in patients with HS.
KERRYPNX Univariate Analysis p-Value
Sex
0.021 *Female x = 7.24 (0.17)
Male x = 6.39 (0.33)
Age β = −0.01 (0.02) 0.738
Current smoker
0.023 *Yes x = 7.35 (0.2)
No x = 6.66 (0.23)
Antidepressant use
0.51Yes x = 7.37 (0.5)
No x = 7.03 (0.16)
Benzodiazepine use
0.692Yes x = 6.82 (0.63)
No x = 7.07 (0.15)
Age of onset β = −0.01 (0.02) 0.667
Time under medical attention β = 0.04 (0.02) 0.042 *
Active lesions in axilla
0.532Yes x = 7.16 (0.22)
No x = 6.97 (0.21)
Scars in axilla
0.607Yes x = 7.15 (0.22)
No x = 6.99 (0.2)
Active lesions in groin
<0.0001 *Yes x = 7.63 (0.18)
No x = 6.09 (0.24)
Scars in groin
0.169Yes x = 7.25 (0.2)
No x = 6.84 (0.22)
Active lesions on genitals
<0.0001 *Yes x = 7.99 (0.24)
No x = 6.16 (0.18)
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KERRYPNX Univariate Analysis p-Value
Scars on genitals
0.022 *Yes x = 7.6 (0.28)
No x = 6.84 (0.18)
Active lesions on buttocks
0.065Yes x = 7.45 (0.26)
No x = 6.86 (0.18)
Scars on buttocks
0.566Yes x = 6.94 (0.26)
No x = 7.12 (0.18)
Active lesions on breast
0.026 *Yes x = 7.65 (0.3)
No x = 6.87 (0.17)
Scars on breast
0.327Yes x = 7.33 (0.31)
No x = 6.98 (0.17)
Active lesions on abdomen
0.219Yes x = 7.6 (0.46)
No x = 7 (0.16)
Scars on abdomen
0.77Yes x = 7.18 (0.44)
No x = 7.04 (0.16)
Active lesions in perianal region
0.144Yes x = 7.47 (0.32)
No x = 6.94 (0.17)
Scars in perianal region
0.168Yes x = 7.46 (0.33)
No x = 6.95 (0.17)
Active lesions on neck
0.805Yes x = 7.2 (0.59)
No x = 7.05 (0.16)
Scars on neck
0.791Yes x = 7.22 (0.61)
No x = 7.05 (0.15)
Number of regions with active lesions β = 0.48 (0.09) <0.0001 *
Number of regions with scars β = 0.1 (0.07) 0.182
Hurley stage
0.01 *
I x = 6.21 (0.35)
II x = 7.02 (0.22)
III x = 7.51 (0.24)
Treatment with oral antibiotics
0.074Yes x = 7.48 (0.28)
No x = 6.89 (0.18)
Treatment with oral contraceptives
0.833Yes x = 7.13 (0.38)
No x = 7.05 (0.16)
Treatment with adalimumab
0.03 *Yes x = 7.82 (0.38)
No x = 6.92 (0.16)
PtGA β = 0.87 (0.13) <0.0001 *
NRS for pain β = 0.32 (0.05) <0.0001 *
NRS for pruritus β = 0.27 (0.05) <0.0001 *
NRS for unpleasant odor β = 0.25 (0.04) <0.0001 *
NRS for suppuration β = 0.25 (0.05) <0.0001 *
Stable relationship
0.032 *Yes x = 6.88 (0.17)
No x = 7.62 (0.3)
p-values of variables significantly associated are marked with * PtGA: Patient’s Global Assessment; values range
from 1 (inactive disease) to 5 (severe disease). NRS: Numeric Rating Scale; values range from 0 (no symptoms) to 10
(maximum intensity of symptoms).
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Variables that were significantly associated or showed trends towards statistical significance
(p < 0.20) were included in the multiple linear regression model, whose results are shown in Table 4.
Variables significantly associated with SD were sex, with a higher risk in females, the presence of active
lesions in the groin and genitals and NRS for pain and unpleasant odor; being in a stable relationship
was an important protector factor for SD. Current smoking, PtGA, time under medical attention and
treatment with adalimumab showed trends toward statistical significance.
Table 4. Multivariate analysis of factors associated with sexual distress in patients with HS.
Multivariate Analysis p-Value
Sex (female) β = 0.57 (0.19) 0.003 *
Current smoker β = 0.27 (0.14) 0.059
Time under medical attention β = 0.03 (0.02) 0.088
Active lesions in groin β = 0.44 (0.18) 0.015 *
Scars in groin β = 0.15 (0.19) 0.449
Active lesions on genitals β = 0.4 (0.19) 0.033 *
Scars on genitals β = 0.05 (0.21) 0.812
Active lesions on buttocks β = 0.19 (0.18) 0.296
Active lesions on breast β = 0.09 (0.21) 0.666
Active lesions in perianal region β = 0.15 (0.21) 0.463
Scars in perianal region β = 0.23 (0.21) 0.28
Number of regions with active
lesions β = 0.15 (0.19) 0.44
Number of regions with scars β = 0.14 (0.12) 0.24
Hurley stage
III vs. I β = 0.07 (0.26) 0.804
III vs. II β = 0.03 (0.19) 0.866
Treatment with oral antibiotics β = 0.02 (0.16) 0.9
Treatment with adalimumab β = 0.38 (0.2) 0.054
PtGA β = 0.3 (0.19) 0.115
NRS for pain β = 0.15 (0.08) 0.049 *
NRS for pruritus β = 0.03 (0.06) 0.615
NRS for unpleasant odor β = 0.13 (0.06) 0.035 *
NRS for suppuration β = 0.05 (0.07) 0.489
Stable relationship β = −0.56 (0.16) <0.001 *
p values of variables significantly associated are marked with * PtGA: Patient’s Global Assessment; values range
from 1 (inactive disease) to 5 (severe disease). NRS: Numeric Rating Scale; values range from 0 (no symptoms) to 10
(maximum intensity of symptoms).
3.3. Correlation between NRS for HS Impact on Sex Life and FSFI-6/IIEF-5 Scores
Scores from NRS for HS impact on sex life and FSFI-6 showed a negative correlation
(β = −0.15 ± 0.02, r2 = 0.16, p < 0.0001), indicating a good concordance between both questionnaires.
Scores from NRS for HS impact on sex life and IIEF-5 also showed a negative correlation
(β = −0.21 ± 0.05, r2 = 0.15, p < 0.001). The mean score on the NRS for HS impact on sex life was
8.27 ± 0.21 in women with sexual dysfunction, and 6.16 ± 0.21 in women without sexual dysfunction
(p < 0.0001). In men, the mean score on the NRS for HS impact on sex life was 7.31 ± 0.47 in those with
erectile dysfunction, and 5 ± 0.58 in those without erectile dysfunction (p < 0.01).
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In women, a score of 8 or more on the NRS for HS impact on sex life was indicative of sexual
dysfunction according to FSFI-6 scores, with a sensitivity of 73% and a specificity of 64% (Figure 1).
In men, a score of 9 or more on the NRS for HS impact on sex life was indicative of erectile dysfunction
according to IIEF-5 scores, with a sensitivity of 52% and a specificity of 81% (Figure 2).
 
Figure 1. ROC curve analysis for comparison between scores of NRS of HS impact on sex life and FSFI-6.
 
Figure 2. ROC curve analysis for comparison between scores of NRS of HS impact on sex life and IIEF-5.
4. Discussion
To our best knowledge, this is the largest cross-sectional study about the impact of HS on sexuality.
Socio-demographic and disease characteristics did not differ from those previously reported in the
literature, and were representative of the general HS population [21–28].
The mean NRS score for HS impact on sex life was significantly higher in women, which tallies
with previous research that indicates higher sexual distress in women than in men with HS [29] or
psoriasis [30]. These differences have been associated with cultural aspects and differences in emotional
and neuroendocrine responses to disfigurement, and with the earlier onset of HS in women (4.5 years
earlier in our sample) [29]. A higher prevalence of lesions at the lower abdomen has also been posed as
a reason for this higher distress in women [29], but in our sample we only observed more involvement
below the abdomen in the groin.
Although in psoriasis the involvement of the anogenital area has been related to sexual
dysfunction [31–33], in HS anogenital involvement has been related to a reduction in quality of
life [2,34], but there are no locations related to sexual dysfunction or to sexual distress [29,34]. In our
83
J. Clin. Med. 2019, 8, 532
investigation, we found an association between active lesions in the groin and genitals and SD, so a
properly medical/surgical intervention at this level could turn into a better sexual life. In previous
research about sexual health in patients with HS, samples were taken from hospital departments [29,34]
and from a patient’s association [34], and there were no important differences in patients’ baseline
characteristics, with the exception of a more prevalent Hurley III stage in our sample. Therefore, these
findings were probably made possible due to the larger size of our sample.
Moreover, subjective symptoms caused sexual distress. The intensity of pain and unpleasant
odor were related with higher scores on NRS for HS impact on sex life. This association may be due
to factors directly related to the nature of the sexual act and/or to psychological factors that could
be related to disease activity [2], highlighting the importance of symptom management to improve
sexual health in patients with HS. Other factors such as antidepressant or benzodiazepine use were not
statistically associated with SD, suggesting that SD is directly related to organic symptoms.
The absence of a stable relationship was not associated with sexual dysfunction in previous
research [29,34]. Nevertheless, we observed that the presence of a stable partner was importantly
related to lower SD. Since having a partner is associated with less self-consciousness and less orgasm
difficulty in both men and women [35], probably feelings of shame, distrust, shyness and rejection
influence SD, which could be lessened by the trust built in a relationship.
There were other factors that showed trends toward statistical significance in the multiple linear
regression model: (1) PtGA, pointing to the importance of disease activity in sexual distress and the
need to control the inflammatory load; (2) current smoking, because it is related to greater disease
activity, since it favors follicular occlusion, a proinflammatory state with activation of neutrophils and
Th17 lymphocytes, induces biofilm formation and suppresses notch signaling, among other effects [36];
moreover, smoking cessation is associated with clinical improvement [37]; (3) time under medical
care, since it reflects time of disease evolution, with cumulative life course impairment [38]; and (4)
Treatment with adalimumab, probably because in our sample it is a better predictor of severity than
Hurley, since the patients treated with adalimumab are the most severe.
Finally, we found a good correlation between the scores on NRS for HS impact on sex life and those
of FSFI-6 and IIEF-5, which indicates an association between the subjective and objective involvement of
the sexual sphere in participants. However, despite this concordance, the ROC curve analyses revealed
that the NRS for HS impact on sex life was not a good tool to assess sexual dysfunction in women
or erectile dysfunction in men, because the cut-off points reach neither an acceptable sensitivity nor
specificity. It is important to the clinician to distinguish between sexual distress and sexual dysfunction,
because the first reveals the suffering of the subject, whereas the second may mean a worse sexual
experience for both members of the stable/sporadic relationship. Therefore, clinicians should assess
both aspects when patients’ sexuality is addressed.
There are some methodological weaknesses in our study: (1) A possible selection bias, since it
only represents patients in contact with support groups and Internet access. The elderly, who may use
the Internet less frequently, or those with low sociocultural status or fear of new technologies, could be
under-represented [39]. Moreover, people already concerned about sexual problems may have been
more likely to answer the questionnaire. Nonetheless, the baseline characteristics of our sample did
not differ from those previously reported in the literature, either in hospital-based or population-based
studies. Given the scarcity of information about HS and sexuality we consider that this study is a
good introduction to the problem, and could lay the foundation for future research. (2) A possible
classification bias, because it was an online questionnaire and HS diagnosis could not be confirmed;
HS characteristics were also self-referred. Nevertheless, an informed population can properly identify
HS, because of its apparent and distinctive clinical manifestations. Since a patients’ association hosted
the questionnaire, it is expected that the participants did suffer from the disease.
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5. Conclusions
This is the largest cross-sectional study about HS and sexuality. We have observed important
sexual distress in patients with HS. Factors related to SD were female sex, the presence of active
lesions in the groin and genital areas, and the intensity of pain and unpleasant odor. Being in a stable
relationship has been an important protector factor against SD. Regarding these results, it seems that
SD in HS patients is due, at least in part, to disease symptoms and active lesions in specific locations,
emphasizing the importance of proper control of the disease based on management guidelines to
improve their sexual health. Women and single patients are more likely to suffer from sexual distress,
so special medical care should be given to them.
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Abstract: Background: The problems in sexual functioning among patients with post-traumatic stress
disorder (PTSD) are often overlooked, although scientific research confirms high rates of sexual
dysfunctions (SD) particularly among veterans with PTSD. The main objective of this study was
to systematically identify predictors of SD among veterans with PTSD. Methods: Three hundred
veterans with PTSD were included in the cross-sectional study. The subjects were assessed by the
Mini-International Neuropsychiatric Interview (MINI) and self-report questionnaires: PCL-5, i.e.,
PTSD Checklist for Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5)
with Criterion A, International Index of Erectile Function (IIEF), Premature Ejaculation Diagnostic
Tool (PEDT), and Relationship Assessment Scale (RAS). Several hierarchical multiple regressions
were performed to test for the best prediction models for outcome variables of different types of SD.
Results: 65% of participants received a provisional diagnosis of SD. All tested prediction models
showed a good model fit. The significant individual predictors were cluster D (Trauma-Related
Negative Alterations in Cognition and Mood) symptoms (for all types of SD) and in a relationship
status/relationship satisfaction (all, except for premature ejaculation (PE)). Conclusions: The most
salient implication of this study is the importance of sexual health assessment in veterans with PTSD.
Therapeutic interventions should be focused on D symptoms and intended to improve relationship
functioning with the aim to lessen the rates of SD. Psychotropic treatment with fewer adverse sexual
effects is of utmost importance if pharmacotherapy is applied. Appropriate prevention, screening,
and treatment of medical conditions could improve sexual functioning in veterans with PTSD.
Keywords: post-traumatic stress disorder; sexual dysfunction; veterans; predictors
1. Introduction
The problems in sexual functioning among patients with post-traumatic stress disorder (PTSD)
are often overlooked clinically and receive little attention in research. However, an increasing body of
scientific research regarding sexual dysfunctions (SD) among veterans who were exposed to military
trauma confirms much higher rates of problems in sexual functioning among veterans with PTSD
than in those without PTSD or in adults without exposure to military trauma [1–5]. The rates of SD
differ across the studies, mainly because of methodological differences. Systematic reviews reported a
prevalence of SD between 8.4% and 88.6% among male veterans with PTSD [3,5]. Persons with PTSD,
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compared with similarly exposed survivors without it, have an increased risk of SD implying that
PTSD, rather than trauma exposure per se, is the more proximal antecedent to sexual problems [3,6–10].
Studies revealed correlation of PTSD with a variety of impairments in the specific domains of sexuality
(desire, arousal, orgasm, resolution) [1–7]. On the other hand, the specific PTSD symptoms or PTSD
symptom clusters may influence the prevalence of SD unevenly. The emotional numbing and avoidance
cluster, for example, appeared to be intimately tied to impairment in sexual functioning and higher
level of sexual anxiety [2,11,12].
1.1. Predictors of Sexual Dysfunction in Veterans with PTSD
Only a few studies and systematic reviews have addressed the possible predictors that have an
impact on sexual functioning in the population of veterans with or without PTSD. Considering
the relationship between overall PTSD symptom severity and SD, studies revealed conflicting
results [5]. Particular PTSD clusters and symptoms have been studied, and it was hypothesized
that autonomic arousal, anger/hostility [13], emotional numbing/avoidance symptoms [2,11,12], and
chronic autonomic arousal and intrusive symptoms [3,14,15] were mostly associated with sexual
problems among veterans with PTSD. Recent studies indicate that emotional numbing may impede
intimacy and attachment, thus serving as a potential mechanism through which symptoms of PTSD
may drive problems and predict SD in these patients. According to the Diagnostic and Statistical
Manual of Mental Disorders, Fifth Edition (DSM-5) [16], numbing symptoms (low positive emotions
and negative emotional state) were included in the new D symptom cluster (Trauma-Related Negative
Alterations in Cognition and Mood). These and other symptoms from this cluster, such as diminished
interest or participation in significant activities, a feeling of detachment or estrangement from
others, and guilt and shame, may impede sexual functioning in veterans with PTSD. SD is more
common among veterans who are male, older, separated, divorced, or widowed, have lower annual
income, mental health diagnoses—particularly PTSD—hypertension, and are prescribed psychiatric
medications [1,4,17]. Returning combat veterans with SD have a reduced quality of life, decreased
sexual intimacy, and increased health-care utilization [18]. PTSD is associated with impairments
in romantic relationship satisfaction [19,20]. Recent research revealed that marital dissatisfaction
is the factor that mediates the relationship between the number of PTSD symptoms and sexual
dissatisfaction [21]. Considering the specific types of SD, age appeared to be the only significant
predictor of erectile dysfunction; age, race, depression, and social support predicted self-reported
sexual arousal problems; and race, combat exposure, social support, and avoidance/numbing
symptoms of PTSD predicted self-reported sexual desire problems in male combat veterans seeking
outpatient treatment for PTSD [2].
1.2. Predictors of Sexual Dysfunction in the General Population
Generally speaking, the predictors, risk, or etiological factors of SD can be separated in two
groups: “organic” (such as diabetes, peripheral vascular disease or venous leaks, injury of the spinal
cord, etc.) and “non-organic” (such as anxiety, depression, cultural taboos, ignorance, relationship
problems, poor communication skills, etc.). However, there is substantial evidence indicating a
multifactorial etiology of sexual function and dysfunction, meaning that the sexual response can be
described as a complex interaction of psychological, interpersonal, social, cultural, physiological, and
gender-influenced processes [22,23]. SD is strongly associated with certain health conditions and
diseases, psychiatric disorders, medication or substance use, lack of knowledge, psychological or
behavioral factors, relationship and cultural factors processes [23].
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1.3. Study Background
More than 20 years after the Homeland War in Croatia (1991–1995), veterans still suffer from
numerous health problems. Patients and/or health professionals may be reluctant to mention and
discuss sexual symptoms [24], and a huge proportion of SD remains undiagnosed. Despite that, clinical
observations and rising awareness have encouraged the recognition and assessment of SD in this
patient group, and case reports [25] and research articles [26,27] regarding SD in veterans with PTSD
in Croatia have been published.
The main objective of this research is to systematically identify predictors of SD among veterans
with PTSD. The main hypothesis of the study is that SD are predicted by overall PTSD symptom
severity and by severity of D symptom cluster (Trauma-Related Negative Alterations in Cognition and
Mood).
2. Experimental Section
2.1. Participants and Procedure
Participants were male war veterans (N = 300) recruited from a pool of patients referred to the
Regional Center for Psychotrauma (RCP) and Department of Psychiatry within the Clinical Hospital
Center (CHC) Rijeka, the Referral Center for PTSD of the Ministry for Health of the Republic of Croatia
(N = 250), and the Daily Hospital for PTSD and Department of Psychiatry within the General Hospital
(GH) Našice for treatment. Most of the veterans participated in operations on different and almost all
battlefields. Thirteen of those whom we approached refused to participate, while two patients did not
complete the questionnaires.
Eligibility was determined by meeting diagnostic criteria for war-related PTSD as defined in
DSM-5 [16]. Three patients were not eligible for the study as they did not meet the criteria for PTSD
diagnosis. We continued recruiting patients until the number of 300 participants was reached. There
were no differences in sociodemographic characteristics between those who refused to participate,
those who did not complete the questionnaires, and those who were not eligible for the study.
The inclusion criteria for the study were: participation in the Homeland War as a soldier,
experiencing at least one war-related traumatic event defined in the DSM-5 criteria for PTSD (personal
experience of combat or exposure to a war zone), male gender, and age below 65. The exclusion criteria
for the study were: active psychosis, moderate or high suicide risk measured by the Mini-International
Neuropsychiatric Interview (MINI) for DSM-IV [28], and deformities, injury, or mutilation of the
genital organs. None of the participants met the exclusion criteria.
Research consisted of two parts, i.e., a clinical interview and self-report questionnaires.
The interviews were conducted by five psychiatrists and two psychologists from the two study
sites. Sociodemographic data were collected through a questionnaire created for study purposes.
The interviews and filling in of the questionnaires were usually completed in one or two sessions.
The study was approved by the Ethics Committees of the Faculty of Medicine, University of Rijeka,
CHC Rijeka, and GH Našice. Written informed consent was obtained from all participants after
detailed information about the study was provided to them.
The study sample included a total of 300 male veterans. At the time of participation in the
study, the majority of participants were in ambulatory treatment (66.8%), while other participants
were involved in day-hospital treatment (19.3%) or club for PTSD (7.5%), or were hospitalized (6.4%).
Table 1 provides further information on sample demographics.
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M(sd) or N(%) M(sd) or N(%) M(sd) or N(%)
Age (years) 52.4 (5.82) 52.4 (5.15) 52.1 (5.74) t = 0.470 0.639
Marital Status (yes)
Married 197 (65.7%) 68 (57.4%) 116 (63%) χ2 = 0.795 0.373
Cohabitation 18 (6%) 5 (31.2%) 11 (68.8%) χ2 = 0.112 0.738
Divorced 33 (11%) 9 (29%) 22 (71%) χ2 = 0.568 0.451
Widower 2 (0.7%) – – –
Not married 37 (12.3%) 9 (27.3%) 24 (72.7%) χ2 = 1.013 0.314
Other 12 (4%) 7 (58.3%) 5 (41.7%) χ2 = 2.964 0.085
In a relationship (yes) 259 (86.3%) 94 (38.8%) 148 (61.2%) χ2 = 11.067 0.001
Financial Status (yes)
Low income 96 (32.7%) 25 (27.5%) 66 (72.5%) χ2 = 3.471 0.062
Medium income 186 (63.3%) 71 (39.7%) 75 (60.3%) χ2 = 4.516 0.034
High income 12 (4.1%) 2 (22.2%) 7 (77.8%) χ2 = 0.679 0.410
Education (yes)
Elementary 39 (13.1%) 14 (40%) 21 (60%) χ2 = 0.417 0.518
Secondary 231 (77.5%) 77 (34.8%) 144 (65.2%) χ2 = 0.038 0.846
Higher 26 (8.7%) 7 (30.4%) 16 (69.6%) χ2 = 0.242 0.697
In the Last Month 1 (yes)
Alcohol 33 (89%) 6 (20.7%) 23 (79.3%) χ2 = 2.960 0.085
Cigarettes 50 (16.7%) 21 (42.9%) 28 (57.1%) χ2 = 2.837 0.092
Marijuana 4 (1.3%) – –
War deployment (months) 29.6 (19.2) 29.6 (19.34) 30 (19.51) t = −0.163 0.871
Cluster B symptoms 15 (3.25) 15.1 (2.92) 14.9 (3.32) t = 0.534 0.594
Cluster C symptoms 6.2 (1.47) 6.1 (1.48) 6.3 (1.46) t = −1.047 0.296
Cluster D symptoms 18.7 (5.15) 17.2 (4.81) 19.4 (5,06) t = −3.612 <0.001
Cluster E symptoms 17.7 (3.9) 16.9 (4.27) 18 (3.64) t = −2.422 0.016
Total PTSD symptoms 57.5 (10.92) 55.2 (10.46) 58.6 (10.71) t = −2.559 0.011
Relationship satisfaction 25.9 (6.37) 1 28.1 (5.15) 2 24.8 (6.01) 3 t = 4.298 <0.001
1 n = 256, range 7–35; 2 n = 148; 3 n = 98.
2.2. Measures
2.2.1. PTSD Checklist for DSM-5 (PCL-5) with Criterion A
The PCL-5 with Criterion A [29] is a self-report measure was revised to match the adapted DSM-5
criteria for PTSD. The interpretation of the PCL-5 should be made by a clinician. A PTSD diagnosis
can be made provisionally considering items rated 2 = moderately or higher as a symptom endorsed
according to the DSM-5 diagnostic rule (at least one B, one C, two D, and two E symptoms present).
DSM-5 symptom cluster severity scores can be obtained by summing the scores for the items within
a given cluster, i.e., cluster B (items 1–5), cluster C (items 6–7), cluster D (items 8–14), and cluster E
(items 15–20). A total symptom severity score (range 0–80) can be obtained by summing the scores
for each of the 20 items. Preliminary validation work was sufficient to make a cut-point score of
33, which was chosen for the purpose of this study [29]. Previous validation studies showed good
psychometric properties for evaluating PTSD [30–33]. Cronbach’s alpha in our study for clusters of
symptoms ranged from 0.67 to 0.85, and to 0.89 for total PCL-5. The Criterion A measure was included
in the assesment according the criteria of DSM-5 [16].
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2.2.2. The International Index of Erectile Function (IIEF)
IIEF [34] is a widely used, multi-dimensional self-report instrument for the evaluation of male
sexual function over the last four weeks [34]. It consists of 15 questions grouped into five domains
that assess erectile function (Q1,2,3,4,5,15), intercourse satisfaction (Q6,7,8), orgasmic function (Q9,10),
sexual desire (Q11,12), and overall satisfaction (Q13,14). Each item is rated from 1 (very low; almost
never or never; extremely difficult) to 5 (very high; almost always or always; not difficult). Scores for
domains are calculated as the sum of the answers, with lower scores indicating worse functioning.
The score for erectile function can be calculated and used to classify the severity of dysfunction as
severe, moderate, mild, or no dysfunction. For other domains, a higher score indicates better function.
The IIEF meets psychometric criteria for test reliability and validity, has a high degree of sensitivity
and specificity, and correlates well with other measures of treatment outcome [34–37]. Cronbach’s
alpha was 0.96 for erectile function, 0.91 for orgasmic function, 0.89 for sexual desire, and 0.91 for
intercourse satisfaction and overall satisfaction.
2.2.3. Premature Ejaculation Diagnostic Tool (PEDT)
PEDT [38,39] is a self-report instrument for the evaluation of the presence and severity of
premature ejaculation. Each PEDT item is rated from 0 (not difficult at all; almost never or never; not at
all) to 4 (extremely difficult; almost always or always, extremely), with a higher score indicating more
difficulties with premature ejaculation. Previous validation studies have shown satisfactory feasibility,
reliability, and validity of the PEDT [38,39]. Cronbach’s alpha for PEDT scale in our study was 0.87.
2.2.4. Male Sexual Dysfunction Criteria
The DSM-5 [16] classification recognizes four male sexual dysfunctions: delayed ejaculation (DE),
erectile disorder (ED), male hypoactive sexual desire (HSD), and premature (early) ejaculation. To be
diagnosed with SD, the symptoms must be present for at least six months, cause significant distress,
and not be caused exclusively by a non-sexual mental disorder, significant relationship distress, medical
illness, or medication. Also, these diagnoses are applicable to men who engage in non-vaginal sexual
activity, but unfortunately, the specific duration criteria remain unknown [16]. For the purposes of this
study, the following criteria were applied for a provisional diagnosis:
• DE—items Q9 or Q10 on IIEF rated 2 or less.
• ED—sum of scores on IIEF items Q1-Q5 and Q15 was 16 or less.
• HSD—items Q11 or Q12 on IIEF rated 2 or less.
• PE—item 2 on PEDT (Do you ejaculate before you want to?) rated 3 (Over half the time—>75%) or 4
(Always or Almost always—100%).
2.2.5. Relationship Assessment Scale (RAS)
The RAS [40,41] is a seven-item measure of global relationship satisfaction. Responses are on
a five-point Likert scale, and either the total or the average score can be used in the interpretation.
Average scores range from 1 to 5; total scores range from 7 to 35 (used in this study). Higher scores
indicate greater relationship satisfaction. The reliability and validity of the English RAS have been
established [41]. Cronbach’s alpha in our study was 0.87.
2.2.6. Mini-International Neuropsychiatric Interview (MINI)
Comorbid psychiatric disorders were diagnosed using the Croatian version of MINI for
DSM-IV [28]. It is a brief and valid structured clinical interview meeting the need for a short but
accurate structured psychiatric interview for multicenter clinical trials and epidemiology studies, to
be used as a first step in outcome tracking in nonresearch clinical settings. This interview enables
researchers to assess the 17 most common psychiatric disorders in DSM-IV.
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2.2.7. Anatomical Therapeutic Chemical (ATC) Classification System
Self-reported data about drug consumption are classified in accordance with the ATC
classification [42]. In brief, the ATC system classifies therapeutic drugs. The purpose of the system is
to serve as a tool for drug utilization research in order to improve the quality of drug use. In the ATC
classification system, the drugs are divided into different groups according to the organ or system on
which they act and their chemical, pharmacological, and therapeutic properties. Drugs are classified
into five different groups.
2.3. Data Analysis
2.3.1. Data Analysis Plan
The aim of the study was to assess the predictive models of several sexual dysfunctions in male
veterans with PTSD. Average score of erectile function, orgasmic function, sexual desire, intercourse
satisfaction, overall satisfaction (all measured by IIEF), and premature ejaculation (measured by
PEDT) were the outcome variables. Prediction variables were characteristics identified as relevant for
sexual dysfunction in previous studies. Two sets of hierarchical regression analyses were executed
for each of the sexual functions (one without and one with relationship satisfaction) in order to
assess the best models for the overall sample of veterans with PTSD and for the subset of veterans
in relationship. In order to control for covariances, predictor variables were entered in the following
steps/models: (1) sociodemographic variables, (2) comorbid disorders (psychiatric and others), (3)
medication used (psychotropic and other drugs), (4) variables related to PTSD (deployment duration
and PTSD symptoms), and (5) relationship satisfaction (subset sample of veterans in relationship).
The exclusion criterion for dichotomous predictors was set to 10 or less events per variable [43].
The inclusion criterion for a prediction variable was a significant association with the outcome variable.
2.3.2. Statistical Analysis
Statistical analysis was performed with Statistica software, version 12 (Dell Inc. Inc., Tulsa, OK,
USA). Data are presented as N (%) or M (sd). Chi-square tests for categorical variables and independent
sample t-tests for continuous variables were used to compare veterans with or without provisional
diagnosis of sexual dysfunction. Pearson and Spearman correlation coefficients were calculated
between sexual functions and the variables of interest. Several hierarchical multiple regressions were
performed to test for the best prediction models for the outcome variables of erectile function, orgasmic
function, sexual desire, intercourse satisfaction, overall satisfaction, and premature ejaculation. All
models were controlled for basic assumptions. Two issues with multicollinearity were encountered, i.e.,
between cluster D and cluster E symptoms with overall PTSD symptoms, and between in-a-relationship
status and relationship satisfaction in the subset sample. Overall PTSD symptoms were excluded from
both sets of samples, and the in-a-relationship status variable from the subset sample. Missing values
were controlled for listwise. Probability significance was set to p ≤ 0.05.
3. Results
3.1. Sociodemographic Data
Sociodemographic data for the overall sample are presented in Table 1.
3.2. Trauma Exposure and PTSD
The average duration of active participation in the Homeland war was 30 (19.516) months, ranging
from 1 month to 70 months.
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Twenty-three percent of participants had sought psychiatric help in the period from 1991 to 1995,
while the war was ongoing. The average intensity for overall PTSD symptoms was 57.5 (10.92) within
the range of 33 to 80. The average intensity of B symptoms was 15 (3.25), of C symptoms 6.2 (1.47), of
D symptoms 18.7 (5.15), and of E symptoms 17.7 (3.90).
3.3. Prevalence of SD and Association with Sociodemographic Data and PTSD
The average score for erectile function was 16 (9.71), which relates to moderate dysfunction.
The average score for orgasmic function was 5.8 (3.31) (theoretical maximum = 8), for sexual desire 5.8
(2.47) (theoretical maximum = 8), for intercourse satisfaction 6.51 (4.71) (theoretical maximum = 12),
and for overall satisfaction 6.3 (2.44) (theoretical maximum = 8). The average score for PEDT was 7.43
(5.14) within the range of 0 to 20.
According to provisional criteria for male sexual dysfunction (described in methodology), the
following rates were found: DE 124 (44%, n = 282), ED 134 (46.2%, n = 290), HSD 128 (44.6%, n = 287),
and PE 59 (21.3%, n = 277). Overall, on the basis of self-reported data, 98 (35.1%) of veterans with PTSD
did not meet, while 181 (64.9%) participants met provisional criteria for at least one male SD in the
last month. Out of possible four SD, one SD had 49 (17.6%) participants, two SDs had 36 participants
(12.9%) participants, three SD had 80 participants (28.7%), and four SD had 16 participants (5.7%).
As presented in Table 1, participants in a relationship and participants with medium income were
less likely to have a provisional diagnosis of SD. Participants who met the provisional diagnosis of SD
were significantly less satisfied with their relationship compared to participants without SD. Veterans
with SD had significantly greater severity of cluster D, cluster E, and overall symptoms of PTSD. They
did not differ for duration of deployment or for cluster B and cluster C symptoms.
Prevalence of comorbid disorders and drug use and association with SD are presented in
Supplementary Materials: Material S1.
3.4. Prediction Models of Sexual Dysfunctions among War Veterans with PTSD
Predictor variables for each model (i.e., sexual function) were selected on the basis of the following
criteria: variables with events greater than 10 and significant correlation with the outcome variable
(Table S2). However, some variables were included regardless, such as age and all clusters of PTSD
symptoms. Also, analysis showed great correlation coefficients between overall PTSD symptoms
intensity and cluster D and E symptom intensity (variance inflation factor (VIF) > 8). Because of
the multicollinearity issues, overall PTSD symptoms were not included in the models. The variable
“in a relationship” had high multicollinearity with relationship satisfaction (VIF > 8), and, therefore,
only relationship satisfaction was included in the models for the subset of veterans in a relationship.
The final steps for all tested models are presented in Supplementary material (Tables S3 and S4).
An overview of individual significant predictors for each sexual function is given in Tables 2 and 3.
Table 2. Overview of individual significant predictors in the final step of hierarchical regression











B β B β B β B β B β B β
In a relationship 7.69 0.28 ** 1.98 0.21 * 0.93 0.13 * 3.94 0.30 ** 1.17 0.15 * 1.99 0.13
Alcohol use dis. 1 −1.62 −0.13 * −1.47 −0.12 *
Diabetes mellitus 1.71 0.12 *
Hypertension, esse. 2 −3.99 −0.20 ** −0.98 −0.15 * −1.49 −0.15 ** −0.71 −0.14 *
Antidepressant −1.3 −0.06 −1.12 −0.15 ** −0.71 −0.14 * −0.36 −0.07
Cluster D symptoms −0.46 −0.24 ** −0.15 −0.23 ** −0.14 −0.29 ** −0.23 −0.25 ** −0.11 −0.23 ** 0.21 0.21 *
* p ≤ 0.05; ** p ≤ 0.01; 1 Alcohol use disorders; 2 Hypertension, essential; significant values are in bold.
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Table 3. Overview of individual significant predictors in the final step of hierarchical regression











B β B β B β B β B β B β
Diabetes mellitus 1.91 0.14 *
Hypertension, esse. 1 −3.08 −0.17 ** −0.78 −0.12 * −0.84 −0.09 −0.48 −0.10
Hyperplasia prost. 2 −2.88 −0.05 −169 −0.08 −2.19 −0.08 −1.99 −0.13 *
Antidepressant −1.17 −0.06 −0.96 −0.15 * −0.73 −0.15 * −0.47 −0.11 *
Cluster D symptoms −0.38 −0.21 ** −0.15 −0.24 ** −0.14 −0.30 ** −0.11 −0.23 ** −0.09 −0.19 ** 0.23 0.23 **
Relationship satisf. 3 0.43 0.29 ** 0.14 0.28 ** 0.06 0.16 ** 0.27 0.39 ** 0.16 0.44 ** 0.05 0.07
* p ≤ 0.05; ** p ≤ 0.01; 1 Hypertension, essential; 2 Hyperplasia of prostate; 3 Relationship satisfaction; significant
values are in bold.
3.4.1. Erectile Function
The initial model tested for erectile function included age, low income, medium income, not
married, married, “in a relationship” status (Model 1: R2 = 0.134, F = 7.060, p < 0.001). In the second
step ongoing major depressive episode (MDE), panic disorder lifetime, essential hypertension, and
hyperplasia of prostate (Model 2: R2 = 0.181, F = 5.816, p < 0.001) were included; in the third step, use
of antidepressants, hypnotics, and sedatives (Model 3: R2 = 0.184, F = 5.514, p < 0.001) was added;
in the fourth step, war deployment in months and cluster B, C, D, and E symptoms were added (model
4: R2 = 0.257, F = 5.651, p < 0.001). Significant predictors did not change through the models. The final
model explained 25.7% of the variance of erectile function. Variables with significant independent
contribution were being in a relationship, having essential hypertension, and severity of D cluster
symptoms (Table 2).
In the subset of participants in a relationship, Model 1, containing age, low income, medium
income, not married, and married, was not significant, since the variable relationship status was
removed. Model 2 accounted for 9.3% (F = 2.200, p = 0.019), Model 3 for 9.98% (F = 2.097, p = 0.22),
and Model 4 for 20.1% (F = 3.273, p < 0.001) of the variance of erectile function. The final model with
relationship satisfaction added explained 27.9% of the variance of erectile function (F = 5.457, p < 0.001).
Significant individual predictors were having essential hypertension, severity of cluster D symptoms,
and relationship satisfaction. (Table 3).
3.4.2. Orgasmic Function
The initial model tested for orgasmic function included age, higher education, low income,
medium income, married, and “in a relationship” status (Model 1: R2 = 0.100, F = 4.619, p < 0.001).
In the second step, ongoing MDE, panic disorder lifetime, essential hypertension, hyperplasia of
prostate, and disorders of lipoprotein metabolism were added (Model 2: R2 = 0.165, F = 4.397, p < 0.001);
in the third step, use of antidepressants, hypnotics, and sedatives (Model 3: R2 = 0.189, F = 4.751,
p < 0.001) was included; in the fourth step, cluster B, C, D, and E symptoms (Model 4: R2 = 0.248,
F = 4.628, p < 0.001) were added. Higher education level was a significant individual contributor until
psychotropic medication was introduced in the third step. The final model explained 24.8% of the
variance of orgasmic function. Significant independent predictors were being in a relationship, use of
antidepressants, having hypertension, and severity of cluster D symptoms (Table 2).
In the subset of participants who were in a relationship, Model 1 was not significant and accounted
for 5.4% variance of orgasmic function. Model 2 (R2 = 0.121, F = 2.601, p = 0.004), Model 3 (R2 = 0.152,
F = 3.098, p < 0.001), and Model 4 (R2 = 0.244, F = 3.839, p < 0.001) were all significant. The final model
explained 29.5% of the variance of orgasmic function (F = 4.679, p < 0.001). Significant individual
predictors were: use of antidepressants, presence of essential hypertension, severity of cluster D
symptoms, and relationship satisfaction (Table 3). There was no significant change in the significance
of individual predictors through the models.
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3.4.3. Sexual Desire
The initial model for sexual desire included age, low and medium income, and “in a relationship”
status (Model 1: R2 = 0.055, F = 4.131, p = 0.003). In the second model, alcohol use disorder (AUD) was
added (Model 2: R2 = 0.074, F = 4.521, p = 0.001); in the third model, antidepressant use was included
(Model 3: R2 = 0.095, F = 4.901, p < 0.001); in the fourth model, cluster B, C, D, and E symptoms
(Model 4: R2 = 0.166, F = 5.482, p < 0.001) were added. All the models were significant, and there
was no change in the significance of individual predictors. The final model explained 16.6% of the
variance of sexual desire in the entire sample. Predictors with independent contribution were being
in a relationship, presence of an AUD, use of antidepressant, and severity of cluster D symptoms
(Table 2).
In the subset sample of veterans in a relationship, the sociodemographic variables entered did
not significantly contribute to the variance of sexual desire (Model 1: R2 = 0.035, F = 2.219, p = 0.068)
Addition of AUD in step two (Model 2: R2 = 0.054, F = 2.789, p = 0.018), antidepressant in step three
(Model 3: R2 = 0.081, F = 3.536, p = 0.002), and clusters of PTSD symptoms in step four (Model 4:
R2 = 0.172, F = 4.930, p < 0.001) significantly increased the variance of sexual desire. The final model
which included relationship satisfaction explained 19.6% of sexual desire in veterans in a relationship
(F = 5.227, p < 0.001). As in the total sample, predictors with significant independent contribution
were use of an antidepressant and severity of cluster D symptoms, but not AUD. A significant
contributor was also relationship satisfaction (Table 3). The significant predictors did not change
through the models.
3.4.4. Intercourse Satisfaction (IS)
The initial model for the intercourse satisfaction consisted of age, low income, medium income,
not married, divorced, married and relationship status (Model 1: R2 = 0.139, F = 6.748, p < 0.001).
In the second model, ongoing MDE, other anxiety disorders, essential hypertension, and hyperplasia
of prostate were added (Model 2: R2 = 0.168, F = 5.287, p < 0.001); in the third (final) model, war
deployment in months, cluster B, C, D, and E symptoms (Model 3: R2 = 0.251, F = 5.714, p < 0.001)
were included. There was no change in individual predictors through the models, and the final model
explained 25.1% of intercourse satisfaction in veterans with PTSD. The identified significant predictors
were being in a relationship, presence of essential hypertension, and severity of cluster D symptoms
(Table 2).
In the subset sample of veterans who were in a relationship, the final model accounted for 31.6%
of intercourse satisfaction (F = 7.382, p < 0.001). All tested models were significant (Model 1: R2 = 0.067,
F = 2.982, p = 0.008; Model 2: R2 = 0.102, F = 2.788, p = 0.003; Model 3: R2 = 0.188, F = 3.987, p < 0.001).
The significance of predictors did not change through the models. In contrast to the overall sample,
essential hypertension was not a significant predictor of IS among veterans in a relationship. Severity of
D cluster symptoms and relationship satisfaction were independent significant contributors (Table 3).
3.4.5. Overall Satisfaction
In the first model for overall satisfaction, the following variables were entered: age, low income,
medium income, and “in a relationship” status (Model 1: R2 = 0.061, F = 4.474, p = 0.002). In the next
step, comorbid diseases, ongoing MDE, panic disorder lifetime, other anxiety disorders, AUD, essential
hypertension, and hyperplasia of prostate were entered (Model 2: R2 = 0.140, F = 4.371 p < 0.001); in
the third step, use of antidepressants (Model 3: R2 = 0.145, F = 4.125, p < 0.001) was included; in the
fourth step, clusters B, C, D, and E symptoms (Model 4: R2 = 0.210, F = 4.652, p < 0.001) were added.
Recurrent panic disorder was a significant predictor until PTSD symptoms were entered in the last
step. The final model explained 21% of the variance of overall satisfaction in veterans with PTSD.
Significant individual predictors of overall satisfaction were being in a relationship, presence of an
AUD, presence of essential hypertension, and severity of cluster D symptoms (Table 2).
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All the models tested for overall satisfaction among veterans with PTSD who were in a relationship
were significant (Model 1: R2 = 0.038, F = 3.188, p = 0.024; Model 2: R2 = 0.117, F = 3.457, p < 0.001;
Model 3: R2 = 0.136, F = 3.717, p < 0.001; Model 4: R2 = 0.215, F = 4.570, p < 0.001). The “other anxiety
disorders” variable was a significant predictor until PTSD symptoms were entered in the fourth step.
The final model in the subset sample explained 38.4% of the variance of overall satisfaction (F = 9.651,
p < 0.001). Significant individual predictors were: presence of hyperplasia of prostate, use of an
antidepressants, severity of cluster D symptoms, and relationship satisfaction (Table 3). It is important
to note that relationship satisfaction by itself (β = 0.435) explained most of the variance of overall
sexual satisfaction.
3.4.6. Premature Ejaculation
In the first model of premature ejaculation in the overall sample, the following sociodemographic
variables were entered: age, not married, married, and “in a relationship” status (Model 1: R2 = 0.054,
F = 3.779, p < 0.01). In Model 2, diabetes mellitus (DM) was added (R2 = 0.067, F = 3.795, p < 0.01), and
cluster B, C, D, and E symptoms were added in Model 3. Significant individual predictors were DM
and severity of cluster D symptoms (Table 2).
Similar findings were reported in the subset sample of veterans in a relationship, as the final model
contributed to 10.7% of the variance of premature ejaculation (F = 3.019, p < 0.001) with the independent
significant contributors DM and cluster D symptoms (Table 3). Model 1, containing sociodemographic
variables (R2 = 0.016, F = 1.257, p = 0.290), and Model 2 (R2 = 0.035, F = 2.079, p = 0.054), containing
comorbid diseases, did not contribute significantly to the variance of premature ejaculation. Model
3, which included clusters of PTDS symptoms, was significant (R2 = 0.104, F = 3.277, p < 0.001).
Relationship satisfaction added in the final model did not alter significantly the variance explained.
4. Discussion
To the best of our knowledge, the present study is the first to suggest patterns of association of
PTSD with different types of SD and to determine the predictors of this relationship. The results of
the study support the main hypothesis that SD in veterans with PTSD are predicted by the severity
of the D cluster of PTSD symptoms. The second part of the hypothesis that states SD are predicted
by overall PTSD symptom severity is partially supported. We found that veterans with SD had
significantly higher PTSD symptom scores than veterans without SD. Furthermore, overall PTSD
symptom severity was significantly correlated with all types of SD (DE, ED, HSD, and PE) as well as
intercourse satisfaction (IS) and overall satisfaction (OS). Analysis revealed significant multicollinearity
of this predictor with D symptoms of PTSD, which implies that the association of PTSD symptom
severity with SD is mediated and mostly depends on the quantity and severity of trauma-related
negative alterations in cognition and mood. Previous studies found high rates of SD among male
veterans with PTSD [1–5]. The results of our study are consistent with the scarce but increasing body
of research that indicates that the severity of PTSD measured by overall scores on PTSD scales is not a
significant predictor of SD in veterans with PTSD [2,5,11,12].
Beside the prevalence and correlation of SD with PTSD, it is important to understand the
background of this relationship. A high score of D symptoms (Trauma-Related Negative Alterations in
Cognition and Mood) appears to be the most prevalent predictor of SD among veterans with PTSD,
emerging as a significant predictor of all types of SD (DE, ED, HSD, PE) as well as of IS and OS. D
cluster includes three new symptoms according to the DSM-5 classification: negative expectations
of self, others, or the world (replacing the sense of foreshortened future), persistent distorted blame
of self or other for trauma, and pervasive negative emotional state. The presence of these symptoms
and/or other symptoms from the D cluster, such as diminished interest or participation in significant
activities, a feeling of detachment or estrangement from others, or a persistent inability to experience
positive emotions, precludes a person’s capacity to engage adequately in sexual behavior(s). As a
result, D symptoms predict lower levels of satisfaction in sexual life. The current DSM-5 classification
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embraces the four-factor model, as it provides a better representation of PTSD’s latent structure than
the tripartite model of DSM-IV [43–46], which has received extensive criticism [47]. Our findings in
veterans are consistent with prior research demonstrating that avoidance/numbing symptoms of PTSD
are strongly linked to self-reported problems in sexual functioning. Nunnink and colleagues found
that self-reported symptoms of emotional numbing predicted a greater likelihood of endorsing sexual
problems [11]. The results of another study that investigated predictors of ED and self-reported sexual
problems among 150 male combat veterans seeking outpatient treatment for PTSD revealed, beside
various demographic, physical, and psychosocial risk factors, a significant zero-order correlation
between avoidance/numbing symptoms and SD [2].
Partner relationship is the next prominent predictor of SD in veterans with PTSD. Results in the
overall sample revealed that being in a partner relationship reduces the risk of DE, ED, HSD, IS, and
OS. Being in a relationship has no predictive value for PE. Analysis in the sample of participants who
were in a partner relationship indicated that a low level of relationship satisfaction was a significant
predictor of DE, ED, HSD, and IS and OS. Relationship satisfaction was not a significant predictor of PE.
The association of PTSD with impairments in romantic relationship satisfaction has been previously
reported [11,19,20]. A recent meta-analysis of 23 studies found an association between the emotional
numbing and avoidance symptom cluster and parent, child, family, and marital/partner functioning
problems [48]. Sexual functioning and relationship satisfaction are also robustly, positively correlated
in many different samples across a variety of adult populations, including those who are dating [49,50],
in long-term relationships [51], and married [52,53]. A lower level of relationship satisfaction in our
study sample was an independent predictor of SD and was not mediated by the severity of any PTSD
cluster. Sexual functioning is one of the essential domains of relationship functioning. Association
between SD and quality of relationship is bidirectional and reciprocal. Relationship problems caused
by family stressors, economic reasons, lifestyle, etc. inevitably affect sexual functioning. Problems
in sexual functioning may have an impact on all other domains of a relationship. In the context of
PTSD, the quality of a relationship also depends on the accommodation capacities of the partner for
mutual acceptance, which is important for healthy sexual functioning. Additionally, PTSD may affect
relationship and sexual functioning indirectly through changes of behavioral patterns. For example,
insomnia and nightmares are less likely to have a direct impact on sexual functioning than numbing
symptoms. On the other hand, these symptoms may lead to sleeping in separate beds, allowing or
encouraging the rituals and avoidant behavior that lessen the quality of a relationship and sexual
functioning. This finding implies that therapeutic efforts directed to promoting relationship satisfaction
in veterans with PTSD could have a positive effect on sexual functioning in most of its domains.
Interestingly, being in a relationship and relationship satisfaction are not significant predictors of PE.
This finding could be explained by considering PE symptoms as more of an individual than a relational
problem, which in turn is not worsened or maintained by disturbances in a partner relationship.
Antidepressant use is a significant predictor of the impairment of orgasmic functioning
and sexual desire, i.e., veterans with PTSD that use antidepressants have increased risk for DE
and HSD. Surprisingly, antidepressant utilization did not show predictive values for ED and
OS. Adverse sexual effects are frequent with commonly prescribed psychotropic drugs and are
usually underestimated [24,54]. The recent clinical guidelines highlight antidepressants as first-line
pharmacotherapeutic agents in the management of PTSD [55,56]. In spite of increasing rates of drug
utilization (80%) among veterans with PTSD [57], some studies revealed a marked inconsistency with
the current guidelines for treatment of PTSD, particularly in the post-conflict settings [58]. In that
context, our finding of antidepressant use as a significant predictor of DE and HSD is important,
bearing in mind that 41.5% of our participants have DE and 45.4% have HSD. The findings are
consistent with a meta-analysis which revealed increased rates of SD among patients in treatment
with antidepressants [54]. Furthermore, higher rates of total and specific-treatment emergent SD
and specific phases of dysfunction were found for drugs with a predominantly serotonergic action,
including selective serotonin reuptake inhibitors (SSRIs) and serotonin and norepinephrine reuptake
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inhibitors (SNRIs) [55,59]. Ejaculation-delaying effect of antidepressants on orgasmic function is,
on the other hand, the basis for the use of either tricyclic antidepressant or SSRIs in treatment of
PE. Among other medications from this pharmacological group, paroxetine has the most prominent
ejaculation-delaying effect [60] caused by its impact on serotonergic receptors, cholinergic receptor
blockade, and inhibition of nitric oxide synthase [61–64]. It is also supported by the results of this
study, as antidepressants are not significant predictors of PE.
Arterial hypertension was a significant predictor of ED, DE, IS, and OS in the overall sample.
It was a significant predictor of ED and DE in the sample of veterans in a relationship. These findings
are consistent with those of numerous studies that emphasize high blood pressure as a risk factor
for SD [65–67]. Actually, vasculogenic ED is considered part of a systemic vasculopathy and has a
known relationship with cardiovascular risk factors such as hypertension, diabetes, dyslipidemia,
and smoking [68]. A research that included 1255 male participants revealed that lower systolic and
diastolic blood pressure were associated with better sexual functioning [67].
The significant predictor of PE in the overall sample and among participants in a relationship was
DM. Patients with DM have higher rates of various SD directly related to the deleterious complications
of their disease. [69–71]. DM is also indirectly related to SD through anxiety and depression that
are often experienced by men with DM [72]. Of these, ED was most commonly reported [69–71].
Some studies reported higher rates of PE in patients with DM, indicating duration, severity, and
poor metabolic control as the main risk factors for PE in diabetic patients. On the other hand,
a close relationship between ED and PE exists. Some authors suggest that the longer the erectile
problem, the worse the anxiety, and the more marked the PE [73]. Because of performance anxiety
regarding their erectile reliability, patients could rush through an intercourse, with PE as a deleterious
consequence [74].
AUD was a significant predictor of SD and OS in the overall sample and in those who patients
were in a relationship. The results are consistent with the findings of a previous research and
meta-analysis [65]. This finding is important in the context of populations of veterans with PTSD, as
repeated heavy drinking is one of the common strategies to alleviate trauma symptoms that may lead
to the development of AUD. The prevalence of AUD in PTSD is also high. For example, in the US,
42% of PTSD subjects met criteria for AUD diagnosis [75]. The prevalence of alcohol-induced sexual
dysfunction is unclear, probably because of underreporting. Sexual disorders ranging from 8% to
95.2% have been reported in men with chronic alcohol use [76–80]. The common dysfunctions reported
were lack of sexual desire [79,80], premature ejaculation [81,82], and erectile dysfunction [76,82–84].
Although the prevalence of the SD was not the main focus of this research, it is indicative that
none of the participants reported being diagnosed with SD. Only one veteran with PTSD reported the
utilization of a medication prescribed to treat ED (sildenafil). This finding is completely inconsistent
with data from previous studies suggesting that SD is strongly related to PTSD, particularly war-related
PTSD [1–5]. A backup check of medical records confirmed only one diagnosis of SD recorded in the
study sample. Two widely used instruments for the assessment of the presence and severity of the
different types of SD were applied with restrictive criteria for severity of SD symptoms, consistent with
DSM-5 for diagnosis of SD (i.e., present in at least 75% of sexual activity occasions) in order to avoid
over-diagnosing minor and potentially transient problems in sexual functioning. According to that
criteria, the following rates were found: SD in 64.9% of patients, DE in 44%, ED in 46.2%, HSD in 44.6%,
PE in 21.3%. The rates of SD differ across studies [6–10], mainly because of different methodological
approaches. Predominantly, two methods for identifying SD have been used in research. In some
studies, the estimation of SD diagnosis was based on reported patients’ symptoms and problems
in sexual functioning, with wide criteria for SD applied. In another study, the presence of SD was
considered if SD diagnosis was recorded or medication for SD was used, which may be a more
conservative approach. Both methods for identifying SD may be problematic. If we chose the second
approach, we could conclude that veterans with PTSD in our sample had superior sexual functioning.
Therefore, we chose the first approach, bearing in mind that self-reported symptoms in questionnaires
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can be used only for an estimation and provisional diagnosis of SD. Clinical interviews are irreplaceable
and necessary to sufficiently diagnose SD if they are conducted by well-trained personnel, who are
also trained about social stigmatization. Conversely, they may contribute to underreporting biases
arising from personal concerns about social stigmatization and lack of privacy, particularly in older
or less educated participants [85]. The rates of SD in this study confirm that the complete absence of
SD diagnosis in our clinical setting could not be a consequence of non-clinically significant problems
among veterans. A dramatically higher self-reported prevalence of SD suggests a number of veterans
may be choosing not to disclose problems in sexual functioning with their healthcare providers because
of embarrassment, discomfort, or lack of knowledge about treatment possibilities.
4.1. Strenghts
This study was primarily designed to assess SD in the population of veterans with PTSD. Veterans
with PTSD were included regardless of their relationship status, as even those not in a current romantic
relationship may engage in sexual behavior and are often overlooked in studies. Data related to military
deployment, sociodemographic and relationship factors, psychiatric comorbidity, psychotropic and
other medication, and medical conditions were systematically collected, as all these factors could be
important contributors to SD. PTSD symptoms were assessed jointly, but, more importantly, the impact
of each cluster of PTSD symptoms (according to DSM-5 classification) on sexual functioning was also
assessed. In assessing SD, we applied a comprehensive approach covering a broader range of possible
sexual health problems as well as perceived sexual satisfaction.
4.2. Limitations
This study has several limitations. Findings from this study may not be reflective of and
generalisable to the broader veteran or nonveteran population. Because of the many variables
tested, data analysis suffered from multiple comparisons, allowing for possible false positive
effects/predictors. Health-care-seeking participants could suffer from more serious problems in
each area covered by the research. Furthermore, the generalisability is limited by a gender-imbalanced
sample, as only male veterans were included in the research. Because of the cross-sectional design, the
temporality of the relationship between the different studied variables and sexual dysfunction could
not be evaluated. The findings were based on self-reported symptoms from questionnaire measures.
Self-reports of sexual activity and satisfaction may be under- or overreported because of stigmatization.
5. Conclusions
One of the most salient implications of the current study is the importance of sexual health
assessment in veterans with PTSD. This study represents an advancement in our currently limited
understanding of patterns of association of PTSD with different types of SD and of the predictors of
that relationship. As veterans with PTSD are more likely to suffer from SD if they experience more
D symptoms and if they are not in a relationship or are less satisfied with the relationship, future
research should develop therapeutic interventions more focused on the negative appraisals, emotional
numbness, and irritability and other negative cognitions and emotions, as well as interventions
intended to improve relationship functioning with the aim to lessen the rates of SD in this population.
Psychotherapy is strongly recommended as the first-line treatment approach in PTSD. Sex therapy is
effective in the variety of the SD, and couple psychotherapy is an established approach for relationship
problems and dissatisfaction. Psychotherapeutic treatments, which would comprehensively cover
different aspects of the problems in patients with PTSD and SD comorbidity, could have greater
compliance rates, less iatrogenic adverse effects, and better treatment effects. Psychotropic treatment
with fewer adverse sexual effects and management of the treatment-emergent side effects are of utmost
importance if pharmacotherapy is applied. Medical conditions, particularly those stress-related and
frequent in study populations with diabetes and hypertension, carry an additional burden of increased
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risk for SD. Appropriate prevention, screening for those conditions, and their active treatment could
improve the sexual life of veterans with PTSD.
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Abstract: Adults with an Autism Spectrum Disorder (ASD) are characterized by impairments in
social interaction and communication, repetitive and stereotyped interests and behaviours as well
as hyper- and/or hyposensitivities. These disorder specific symptoms could be associated with the
development of sexual disorders. The Dual Control Model of Sexual Response presents one approach
that is frequently used to explain the emergence of sexual dysfunctions. The aim of the present study
was to assess the extent of symptoms of sexual dysfunctions in men and women with ASD and
to evaluate their association with the individual propensity of sexual excitation and inhibition as
defined by the Dual Control Model. Both men and women with ASD were more likely to report about
sexual dysfunctions than individuals from the control group. In men with ASD, sexual inhibition was
significantly correlated with the emergence of sexual dysfunctions, while there was no association
between sexual functioning and sexual excitation. In women, the opposite pattern was found.
Especially the peculiarities in sensitive perception could be responsible for the observed problems
with sexual functioning in individuals with ASD. The present findings highlight the great need for
specialized treatment programs addressing the frequently observed sexuality-related problems in
individuals with ASD. However, up to now such treatment programs are lacking.
Keywords: sexual dysfunction; autism; erectile dysfunction; sexual satisfaction; Asperger syndrome;
sexual desire; lubrication; sexual intercourse; sexual excitation; sexual inhibition
1. Introduction
Autism Spectrum Disorder (ASD) is characterized by impairments in social interaction and
communication, as well as repetitive and stereotyped interests and behaviours [1]. It is estimated that
up to 1.7% of the population are affected by ASD [2,3]. About 50% of individuals with ASD have
average intellectual functioning and in the meantime more and more adults are being diagnosed in
later life [4]. Just like in other neurodevelopmental disorders, there is a male preponderance in ASD
and the male to female ratio is estimated to be around 3–4:1 [5,6]. However, these reported gender
differences are currently subject of a controversial discussion and it is suggested that this effect might
be largely attributable to the possible gender-biased artefact of a male-symptomatic based diagnostic
system with later diagnosed females requiring heavier symptom loads for diagnosis [7].
Nevertheless, all individuals with ASD have in common that they have (in varying degrees)
difficulties in interpreting non-verbal cues, such as decoding and interpreting facial expressions
and have limited capabilities in theory of mind skills [1]. When throughout development social
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interactions become more complex and romantic and sexual relationships become increasingly
important, the learned social skills often cannot keep up with the social demands needed for the
initiation and maintenance of romantic peer-relationships [8]. Thus, many stereotypes around
individuals with ASD concerning sexuality related issues have arisen, such as, ASD individuals
are seen as being only sparsely interested in sexual and romantic relationships or as being mainly
asexual [9,10]. Contrary to these stereotypes, however, in recent years a growing body of research
has accumulated showing that most individuals with ASD report a general interest in solitary and
dyadic sexual behaviours and show the full range of sexual behaviours, just like their clinically
non-affected counterparts [11–14]. Nevertheless, the deficits in intuitively understand social and
nonverbal communication cues, difficulties in perspective-taking, inflexibility, affective dysregulation,
repetitive and stereotyped interests and peculiarities in sensitive perception leading to either over- or
underreactions to sensory stimuli can hamper the development of romantic and sexual relationships,
can be associated with impaired sexual functioning and sometimes also with the development of
sexual disorders [15–17].
In a first study of our working group, focusing on paraphilias and hypersexuality in
high-functioning men and women with ASD, it was found that high-functioning ASD men reported
more frequently about masochistic, sexually sadistic, voyeuristic, frotteuristic and paedophilic
fantasies and more frequently about frotteuristic behaviours compared to men from a control group.
Furthermore, more men with ASD reported about hypersexual fantasies and behaviours than their
non-affected peers. High-functioning ASD women reported more frequently about masochistic
behaviours than healthy women, while no other differences occurred [18]. Men with ASD usually
show a more pronounced ASD symptomatology regarding for example, repetitive behaviours or
hypo- and hypersensitivities, which could be one possible explanation for the higher prevalence of
hypersexual and paraphilic fantasies and behaviours in ASD men compared to ASD women [18,19].
Thereby, the more frequently observed repetitive behaviours and obsessive interests could translate
into sexualized interests and behaviours, which result in a faster habituation leading the individual to
seek novel sexual activities, for example, paraphilic sexual activities.
Besides paraphilic and hypersexual behaviours, the disorder-inherent deficits and symptoms
could also be accompanied by sexual dysfunctions in ASD men and women. Sexual dysfunctions
are disorders characterized by a clinically significant disturbance in a person’s ability to respond
sexually or to experience sexual pleasure [1]. Sexual dysfunctions are usually classified in accordance
with the four phases of the sexual reaction cycle: disorders of sexual appetence (e.g., female sexual
interest/arousal disorder), disorders of sexual desire (e.g., erectile disorder, male hypoactive sexual
desire disorder), orgasm disorders (e.g., premature (early) ejaculation and delayed ejaculation, female
orgasmic disorder) and sexual pain disorders. (e.g., genito-pelvic pain/penetration disorder). In the
general population it is estimated that about 40% to 50% of all women report at least one sexual
dysfunction throughout their lifetime, while the life-time prevalence in men is estimated to be about
20% to 40% [20–22].
Bancroft and Janssen have developed a theoretical model, which could help to explain some
aspects of the emergence of sexual dysfunctions in both men and women: the Dual Control Model
of Sexual Response [23]. The Dual Control Model postulates that whether or not a sexual response
occurs in a particular situation depends on the interaction between an excitatory and an inhibitory
neuroanatomical and neuroendocrinological network [23,24]. Individuals high in sexual inhibition
and low in sexual excitation are more likely to develop sexual dysfunctions [23,25,26].
Based on these findings we aimed at assessing symptoms of sexual dysfunctions in men and
women with ASD using standardized assessment scales and at evaluating the association between
the individual propensity of sexual excitation and inhibition and sexual dysfunctions in both ASD
individuals and healthy controls. Due to the above-stated ASD specific symptoms we hypothesized
that (1.) both men and women with ASD would show more signs of sexual dysfunctions than healthy
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controls and (2.) that in individuals with ASD as well as in healthy controls higher sexual excitation
and lower sexual inhibition scores would be related with less signs of sexual dysfunctions.
2. Materials and Methods
2.1. Participants
The present study included n = 96 adults with high-functioning Autism or Asperger syndrome
who were compared to n = 96 healthy controls. In order to control for the influence of age and education
on the sexual outcome measures the participants were matched concerning these variables (Table 1).
All patients with ASD self-reported that they had been diagnosed by an experienced psychiatrist or
psychologist. However, due to data protection regularities we did not gather any more information
from the diagnosing clinicians about the diagnostic procedures. In Germany, mental disorders are
usually diagnosed based on the diagnostic criteria of the International Classification of Diseases, 10th
version (ICD-10) of the World Health Organization (WHO) and thus it could be assumed that all
diagnoses of our study participants were made according to the ICD-10. Mean age at which patients
received their ASD diagnosis was 35.7 years (SD = 9.1 years; range = 17 to 55 years). To assess
the extent of autism symptoms all participants rated the German version of the Autism Spectrum
Quotient-Short Form (AQ-SF) [27]. ASD patients had significantly higher scores on the AQ-SF than
the healthy controls (Table 1). While all of the ASD patients scored above the proposed cut-off value of
17 points in the AQ-SF, none of the healthy controls did so. Both, the ASD individuals as well as our
control participants had on average 12 years of school education suggesting that all of them had at
least average intellectual functioning.
Table 1. Sociodemographic and clinical characteristics of study participants.
ASD (n = 96) HCs (n = 96)
Male (n, %) 56 (58.3%) 57 (59.4%)
Age (years, SD) 39.2 (9.5) 37.9 (9.7)
School education (years, SD) 11.9 (1.5) 12.4 (1.3)
AQ sum score (M, SD) 26.7 (4.9) 6.4 (3.3)
Regular use of alcohol (n, %) 21 (21.9%) 50 (52.1%) **
Regular use of illegal drugs (n, %) 7 (7.3%) 12 (12.5%)
Any psychiatric disorders other than ASD 34 (35.4%) ** 0
Endocrine disorders 5 (5.2%) 0
Genital abnormalities 0 0
Regular medication intake 57 (59.4%) ** 16 (16.7%)
Regular intake of psychopharmacological drugs 30 (31.3%) ** 2 (2.1%)
Hormone replacement therapy 4 (4.2%) 2 (2.1%)
ASD = Autism Spectrum Disorder; HCs = Healthy Controls. Regular intake is defined as at least three times a week.
** p ≤ 0.01.
Of the ASD patients 78.2% (n = 75) indicated being exclusively or predominantly heterosexual,
10.4% (n = 10) being exclusively or predominantly homosexual, 8.3% (n = 8) being equally hetero- and
homosexual and 3.1% (n = 3) indicated having no sexual orientation. In contrast, all healthy controls
(HCs) were exclusively or predominantly heterosexual. Sexual orientation was assessed using the
Kinsey scale [28]. More HCs (n = 78, 81.3%) were currently in a relationship than individuals with
ASD (n = 27, 28.1%; p < 0.001) and more HCs (n = 96, 100%) indicated that they had previously been in
a relationship lasting more than three month than individuals with ASD (n = 60; 62.5%; p < 0.001).
The control participants consumed alcoholic beverages on a more regular basis than the ASD
individuals. On the other side more individuals with an ASD reported about psychiatric comorbidities,
about regular medication intake in general and intake of psychopharmacological drugs in specific.
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2.2. Procedure
All information about study participants were gathered using self-report questionnaires. These
could be answered at home. Individuals diagnosed with ASD were recruited via self-help groups
throughout Germany and through the Autism outpatient centre at the University Medical Center
Hamburg-Eppendorf, Germany. Healthy controls were recruited through advertisements at the
University Medical Center Hamburg-Eppendorf, at the University Medical Center Mainz, at local
shopping malls and through personal contacts of the principal investigators.
The ethical review board of the Hamburg Medical Council approved the study protocol of the
present study (PV4380).
2.3. Measures
2.3.1. International Index of Erectile Function (IIEF)
The IIEF consists of 15 items and assesses the extent of sexual problems in male respondents.
Thereby, sexual functioning is measured on five subscales: erectile functioning, orgasmic functioning,
sexual desire, satisfaction with sexual intercourse and overall sexual satisfaction. Lower scores on each
subscale represent more problems. The guidelines on the clinical application of the IIEF recommend
that patients with a score below 14 out of 30 points on the erectile functioning subscale should be
considered for treatment with Sildenafil [29]. Internal consistency for the total score as well as for all
subscales of the original version of the IIEF was between α = 0.73 and 0.91 [29]. In the validation study
of the German version of the questionnaire internal validity of the total score was α = 0.95, however,
in contrast to the English version only a four-factorial solution was found [30]. In a follow-up study
with 261 German men the original five factor structure could be replicated by confirmatory factor
analysis, although a four-factor model represented an acceptable fit as well [31]. Nevertheless, in the
present study we followed the original five-factor model of the questionnaire.
2.3.2. Female Sexual Function Index (FSFI)
The FSFI consists of 19 items and assesses the extent of sexual problems in women on six domains:
sexual desire, sexual arousal, lubrication, orgasm, sexual satisfaction and sexual pain. Lower scores
represent more problems. Internal consistency for the total score as well as for all subscales of the
original version of the IIEF was above α = 0.82 and test-retest reliabilities were between r = 0.79 and
0.86 for the subscales [32]. The German validation study was performed using an online sample
of 1243 German women and supported the six factorial design of the original version. Internal
consistencies were between α = 0.75 and 0.95 for the total score and the scores of the subscales [33].
2.3.3. Sexual Inhibition/Sexual Excitation Scales-Short Form (SIS/SES-SF)
Based on the Dual Control Model of Sexual Response the SIS/SES-SF is a 14-item questionnaire
that assesses participants’ reactions in sexual situations on three subscales: one sexual excitation
subscale (SES) and two sexual inhibition subscales (SIS1 and SIS2) [34]. While SIS1 measures sexual
inhibition due to a threat of performance failure, SIS2 assesses sexual inhibition due to a threat of
performance consequences, for example, unwanted pregnancy or sexually transmitted diseases [35].
In a first validation study of the German version of the SIS/SES-SF, internal consistencies of α = 0.82
for SES, α = 0.60 for SIS1 and α = 0.70 for SIS 2 were reported [36].
3. Results
3.1. Relationship and Sexual Satisfaction
While more women from the control group viewed sexuality as an important part in their lives
(HCs: 53.8% vs. ASD: 20%), no differences occurred concerning relationship and sexual satisfaction
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between women with ASD and women from the control group. Moreover, more female controls rated
themselves as being sexually attractive (HCs: 53.8% vs. ASD: 20%).
When comparing ASD men to men from the control group, it was found that more male controls
were satisfied with their current relationship (HCs: 63.8% vs. ASD: 11.1%) and sexual life (HCs: 59.6%
vs. ASD: 10.7%). Furthermore, more male controls viewed themselves as being sexually attractive
(HCs: 73.7% vs. ASD: 3.6%), while no differences occurred concerning the importance of sexuality.
Finally, when comparing ASD women with ASD men it was found that more ASD women were
currently in a relationship (women: 46.2% vs. men: 16.1%), more ASD women were satisfied with their
current relationship (women: 44.4% vs. men: 11.1%) and ASD women viewed themselves as more
sexually attractive than ASD men (women: 20.0% vs. men: 3.6%). On the other side more ASD men
viewed sexuality as an important part in their life (women: 20.0% vs. men: 50.0%). No differences
occurred concerning sexual satisfaction.
3.2. Sexual Dysfunctions
The female controls scored significantly higher on all FSFI subscales indicating that they reported
less problems with sexual desire, sexual arousal and sexual satisfaction, lubrication, orgasm quality
and less sexual pain compared to the women with ASD (Table 2). The male controls also reported
about significantly better overall sexual functioning than the ASD men. However, when assessing the
IIEF subscales this accounted only for erectile functioning and sexual intercourse satisfaction, while no
differences were found concerning orgasmic functioning and sexual desire. Furthermore, more ASD
men than male controls were below the cut off for erectile functioning problems justifying the use of
medication to treat these problems, however, this difference only closely approached the intended
level of significance (Table 2).
Table 2. Average questionnaire sum and subscale scores compared between autism spectrum disorder
(ASD) patients and healthy controls (HCs).
ASD HCs t/χ2 p
Women
SES 10.06 (SD = 4.14) 14.6 (SD = 2.67) 3.66 0.001
SIS1 11.94 (SD = 1.80) 9.53 (SD = 1.41) −4.23 0.0001
SIS2 14.22 (SD = 1.66) 12.71 (SD = 1.94) −2.37 0.03
FSFI Sum score (max. 95) 38.21 (SD = 22.65) 78.67 (SD = 9.48) 10.31 0.0001
FSFI Desire (max. 10) 3.3 (SD = 1.95) 6.27 (SD = 1.53) 7.52 0.0001
FSFI Arousal (max. 20) 8.5 (SD = 6.05) 16.87 (SD = 2.42) 8.03 0.0001
FSFI Lubrication (max. 20) 10.1 (SD = 7.83) 18.33 (SD = 1.68) 6.42 0.0001
FSFI Orgasm (max. 15) 6.45 (SD = 4.97) 12.80 (SD = 2.51) 7.14 0.0001
FSFI Satisfaction (max. 15) 6.95 (SD = 3.47) 11.93 (SD = 2.46) 7.34 0.0001
FSFI Pain (max. 15) 4.25 (SD = 6.49) 12.47 (SD = 4.19) 6.67 0.0001
Men
SES 17.5 (SD = 3.20) 13.89 (SD = 2.53) −4.56 0.0001
SIS1 10.04 (SD = 2.25) 9.56 (SD = 1.85) −0.86 0.40
SIS2 12.67 (SD = 2.75) 11.96 (SD = 2.46) −0.97 0.34
IIEF sum score (max. 75) 39.96 (SD = 14.35) 55.70 (SD = 19.11) 6.89 0.0001
IIEF erectile function (max. 30) 15.54 (SD = 7.56) 23.19 (SD = 9.50) 4.73 0.0001
IIEF orgasmic function (max. 10) 8.0 (SD = 3.19) 8.3 (SD = 3.12) 0.05 0.61
IIEF sexual desire (max. 10) 6.69 (SD = 1.98) 7.07 (SD = 1.57) 1.13 0.26
IIEF intercourse satisfaction (max. 15) 2.12 (SD = 4.11) 9.52 (SD = 4.58) 9.03 0.0001
IIEF overall satisfaction (max. 10) 4.65 (SD = 1.83) 7.63 (SD = 2.36) 7.49 0.0001
Below cut off for erectile function problems (<14) 12 (21.4%) 5 (8.8%) 3.54 0.06
FSFI = Female Sexual Function Index, IIEF = International Index of Erectile Functioning.
In order to address the impact of the assessed clinical characteristics on sexual functioning in
our ASD participants, we calculated two linear logistic regression analyses (one for the male ASD
participants and one for the female ASD participants) with overall sexual functioning (IIEF sum score
in men and FSFI sum score in women) as the outcome variable and regular alcohol or illegal drug
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intake, any psychiatric disorders, any endocrine disorders, genital abnormalities, regular intake of
psychopharmacological agents and hormone replacement therapy as predictors. Table 3 gives an
overview about the results of the logistic regression analyses showing that neither in ASD men nor in
ASD women any of the additionally assessed clinical features had a significant influence on the overall
sexual functioning scores.
Table 3. Linear logistic regression addressing the relationship between clinical factors and sexual
dysfunctions in individuals with Autism Spectrum Disorder (ASD).
Coefficients
b SE p Exp(B) 95% CI
ASD Men
Regular alcohol intake 0.01 7.14 0.96 0.37 −14.53–15.26
Regular intake of illegal drugs 0.25 11.55 0.27 13.02 −11.07–37.10
Any other psychiatric disorder 0.04 6.43 0.86 1.15 −12.25–14.56
Regular intake of drugs 0.01 6.87 0.99 0.06 −14.28–14.40
Regular intake of
psychopharmacological drugs −0.51 8.19 0.08 −15.15 −32.24–1.94
ASD Women
Regular alcohol intake 0.1 19.51 0.79 5.21 −37.74–48.16
Regular intake of illegal drugs 0.24 25.44 0.51 17.32 −38.68–73.32
Any other psychiatric disorder 0.03 14.58 0.93 1.40 −30.70–33.50
Endocrinological disorders −0.50 22.86 0.21 −30.30 −80.61–20.02
Regular intake of drugs 0.37 20.34 0.30 22.36 −22.40–67.13
Regular intake of
psychopharmacological drugs −0.46 16.26 0.23 −20.65 −56.43–15.13
Hormone replacement therapy −0.08 14.88 0.81 −3.76 −36.51–28.99
3.3. Sexual Excitation and Sexual Inhibition
Table 2 also provides an overview about the SIS/SES-SF scores in ASD women and men compared
to the HCs. While ASD women had significantly lower scores in sexual excitation compared to their
non-ASD counterparts, ASD men had significantly higher scores on the sexual excitation subscale.
Furthermore, women with ASD also had higher scores in SIS1 and SIS2, while no differences occurred
between ASD men and the HCs.
3.4. Correlational Analyses
Women with ASD scoring higher on SES reported fewer overall problems with sexual functioning
(Table 4). More specifically, higher SES scores were correlated with fewer problems with sexual desire,
sexual arousal, lubrication and orgasm. No significant correlations were found between SIS1 and SIS2
and any of the FSFI subscales in ASD women. Comparably, in healthy women SES was also positively
correlated with overall sexual functioning. Furthermore, SIS2 was negatively correlated with sexual
desire and sexual arousal, meaning that those with higher SIS2 scores reported about more problems
with sexual desire and sexual arousal.
In the male controls higher scores in SES were correlated with higher scores with overall sexual
functioning, erectile functioning, sexual desire and overall sexual satisfaction (Table 5). In contrast, no
association was found between SES and any of the IIEF subscales in ASD men, however, SIS1 and SIS2
were negatively correlated with overall sexual functioning as well as most of the IIEF subscales.
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Table 4. Correlational analysis between the sexual inhibition/sexual excitation scales short form















SES 0.40 ** 0.48 ** 0.56 ** 0.43 ** 0.51 ** −0.16 0.11
SIS1 −0.19 −0.19 −0.27 −0.26 −0.29 0.20 −0.14
SIS2 −0.26 −0.11 −0.20 −0.20 −0.09 0.06 −0.14
Healthy controls
SES 0.58 ** 0.50 ** 0.30 0.13 0.45 ** 0.64 ** 0.63 **
SIS1 −0.27 −0.04 −0.13 −0.26 −0.15 −0.13 −0.26
SIS2 −0.12 −0.46 ** −0.43 ** −0.12 −0.03 −0.07 0.22
** p < 0.01.














SES 0.19 0.21 0.17 0.10 0.18 0.01
SIS1 −0.37 ** −0.40 ** −0.31 * −0.10 −0.37 ** −0.16
SIS2 −0.34 ** −0.36 ** −0.26 * −0.37 ** −0.34 ** −0.04
Healthy controls
SES 0.43 ** 0.45 ** 0.10 0.46 ** −0.01 0.30 *
SIS1 −0.01 −0.03 −0.23 0.06 0.14 0.07
SIS2 0.02 0.06 −0.21 −0.05 0.17 −0.03
* p < 0.05; ** p < 0.01.
4. Discussion
To our knowledge, this is the first study to explore symptoms of sexual dysfunctions using
self-report scales in a cohort of women and men with high-functioning ASD in comparison with a
matched control group. In line with previous research, significantly less ASD men and women
were currently in a romantic relationship compared to the HCs [37,38]. As was suggested in
the introduction the disorder-specific symptoms like deficits in intuitively understanding social
and nonverbal communication cues, difficulties in perspective-taking, cognitive and behavioural
inflexibility as well as affective dysregulation, might hamper the initiation of romantic relationships in
ASD individuals. Furthermore, both men and women with ASD reported lower relationship and sexual
satisfaction than the HCs [39]. Within the present study we did not evaluate whether or not the current
spouse of our study participants was diagnosed with ASD as well, however, this seems to be quite
important, because it was shown that having a relationship with another autistic individual leads to
an improved relationship satisfaction [13]. Women with ASD often have better social learning abilities,
share more common interests with their peer group, have more advanced coping strategies and show
less overt restricted interests and repetitive behaviours [40,41]. Thus, their problems in initiating and
maintaining a romantic relationship are often not as pronounced as in ASD men, explaining why more
women with ASD than men within the present study were in a romantic relationship [42]. Although
fewer men with ASD were in a relationship compared to female ASD individuals, more men reported
that sexuality was an important part in their life. These unfulfilled sexual desires could indicate that
overall ASD men experience more distress concerning their own sexuality than ASD women.
Concerning sexual functioning it was found that men with ASD reported more problems with
erectile functioning than the HCs. However, despite the findings of previous research that men with
erectile dysfunctions from the general population usually have lower SES scores than those without
erectile dysfunctions, the ASD men had significantly higher scores in sexual excitation than their
non-affected counterparts [23,25,26]. This quite unexpected result could be the consequence of the
peculiarities in sensitive perception in ASD men. On the one side the hypersensitivities experienced
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by many ASD men could cause that discrete (and even non-sexual) cues could be perceived as quite
intense and sexually arousing, meaning that ASD men get sexually aroused more easily. In terms of the
Dual Control Model this could be translated to a higher sexual excitation (e.g., Item 1 of the SIS/SES-SF:
“When a sexually attractive stranger accidentally touches me, I easily become aroused”). On the other
side, as quickly as sexual arousal might arise in ASD men, it could also decline again because due
to the pronounced hypersensitivity a constant and increasingly strong stimulation is necessary in
order to hold sexual arousal on an adequate level. This in many cases might not be possible and thus
in the long run men with ASD experience more problems with erectile functioning because of the
possibly more rapidly decreasing sexual arousal during (sexual) stimulation. Supporting this line of
argument, the individual propensity of sexual excitation did not correlate neither with the IIEF sum
score nor with any of the IIEF subscales, suggesting that sexual excitation might refer to a different
kind of behaviour in ASD men compared to healthy men. A further possible explanation could be that
ASD men have difficulties in recognizing and classifying signs of excitement and therefore answered
the questions regarding excitement in a different manner than the male controls. Concerning the
individual propensity of sexual inhibition, no differences were found between ASD men and the male
controls. Furthermore, medium to large correlations in the expected direction were found between
both sexual inhibition factors and the IIEF sum score and most of the IIEF subscales in the male ASD
sample. These findings indicate that just like their non-affected counterparts, ASD men with a stronger
propensity of sexual inhibition due to a threat of performance failure or due to a threat of performance
consequences report about more sexual dysfunctions [23,26].
Comparably to the ASD men, the ASD women also reported significantly more sexual
dysfunctions across all of the FSFI domains compared to the female controls. Just like in the ASD men
this could be the consequence of the peculiarities in sensitive perception. However, the significantly
lower sexual excitation and significantly higher sexual inhibition scores suggest that while in men
hypersensitivities might be more important in the aetiology of sexual dysfunctions, in women it might
rather be hyposensitivities. Women with ASD might need more intense sexual stimulation to become
and stay sexually aroused during having sex and to reach an orgasm, explaining the lower sexual
excitation scores. However, the ASD women in the present study also reported more frequently about
sexual pain problems, suggesting that not only hyposensitivities but also hypersensitivities could be
of relevance and it could be possible that normotypical sexual intercourse is perceived as painful by
some ASD women. Both women with ASD and female controls scoring higher on sexual excitation
reported better sexual functioning. Comparably, previous research found that in women from the
general population higher SES scores were positively correlated with a more positive attitude towards
sexuality, higher overall sexual functioning, higher sexual desire, higher sexual arousal, less problems
with lubrication and higher orgasm quality [36,43,44]. Although women with ASD had significantly
lower sexual inhibition scores than female HCs, no association was found between sexual inhibition
and sexual functioning in the ASD women. ASD women have an up to three times increased risk to be
sexually victimized than non-ASD women, which could explain the higher sexual inhibition scores.
It could have been expected that those individuals with an especially pronounced propensity of sexual
inhibition would also show more sexual dysfunctions, however, this was obviously not the case [45].
The findings of the present study are limited because diagnoses were assessed via self-report and
one cannot be sure that all participants were diagnosed by a trained psychologist or psychiatrist. Due to
data protection regulations we were not allowed to contact the diagnosing clinicians in order to verify
the diagnoses of our study participants. We tried to reduce false positives by using the well-established
cut-off of the German version of the AQ-SF, which proved in other studies to be sufficiently sensitive
and specific to assess autistic symptomatology [27]. Nevertheless, future studies should choose a more
standardized assessment approach concerning the verification of clinical diagnoses, for example by
conducting a clinical interview. Furthermore, all participants were recruited through ASD self-help
groups or ASD outpatient care centres, indicating that their contact with the medical system was due
to their symptomatology. Although we assessed comorbid psychiatric disorders in general, we did
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not evaluate specific disorders, such as depressive or anxiety disorders, which are highly prevalent in
autistic individuals and could affect sexual well-being and functioning. Using diagnostic interviews in
future studies could help to also prevent this shortcoming. Furthermore, we did not assess intellectual
functioning of our participants (e.g., by assessing IQ scores), however, as our study participants had on
average 12 years of school education it can be assumed that all participants possessed at least average
intellectual abilities. It is possible that especially individuals with a higher interest in sexuality-related
issues and perhaps also with more sexual problems, were more likely to volunteer to participate in the
present study leading to a sampling bias and an overestimation of sexual problems. However, it is
likely that this should have also accounted for the individuals in the control group, thereby equalizing
a possible overestimation of the actual rate of sexual dysfunctions in the ASD group at least to some
degree. Our results are further limited by the fact that we did not evaluate whether or not the spouses
of our ASD individuals were diagnosed with ASD as well. As stated above previous research has
suggested higher sexual and relationship satisfaction when both companions are diagnosed with ASD.
Thus, future studies addressing sexual functioning of ASD individuals should definitely consider this
point. Finally, we did not evaluate hormonal profiles of our study participants, although differences in
hormone serum concentrations could have a great impact on sexual functioning as well. Future studies
should therefore assess the hormonal profiles of ASD individuals in order to find out if the increased
prevalence of sexual dysfunctions found in ASD individuals is due to somatic or psychiatric reasons
or both. At least though we did not find any differences in the self-reported frequency of endocrine
disorders, genital abnormalities or hormonal substitution treatment.
The present study has shown that a considerable number of individuals with ASD report about
a general relationship and sexual dissatisfaction and about sexual dysfunctions. Furthermore, the
sexual problems are probably to a large part attributable to the disorder-specific symptoms, such as
impaired social and interpersonal skills, difficulties in perspective taking and theory of mind and the
peculiarities in sensitive perception. This points out that there is a great need for specialized treatment
programs teaching individuals with ASD how they can, despite their disorder, have a fulfilling and
satisfying sexual life. Unfortunately, such treatment programs are almost non-existent up to now, at
least for adults with high-functioning ASD.
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Abstract: This paper explores the subjective perception of some personal and interpersonal aspects of
the lives of transgender people and the relationship they have with their mental health. One hundred
and twenty transgender people (60 men and 60 women) participated in semi-structured interviews.
Following quantitative methodology, analysis highlighted that social loneliness is the main predictor
of lower levels of mental health (anxiety and depression) for both genders and recognized romantic
loneliness as the strongest factor among transgender men. In both cases, higher levels of loneliness
were associated with lower levels of mental health. The results have guided us to improve
institutional and social responses and have provided an opportunity to promote the mental health of
transgender people.
Keywords: transgender; anxiety; depression; social loneliness; romantic loneliness
1. Introduction
The mental health of transgender people is frequently disturbed in several spheres [1]. According
to this, the Minority Stress Model asserts that mental health distress is often the result of a hostile
or stressful social environment [2]. This model describes the processes by which sexual and gender
minorities are subjected to minority stress: (a) distal or external stressors (environmental), such as
exposure to discrimination and violence; (b) proximal interpersonal stressors such as feelings or
expectations that external stressors will occur and the need to protect oneself from these external
stressors; and (c) proximal personal stressors that reflect an internalization of negative attitudes and
prejudice from society. Conversely, interactive and internalized proximal resilience is also possible,
with internalization of positive self-image, use of adaptive coping skills and community attachments.
Interactive and internalized proximal stressors are frequently described as distressing. The cumulative
stressors can serve to overwhelm themselves and to lead to poor mental health outcomes [3].
Over the last decades, several studies have been focused on transgender people’s mental health
and other personal and interpersonal variables (stressors) including self-esteem and body image [4],
coping skills [5], social and emotional loneliness [6], sexual satisfaction [7] or anxiety and depression [8],
yet there are no studies in Spain analysing how all these topics are able to explain the state of
transgender people’s mental health.
This work focuses on internalized proximal stressors (self-esteem, body image and coping
skills) and interpersonal ones (social and emotional loneliness and sexual satisfaction), as well as the
associations occurring in transgender people’s mental health (anxiety and depression). To improve the
empowerment and mental health of transgender people, proximal stressors (more modifiable taking
into account personal aspects) need to be identified, which would provide both transgender people
and professionals the opportunity to intervene.
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1.1. Mental Health: Anxiety and Depression in Transgender People
The concepts of mental health and the specific nature of the relationship between anxiety and
depression have been much debated. Research from the past decades has been reviewed to assess
whether there is a quantitative or qualitative difference between anxiety and depression. Anxiety
and depression syndromes have been studied both separately and combined to determine whether a
quantitative or qualitative difference exists between them [9]. In the end, although there are several
studies supporting comorbidity between anxiety and depression [10], they are commonly perceived
as different; depressed disorders are characterized by a devaluation of self and negative attitudes
toward the past and future, whereas anxiety disorders are marked by themes of danger and anticipated
harm [11].
Although mental health problems may be self-limiting or may respond to self-help or
to lay-help [12], delaying or avoiding formal care can result in problematic consequences.
Too, the duration of untreated illness is associated with worsened outcomes in mental health problems
such as major depressive and anxiety disorders [13]. The stigma resulting from a context in which
power is exercised to the detriment of members of a social group [14], in this case, transgender
people, includes such behaviours as labelling, separation, stereotype awareness and prejudice and
discrimination. This stigma, along with mental health problems, is an important factor which
prevents people from seeking help [15]. Additionally, this stigma plays an important role in limiting
the opportunities and access to resources of transgender people in a number of critical domains
(e.g., employment, healthcare, etc.), while continuously having a detrimental effect on their mental
health [16]. A large body of literature points out that transgender people experience greater mental
health problems, such as depression and anxiety [17,18] than do cisgender individuals (cisgender
refers to those who are not transgender). Concretely, transgender people experience greater quantities
of stressors from childhood which result in an increase of mental health problems such as depression
and anxiety [19]. Transgender individuals, too, face a host of minority stressors specific to their sexual
and gender minority identities. Viewed from a broader perspective, stigmatized people may be more
susceptible to mental health problems due to the accumulation of stressors experienced over the course
of a lifetime, as opposed to simply experiencing those stressors in isolated, discrete moments [18].
In addition, many community-based surveys have found that women (with no differences
between cisgender and transgender), on average, experience depressed moods more frequently than
men, as measured by self-report scales [20]. Women also self-report higher levels of anxiety [21]. Too,
though the range of anxiety being studied varies, findings show that transgender men experience
anxiety more frequently than transgender women [8,22,23].
1.2. Proximal Stressors in Transgender People
Transgender people have been found to face multiple difficulties and interpersonal challenges [24].
Forms of rejection from family and loved ones [25], low levels of self-esteem [26] and body image
problems resulting from an attempt to reject those body parts that they do not identify with [27], are all
examples of such challenges. Furthermore, although the association between transgender status and
sexuality is commonly taken for granted and though research exists regarding improvements in sexual
functioning after transition [28] and the importance of sexual life for humans in general [29], there is
no substantial evidence pointing to sexual satisfaction in this population but rather to an unsatisfactory
sex life [30]. In any case, the importance of social relations is not unique to the transgender population;
humans are social beings who form attachments from the moment they are born [31]. They have a
fundamental, adaptive need to belong [32]. Additionally, coping skills are vital to living a successful
life and to maintaining a healthy mental health state [33,34]. Coping mechanisms, therefore, have been
theorized to buffer the effects of mental health problems which result from stigmatization [2].
The impact that stressors have on both physical and mental health have been summarized in
previous studies [3]. This literature, however, does not take gender into account when studying
transgender status, nor have previous studies looked at transgender men or women individually.
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Finally, although certain stressors were studied both separately and jointly, no comprehensive studies
yet exist in which proximal stressors are examined, including that of self-esteem, body image, coping
skills, loneliness (social, family and romantic) and sexual satisfaction.
1.3. Associations Between Proximal Stressors and Mental Health for Transgender People
Much research exists linking different stressors to anxiety and depression. A large body
of literature exists in which the relationship between self-esteem and depression is discussed.
Furthermore, there is a growing body of longitudinal studies which indicate low levels of self-esteem
predetermine depression; and correspondingly, people with high levels of self-esteem appear to have a
lesser risk of suffering from depression [35]. In the same line, several theories postulate that a higher
level of self-esteem serves as a buffer against anxiety [36]. This association was found within the
transgender population as well, in relation to both anxiety and depression [37,38].
Body image is yet another factor that plays an important role in mental health [39]. Dissatisfaction
with body image has been associated with an increase in mental health problems [40], a fact which
holds true in the case of the transgender population [41]. The reinforcement of coping strategies,
on the other hand, has proven effective in the management of issues encountered in the day to day,
specifically in the prevention of problems related to mental health [42]. In fact, problem-focused
coping predicted positive mental health outcomes among transgender youth [43] and the application
of avoidant coping strategies during transitioning to manage gender-related stress has been associated
with both depression and anxiety [8].
Interpersonal context has shown to be a major theme in the prevention or reduction of mental
health problems. General loneliness was found to be an important variable for mental health [44].
Some authors have demonstrated that the emotional loneliness resulting from being cut-off from
one’s family is the strongest variable related to issues in mental health [45]. A large percentage of
transgender individuals experience family rejection, social isolation and loneliness, which can result in
a number of negative issues including mental health problems [46].
Sexuality is also a central topic for human development [47]. Specifically, there is a reciprocal
relationship between certain mental problems such as anxiety and depression and sex problems [48].
Some studies in which other excluded populations were subjects, discovered that sexual satisfaction
predicts positive mental health [49–52]. In terms of the transgender population, most studies which
investigate sexual function are focused only on post-surgical outcomes [53].
Previous work studies the relationship that exists between different stressors and mental health
but does not take into account the role that gender may play in this relationship owing to the fact that
men and women are usually studied together [54], nor are the ways in which gender could affect the
associations between stressors and mental health yet determined.
In summary, existing research has demonstrated that self-esteem, body image, coping skills,
loneliness and sexual satisfaction are predictors of depression and anxiety. However, existing studies
have not yet examined the relationships that exist between each of these variables and how gender
moderates these relationships. The purpose of this study, therefore, is to examine the pattern of
connections among each of these variables as they relate to transgender individuals, both transgender
men and women. The current study aims to investigate (1) whether higher levels of self-esteem,
body image, proactive coping skills, sexual satisfaction and lower levels of loneliness will be associated
to better mental health and (2) whether differences exist between men and women.
2. Experimental Section
2.1. Participants
The sample consisted of 120 transgender people residing within Spain (93.3% Spanish and
6.7% foreigners, all from South America), 60 men (female-to-male) and 60 women (male-to-female).
Participants were recruited in different cities and villages by this article’s authors. Contact was made
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via phone call or emails sent to people in LGTB or Transgender non-profit organizations and internet
forums on websites aimed at LGTB or transgender information. The age range of the sample was 18
to 63 years old (M = 33.8; S.D. = 10.1). Of the participants, 19.1% had primary studies, 15% finished
secondary school, 38.3% finished professional training and 27.5% finished university. We selected
participants while maintaining a balanced number of men and women in three different reassignment
moments (i.e., persons who assumed gender without any hormonal or surgery treatment, persons in
hormonal treatment, persons in surgery reassignment process and persons who fully reassigned their
sex). After stratifying by gender and reassignment moments, they were selected under a “snowball”
sampling scheme [55].
2.2. Procedure
The people who responded positively to the recruitment method were given a standard
description of the study and were evaluated for their eligibility to participate which consisted of
the following criteria: individuals had to identify themselves as exclusively transgender at the time of
the interview, did not have any mental health problem diagnosis or current state that impede to answer
accurately to an interview (e.g., schizophrenia or being under the influence of drugs, etc.), expressed a
consistent desire to have reassignment surgery and were 18 years of age or older. Eligible participants
who expressed an interest in participating in the study were interviewed in-person at a location of
their choosing (e.g., home, cafeteria, etc.). Individuals participating in the study did so voluntarily and
there were no incentives in exchange for participation. The study was conducted in Spanish.
Face to face interviews lasting about 90 min were conducted in which each participant was orally
asked all the questions in order to assure that everything was fully understood, taking into account
the modest educational level of a considerable percentage of participants. First author of this paper
introduced herself as member of the university staff and expressed our interest in the experiences of
transgender people. Only upon establishing rapport, informing participants that they were free to
leave the study whenever they wished and that their participation was confidential and voluntary and
explicitly obtaining informed consent, did interviews commence. Upholding these ethical standards is
vital for the collection of good quality data. The Good Practice Manual for Research of CSIC (2011)




Self-esteem. The instrument used was the Tennessee Self-Concept Scale 2nd Edition (TSCS:2)
developed by Fitts and Warren as a review of Tennessee Self-Concept Scale [57,58]. The complete scale
consists of 82 statements. The items are classified into three dimensions: (1) identity and self-concept:
how does the individual see him/herself (30 items); (2) self-satisfaction or self-esteem: how does the
individual accept him/herself (30 items); (3) self-behaviour: how does the individual behave towards
him/herself (30 items). The short form is used with the first 20 questions and gives an indication
of whether a person tends to see him/herself as generally positive and consistent or negative and
variable. Scores from 1 (always false) to 5 (always true) are used, with higher scores reflecting higher
levels of self-esteem. This instrument was chosen because it is standardized, easy to administer and
has presented a good validity showing high correlations with other self-esteem scales [57]. Cronbach’s
alpha in this study was 0.83.
Body Image. The Body Image Scale [59] was used. A higher score indicates higher levels of
dissatisfaction. On the 14-item Appraisal of Appearance Inventory (AAI), three independent observers
(the diagnostician, a nurse from the gender team and the researcher) rated their subjective appraisal
of the appearance of the subject on a 5-point scale of femininity/masculinity. Higher scores indicate
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higher levels of incompatibility with the appearance of the new gender. Cronbach’s alpha in this study
was 0.93.
Coping Skills. The Coping Skills Scale summarizes the dimensions described by Lazarus and
Folkman [60,61]. It is a multidimensional instrument that assesses active coping, social support coping,
avoidant coping cognitive passivity and repression and avoidant coping behaviour or refusal.
Certain items were eliminated from the scale for use in this study as they were not considered to be
adequate indicators of the coping strategy. The scale has been adapted according to the characteristics of
the participating sample and by combining the two avoidance coping subscales into one. The response
format, however, was not altered: a scale from 1 (I have never faced a situation like that) to 4 (I have
come into contact with a situation like that many times) was applied. An exploratory factor analysis was
conducted in order to pinpoint these modifications, yielding five factors (66.95% variance explained)
that ultimately were grouped into three factors to rule out the items in our sample did not indicate the
use of the strategy for coping in the original scale: active coping strategy, coping strategies and social
support avoidant coping strategy, which account for 60.96% of the variance.
In our study, internal consistency for the subscale of social support coping corrected (7,8,13,17)
was an alpha of 0.70 for active coping subscale corrected (1,6,9,12) alpha was of 0.75 and avoidant
coping subscale corrected (2,3,4,5,14) was 0.77.
Social and emotional loneliness. The short version of the Social and Emotional Loneliness Scale for
Adults (SELSA-S) was used to measure both types of loneliness [45]. In fact, SELSA-S consists of three
subscales labelled (a) social loneliness, (b) family-emotional loneliness and (c) romantic-emotional
loneliness. Participants rated 15 items, 5 of every subscale. Items were rated on a 7-point Likert-type
scale that ranged from 1 (strongly disagree) to 7 (strongly agree). The total score of every subscale was
obtained by summing up the items, with possible scores ranging from 7 to 35. There is no total score
for loneliness because this measure comes from a multidimensional perspective of loneliness. In this
study Cronbach’s alpha was 0.83 for family-emotional, 0.77 for social and 0.74 for romantic-emotional.
Sexual satisfaction. The subscale of sexual satisfaction of the Multidimensional Sexual
Self-Concept Questionnaire (MSSCQ) was used to measure this aspect [7]. A total 5 of 5 items
were scored on a 7-point Likert-type scale (expanding upon the original 5-point Likert-type scale)
ranging from 1 (not at all characteristic of me) to 7 (very characteristic of me) comparable to a SELSA
scale. Alpha was 0.96 and 0.95 in this study.
2.3.2. Moderator Variable
Gender was recorded as 0 for transgender women and 1 for transgender men.
2.3.3. Outcome Variables
The Anxiety and Depression subscales of The Symptom Checklist of Derogatis (SCL-90-R) were
used to assess anxiety and depression [62]. Twenty-three items were scored, ten items for anxiety and
thirteen for depression. For each item the person was asked to rate severity of depression experienced
over the past week. Responses were scored on a five-point scale ranging from (1) not at all to (5)
extremely. Cronbach’s alpha was 0.92 for anxiety and 0.94 for depression,
For all the scales and subscales, a total score was obtained by adding up the individual scores and
dividing them by the number of items answered.
2.4. Analysis Strategy
As the method of obtaining data was the interview method, no missing data was obtained; all
of the participants answered every question. After data curation, statistical techniques were used
to process the data using descriptive, Pearson correlations and hierarchical regression analysis with
the IBM SPSS 22 package (IBM, Armonk, NY, USA). Firstly, pertinent analyses were carried out to
verify the reliability, normality, independence and homoscedasticity assumptions using Cronbach’s
alpha, Kolmogorov-Smirnov test and Q-Q plots, the collinearity statistics (tolerance index and variance
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inflated factor—VIF and the Breusch-Pagan test respectively. Secondly, independent samples t-test were
used to assess the statistical significance of gender differences. Thirdly, Pearson bivariate correlations
were used to explore the associations between men’s and women’s mental health and stressors.
Fourthly, hierarchical multiple linear regression analysis was used to study the moderating effect of
gender on the criterion variables (anxiety and depression). Before computing these, the assumptions of
the presence of normality, linearity and homoscedasticity, along with the absence of multicollinearity
were tested. Predictors were entered into the first step (main effects) and interactions between gender
and predictors were entered in the second step (interactions between gender and those predictor
variables that showed a different association seem to have responded in a different way in relation to
the gender of the participants). When an interaction is significant, two separate regression models for
each level of the moderator were conducted. Alpha level of 0.05 was used. Finally, power analysis
was obtained using the G*Power program [63] and heteroscedasticity between the predictor and the
criterion variable was run through the macro Heteroskedasticity SPSS [64].
3. Results
The Cronbach’s alpha showed a good reliability and the residual variance was constant with
normality distribution.
All the predictors showed a linear relationship with anxiety and depression as it was observed
in the scatterplot of the standardized residuals with the standardized predicted values. Q-Q plots
and the level of significance obtained when applying the Kolmogorov-Smirnov test (up to 0.05)
showed a good normality. When testing multicollinearity, the tolerance index values for the studied
variables were up to 0.78 for anxiety and 0.69 for depression, which indicated the independence of
the contributions of the predictor variables, producing variance inflated factor (VIF) scores lower
than 10 for all the predictors. Finally, heteroscedasticity was an accomplished assumption because
Breusch-Pagan (LM = 9.87; p = 0.20 for anxiety and LM = 3.05; p = 0.96 for depression) test was not
found significant.
3.1. Gender Differences in Proximal and Mental Health Variables
Descriptive statistics of predictor and outcome variables are displayed in Table 1 for transgender
men and women respectively. To examine whether there are mean differences based on the study
variables, t-tests for independent samples were conducted. Differences in anxiety, body image, social
loneliness and sexual satisfaction were found. Transgender women showed higher levels of anxiety,
social loneliness and sexual satisfaction and a poorer body image.
Table 1. Descriptive statistics for men and women in predictor and outcome variables.
N = 120 Answer Range
Mean SD t p
Tr. Men Tr. Women Tr. Men Tr. Women
Anxiety 1–5 1.13 1.43 0.78 0.84 1.92 <0.05
Depression 1–5 1.65 1.89 0.94 0.98
Body Image 1–5 2.81 3.09 0.58 0.72 2.35 <0.05
Self-esteem 1–5 3.42 3.44 0.54 0.53
Active coping 1–4 2.74 2.79 0.48 0.48
Soc. support coping 1–4 2.59 2.52 0.58 0.72
Avoidant coping 1–4 2.17 2.25 0.46 0.50
Social loneliness 1–7 3.30 3.54 1.39 1.45
Family loneliness 1–7 3.78 3.54 1.67 1.77
Romantic loneliness 1–7 3.82 4.39 1.55 1.39 2.13 <0.05
Sexual satisfaction 1–5 2.53 2.91 0.99 1.10 2.01 <0.05
3.2. Proximal Aspects and Mental Health for Transgender Men and Women
Bivariate correlations of interpersonal variables with anxiety and depression for both men and
women, are shown in Table 2. All the stressors were associated with anxiety and depression except for
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the case of active and social support coping strategies which were not significantly correlated with
anxiety. Similarly, high correlations were observed between anxiety and depression.
Table 2. Bivariate correlations for all the sample (men and women together).
1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11.
1. Anxiety 0.75 * −0.29 ** −0.22 * −0.09 −0.06 0.29 ** 0.40 ** 0.48 ** 0.19 * −0.19 *
2. Depression −0.53 ** −0.45 ** −0.26 ** −0.25 ** 0.58 ** 0.50 ** 0.59 ** 0.23 ** −0.41 **
3. Body image 0.41 ** 0.18 * 0.20 * −0.46 ** −0.43 ** −0.35 ** −0.17 0.51 **
4. Self esteem 0.51 ** 0.25 ** −0.36 ** −0.57 ** −0.54 ** −0.23 ** 0.33 **
5. Active cop. 0.32 ** −0.33 ** −0.35 ** −0.43 ** −0.10 0.24 **
6. Soc. supp. cop. −0.24 ** −0.18 * −0.27 ** 0.02 −0.03
7. Avoidant cop. 0.33 ** 0.39 ** 0.17 −0.33 **
8. Fam. lonel. 0.69 ** 0.12 −0.19 *
9. Soc. lonel. 0.31 ** −0.26 **
10. Rom. lonel. −0.38 **
11. Sex. satisfact.
* p < 0.05; ** p < 0.01.
To identify whether associations of stressors with anxiety and depression varied by gender,
two separate bivariate correlational analyses were conducted for transgender men and women
(see Table 3). Regarding the correlation between the stressors and anxiety, men showed higher
associations for family loneliness, whereas women showed higher associations for body image and
social loneliness. With respect to the correlations between stressors and depression, men showed
higher correlations for family and social loneliness, whereas women presented higher correlations
for body image and avoidant coping strategies, interestingly not showing significant correlations
with loneliness. Some correlations differ for men and women: anxiety and self-esteem, body image,
avoidant coping strategy and romantic loneliness, depression and active coping strategy, social support
coping strategy and romantic loneliness. These variables would be entered in the regression models as
interactions with gender (see Table 3).
Table 3. Bivariate correlations for men and women separately (transgender men above the diagonal
and transgender women below the diagonal).
1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11.
1. Anxiety 1 0.73 ** −0.22 −0.26 * −0.01 −0.08 0.23 0.47 ** 0.52 0.29 * −0.22
2. Depression 0.77 ** 1 −0.51 ** −0.56 ** −0.20 −0.28 * 0.52 ** 0.61 ** 0.69 ** 0.40 ** −0.47 **
3. Body image −0.44 ** −0.63 ** 1 0.34 ** 0.04 0.15 −0.33 ** −0.31 * −0.21 −0.24 0.57 **
4. Self esteem −0.19 −0.36 ** 0.48 ** 1 0.49 ** 0.22 −0.36 ** −0.62 ** −0.65 ** −0.32 * 0.36 **
5. Active cop. −0.17 −0.33** 0.29 * 0.53 ** 1 0.35 ** −0.25 −0.37 ** −0.44 ** −0.01 0.12
6. Soc. supp. cop. −0.03 −0.21 0.26 * 0.28 * 0.29 * 1 −0.31 * −0.18 −0.19 −0.01 0.02
7. Avoidant cop. 0.34 ** 0.63 ** −0.60 ** −0.37 ** −0.42 ** −0.18 1 0.24 0.40 ** 0.36 ** −0.44 **
8. Fam. lonel. 0.38 ** 0.43 ** −0.51 ** −0.52 ** −0.33 ** −0.20 0.43 ** 1 0.71 ** 0.16 −0.17
9. Soc. lonel. 0.44 ** 0.49 ** −0.51 ** −0.44 ** −0.43 ** −0.32 * 0.38 ** 0.69 ** 1 0.41 ** −0.35 **
10. Rom. lonel. 0.03 0.01 0.20 −0.15 −0.23 0.08 −0.05 0.11 0.19 1 −0.47 **
11. Sex. satisfact. −0.24 −0.43 ** 0.44 ** 0.32 * 0.36 ** −0.06 −0.26 * −0.19 −0.23 −0.39 ** 1
* p < 0.05; ** p < 0.01.
3.3. Proximal Stressors as Predictors of Mental Health (Anxiety and Depression)
To test the effects of all predictor variables on symptoms of anxiety and depression, taking into
account the role of gender variable in those relationships (moderating effect), two hierarchical multiple
regression analysis were conducted using the two-step model with two steps of independent variables.
Taking into account anxiety as a criterion variable, the main effects model was significant
(F (1, 118) = 36.87, p < 0.001). This model accounted for 23% of the variance of anxiety. In order
to the study the moderating effect of gender, the interaction of each predictor with gender was also
included in a second step (i.e., self-esteem, body image, avoidant coping strategy and romantic
loneliness). The interactions model produced an increment of 4% variance and romantic loneliness ×
gender interaction was found to be significant. Hence, the interaction effects model was selected to
explain anxiety (F (1, 117) = 7.79, p < 0.01) and its observed power was 0.85. In this sense, the predictor
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found to be significant for both genders was social loneliness and the predictor found only for men was
romantic loneliness. Therefore, higher scores in social loneliness were associated with higher levels of
anxiety for transgender men and women and higher scores in romantic loneliness were associated
with higher levels of anxiety only for transgender men (F (1, 58) = 32.77, B = −0.78, p < 0.001) (see
Table 4 and Figure 1).
Regarding the regression analysis conducted to explain depression, the main effects model was
also significant (F (1, 116) = 12.15, p < 0.001). This model accounted for 53% of the variance of
depression. The interaction of each predictor with gender was also included in a second step (i.e.,
active coping strategy, social support strategy and romantic loneliness) to study the moderating effect
of gender. The interactions model produced an increment of 5% variance and romantic loneliness
× gender interaction was found to be significant. Hence, the interaction effects model was selected
to explain depression (F (1, 115) = 10.84, p < 0.001) and its observed power was 0.99. In this sense,
the predictor found to be significant for both genders was social loneliness, avoidant coping strategy
and body image and the predictor found only for men was romantic loneliness. Therefore, higher
scores in social loneliness, avoidant coping strategy and a poor body image was associated with
higher levels of depression for transgender men and women, and higher scores in romantic loneliness
explained higher levels of depression for transgender men (F (1, 55) = 6.31, B = −0.49, p < 0.05) (see
Table 4 and Figure 1).
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Figure 1. Romantic loneliness × gender interaction effect on mental health: (a) Depression; (b) Anxiety.
4. Discussion
The study aimed to investigate the situation and the relationship between proximal stressors
and mental health capacity among transgender adults in Spain. Several significant differences were
found in some stressors and in the mental health of both men and women. Specifically, transgender
women were found to have higher levels of anxiety, poorer body image, higher social loneliness and
higher sexual satisfaction, similar to the results found in previous literature [65,66]. Women have
been particularly stigmatized because by transitioning from male to female and deviating from their
expected gender role, prior social status is lost [1,67]. Perhaps women show greater sexual satisfaction
due to the fact that their sexual life is a private sphere, one that is not publicly visible and, unlike other
contexts such as social relationships, it is a realm in which they can experience more freedom. There is
no literature on this subject but it has become a topic of special interest for future research.
On the subject of mental health, anxiety and depression typically occur simultaneously [68], a fact
which holds true for transgender people as well [69], although they are commonly accepted as separate
concepts [70]. Considering the association between proximal stressors and mental health, this study
investigated the effects of proximal personal (self-esteem, body image and coping skills) and proximal
interpersonal (social, family and romantic loneliness and sexual satisfaction) stressors on transgender
men’s and women’s psychological health (anxiety and depression). Identifying which are the most
important predictors and how to minimize them would be a useful tool for the design of future clinical
and research interventions. The findings are consistent with previous research in that several proximal
stressors were found to be associated with poor mental health among transgender people [8,46,71].
With respect to the ways in which these stressors are associated with poor mental health, social
loneliness accounts for anxiety in both men and women, whereas romantic loneliness only accounts for
it in men. Additionally, depression is accounted for by the level of social loneliness, body image and
the use of avoidant coping skills in both men and women, though it is only accounted for by romantic
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loneliness, again, in in the case of men. Gender differences, therefore, are only significant in the case of
romantic loneliness. These results substantiate previous findings regarding these variables and that of
psychological health in different populations. In fact, there is empirical evidence regarding the fact
that loneliness anticipates anxiety and depression [44,72–75]. There are no previous studies, however,
concerning the role of gender in regard to romantic loneliness.
On the other hand, coping skills also play a role in one’s mental health. The use of ineffective
coping skills can either hinder or promote anxiety and depression [33]. The coping strategy of
avoidance, which has shown to be ineffective in resolving complex life circumstances, causes people to
experience significant levels of distress [76]. Discomfort with body and high desire of reassignment
between the participants (at different levels) is common among members of our sample, related with a
poor mental health [27].
For the results of our study to be accurately interpreted, certain limitations must be considered.
First, the measures used in the study were all self-reported, a factor that may be associated to higher
levels of response bias. Nevertheless, self-reported measures are an effective method in which to
assess mental health [77]. Second, the study used a cross-sectional design which does not allow
for understanding causal pathways. Nevertheless, the study contributes to our understanding of
the significant association between proximal stressors and mental health, taking into account the
moderating effect of gender. Third, the use of convenience sampling limits the generalizability of the
findings, although it allowed us to access people in different situations. Fourth, the bidirectionality of
the relationship between some of the stressors and the mental health can be considered a limitation.
This issue is partially ameliorated by the fact that the outcome variables had a timeframe that was
more proximal to the reporting period, whereas the independent variables had more distal timeframes,
meaning that a larger body of literature exists in which proximal stressors foresee issues related to
mental health. Finally, no other situations of disadvantage linked to mental health (socioeconomic
status, culture, ethnicity, etc.), that could potentially have affected what was found in the analysis
have been studied. Thus, in addition to transgender experience, gender was included as an important
variable to be considered.
Future research should delve deeper, including looking into distal stressors and other mental
health indicators. It could be interesting as well to separate those who have long-term mental health
issues and those who do not. In this way, data collection and research projects are possible not only in
the short-term but long-term as well, which would then allow for a more developmental perspective.
Finally, qualitative research would allow for better understanding of subjective experiences in relation
to stressors and mental health. All these research suggestions could be useful for a better understanding
of the transgender experience.
Finally, notwithstanding the mentioned limitations and future research suggestions, the current
study contributes to the literature on the subject by (1) exploring proximal personal and proximal
interpersonal stressors and mental health in the transgender population, as well as differentiating
between men and women; (2) highlighting the relationship between proximal stressors and mental
health in this population; and (3) emphasizing the role of gender as a moderator of the relationship
between stressors, specifically romantic loneliness and mental health. These contributions could
lead to professional intervention which would promote the mental health of transgender people.
Based on our results, interventions looking to reduce social loneliness, avoidant coping strategies,
poor body image and romantic loneliness (among men) would be compelling, as would the impact
each has on transgender individuals’ mental health. Practitioners should to be aware the importance
of relationships and the impact of loneliness on in transgender’s mental health. Promoting a good
relational network, both friendships and romantic partners, has always to be considered in any
intervention with this population. In fact, working on social meaningful connections would buffer
other feelings of loneliness, such as romantic loneliness. In this case, this seems to be especially
important for transgender men in the context of romantic relationships.
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Additionally, it is known that this population lives in stressful an environment due to different
situations such as stigma, transphobia, and/or violence [1]. All these circumstances may promote the
utilization of avoidant coping strategies in order to protect themselves from distress. However, as we
have observed in this study, the use of these strategies may individuals be more prone to depression.
Finally, practitioners should focus on individuals’ body image. This is an important aspect in
order to prevent depression. Developing an accurate evaluation and intervention and also working
on individuals’ context to prevent from discrimination due to body image are important elements to
be considered.
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Abstract: This study of parents in Romania explores how perceptions of their couple relationship
quality and of factors associated with it (such as sexual communication anxiety and sexual
perfectionism) were related to their perception of aspects describing parenting dimensions relevant
to the sexual education and sexual health of their children. The hypotheses tested in this study
were supported by the data collected from 106 participants (aged 25 to 51 years), parents of 1 to
3 children: (1) sexual communication anxiety with one’s partner (but not sexual perfectionism)
is a significant predictor for parents’ self-efficacy, outcome expectancy and communication
and parenting behavior related to sexuality education; (2) parents’ self-efficacy and outcome
expectancy about parent-child communication on sexual topics (including involvement in risky
sexual behaviors) predict the level of parenting behavior in this respect; (3) parents’ sexual
communication anxiety (but not their sexual perfectionism) together with their self-efficacy and
outcome expectancy regarding parent-child communication about sexuality predict the level of
parental sexuality-communication-and-education behavior.
Keywords: sexual communication anxiety; sexual perfectionism; parent-child communication; risky
sexual behavior
1. Introduction
Available data from most parts of world indicate that young people are often lacking competencies
and are erroneously or partially informed about sexuality, sexual health and sexual risk behavior,
and that they are the population that is at the highest risk of negative outcomes associated with sexual
health, but the literature also indicates that many of these aspects could be overcome through effective
sexuality education programs and interventions [1–3]. Thus, improving or optimizing sexual health
in young people should and oftentimes does constitute a priority for families and care-givers, local
communities, states and global society.
There is a considerable need expressed and identified for successful sexuality education programs
and interventions, both formal and informal, for young people and for parents, given the costs and
consequences of a lack of competencies and of risky sexual behavior in young people [4]. In line with
this, identifying psychosocial factors relevant to the quality of the parent-child relationship and thus
for the sexuality education and sexuality communication behavior between parents and their children
is a promising line of research [5–7].
The quality of a couple’s relationship and their perception of it could influence a number of
aspects of the parent-child relationship [8] and vice versa [9,10]. Kouros and colleagues [11] found a
positive association between daily evaluations of the emotional quality of a parent’s intimate/couple
relationship and that of the parent-child relationship after controlling for relationship satisfaction
and conflict and for parenting levels [11]. This spillover effect [10–12], that is the transfer of a person’s
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(particularly negative) affect, mood and behavior from one context to another or from one interaction
to another, could be bidirectional [10,11]. The compensation hypothesis proposes that a compensation
of negative aspects of the couple relationship might translate into a person investing parenting
resources (time, attention, knowledge) and positive affect into their parent-child relationship [13].
The two models should not necessarily be mutually exclusive [11]. Studies investigating the influence
that the quality of parent-child relationship might have on the parents’ couple relationship or the
bi-directionality of these influences have found support for both hypotheses [9,10,14].
Empirical evidence exists highlighting the (primary and secondary) effect that some parenting
interventions might have on childrens’ behavior, on the parent-child relationship and also on the
couple relationship [9]. Also, it appears that mothers might be less vulnerable than fathers to the
spillover effect from the couple relationship into the parent-child relationship [14].
Parents’ concern over their communication with their children on sexuality topics is an aspect
commonly addressed by parental programs and interventions (as a means or a goal) due to
communication’s intrinsic role in parent-child relationships [15,16]. Studies investigating parental
connectedness [17] with its component parent-child (sexual) communication, found communication
(and connectedness) to be playing a protective role against certain sexual risk behavior in which young
people might engage [18,19].
Communication on sexual topics between adolescents and parents predicted adolescents’ sexual
communication with their partners on similar topics and for the sexually active ones it predicted
the use of protection during sex (such as condoms) [20]. Although some parents express fear of the
possibility that communication about sexuality might cause adolescents and young people to start
their sex lives earlier or increase the chances of them engaging in particular sexual behavior, data
generally does not support this association [15,19,21,22].
The majority of parents report they wish to communicate “openly” with their children on this
subject [23], although data indicates that many of the adolescents perceive their communication
on various sexuality issues with their parents to be less than satisfactory [22]. Generally, mothers
tend to communicate more (frequently and diversely) than fathers about sexuality and more with
their daughters than with their sons [24]. Also, there is a similar discrepancy with regard to
parent-child sexuality communication related outcomes (e.g., sexually protective behavior) in favor of
girls/daughters [15]. Widman and colleagues [15] suggest that besides other factors associated with
the parent-child relationship, the quality of the parents’ couple relationship might interact with the
parent-child communication and with its effects on children and young people’s sexual behavior [15].
The perceived self-efficacy and outcome expectancies (both in parents and in young people) about
certain sexuality and sexuality education behaviors and outcomes were identified as good predictors
for the level of sexually protective behavior in which young people engage and for their intentions
in that sense [25–27]. Perceived self-efficacy is a person’s beliefs and expectations of their capacity to
successfully follow a certain behavior while outcome expectancy is the person’s beliefs regarding the
likelihood of a particular behavior to produce a certain outcome [28].
The sexuality (education) and sexual health of young people with intellectual or developmental
disabilities has not been the subject of many research efforts thus far [29]. Significantly fewer aspects
of the association between couple relationship factors and parent-child relationship factors in parents
and their children with developmental problems or difficulties have been investigated. In comparison
to others, these parents experience higher levels of stress and lower levels of couple relationship
satisfaction [30,31].
Although the literature on the subject is not extensive, it is known that young LGBT people and
their parents face various additional and specific challenges regarding sexuality education, sexual
health and general well-being [32]. Research efforts in the health promotion and prevention of risk
behavior in sexual and gender minorities revealed that positive parenting practices, acceptance and
support from families, and communication between parents and LGBT youth were found to have
protective roles for young people’s health and well-being [32].
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There is very little research in the area of sexual risk behavior and sexuality education with
participants, young or otherwise, from Romania. Romania does not have sexuality education in the
national curriculum; currently, it lacks a national strategy and has had inconsistent or partially
successful public policies regarding sexual and reproductive health. Data provided by reports
from various international health promotion organizations have, in recent years, placed Romania in
undesired leading positions among European countries with respect to various sexual and reproductive
health outcomes [33].
This study aims to explore the ways in which, for parents in Romania, the perception of their
couple-relationship quality and of several factors associated with it (such as sexual communication
anxiety and sexual perfectionism) is related to the perception of factors describing parenting
dimensions relevant for the sexuality education of children and young people. The perception
of the quality of the couple relationship was previously, in studies [34] of adult participants from
Romania, associated with their perception of the quality of their sexual relationship, with their anxiety
to talk about sexual issues with their partners, and with aspects of their sexual perfectionism. Sexual
communication anxiety is the anxiety or fear associated with a real or anticipated communication with
one’s sexual partner about sexuality [35]. Perfectionism is defined as a person’s constant striving to
avoid mistakes (flawlessness), their establishing extremely high standards of performance, accompanied
by a tendency to make excessively critical self-evaluations and to be preoccupied with others’ negative
evaluations of them [36]. Sexual perfectionism refers to the perfectionistic beliefs, standards and
expectations people have for sexual performance and relationships, i.e., perfectionism related to the
sexual aspects of a relationship [37,38].
Thus, the following hypotheses were tested: (1) Sexual communication anxiety and sexual
perfectionism are significant predictors (individually and together) for parents’ self-efficacy, outcome
expectancy and communication-and-parenting behavior regarding sexuality education; (2) Parents’
self-efficacy and outcome expectancy about parent-child communication on sexual topics are predictors
(separately and together) of the level of parenting behavior in this respect; and (3) Parents’ sexual
perfectionism and sexual communication anxiety together with their self-efficacy and outcome
expectancy regarding parent-child communication about sexuality predict the level of parental
sexuality-communication-and-education behavior.
2. Experimental Section
The research design was non-experimental, correlational and predictive (with an exploratory
component), with five variables: (1) sexual communication anxiety (SCA), (2) multidimensional sexual
perfectionism (MSP), (3) parental self-efficacy about communicating with children about sexuality
(SESC), (4) parental sexuality-education-and-communication behavior (SECB) and (5) parental outcome
expectancy about communicating with children about sexuality (OECS).
2.1. Participants and Procedure
Data were collected online from a convenience sample (“chain” selection, [39]) of N = 106
participants from various regions in Romania between April and June 2017. The participants were
aged between 25 and 51 years (M = 37.83 years, SD = 5.99). A percentage of 92.5% of them were women;
76.4% of the participants were married, 16% divorced, 5.7% were unmarried but in a relationship and
1.9% were single at that time. For participants in a relationship at that time (98.1%), the mean duration
of that relationship was M = 13.48 years (SD = 7.07). The mean duration of the participants’ longest
relationship was 13.64 years (SD = 6.94). The mean number of participants’ sexual/romantic partners
up to the study time was M = 4.86 (SD = 5.11). 96.4% of the participants had university degrees.
46 (43.4%) participants were raising 1 child, 56 (52.8%) were raising 2 children and 4 participants (3.8%)
were parents to 3 children. The mean age of the 170 children raised by the study participants was
M = 8.34 years (SD = 5.54).
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The selection was based on a single criterion: participants had to be parents (legal guardians)
of at least one child (younger than 18 years) at the moment of the study. The survey was completed
anonymously online on the www.esurveycreator.com platform. General research ethics prescriptions
were followed, as well as the regulations on Research Ethics of Babes-Bolyai University (informed
consent, confidentiality and anonymity of the data).
2.2. Instruments
(1) Multidimensional Sexual Perfectionism Questionnaire (MSPQ) [37,38] for MSP, (2) Sexual
Communication Apprehension Items (SCAI) [35] for SCA; (3) Parenting and Child Sexuality
Questionnaire (PCSQ) [40] for SESC and SECB; (4) and Parenting Outcome Expectancy Scale
(POES) [41] for OECS. All measures were previously indicated by the literature to have had
good psychometric qualities. Socio-demographic items were created for the purpose of this study
(e.g., gender, educational background, professional status, relationship status, relationship lengths,
number of lifetime partners, number of children, self-rated religiosity level).
Data analyses were performed with the Statistical Package for the Social Sciences (SPSS 17.0)
program. Normality of score-frequency-distribution tests, correlation analyses and simple and multiple
(hierarchical) linear regression analyses were conducted.
3. Results
The results (Spearman rho coefficients) of the correlation analyses on subscale scores of study
measures can be seen in Table 1.
Table 1 shows significant Spearman rho correlation coefficients (p < 0.01, 2-tailed) of adequate
values, describing the relation between global scores on OECS and PCSQ (rest = 0.628, p < 0.01),
on OECS and SCAI (rs = −0.564, p < 0.01) and on PCSQ and SCAI (rs = −0.516, p < 0.01). MSPQ
global scores had no statistically significant relation with global scores on other measures in the study,
although the Spearman rho correlation coefficient’s value for the MSPQ and SCAI global scores almost
reached statistical significance (p = 0.06, 2 -tailed). Of particular interest are PCSQ subscales 1 and 2,
which assess two different variables of the study: the OECS scores significantly positively correlate
with the PCSQ1-SE scores (rest = 0.657, p < 0.01) and with the PCSQ2-B scores (rs = 0.478, p < 0.01);
the SCAI global scores significantly negatively correlate with the PCSQ1-SE scores (rs = −0.526, p <
0.01) and with the PCSQ2-B scores (rs = −0.391, p < 0.01) (see Table 1).
Regarding sexual perfectionism and its dimensions’ correlations with other variables of the study,
the only statistically significant ones were between scores on: MSPQ2-PS and PCSQ1-SE (rest = −0.330,
p < 0.01); MSPQ3-DP and PCSQ1-SE (rs = −0.215, p < 0.05); MSPQ5-PSD and OECS (rs = −0.245,
p < 0.05), MSPQ5-PSD and PCSQ1-SE (rs = −0.392, p < 0.01); MSPQ5-PSD and SCAI (rs = 0.301,
p < 0.01); and MSPQ global scores and PCSQ1-SE (rs = −0.300, p < 0.01) (see Table 1).
Simple linear regression analyses were carried out to test the predictor quality of some study
variables as posited by hypotheses 1 and 2. Simple linear regression equations (df = 1 and residual
df = 104) indicated that the following significant predictors were found: (1) the MSPQ5-PSD scores
predicted the PCSQ1-SE scores (F = 12.557, p < 0.01; R2 = 0.108) and SCAI global scores (F = 11.384,
p < 0.01 R2 = 0.099); (2) the SCAI global scores predicted the PCSQ1-SE scores (F = 39.982, p < 0.01,
R2 = 0.278), PCSQ2-B scores (F = 22.244, p < 0.01, R2 = 0.176) and POES scores (F = 47.265, p < 0.01,
R2 = 0.312); (3) the POES scores predicted the PCSQ1-SE scores (F = 81.050, p < 0.01, R2 = 0.438) and
PCSQ2-B scores (F = 32.401, p < 0.01, R2 = 0.238) and (4) the PCSQ1-SE scores predicted the PCSQ2-B
scores (F = 74.308, p < 0.01, R2 = 0.417) and POES global scores (F = 81.050, p < 0.01, R2 = 0.438).
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Simple linear regression analyses were followed (when the case) by a multiple linear regression.
For all regression models proposed, the data satisfactorily verified all the assumptions of a multiple
regression analysis [39,42,43].
The regression equation found for the “predictors SCA and MSP-PSD and criterion SESC” model
was significant: F(2,103) = 22.821, p < 0.000, with R2 = 0.307. The SESC predicted level was 220.912–0.658
(SCA) −1.280 (MSP-PSD), where 220.912 was the constant’s regression coefficient’s value. Only SCA
predicted SESC significantly at a p < 0.01 level, but at p < 0.05 both predictors were significant.
The regression equation found for the “predictors OECS and SESC and criterion SECB” model
was significant: F (2,103) = 37.782, p < 0.000, with R2 = 0.423. The SECB predicted level was
−0.500 + 0.210 (SESC) + 0.151 (OECS), where −0.500 was the constant’s regression coefficient’s value.
Only SESC was a significant predictor for SECB. The regression equation found for the “predictors
OECS and SCA and criterion SESC” model was significant: F (2,103) = 46.381, p < 0.000, with R2 = 0.474.
The SESC predicted level was 1.247–0.320 (SCA) + 2.062 (OECS), where 1.247 was the constant’s
regression coefficient’s value. Both SCA and OECS were significant predictors for SESC.
The regression equation found for the “predictors SCA and SESC and criterion SECB” model was
significant: F (2,103) = 38.144, p < 0.000, cu R2 = 0.426. The SECB predicted level was 15.114–0.056
(SCA) + 0.215 (SESC), where 15.114 was the constant’s regression coefficient’s value. Only SESC was a
significant predictor for SECB.
A two-step hierarchical regression analysis was carried out to test the third hypothesis of this
study. One of the distal predictors (i.e., MSP) for the SECB criterion was excluded from the analysis
due to the fact that previous analyses revealed that it was not a good predictor for the dependent
variable of the model. As such, the first predictor block included only SCA as an independent variable
while the second regression predictor block contained SESC and OECS (see Figure 1). Tests of the
model data revealed that it met the assumptions of a multiple regression analysis.
Figure 1. Hierarchical multiple regression model (Hypothesis 3 of study).
The linear hierarchical (2-step) regression analysis returned significant (p < 0.001) regression
equations for both models (steps): model 1 (only predictor block 1) and model 2 (predictor blocks 1 and
2) (see Table 2).
Table 2. Parameters of the hierarchical regression models (model 1 and model 2).
Regression
Model
Model Parameters Change Parameters
R R2 R2 Adjust. F p R2 Change F Change pFch
1 0.420a 0.176 0.168 22.244 0.000 a 0.176 22.244 0.000
2 0.654b 0.428 0.411 25.465 0.000 b 0.252 22.481 0.000
R = correlation coefficient; R2 = determination coefficient; R2 adjust. = adjusted determination coefficient; F = global
significance of predictor; p = level of significance; a Predictors: (Constant), SCA; b Predictors: (Constant), SCA,
OECS, SESC; Criterion: SECB.
For model 1, the regression equation was F (1,104) = 22.244, p < 0.000, with R2 = 0.176. The level of
the predicted SECB was 59.470–0.215 (SCA), where 59.470 was the constant’s regression coefficient
value. For model 2, the regression equation was F (2,102) = 25.465, p < 0.000, with R2 = 0.428. The level
of the predicted SECB was 7.573 - 0.045 (SCA) + 0.104 (OECS) + 0.201 (SESC), where 7.573 was the
constant’s regression coefficient value (see Table 3). Both models contributed significantly (F value is
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significant, p < 0.000) to the capacity of predicting the criterion in comparison to models with estimated
population parameters [44].


















(Constant) 59.470 2.655 22.399 0.000 54.205 64.735
SCAI total −0.215 0.046 −0.420 −4.716 0.000 −0.305 −0.124 −0.420 −0.420 −0.420
2
(Constant) 7.573 12.881 0.588 0.558 −17.976 33.123
SCAI total −0.045 0.048 −0.089 −0.950 0.344 −0.140 0.049 −0.420 −0.094 −0.071
POES total 0.104 0.149 0.074 0.698 0.487 −0.192 0.400 0.487 0.069 0.052
PCSQ1-SE 0.201 0.038 0.550 5.328 0.000 0.126 0.276 0.646 0.467 0.399
B = regression coefficient/slope value; SE = coefficient standard error; β = standardized coefficient value; t = significance
of coefficient test statistic; p = probability significance level.
Both models explained a significant variance at the criterion level (see Table 2). Model 1 indicated
that SCA significantly (p < 0.000) predicted the criterion SECB, i.e., 17.6% of its variance. Model 2
indicated that together the three predictors (SCA, OECS and SESC) significantly (p < 0.000) predicted the
criterion SECB, i.e., 42.8% of its variance. Thus, adding the two predictors (in block 2) to the hierarchical
regression brought a significant (p < 0.000) improvement to the prediction model (R2 change = 0.252) of
SECB. Adding OECS and SESC as predictors increased the percentage of criterion-variance prediction
by 25.2% [44].
The values of the adjusted coefficient of determination (R2 adjust.) for both models of the
hierarchical regression analysis were very similar to those of the coefficient of determination R2
(see Table 2), which indicates that if they were to be derived from the population and not from the
study sample the two models of the hierarchical regression would explain approximately similar levels
of the criterion variance. It could be thus said that the two models have a high generalizability level
(Field, 2013).
Table 3 indicated that when SCA was the only independent variable in the model, it was a
significant predictor for SECB (t = −4.716, p < 0.000), but once the other two predictors (OECS and
SESC) were introduced in the regression analysis, SCA did not remain significant as a predictor of
SECB (t = −0.950, p = 0.344). Also, OECS proved not to be a significant predictor for SECB when
considered together with the other two predictors (t = 0.698, p = 0.487). In this model (i.e., 2) the only
predictor that remained significant for the criterion variance was SESC (t = 5.328, p < 0.000). Thus,
although the three predictors had, separately, a significant direct influence on the criterion (as shown
by the results of simple regression analyses), when their interaction was taken into consideration
(controlling for levels of any two of them), the only one retaining a significant direct influence on SECB
in this model was SESC. SCA and OECS lost their influence in this model as direct predictors of SECB
and only showed an indirect influence [44].
Based on these results a mediation model was proposed with SESC mediating the relation/path
between the predictors SCA and OECS with SECB. Figure 2 describes this model. The validity of this
model needs further testing in future studies.
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Figure 2. Mediation model of the relation between the predictors SCA, OECS and the criterion SECB
by the predictor SESC.
The information offered by the parents in Romania participating in the study based on their
answers to the socio-demographic data questionnaire revealed that a percentage of 94.3% (N = 100)
did not consider their children to have ever been in a sexual risk situation. Only 31.13% (N = 33) of
them were able to describe what in their opinion could constitute such a situation (e.g., exposure
to online pornography, unprotected sex or being approached for sex by strangers, adults or older
children/young people). 23.6% (n = 25) of the 106 participants reported that they had never used
any type of resources to help them with the communication about sexuality and sexuality education
they provided to their children; the majority of the participants, 64.2% (n = 68), mentioned books as a
source of information, while 56.6% (n = 60) of them mentioned online resources and 40.6% (n = 43)
of them mentioned talking to friends. Only 17.9% (n = 19) had talked to professionals while 11.3%
(n = 12) had attended a specific course/training. During the 6 months prior to the study, 35 (33%)
participants did not use any type of resource, 27 (25.5%) participants used them rarely, another 27
participants used them moderately frequently, while only 14 (13.2%) used them quite frequently and
3 (2.8%) used them very frequently. 17.9% (n = 19) of participants had not communicated to their
children about sexuality in the 6 months prior to the study, 27.4% (n = 29) had only communicated
rarely, 32.1% (n = 34) had communicated moderately frequently, 21.7% (n = 23) quite often, and 0.9%
(n = 1) reported communicating very often.
Participants’ self-rated level of religiosity was not a good predictor for any of the variables of
the study. The number of sexual partners that participants estimated they had had by that time
(M = 4.86, SD = 5.109) proved to be a moderate predictor for their level of self-efficacy regarding
communication with children on sexuality topics and for their level of sexuality education parenting
behavior. The majority of participants responded to the three optional open-ended questions in
PCSQ [40] regarding communication about sexuality and sexuality education programs, i.e., all of the
participants responded to the question “Please describe how you communicate with your child about
sexuality?”, more than 99% of them responded to “What would make it easier for you to talk to your
child about sexuality?” and 95% responded to “What additional information or topics would you like
to see included in a parenting program to help parents develop skills to support children’s developing
sexuality?”.
The responses to the first of these questions were very diverse, although participants
predominantly answered that they communicated “openly” and in a “relaxed” way, and that they
had “positive” and “natural” conversations on the topic with their children, many using, as expected,
the verbal approach to communication. Only seven participants stated they didn’t communicate
with their children about sexuality, citing mainly the child’s “inappropriate” age as a reason for
it. Some parents (around 25%) used the only-answer-when-asked approach, while others (also
approximately 25%) mentioned they initiated conversations. Many of them stressed the anatomic and
physiological aspects of development in their conversations with their children and expressed beliefs
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about the “age-appropriateness” of the conversations’ content. One parent said “With honesty, trust
and responsibility and without thinking my children are too young to know the truth. I tell them what
they need to know at their age based on their cognitive development phase. I answer their questions
about sexuality. We do not hide our bodies, we use the appropriate names for genitalia” while another
said, “I haven’t talked to my children about this subject. I don’t feel prepared for such conversations. I
don’t have the necessary courage to talk to them.”
To the second question, 13 participants responded with “I don’t know”, while 18 parents (17%)
said schools (and also sometimes pre-schools) should provide sexuality education classes for children.
Participants mostly mentioned the following means of facilitating communication with children about
sexuality: being properly informed and trained; having access to various types of resources and
support; changed societal and individual (their own) attitudes regarding sexuality; their children’s
age and perceived interest for the topic. Almost a fifth of the participants considered that the
communication with their children about sexuality was good and it couldn’t be improved. One parent
said that “Sexuality education in schools using accurate scientific resources and leaving aside any
unnecessary self-consciousness would help”, while another participant responded that ”It would
be helpful to involve parents in having all the necessary knowledge to approach all the aspects of
sexuality in a competent and relaxed way”.
To the third open-ended question, approximately one third of the participants responded by
saying they wouldn’t add anything to a sexuality education parenting program besides the topics
already mentioned in the previous item of PCSQ. Almost a quarter of the respondents considered that
the parent-child relationship and communication about sexuality should be part of a parental sexuality
education program, and a similar number of parents thought that such a program should include
information on how to access accurate information sources for both parents and children and also
information about children’s and adolescents’ development and about age-appropriate communication.
Approximately 10% of the parents considered that information about negative consequences of sexual
activity, sexually transmitted infections, protection, pregnancy and contraception, sexual orientation
and gender identity, morality, religion and their relation to sexuality, should be added. A few parents
mentioned that a sexuality education parenting program should also be about romantic relationships,
consent, abuse, media influence and pornography. One participant said that “If we want a healthier
generation, adopting older generations’ models will only bring negative consequences; as such,
sexuality education should be provided by professionals and with minimum involvement from
dilettantes in the subject, be they well-intended parents” and another noted, “How to communicate so
that we don’t push them away from us and that they come and ask for advice when they need it, even
in this sensitive domain. Children rarely talk to their parents about this subject”.
4. Discussion
The results of the investigation on parents from Romania support the fact that participants’
level of sexual communication (with their partner) anxiety predicted their level of parental outcome
expectancy and self-efficacy regarding communication with children about sexuality, as well as the
level of communication-with-children-about-sexuality behavior they engaged in.
With regard to the sexual perfectionism dimensions, partners’ self-directed (towards respondent)
sexual perfectionism was found to be a significant predictor for respondents’ level of sexual
communication anxiety and for their level of parental self-efficacy about discussing sexuality.
Moreover, this dimension of sexual perfectionism proved to be significantly correlated with
the majority of the study’s variables and their dimensions, with the exception of parental
communication-about-sexuality-and-sexuality-education behavior. As a result of that, sexual
perfectionism was replaced by this dimension (partners’ self-directed sexual perfectionism) throughout
the following analyses of the study. Sexual communication anxiety and partners’ self-directed sexual
perfectionism together significantly predicted the level of parental self-efficacy of communication
with children about sexuality, sexual communication anxiety being a mediator in their relation.
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Other multiple prediction models were not tested due to the fact that partners’ self-directed sexual
perfectionism was not a significant predictor for the other variables. Since no prior results on this
subject (hypothesis 1) were found in literature, a comparison could not be made, but theoretical models
and other connected results encouraged such a hypothesis being formulated and the attempt made in
this direction by this study indicated promising results.
Regarding the second hypothesis of the study, the data analysis revealed that parental self-efficacy
and outcome expectancy about communicating with children on topics of sexuality were significant
predictors (both separately and together) for the parental level of communication about sexuality and
sexual education with the children. Parents’ communication self-efficacy appeared to mediate the
relation of the other two variables.
Both self-efficacy and outcome expectancy were good predictors for each other. When taking into
account their interaction, only self-efficacy about communicating with children on sexuality topics
remained significant in predicting the level of communication behavior between parents and children
about sexuality. These results confirmed, on the one hand, the predictions of Bandura’s theory of
self-efficacy regarding the role that self-efficacy and outcome expectancy played in predicting the
performance and intention to perform certain behaviors. On the other hand, they partially contradicted
Bandura’s view [28] of these processes, offering alongside other results [45] valuable insights about the
possibility of a bi-causal relation existing between parental self-efficacy and outcome expectancy with
regard to their communication with children on sexuality topics.
The third hypothesis of the study tested a two-step multiple prediction model for the level of
parental communication-with-children-about-sexuality behavior. Sexual communication anxiety was
a predictor in the first block of predictors and parental outcome expectancy and self-efficacy regarding
communication with children about sexuality were in the second prediction block. The results of
the model testing pointed out that only parental self-efficacy about communication with children
on sexuality topics remained a significant predictor for their levels of parenting behavior in that
respect. The other two predictors had only an indirect effect over the parental communication
with children about sexuality. A path model describing these relations was built. These findings
are among the very few results proposing a model that describes the relations between these
variables (i.e., characterizing parents’ perceptions of their couple relationship and of their parental
relationship and parenting aspects) with an explanatory value for the variance in the levels of parents’
communication-with-children-about-sexuality behavior and with implications both at a theoretical
and a practical level.
From a practical point of view, these results have a potential applicability in the configuration
of new or in the adjustment of already-existing family counselling interventions, as well as in
educational approaches such as sexuality education programs addressed to young people and/or
to their parents. Based on the explored model of prediction and mediation from this study, these
interventions could target the perception of a couple’s sexual relationship or of the parent-child
relationship with the projected outcome of changing the sexuality-communication behavior between
parents and children while also bringing other secondary benefits in the parent-child relationship and
also in the couple relationship. Specifically, these benefits refer to lowering the levels of anxiety about
communication on sexual topics with one’s partner or the levels of one’s sexual perfectionism, which
in turn could contribute to the quality of one’s intimate relationships. Understandably, these results,
especially the ones obtained by testing exploratory hypotheses, need further investigation in future
studies with the purpose of better comprehending this research area and the associations between
individual characteristics, family dynamics and processes which influence the sexual health outcomes
in young people.
There are some possible limitations to the conclusions drawn from the results of this study. Among
them might be the characteristics of the study sample (e.g., mostly women, mostly married or in a
long-term relationship, mostly holding a university degree), while others relate to the study procedure
and the assessment instruments (e.g., access restricted to online participation, some of instruments
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translated but not validated), and others relate to the data sample. Our opinion is that these possible
limitations affecting the generalizability of our conclusions could be seen as an opportunity and
a basis for future studies, where their influence on the results could be additionally investigated
and understood.
In conclusion, the study successfully explored and investigated how factors characterizing
parents-from-Romania’s perceptions of their (sexual) couple relationships and of their parent-child
relationships were both relevant for their communication with their children on sexual topics. The more
anxious participating parents were about communicating about sexual issues with their partner and
the less confident they were about their capacity to communicate with their children about sexuality
or about the effects of such a communication, the less likely they were to talk with their children
about sexuality.
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Abstract: This study examined whether methadone (hereinafter referred to as MTD) maintenance
treatment (MMT) is correlated with sexual dysfunction (SD) in heroin-dependent men. This was
conducted to determine the prevalence of sexual dysfunction and if there is a relationship
between duration and dose among men on MMT and its impact on the quality of life. The study
combined a retrospective and a cross-sectional survey based on the Kinsey Scale, TECVASP,
and PRSexDQ-SALSEX clinical interviews of 85 patients who are currently engaged in MMT.
Sexual dysfunction in all five PRSexDQ-SALSEX domains (lack of libido, delay in orgasm, inability
to orgasm, erectile dysfunction, and tolerance or acceptance of changes in sexual function) was
associated with dose and long-term use of heroin. All dimensions of SD were affected by the MTD
intake. From the analysis of our sample, we may conclude that dose of MTD and overall score of
SD were directly associated. However, no evidence was found to prove that treatment duration and
severity of SD were linked. It is notable that only one tenth of the patients spontaneously reported
their symptoms of the sexual sphere, but up to a third considered leaving the MMT for this reason.
Keywords: opioid-related disorders; methadone; adverse effects; erectile dysfunction;
medication adherence
1. Introduction
Opioid dependence is a rising drug use disorder with a substantial contribution to the global
disease burden. The absolute number (age standardized prevalence) of people with opioid dependence
worldwide increased from 10.4 million (0.20%) in 1990 to 15.5 million (0.22%) in 2010, and the disability
adjusted years of life lost attributable to opioid dependence rose from 5.3 million (0.21% of global
disease burden) in 1990 to 9.2 million (0.37%) in 2010 [1]. Opioid substitution treatment, either with
methadone or buprenorphine, has been shown to be safe and effective in suppressing illicit opioid
use, improving physical and mental wellbeing, and reducing all cause and overdose mortality [2].
However, methadone is more commonly used for maintenance treatment [3]. Methadone maintenance
treatment (MMT) is a comprehensive treatment program that involves the long-term prescribing
of methadone as a substitution therapy for opioid dependence. Despite the effectiveness of the
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methadone maintenance treatment [4], previous studies have found that sexual dysfunction, including
hypoactive sexual desire disorder, erectile dysfunction, and orgasmic dysfunction, is common in
heroin users and individuals being treated for heroin addiction [5]. In a recent meta-analysis,
the meta-analytical pooled prevalence for sexual dysfunction among methadone users was 52%
(95% confidence interval, 0.39–0.65). Hypoactive sexual desire disorder and low libido were the
most prevalent sexual dysfunctions, accounting for 51% of cases [6]. Several hypotheses have been
suggested to explain the correlation between methadone use and sexual dysfunction. One well-known
hypothesis is that methadone exerts neuroendocrinological effects on the tubero-infundibular and
hypothalamic-pituitary-gonadal axes. The chronic stimulation of the μ-opioid receptors by methadone
alters the function of the tubero-infundibular axis and the dopaminergic control of prolactin,
with a consequential impact on sexual functioning [7]. A high level of circulating prolactin causes the
inhibition of the gonadotropin-releasing hormone, which lowers the levels of sex hormones, especially
testosterone. Men with low testosterone levels may exhibit a decrease in sexual interest [8]. A recent
qualitative study has found that some MMT subjects who experienced sexual dysfunction chose
to withdraw from interactions with their partners, which led to conflicts. Such conflicts negatively
impacted the rehabilitation. Furthermore, inappropriate reactions to the sexual problems included
premature treatment discontinuation under pressure from partners, methadone dose reduction, and the
use of other illicit drugs to enhance sexual performance [9]. The measurement of the health-related
quality of life construct (HRQoL) is widely used in the field of health. This represents individual
responses to the physical, mental, and social effects that a health alteration produces on daily life.
In drug addiction, this construct has been used for a relatively short time [10].
Although sexual dysfunction is not life threatening, it may often result in withdrawal from sexual
intimacy, thereby reducing quality of life [11]. Therefore, we conducted this study to investigate sexual
dysfunction in men and women on MMT. We also investigated the correlation and association between
sexual dysfunction and quality of life in this group of patients.
2. Experimental Section
Methods and study design: this cross-sectional study was conducted in the drug detoxification
unit in Complejo Asistencial de Salamanca Hospital in Salamanca, Spain, which is the Castilla y León
regional reference unit for the treatment of addictions in hospitalization. The research period was from
May 2017 to October 2018.
Participants: all participants were recruited on admission to the drug detoxification unit to
voluntarily withdraw or reduce methadone. Subjects were eligible for this study if: (1) They were men
or women over 18 years old; (2) they had been engaged in MMT; (3) they had a diagnosis of mental
and behavioral disorders due to the use of opioids (F11.3 ICD-10); (4) their urine was found to be
negative in drug use in the weekly analytical control for the six months prior to admission; and (5)
they were not under treatment with any psychodrugs except benzodiazepines.
Interviews and measures: an original form was developed to record the information of the
participants. The questionnaire included items on demographic characteristics (sex and age) and
methadone treatment status (such as the time of receiving MMT and methadone dose). It also include if
they were being treated with benzodiazepines or not and if they were, the equivalent dose in diazepam.
The Kinsey scale [12], also called the Heterosexual–Homosexual Rating Scale, is used to describe
a person’s sexual orientation based on their experience or response at a given time. It consists of nine
items that explore the importance of sexual life for the patient and the degree of satisfaction with it,
the identification of the patient with the different groups of sexual orientations, and the frequency of
sexual intercourse of the patient. The first seven items are answered on a scale of 1 to 5 and the last
two are of a dichotomous nature. The scale is self-applied and typically ranges from “0”, Exclusively
heterosexual to “1”, Predominantly heterosexual, only incidentally homosexual; “2”, Predominantly
heterosexual, but more than incidentally homosexual; “3”, Equally heterosexual and homosexual; “4”,
Predominantly homosexual, but more than incidentally heterosexual; “5”, Predominantly homosexual,
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only incidentally heterosexual; and “6”, Exclusively homosexual. In both the male and female volumes
of the Kinsey Reports, an additional grade, listed as “X”, indicated no socio-sexual contacts or reactions.
PRSexDQ-SALSEX is a brief and clinician-administered questionnaire that includes seven
questions in total [12]. The presence of sexual function impairment in patients with psychiatric
disorders is very common and could be an effect of the medication (mainly antidepressants and
neuroleptics) [13]. Questions A and B are screening items used to assess whether the patient had
noticed changes in sexual function since pharmacotherapy or during the last four weeks and reported it
spontaneously. Items 3–7 are questions evaluating five dimensions of SD on a scale of 0–3: loss of libido,
delayed orgasm or ejaculation, lack of orgasm or ejaculation, erectile dysfunction in men/vaginal
lubrication dysfunction in women, and patient’s tolerance. The total score of PRSexDQ-SALSEX ranges
from 0 to 15 [14].
For the measurement of the health-related quality of life (HRQoL), the test specifically designed
for the drug-dependent population TECVASP [15] was used. TECVASP (acronym in Spanish of
Test for the Evaluation of the Quality of Life in Addicts to Psychoactive Substances) consists of 22
items (18 positive and four negative [items 15, 19, 20, and 21]), with a graduated response format of
five alternatives. The response alternatives are coded with the following scores: (a) in the positive
items: nothing (5 points), little (4 points), sometimes (3 points), enough (2 points), and a lot (1 point);
(b) in the negative items: nothing (1 point), little (2 points), sometimes (3 points), enough (4 points),
and a lot (5 points). In this way, for each item, a higher score represents a more positive assessment of
the content, and in the test, a higher score represents a better HRQoL.
Statistical Analysis: Kolmogorov-Smirnov was one sample test used to examine the quantitative
variables’ distribution. Normally distributed variables were described as mean ± standard deviation;
otherwise, their information was summarized by median ± interquartile range. Categorical response
features were measured through absolute or relative frequencies and percentages. Differences
between two independent groups were tested by the Student’s t-test (for normal distribution data) or
Mann-Whitney U test. Comparisons of more than two independent groups were studied by ANOVA
(for data with parametric distribution) or the Kruskal-Wallis test (for non-normal distributions).
The Chi-Square test, Fisher’s exact test, and tau de Kendall measure were used to evaluate the
association in qualitative variables.
Patients were classified based on the categorization of SALSEX total score into four different
groups: no Sexual Dysfunction (SD) (a score of 0 points), mild SD (a score of 1–5 points, where no items
scored ≥ 2), moderate SD (a score of 6–10 points or an item scoring 2 and no items scoring 3), or severe
SD (a score of 11–15, or any items scoring 3 points). In addition, based on the cut-off points of the first
and third quartiles, the dose of methadone (MTD) consumed was categorized as <30 mg, 30–60 mg,
and >60 mg. Subsequently, Correspondence Factor Analysis (CFA) was used to analyze the relationship
between methadone consumption and sexual problems, taking into account tolerance, dose, and time
of methadone treatment. CFA is a statistical technique that produces a graphical representation of
a contingency table, facilitating the interpretation of the association between two categorical variables.
The categories of these variables are represented by points on a plane. For a correct interpretation
of a CFA representation, it should be taken into account that two close points in the graph refer to
positive associated categories.
Finally, relationships between sexual activity and quality of life of patients based on SD severity
groups were studied. Differences in questions with five Likert response options were evaluated by
means of an ANOVA or Kruskal-Wallis test, since this treatment is admitted when the number of
Likert alternatives is greater than four. The global quality of life score was computed by the sum of the
22 items’ scores of the TECVASP scale. Here, it is important to note that: (i) there were 18 inverse items
and four direct questions; (ii) scores’ range vary from 22 to 110 points; and (iii) the higher the score in
the test, the worse the quality of life of patients.
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3. Results
3.1. Clinical and Sociodemographic Characteristics of Patients
Patients’ characteristics are shown in Table 1. The sample consisted of 85 patients, mainly men
(n = 72, 84.7%), with a mean age of 43.1 ± 7.7 years, with 23 years being the youngest patient and
58 years the oldest. The mean dose of methadone consumed by patients was 49.01 ± 29.87 mg,
with a mean treatment time of 7.21 ± 6.95 years. Differentiating by sexes, the mean age of men was
42.76 ± 7.79 years, and the mean duration of treatment and mean dose were 6.34 ± 6.74 years and
45.33 ± 25.29 mg, respectively. For women, the mean age was 44.85 ± 7.2 and they consumed a mean
dose of 69.38 ± 43.92 mg, during 9.85 ± 7.78 years of treatment.
Table 1. Clinical and sociodemographic characteristics.
Characteristic N = 85
Age (years) 43.1 ± 7.7
<30 years, n (%) 6 (7.1)
30–40, n (%) 22 (25.9)
40–50, n (%) 45 (52.9)
>50, n (%) 12 (14.1)
Sex (males), n (%) 72 (84.7)
Treatment time (years) 7.21 ± 6.95
MTD 1 dose 49.01 ± 29.87
MTD 1 tolerance
Good tolerance, n (%) 37 (43.5)
Middle tolerance, n (%) 44 (51.8)
Poor tolerance, n (%) 4 (4.7)
Personality disorder, n (%) 49 (57.6)
Consumption of self-administered benzodiazepines, n (%) 27 (31.8)
Dose (mg) 95.19 ± 98.45
Consumption of medicated benzodiazepines, n (%) 22 (25.9%)
Dose (mg) 36.36 ± 32.74
1 MTD, Methadone.
About half of the patients from the sample suffered from a personality disorder (n = 49,
57.6%). One-third of the patients consumed self-administered benzodiazepines (31.8%; mean dose
95.2 ± 98.5 mg), while one quarter took benzodiazepines by medical prescription (25.9%; mean dose
36.4 ± 32.7 mg). There was a significant statistical difference between the doses of self-administered
and medicated doses of benzodiacepines (p = 0.001), with the self-administered benzodiazepines being
the greater dose. None of the patients taking self-administered benzodiazepines had received medical
advice to get them.
Differences between Sexes in Clinical and Sociodemographic Characteristics
Table 2 contains features of patients according to their sex. During their treatment time, which was
significantly different in men and women (p = 0.01), men received a lower dose of MTD. Tolerance
toward MTD was significantly better in men than women, who presented low percentages of good
tolerance. Although the doses of both self-administered and medically prescribed benzodiazepines
were lower in women, no statistically significant differences were observed by sex. No age difference
was found between sexes.
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Table 2. Comparison of sexes in clinical and sociodemographic characteristics.
Characteristic Men (n = 72) Women (n = 13) p-Value
Age (years) 42.76 ± 7.79 46 ± 15.5 0.49
Treatment time (years) 6.74 ± 6.74 9 ± 17.5 0.01
MTD’ dose (mg) 45.33 ± 25.29 60 ± 23.5 0.20
MTD’s tolerance - - 0.01
Good tolerance, n (%) 35 (48.6) 2 (15.4)
Middle tolerance, n (%) 35 (48.6) 9 (69.2)
Poor tolerance, n (%) 2 (2.8) 2 (15.4)
Personality disorder, n (%) 41 (56.9) 8 (61.5) 0.77
Dose of self-administered benzodiazepines (mg) 96.46 ± 103.78 85 ± 44.44 0.74
Dose of medicated benzodiazepines (mg) 40 ± 36.52 20 ± 40.0 0.59
3.2. Sexual Activity, Frequency of SD and Group Differences in SALSEX Scores
83.5% of the participants described themselves as heterosexual, 35.3% had an exclusively
monogamous sexual relationship, and 23.5% had non-monogamous sexual relations. Furthermore,
15.3% had sexual intercourse in the last semester to get money or cover a material need, or paid
for sexual intercourse (24.7%). Kinsey results showed that a high percentage of the sample gave
importance to sex (71.7%), but only 24.7% were satisfied with their sexual activity.
At the same time, a total of 85.9% of the patients in this investigation suffered from SD. Among
them, 24.7% showed mild SD, 21.2% suffered from moderate SD, and 40% had severe SD. There was
a highly significant difference between men and women in terms of the PRSexDQ-SALSEX total score
(p = 0.000; Figure A1), being more serious in female patients. 76.5% felt alteration in their sexual
activity after the beginning of methadone treatment, but only 11.8% reported it to the doctor without
being questioned. In addition, 76.9% of patients were disturbed by SD and 32.7% of them considered
interrupting the MTD treatment.
Dysfunction groups showed a statistically different behaviour in items 5 (p = 0.037), 6 (p = 0.003),
and 7 (p = 0.005) of the Modified Kinsey scale. Patients without sexual dysfunction had sex more
frequently than patients with SD (Figure 1, median values of items 5 and 6), with the patients having
severe sexual dysfunction having the lowest score.
Figure 1. Differences in Kinsey questionnaire items, distinguished by the four SD classes of SALSEX.
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Impact of Treatment Duration, Methadone Dose Consumed, Tolerance toward Methadone, and Effect
of Using Benzodiazepines on Sexual Dysfunction
Generally, correlation analysis allowed us to conclude that the dose of MTD and overall score of
SD were directly associated (Pearson correlation coefficient 0.332; p = 0.002). However, no evidence
was found that treatment duration and severity of SD were linked (Pearson correlation coefficient
0.183; p = 0.094).
The frequency of SD problems by dose and tolerance toward MTD are summarized in Tables 3
and 4. Differences (Kruskal-Wallis analysis) between the four SD groups of patients (no SD, mild SD,
moderate SD, severe SD) showed statistically significant dissimilarities on MTD’s dose (p = 0.005) and
MTD’s tolerance (p = 0.000). Patients with severe sexual dysfunction were those who took higher doses
of MTD, as well as those who showed the worst tolerance towards the opiate. All cases with poor
tolerance toward MTD presented severe sexual dysfunction.
Table 3. Comparison of clinical characteristics between patients with no SD and patients with SD,




SD Patients (n = 73) p-Value
Mild (n = 21) Moderate (n = 18) Severe (n = 34)
Age (years) 44 ± 9.75 43 ± 11 45.5 ± 10 42.5 ± 10.5 0.871
MTD’s dose (mg) 32.5 ± 13.75 40 ± 28 39 ± 18.75 53 ± 40.75 0.005
MTD’s tolerance
Good tolerance, n (%) 9 (75) 13 (61.9) 10 (55.6) 5 (14.7)
0.000Medium tolerance, n (%) 3 (25) 8 (38.1) 8 (44.4) 25 (73.5)
Poor tolerance, n (%) - - - 4 (11.8)
Personality disorder, n (%) 8 (66.7) 11 (52.4) 10 (55.6) 20 (58.8) 0.947




Mild SD Patients (n = 21) Moderate/Severe SD Patients (n = 52)
DL DEO A ELP DL DEO A ELP
MTD dose
<30 mg 0 87.5 75 12.5 50 100 72.7 54.5 81.8
30–60 mg 0 72.7 72.7 18.2 27.3 95.8 79.2 83.3 83.3
>60 mg - 0 100 50 0 94.1 94.1 88.2 94.1
MTD tolerance
Poor - - - - - 100 100 100 100
Medium 0 62.5 75 0 12.5 93.9 87.9 87.9 87.9
Good 0 76.9 76.9 30.8 46.2 93.3 66.6 53.3 80
Decreased libido (DL); Delay in ejaculation/orgasm (DEO); Anorgasmia (A); Erection/lubrication problem (ELP).
In Table 4, the percentage of patients suffering from some libido, eyaculation/orgasm, anorgasmia,
or erection/lubrication problem are summarized, regardless of whether the symptoms were mild.
Patients who did not suffer from SD, did not present problems in any of the evaluated dimensions
(decreased libido (DL), delay in eyaculation/orgasm (DEO), anorgasmia (A), and erection/lubrication
problem (ELP)). However, all dimensions of SD were affected by the MTD intake in those with mild,
moderate, or severe SD. Patients treated with a lower amount of MTD suffered from less problems of
delay in ejaculation/orgasm or in the inability to ejaculate/have orgasm during intercourse. The same
occurred with those patients with a better tolerance to this opiate. The dose associated with the highest
erection/lubrication problem (94.1%) was more than 60 mg of MTD.
As seen in the CFA graphical representation (Figure 2a) and remembering that the proximity
between points can be understood as a direct association between categories, it was observed that:
• Patients which had no SD or their SD was not severe showed good tolerance to MTD;
• Patients with moderate SD were those that had good or medium tolerance;
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• Severe SD was associated with poor MTD tolerance.
Figure 2. CFA graphical representations of the categories of two qualitative variables: (a) Tolerance to
MTD (red) vs severity of SD (blue); (b) dose of MTD (green) vs severity of SD (blue).
After examining the influence of mg of dose with the grade of dysfunction (Figure 2b), it could be
concluded that:
• Patients which had no SD or their SD was mild were those who took a dose between 0 and 30 mg;
• Patients with moderate SD took 30–60 mg of MTD;
• Severe SD was associated with the highest doses: 60–200 mg.
Finally, 57.6% of the patients also used benzodiazepines (both self-administered and medically
prescribed). Due to this last characteristic, the presence of DS was then examined depending on whether
the patients used methadone alone or methadone combined with benzodiazepines. Firstly, SALSEX
scores difference analysis between both groups presented non-significant differences (p = 0.242).
In other words, no significant evidence was found to corroborate that the use of benzodiazepines
combined with methadone influences the presence and/or severity of DS. Secondly, CFA graphical
representation (Figure A2) shows the differences in the association between DS and doses of MTD
and DS and tolerance to MTD in patients who only consume MTD (panels a and c) and patients who
consume both methadone and benzodiazepines (panels b and d). In the case of patients who only take
MTD the association between not suffering from SD or mild SD and having a good tolerance to MTD
is very strong (panel a), while those who consume MTD and benzodiazepines suffer from moderate
SD, although they have a good tolerance to MTD (panel b). Regarding the dose consumed, patients
taking a dose of 0–30 mg of MTD and also benzodiazepines (panel d) are associated with mild SD,
while patients who only take MTD (dose of 0–30 mg) are associated with a diagnosis of no presence of
DS (panel c).
3.3. Quality of Life in Presence of Sexual Dysfunction Problems
The mean score of the quality of life test TECVASP was 58.12 ± 13.74 points. Statistically significant
differences were found for SALSEX classes in questions 4 (p = 0.006), 10 (p = 0.019), 14 (p = 0.034),
16 (p = 0.019), and 22 (p = 0.005).
Figure A3 contains the global quality of life score test for patients that had no SD versus patients
which suffered from SD of any grade. The median score of the SD group was higher than the median
score of patients without dysfunction problems, mirroring the results of worse quality of life in those
patients. A comparison of four classes of SD reported a significant difference (p = 0.011, Figure A2b),
where patients with severe sexual dysfunction suffered from the worst quality of life and patients with
mild sexual dysfunction had the best quality of life.
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4. Discussion
The Kinsey scale results showed that a high percentage of the sample gave importance to sex
(71.7%), but only 24.7% were satisfied with their sexual activity. Patients in MMT had problems with
sexual function in one or more of the five PRSexDQ-SALSEX domains (loss of libido, delayed orgasm or
ejaculation, lack of orgasm or ejaculation, erectile dysfunction in men/vaginal lubrication dysfunction
in women, and patient’s tolerance.). The research literature has noted high rates of sexual dysfunction
in heroin users and MMT patient populations [14]. Our study found that 85.9% of participants in MMT
had sexual dysfunction (40% of them severe dysfunction), which is perhaps higher than reported in
other studies [15,16], although the results found varied greatly [17,18].
Older age, for example, was highly hypothesized to be correlated with increased sexual
dysfunction in patients receiving methadone [19]. In our sample, we did not find statistically significant
differences between the presence of sexual dysfunction and age (p = 0.871). There are also significant
differences (p = 0.005) in the methadone dose among patients who presented mild, moderate, or severe
sexual dysfunction. This finding agrees with what was found by others [11], who showed that patients
on higher methadone doses had more sexual dysfunction, and differed slightly from others [14].
Although it is commonly accepted that sexual dysfunction is a direct pharmacological effect of
opioids, recent studies have revealed that the etiology of sexual dysfunction in methadone-maintained
patients is rather complex [20,21]. Some research has suggested that heroin, amphetamine, alcohol,
tobacco, and marijuana can cause sexual dysfunction by a number of mechanisms, including effects
on the male reproductive system at the level of the hypothalamus, the pituitary gland, and the
testes [22,23]. Additionally, because of this, those patients who had positive toxic control in the six
months prior to our study were excluded from the sample. Other factors commonly pointed out are
psychological factors (i.e., psychiatric symptoms). To avoid this, we have excluded all those patients
who had a psychiatric diagnosis, apart from a substance use disorder (except for personality disorder).
The diagnosis of personality disorder appears in 57.6% of the sample, which in itself is linked to sexual
dysfunction [24,25], however, and as a limitation of this research, we did not consider physical health
and biological factors (i.e., sex hormone), which also significantly contribute to it [26].
There were several limitations to our study. Firstly, we found that a proportion of the participants
in MMT used benzodiazepines (both self-administered and medically prescribed) during methadone
treatment. This was the only admitted psychopharmacological treatment, and although its presence
may interfere with the results [27] (benzodiazepines are psychotropic drugs with some adverse
sexual effects) [28], it is not easy to find patients on methadone treatment in monotherapy. Secondly,
another limitation of the study is bias due to its retrospective design (instead of prospective one);
however, the relatively high mean duration of methadone treatment (6.34 ± 6.74 and 9.85 ± 7.78
years of treatment for men and women, respectively) avoids bias in the recalling symptoms of sexual
dysfunction prior to initiating MMT, which would influence the result of this study. We emphasize
that they did not take antidepressants or antipsychotics, which have been shown in the literature to
cause many sexual dysfunctions [29].
Sexual functioning is critical for improving the quality of life in patients enrolled in an opioid
rehabilitation program. The methadone treatment programs should be progressively oriented to the
person, valuing their opinions, encouraging their active participation in the process, and improving
their quality of life levels, so that the approach to their problems is similar to that of any another
health issue.
Clinical implications: clinicians may consider asking about sexual dysfunction while treating
heroin dependents, as only 11.8% of the patients in our sample reported it without being questioned
about it; however, 32.7% of them considered interrupting the treatment for this reason. As the
results of our study showed high rates of sexual dysfunction secondary to methadone treatment
(not spontaneously reported), we think it is very important to use scales like these, including brief and
relatively nonintrusive questionnaires that ease the exploration and detection of these symptoms and
avoid discontinuation of the treatment
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5. Conclusions
A high prevalence of sexual life dissatisfaction was found in our sample. It suggests that the sexual
dysfunction of MMT patients deserves special attention from specialists of addiction treatment settings.
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Appendix A
Figure A1. Difference between men and women in SALSEX total score. The ◦ symbol represents an
outlier and the * symbol corresponds to extreme value.
Figure A2. Cont.
157
J. Clin. Med. 2019, 8, 321
Figure A2. CFA graphical representations of the categories of two qualitative variables: (a) Tolerance to
MTD (red) vs severity of SD (blue) of patients that only use MTD; (b) tolerance to MTD (red) vs severity
of SD (blue) of patients that use MTD and benzodiazepines; (c) dose of MTD (green) vs severity of SD
(blue) of patients that only use MTD; (d) dose of MTD (green) vs severity of SD (blue) that use MTD
and benzodiazepines.
Figure A3. Quality of life based on SALSEX classes (no SD, mild SD, moderate SD, and severe SD).
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Abstract: Problems arising from hypersexual behavior are often seen in clinical settings. We aimed to
extend the knowledge about the clinical characteristics of individuals with hypersexual disorder (HD).
A group of people who fulfilled the proposed diagnostic criteria for HD (men with HD, n = 50) was
compared to a group of healthy controls (n = 40). We investigated differences in sociodemographic,
neurodevelopmental, and family factors based on self-report questionnaires and clinical interviews.
Men with HD reported elevated rates of sexual activity, paraphilias, consumption of child abusive
images, and sexual coercive behavior compared to healthy controls. Moreover, rates of affective
disorders, attachment difficulties, impulsivity, and dysfunctional emotion regulation strategies were
higher in men with HD. Men with HD seem to have experienced various forms of adverse childhood
experiences, but there were no further differences in sociodemographic, neurodevelopmental factors,
and family factors. Regression analyses indicated that attachment-related avoidance and early onset
of masturbation differentiated between men with HD and healthy controls. In conclusion, men with
HD appear to have the same neurodevelopment, intelligence levels, sociodemographic background,
and family factors compared to healthy controls, but they report different and adverse experiences in
childhood, problematic sexual behavior, and psychological difficulties.
Keywords: hypersexuality; sexual addiction; sexual compulsivity; phenomenology; comorbidities
1. Introduction
Hypersexual disorder (HD) is characterized by intense, repetitive sexual fantasies, urges, and
behaviors that lead to clinically significant psychological impairment [1–3]. Kafka [3] proposed that
hypersexual disorder should be included as a category in the Diagnostic and Statistical Manual of
Mental Disorders, 5th edition (DSM-5) [4], but the proposal was ultimately rejected. One of the
reasons given was the lack of experimental research on hypersexual disorder [5,6]. In the forthcoming
version of the International Classification of Diseases, ICD-11, hypersexual disorder will be classified
as compulsive sexual behavior disorder [7].
Alarming numbers are shown by a recent representative study of men (n = 1151) and women
(n = 1174) in the United States that found 10.3% of men and 7% of women showed clinically relevant
levels of distress and/or impairment due to difficulties in controlling sexual urges, feelings, and
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behaviors [8]. Manifestations of hypersexual behavior can include both real-world sexual contacts
and online sexual activities. Online use of sexual content in combination with masturbation is the
most common behavior that leads to men being diagnosed with hypersexual disorder according to the
Kafka criteria [3,9].
Cooper [10] pointed out that the triad of access, affordability, and anonymity enables people
to access whatever content they like anonymously, regardless of economic and social constraints.
Of course, internet usage patterns vary greatly between individuals with some engaging excessively
in online sexual activities [11] whereas others use dating platforms to find partners for sexual
encounters [12]. The main driving forces for excessive online sexual activity may be the anticipated
and experienced gratification associated with sexual arousal and the accessibility of virtually all types
of sexual stimulus [13].
Little is known about the clinical characteristics of people with HD. Data from a study without a
control group suggest that most subjects with men with HD are in intimate relationships, educated,
and employed [14]; however, many also report intimacy deficits due to disengagement from family
and a history of sexual, physical, and/or emotional abuse [15]. Intensive use of pornography [16,17]
and hypersexual behavior in general [18] have been linked to risky sexual behaviors. Studies indicate
that psychiatric comorbidities, particularly mood disorders, are prevalent in HD with rates ranging
from 72%–90% in the case of mood disorders [14,19–21], and 42% in the case of substance use
disorders [22]. Findings on the relationship between hypersexual disorder and impulsivity are mixed.
Two studies [23,24] of treatment-seeking individuals fulfilling the proposed criteria for hypersexual
disorder [3] found that between 48% and 53.3% displayed elevated impulsivity in self-report measures.
Reid, Berlin, and Kingston [25] suggested that a context-specific form of sexual impulsivity, but not
general impulsivity, might be prevalent in hypersexual disorder. Hypersexual behavior has been
shown to be associated with neuropsychological impairments and alterations in attentional bias [26]
and executive control [27,28].
From a biological perspective, the testosterone system plays a crucial role for the development
and maintenance of sexual behavior [29]. As a marker of prenatal androgen exposure, the ratio of the
lengths of the second and fourth digits (2D:4D) can be used, and there is some evidence that a lowered
2D:4D ratio might be connected to hypersexual behavior [30], although mixed findings have been
reported. Some studies of the general population have demonstrated that a lower 2D:4D ratio (a more
masculine pattern) is linked to having a higher number of sexual partners and more offspring [30–32],
whereas others have shown that a high 2D:4D ratio is linked to promiscuity in men [33].
The aim of this study was to investigate the clinical and some specific (neuro-)developmental
characteristics of men with hypersexual disorder in a large sample of people who fulfill the proposed
diagnostic criteria [3] and compare them with healthy controls. Furthermore, detailed analyses should
identify potential risk factors contributing to hypersexual behavior, such as biographical factors, i.e.,
adverse childhood events and attachment difficulties [34], as well as early age of sexual interest [35].
We present data on parameters not previously measured in comparable samples and we discuss the
results in the light of the current understanding of hypersexuality.
2. Experimental Section
2.1. Recruitment
2.1.1. Hypersexual Disorder Group
Men with HD were recruited between December 2016 and August 2017 through a press release by
the Section of Clinical Psychology and Sexual Medicine, Department of Psychiatry, Social Psychiatry,
and Psychotherapy at Hannover Medical School, Germany. The press release was taken up by
local newspapers and social media (e.g., www.facebook.com, www.instagram.com) and resulted in
539 self-identified men with HD expressing an interest in participating in the study (see Figure 1).
Two-hundred-and-sixty men responded to an email asking for a telephone number. Fifty-nine of
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the 260 individuals who provided a telephone number could not be reached by telephone, but the
remaining 201 were screened for hypersexual disorder in a semi-standardized telephone interview of
about 45 minutes carried out by a trained psychologist using Kafka’s [3] proposed criteria. Individuals
were eligible for the study if they fulfilled Kafka’s [3] proposed criteria for hypersexual disorder.
The questionnaires used in this study were sent by mail to eligible participants. Three participants
whose scores did not reach the cut-off (53) of Hypersexual Behavior Inventory 19 [36] were excluded
post hoc. Kafka’s [3] criteria for hypersexual disorder consist of clinically significant symptoms that
arise from sexual urges, fantasies or behaviors, and recur over a period of 6 months that individuals
struggle to control and are not due to the direct physiological effect of an exogenous substance.
Seventy-three of the 201 individuals who were screened met these criteria and were deemed eligible
for the study; 50 decided to participate and they formed the hypersexual disorder group (HD group,
see Figure 1 chart).
Figure 1. Recruitment of the hypersexual disorder group.
2.1.2. Healthy Controls
Healthy controls were recruited via advertisements on the Hannover Medical School, Germany,
intranet homepage. Eighty-five individuals responded to the advertisements (see Figure 2) of whom 56
responded to an email asking for a telephone number. Twenty-nine of these 56 could not be reached via
telephone for screening. The controls were matched for age (p = 0.587) and education (p = 0.503) with
HD group. Data from two healthy controls were subsequently excluded from analysis (one reported
a severe head injury prior to study participation, one reported a homosexual orientation, and one
control participant did not show up to assessment).
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Figure 2. Recruitment of healthy controls.
2.1.3. Exclusion Criteria
Exclusion criteria for all participants were: intellectual disability (as measured by Wechsler Adult
Intelligent Scale-IV), a psychotic disorder (assessed with Structured Clinical Interview for DSM-IV Axis
1 disorders, SCID-I), severe head injury, homosexual orientation on the Kinsey scale, and pedophilic
sexual preference (assessed in a semi-structured interview). In our Sex@brain project we focused on
heterosexual participants due to the heterosexual nature of the stimuli in the upcoming experiments.
All participants declared that their primary sexual interest was in women although some reported a
history of same-sex sexual contact.
All participants provided written, informed consent before participating and received monetary
compensation for participation. They were informed that they could withdraw from the study at any
time. The study was conducted in accordance with the Declaration of Helsinki and was approved
by the ethics commission of the Hannover Medical School, Germany. The results reported here were
obtained as part of a larger assessment that included a neuropsychological test battery and functional
magnetic resonance imaging.
2.2. Measures
The variables were classified into three categories: (1) sociodemographic, neurodevelopmental,
and family factors, (2) sexual characteristics, and (3) psychological characteristics including psychiatric
comorbidities. For an exact description of items please see the notes to Tables 1–4.
2.2.1. Sociodemographic, Neurodevelopmental, and Family Factors
A questionnaire was used to collect sociodemographic data, namely age, highest educational
qualification, employment status, lifetime criminal history, and relationship status. There were
also questions about neurodevelopmental perturbations, sibling position, parental health at birth,
and maternal and paternal age at birth. Aversive childhood experiences were assessed with
the Childhood Trauma Questionnaire (CTQ) [37]. The developmental and neurodevelopmental
perturbations investigated were birth complications, prolonged bedwetting, delayed walking, delayed
speech development, and childhood accidents leading to unconsciousness. Handedness was
determined using a 10-item adaptation of the Edinburgh Handedness Inventory [38] and 2D:4D
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ratio was estimated using images obtained from a portable scanner. The lengths of digits of the right
hand were estimated independently by two research assistants (inter-rater reliability: r = 0.83) and
calculations were based on the means of the two ratings.
Intelligence was estimated from the four subtests of the fourth edition of the Wechsler Adult
Intelligent Scale (WAIS-IV) [39] that are most highly correlated with full scale IQ as measured by the
German WAIS-IV. These four subtests are Vocabulary (verbal comprehension; r = 0.7), Block Design
(perceptual reasoning; r = 0.65), Arithmetic (working memory; r = 0.73), and Coding (processing speed;
r = 0.5).
2.2.2. Sexual Characteristics
Sexual development and behavior were assessed via a semi-structured interview and a set of
questionnaires. We collected data on age at first ejaculation, masturbation in the week prior to
assessment (duration and frequency), intercourse in the week prior to assessment, and lifetime total
of sexual partners. Moreover, we assessed duration and frequency of pornography consumption,
number of affairs, paraphilias, sexual coercive behavior, consumption of child abuse images, and sexual
dysfunctions. Specific instruments were used to measure sexual excitation and inhibition proneness
(Sexual Excitation Scale, SES and Sexual Inhibition Scale, SIS) [40], symptoms of hypersexual disorder
(Hypersexual Behavior Inventory-19, HBI-19) [36], symptoms of cybersex addiction (Internet Addiction
Test for online sexual activities—short version, sIATsex; [41] and sexual addiction (Sexual Addiction
Screening Test-Revised, SAST-R) [42].
2.2.3. Psychological Characteristics and Comorbidities
Psychiatric comorbidities were diagnosed using the German version of the SCID-I [43]. Additional
questionnaires were used to assess impulsivity (Barrat Impulsiveness Scale-11, BIS-11) [44], substance
abuse (Fagerström Test for Nicotine Dependence, FTND) [45], hazardous and harmful patterns of alcohol
consumption (The Alcohol Use Disorder Identification Test, AUDIT) [46], depressive symptoms (Beck
Depression Inventory-II, BDI-II) [47], bonding (Experiences in Close Relationships-Revised, ECR-R) [48],
alexithymia (Toronto Alexithymia Scale, TAS-26) [49], and emotion regulation (ERQ, Emotion Regulation
Questionnaire [50]; Fragebogen zur Erhebung der Emotionsregulation, FEEL-E [51].
Attention deficit hyperactivity disorder (ADHD) was diagnosed on the basis of scores ≥15 on
both the Wender Utah Rating Scale (WURS-K) [52] and ADHD self-assessment scale (ADHS-SB) [53].
2.2.4. Logistic Regression Analysis
To identify possible predictive factors for hypersexual disorder we carried out a binary logistic
regression analysis with group classification as dichotomous dependent variables. Our aim was
to identify factors that differentiated between men with HD and healthy controls. The number of
independent variables was chosen on recommendations by Agresti [54] (p. 138).
2.3. Data Analysis
All analyses were executed with SPSS Statistics Version 24 (IBM® Corporation, Amonk, NY, USA).
Analyses were carried out using independent t-tests, Mann–Whitney U tests or Fisher’s exact tests
for dichotomous variables. Fisher tests for tables larger than 2 × 2 were also used, as all polytomous
categorical variables had at least one expected cell frequency of less than 5. As this was one of the
first extensive phenomenological studies that included both men with hypersexual disorder and
healthy controls in the search for group differences regarding the theoretically derived set of clinical
variables tested here, we opted for an exploratory approach and report two-tailed significance levels
without correction for multiple comparisons (all analyses p < 0.05). However, for interested readers we
also included Bonferroni corrected significance in Tables 1–4. Effect sizes for parametric tests were
expressed as Cohen’s d, with d = 0.2 indicating a small effect, d = 0.5 a medium effect, and d = 0.8 a
large effect [55]. There are variations in group sizes on the various tests because questionnaires with
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missing data were excluded from analysis. To control for the effects of psychiatric disorders other than
hypersexual disorder, all group comparisons were also computed after excluding participants with a
history of any SCID-I diagnosis; this procedure yielded an N of 45 (HD = 21; HC = 22). The results of
these analyses are presented in the Supplementary Materials.
3. Results
3.1. Sociodemographic, Neurodevelopmental, and Family Factors
As intended by subject matching there were no group differences in the sociodemographic
variables regarding age (t(83) = 0.55, p = 0.587) and highest educational qualification (Fisher’s exact
test (N = 85), p = 0.503; see Table 1). Also, employment status (Fisher’s exact test (N = 85), p = 0.458),
lifetime criminal history (Fisher’s exact test (N = 85), p = 0.368), and relationship status (Fisher’s exact
test (N = 85), p = 0.128) were not different between groups. There were also no differences in scores on
the four WAIS-IV subscales used including the subtests vocabulary (t(82) = −1.28, p = 0.204), block
design (t(82) = 0.92, p = 0.359), arithmetic (t(82) = 0.112, p = 0.911), and coding (t(82) = 1.66, p = 0.100),
indicating similar intelligence levels among groups.
Indicators of neurodevelopmental perturbations were similar in men with HD and healthy
controls including general developmental factors during childhood (Fisher’s exact test (N = 82), p = 1)
distribution of handedness (Fisher’s exact test (N = 85), p = 0.645) and 2D:4D finger length ratio
(t(77) = 0.34, p = 0.738).
Our data show that men with HD and healthy controls grew up in families with similar structural
family factors such as number of children in the household in which the participant grew up
(t(78) = 0.01, p = 0.995); position in the birth order (w(78) = 718, z = −0.402, p = 0.687); position
among children in the household (w(78) = 750, z = −0.464, p = 0.642); maternal age at birth (t(79) = 0.88,
p = 0.384); and paternal age at birth (t(73) = 0.09, p = 0.93). Men with HD reported more frequently
maternal psychiatric problems (Fisher’s exact test (N = 62), p = 0.001), but not paternal psychiatric
problems (Fisher’s exact test (N = 68), p = 0.307) than healthy controls. Furthermore, the aversive
childhood memories of men with HD differed substantially from healthy controls. Men with HD
reported elevated rates of overall adverse childhood experiences (CTQ; t(68) = 2.71, p = 0.009, d = 0.57),
in particular emotional abuse (t(73) = 3.53, p < 0.001, d = 0.73), emotional neglect (t(81) = 2.46, p = 0.016,
d = 0.54), and sexual abuse (t(45) = 2.49, p = 0.017, d = 0.49) compared to healthy controls. However,
physical abuse (t(80) = 1.60, p = 0.113) and physical neglect (t(83) = 1.49, p = 0.141) did not reach
statistical significance.




(n = 38) p-Value d
Sociodemographic Variables % M (SD) % M (SD)
Age 36.51 (11.47) 37.92 (12.33) 0.587 a
Highest educational qualification b
no school-leaving qualification 2 0
0.503 c
secondary school leaving certificate 4 3
of 4 years secondary education
secondary school leaving certificate (5 years) 11 5
completed apprenticeship 28 26
secondary school leaving certificate (8 years) 21 40




in training 27 30
retired 4 8
employed 66 48
Lifetime criminal history (yes) e 19 11 0.368 c
Current intimate relationship (yes) 43 61 0.128 c
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(n = 38) p-Value d
Neurodevelopmental Factors
Developmental perturbations (yes) f 43 42 1 c
Handedness g
right 83 79
0.645 cleft 4 10.5
ambidextrous 13 10.5
2D:4D finger length ratio h 0.97 (.33) 0.96 (0.29) 0.738 a
Family Factors
Number of siblings 1.51 (1.42) 1.51 (0.93) 0.995 a
Position in the birth order i 1.67 (0.95) 1.72 (0.82) 0.687 j
Position among children in the household k 1.57 (0.94) 1.72 (0.82) 0.642 j
Age at participants birth
Paternal 30.02 (8.41) 29.88 (4.57) 0.930 a
Maternal 27.64 (7.77) 26.35 (4.79) 0.384 a
Childhood Trauma Questionnaire (CTQ) l,m 57.42 (16.06) 49.97 (8.38) 0.009 a,* 0.57
Emotional abuse 10.13 (4.76) 7.29 (2.51) 0.001 a,†,* 0.73
Physical abuse 7.32 (3.67) 6.26 (2.38) 0.113 a
Sexual abuse 6.28 (2.38) 5.03 (3.42) 0.017 a,* 0.49
Emotional neglect 11.74 (4.86) 9.24 (3.5) 0.016 a,* 0.54
Physical neglect 7.34 (3.02) 6.53 (1.67) 0.141 a
Psychiatric problems n
Father (yes) 20 3 0.307 c
Mother (yes) 39 9 0.001 c,†,*
Intelligence [WAIS-IV] o
Vocabulary 46.26 (7.40) 43.97 (8.97) 0.204 a
Block-design-test 48.91 (9.68) 50.79 (8.77) 0.359 a
Arithmetic 17.15 (3.10) 17.24 (3.84) 0.911 a
Coding 66.67 (15.73) 71.92 (12.62) 0.1 a
Note. a Statistical analysis: t-test. b 0 = no school-leaving qualification; 1 = secondary school leaving certificate
of secondary education (4 years); 2 = secondary school leaving certificate (5 years); 3 = completed apprenticeship
4 = secondary school leaving certificate (8 years); 5 = university degree. c Statistical analysis: Fishers exact test.
d 0 = unemployed; 1 = in training; 2 = retired; 3 = employed. e Criminal status was assessed with a semi-structured
interview (voluntary disclosure of confidential information) in which we asked participants to disclose all incidents
of criminal behavior regardless of whether they had resulted in conviction. Lifetime history of any criminal
behavior was coded 1; absence of criminal behavior was coded 0. f Assessed with a semi-structured questionnaire.
Coded 1 if any of the following problems had occurred, otherwise coded 0: Complications at birth, problems
with toilet training, problems with development of speech, problems with development of walking, head injuries,
cranio-cerebral trauma, unconsciousness, childhood diseases (e.g., measles, mumps, rubella, diphtheria, chickenpox,
poliomyelitis, meningitis, cerebral abscess, encephalitis and other illnesses resulting in a long stay in hospital).
g Handedness was assessed using a 10-item adaptation of the German version of the Edinburgh Handedness
Inventory [38]. h The participants’ right hands were photocopied to measure individual finger lengths. This was
done by laying the surface of the palm of the right hand onto a photocopier, the photocopied image was then used
to estimate the ratio. The basal crease where the finger joins the palm and the distal point of the fingertip were used
as landmarks to assess length. 2D:4D ratio was calculated by two independent raters, by dividing the length of the
second digit by the length of the fourth digit. The computed means of the two raters were used. i Position in birth
order with regard to mother’s other children. (What position are you in the birth order of your full siblings and the
half-siblings on your mother’s side?). j Statistical analysis: Wilcoxon–Mann–Whitney Test. k Position with regard to
children growing up in the same household. (What position are you with regard to the siblings you grew up with?).
l Five dimensions of childhood trauma were assessed via retrospective self-reports using the German version of the
Childhood Trauma Questionnaire [37]. m Higher values indicate more problems. n Participants were asked about
maternal and paternal psychiatric problems in a semi-structured interview. Presence was coded 1, absence 0. o Sum
scores in the German version of the Wechsler Adult Intelligence Scale WAIS—Fourth Edition [39]. * p-values < 0.05
were considered significant. † significant after Bonferroni α-correction. In this section p-values < 0.002 (0.05/22)
were considered as significant.
3.2. Sexual Characteristics
The sexual history from men with HD differed substantially from healthy controls (see Table 2).
First of all, men with HD had earlier sexual experiences than control group. Men with HD reported that
they were over a year younger when they started masturbating (t(79) = 3.59, p < 0.001, d = 0.80) and about
a year younger when they first ejaculated (t(77) = 2.79, p = 0.007, d = 0.63). But they did not differ in age
of first intercourse (t(83) = 1.868, p = 0.065). Men with HD and healthy controls reported similar duration
of last/current relationship in months (t(42) = 0.14, p = 0.886), and number of children (w(75) = 728,
z = −0.081, p = 0.936). However, men with HD differed in their sexual relationships from healthy
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controls. On average men with HD reported about eighty more female sexual partners (w(79) = 470.5,
p = 0.001) and female coital partners (w(81) = 443, p < 0.000) than healthy controls. Moreover, despite
their predominant heterosexual orientation, men with HD reported sexual activities with men with
more male sexual partners (w(83) = 567.5, p < 0.000) and male coital partners (w(83) = 664, p = 0.002),
whereas healthy controls reported almost no sexual activities with men. Moreover, men with HD were
more likely to report that they had an affair during their last or current relationship (Fisher’s exact test
(N = 81), p < 0.001), with 67% reporting an affair compared to only 19% in healthy controls. Furthermore,
men with HD report more received problems through online sexual activities than healthy controls
indicated by a group difference in sIATsex score (t(80) = −11.70, p < 0.001, d = 2.45). Accordingly, they
reported that they consumed pornography more often in the week before the assessment (Fisher’s
exact test (N = 84), p < 0.001), about 85% of men with HD reported at least three times of pornography
consumption per week, compared to about 40% in healthy controls. Moreover, men with HD watched
on average about seventy minutes more of pornography (t(47) = −3.61, p = 0.001, d = 0.73) than healthy
controls. Duration of pornography consumption varied greatly between groups, with more than half
of men with HD watching over an hour per week, compared to only 9% in healthy controls. Relating
to sexual excitation and inhibition, men with HD reported more pronounced sexual excitation (SES:
t(83) = 5.01, p < 0.001, d = 1.09), a lower sexual inhibition due to threat of performance consequences
(SIS2: t(83) = −3.75, p < 0.001, d = 0.82). However, men with HD showed a higher score for perceived
threat of performance failure (SIS1; t(80) = 2.30, p = 0.024, d = 0.48). Interestingly, the prevalence of
reported sexual dysfunction was similar in men with HD and healthy controls (Fisher’s exact test
(N = 85), p = 0.765), specifically there were no differences in erectile disorder, hypoactive desire disorder,
premature and delayed ejaculation.




(n = 38) p-Value d
Sexual History and Development % M (SD) % M (SD)
Onset of masturbation 11.16 (2.41) 12.97 (2.06) <0.001 a,†,* 0.8
Age at first ejaculation 11.91 (1.67) 12.81 (1.06) 0.007 a,* 0.628
Age at first intercourse 16.57 (3.08) 17.71 (2.37) 0.065 a
Number of sexual partners b
Male 75.32 (376.12) 0.03 (0.16) <0.001 c,†,*
Female 99.10 (211.10) 19.24 (22.00) 0.001 c,†,*
Number of coital partners d
Male 16.90 (76.52) 0.03 (0.16) 0.002 c,*
Female 86.71 (204.43) 15.00 (19.65) <0.001 c,†,*
Number of relationships 4.81 (3.51) 5.35 (3.82) 0.506 a
Duration of last/current relationship [in month] e 66.90 (99.24) 70.67 (73.48) 0.886 a
Number of children 0.74 (1.06) 0.77 (1.03) 0.936 c
Affairs in last/current relationship (yes) 67 19 <0.001 f,†,*







Duration (minutes) 87.53 (125.50) 18.93 (19.82) 0.001 c,†,* 0.73
Hypersexual Behavior Inventory (HBI-19) h,y 72.37 (10.31) 30.26 (10.09) <0.001 a,†,* 4.123
Sexual Addiction Screening Test (SAST-R) I,y 13.04 (3.20) 2.61 (2.71) <0.001 a,†,* 3.49
Short Internet Addiction Test—modified for cybersex
(sIATsex) j,y 39.62 (10.59) 17.11 (7.07) <0.001
a,†,* 2.45
Sexual excitation (SES) k,y 60.92 (9.79) 50.41 (9.39) <0.001 a,†,* 1.093
Sexual inhibition k,y (SIS1/Threat of performance failure) 35.79 (8.18) 32.39 (5.39) 0.024 a,* 0.481
Sexual inhibition k,y (SIS2/Threat of performance
consequences)
25.66 (4.90) 29.45 (4.26) <0.001 a,†,* 0.819
Sexual dysfunctions (yes) l 17 13 0.765 f
Note. a Statistical analysis: t-test. b Number of partners with whom the participant engaged in sexual behavior
of any kind (including petting). c Statistical analysis: Wilcoxon–Mann–Whitney U Test. d Number of partners
with whom the participant in vaginal or anal intercourse. e Participants were asked: How long has your current
relationship lasted? or How long did your last relationship last? d Positive responses to the question Have you had/
did you have sex with others in your current/last relationship? were coded 1; negative responses were coded 0.
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f Statistical analysis: Fisher’s exact test. g Frequency of pornography consumption was classified as
follows: 5 = Several times a day, 4 = once a day, 3 = several times a week, 2 = once a week, 1 = less than
that. h Hypersexual behavior was assessed using the Hypersexual Behavior Inventory-19, for which
the suggested cut-off score is 53 [36]. i Sexual addiction was assessed using the first 20 Items of the
Sexual Addiction Screening Test-Revised [42]. j Cybersex addiction was assessed using an adaption of
an Internet Addiction Test [41]. k Propensity to sexual excitation and inhibition was assessed using
German versions of the Sexual Inhibition and Sexual Excitation Scales. Sexual inhibition was assessed
using two independent subscales “Threat of performance consequences” and “Threat of performance
failure” [40]. l All data given in this section based on the ICD-10 criteria for sexual dysfunctions.
y Higher values indicate greater problems. * p-values < 0.05 were considered significant. † significant
after Bonferroni α-correction. In this section p-values < 0.002 (0.05/22) were considered as significant.
Paraphilias like exhibitionism, voyeurism, masochism, sadism, fetishism, frotteurism or
transvestism were more prevalent in men with HD (Fisher’s exact test (N = 85), p < 0.001) (see
Table 3). Men with HD were also more likely to report sexually coercive behavior (Fisher’s exact test
(N = 85), p < 0.001) and a higher rate of having consumed images of child abuse at least once in their
lives (Fisher’s exact test (N = 82), p = 0.009); none of the healthy controls reported having consumed
child abuse images.




(n = 38) p-Value
n % n %
Paraphilias (yes) a 22 47 1 3 <0.001 †,*
Exhibitionism (yes) 3 6 0 0 0.25
Voyeurism (yes) 5 11 0 0 0.062
Masochism (yes) 7 15 0 0 0.015 *
Sadism (yes) 5 11 0 0 0.062
Fetishism (yes) 16 34 1 3 <0.001 †,*
Frotteurism (yes) 4 8 0 0 0.125
Transvestism (yes) 1 2 0 0 1
Sexual coercive behavior (yes) b 33 70 8 21 <0.001 †,*
Lifetime consumption of images of child abuse (yes) c 38 81 0 0 0.009 *
Note. Statistical Analysis: Fisher’s exact tests. a All data given in this section are based on the ICD-10
criteria for paraphilias. b Sexual violence was assessed using a four-item questionnaire asking about verbal
assault, non-consensual sexual recordings, non-consensual touching/rubbing, and non-consensual penetration.
c Consumption of images of child abuse was assessed with a semi-structured interview (voluntary disclosure of
confidential information) in which participants were asked to disclose consumption regardless of whether this
was known to the legal system. Any lifetime history of consumption of images of child abuse was coded 1; other
responses were coded 0. * p-values < 0.05 were considered significant. † significant after Bonferroni α-correction.
In this section p-values < 0.002 (0.05/22) were considered as significant.
3.3. Psychological Characteristics and Comorbidities
Most importantly, men with HD revealed more often psychiatric symptoms such as depression,
impulsivity or symptoms of ADHD (see Table 4). Separate analysis of current diagnoses of SCID-I
subcategories revealed a higher rate of affective disorders in the HD group (Fisher’s exact test (N = 85),
p = 0.015). This increased rate of diagnoses was supported by the psychometric assessment of depressive
symptoms with higher symptoms in men with HD (BDI-II; t(79) = 5.47, p < 0.001, d = 1.13). Rates of
current SCID-I diagnosis of substance abuse and/or dependency were similar in the two groups
(Fisher’s exact test (N = 85), p = 1.000), just as psychometric assessment of alcohol consumption (AUDIT;
t(82) = −0.93, p = 0.354) and nicotine abuse (FTND; t(83) = 0.73, p = 0.471, d = 0.16). However, rates
of current anxiety disorders (Fisher’s exact test (N = 85), p = 0.690), obsessive-compulsive disorders
(Fisher’s exact test (N = 85), p = 1.000), and somatic symptoms and eating disorders (Fisher’s exact
test (N = 85), p = 1.000) did not differ between the groups. Taken together, men with HD and healthy
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controls showed similar proportions of current SCID-I (Fisher’s exact test (N = 80), p = 0.104) and
lifetime SCID-I diagnosis (Fisher’s exact test (N = 85), p = 0.190). However, men with HD were more
likely to display symptoms of ADHD at the time of assessment (ADHS/SB; t(73) = 6.31, p < 0.001,
d = 1.37) and to report childhood symptoms of ADHD (WURS-K; t(82) = 3.76, p < 0.001, d = 0.82),
Moreover, men with HD revealed greater impulsivity than healthy controls (BIS-11; t(81) = 3.76,
p < 0.001, d = 0.83). The results relating to emotion regulation were mixed: men with HD were more
likely to use maladaptive emotion regulation strategies (FEEL-E-maladaptive strategies; t(81)= 3.54,
p < 0.001, d = 0.78) and “reappraisal” strategies (ERQ: Reappraisal; t(83) = −2.477, p =.015, d = 0.545)
but use of adaptive strategies (FEEL-E-adaptive strategies; t(81) = −1.26, p = 0.212) was similar as
was use of the “suppression” strategies (ERQ: Suppression; t(83) = 1.852, p = 0.068). Men with HD
reported more symptoms of alexithymia (TAS-26; t(79) = 4.11, p < 0.001, d = 0.92) elevated scores in both,
attachment-related anxiety (ECR-R anxiety: t(78) = 5.413, p < 0.000, d = 1.245) and attachment-related
avoidance (ECR-R avoidance: t(82) = 4.908, p < 0.000, d = 1.064).






% M (SD) % M (SD)
Lifetime Scid-i Diagnosis (yes) a 55 39 0.191
Current Scid-i Diagnosis (yes) a 43 25 0.104
Depression
Lifetime affective disorders (SCID-I) a 50 13 <0.000 †,*
Current affective disorders (SCID-I) a 15 0 0.015 *
Symptoms of depression (BDI-II) b,y 17.25 (11.60) 5.92 (7.72) <0.001 †,* 1.129
ADHD and impulsivity
ADHD (ADHS-SB) c,y 21.74 (11.26) 8.43 (7.45) 0.001 †,* 1.374
Childhood symptoms of ADHD (WURS-K) d,y 26.59 (15.34) 15.00 (12.34) 0.001 †,* 0.824
Impulsivity levels (BIS-11) e,y 68.24 (11.22) 59.62 (9.25) <0.001 †,* 0.83
Substance abuse
Lifetime substance abuse and/or dependency (SCID-I) a 24 24 1
Current substance abuse and/or dependency (SCID-I) a 23 21 1
Alcohol abuse (AUDIT) f,y 6.57 (5.68) 7.68 (4.98) 0.354
Nicotine dependence (FTND) g,y 3.87 (6.23) 2.95 (5.3) 0.471
Lifetime anxiety disorders (SCID-I) a 11 8 0.724
Current anxiety disorders (SCID-I) a 8 5 0.687
Lifetime obsessive compulsive disorder (SCID-I) a 4 3 1
Current obsessive compulsive disorder (SCID-I) a 4 3 1
Lifetime somatic problems, eating disorder or other (SCID-I) a 4 0 0.499
Current somatic problems, eating disorder or other (SCID-I) a 2 0 1
Emotional Difficulties
Symptoms of alexithymia (TAS-26) h,y 47.56 (10.31) 38.92 (8.35) 0.001 †,* 0.915
Maladaptive emotion regulation strategies (FEEL-E) i 107.51 (21.3) 91.68 (18.97) <0.001 †,* 0.781
Adaptive emotion regulation strategies (FEEL-E) i 115.42 (18.4) 120.77 (20.28) 0.212
Emotion Regulation: Reappraisal (ERQ) j 22.3 (8.62) 26.68 (7.45) 0.015 * 0.545
Emotion Regulation: Suppression (ERQ) j 16.19 (5.16) 14.18 (4.72) 0.068
Attachment style: Anxiety (ECR-R) k,y 75.85 (22.84) 50.15 (18.17) <0.000 †,* 1.245
Attachment style: Avoidance (ECR-R) k,y 57.87 (13.7) 41.35(17.16) <0.000 †,* 1.064
Note. Statistical analysis for SCID-I diagnosis: Fisher’s exact test, for all other analysis: t-test. a The Structured
Clinical Interview for DSM-IV (SCID-I) [56] was used to determine the presence of psychiatric disorders. Presence
of a disorder was coded 1, absence was coded 0. b Symptoms of depression were assessed using the Beck
Depression Inventory-Second Edition [47]. c Childhood and adult problems with attention and hyperactivity were
assessed using an 18-item self-report scale for the assessment of attention deficit hyperactivity disorder (ADHD) for
adults [53]. d We screened for attention-deficit disorder using the short version of the Wender Utah Rating Scale [52].
e Impulsivity was assessed using the German translation of the Barratt Impulsiveness Scale (Barratt & Patton,
1995). f We screened for harmful alcohol consumption using the Alcohol Use Disorders Identification Test [46].
g Nicotine dependence was assessed using the Fagerström Test for Nicotine Dependence [45]. h Alexithymia was
assessed using a German version of the Toronto Alexithymia Scale-26 [49]. i Use of adaptive and maladaptive
emotion regulation strategies was assessed using the FEEL-E questionnaire [51]. j Emotion regulation strategies
reappraisal and suppression were assessed using Emotion Regulation Questionnaire [50]. k Attachment style was
assessed using the attachment-related anxiety and attachment-related avoidance subscales of the Experience in
Close Relationships-Revised Scale [48]. y Higher values indicate greater problems.
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3.4. Logistic Regression Analysis
The variables that differentiated best between men with HD and healthy controls were age at
onset of masturbation (OR = 0.55, 95% CI (0.35, 0.86)) and avoidant attachment style (OR = 1.06, 95% CI
(1.01,1.11)). Non-significant were child traumata and anxious attachment style. The specified regression
model had a good fit (with Nagelkerke R2 = 0.55 and Hosmer–Lemeshow Test: χ2(7) = 11.76, df = 7,
p = 0.11) and explained about 55% of the variance between the two groups. The mean classification
accuracy was 80.0% (78.1% specificity, 81.4% sensitivity).
4. Discussion
This study is one of the first to analyze phenomenological data from a large sample of individuals
who met the proposed criteria for hypersexual disorder [3] and compare them with a group of healthy
controls. A considerable number of sociodemographic, neurodevelopmental, and family factors,
as well as sexual characteristics, psychological characteristics, and comorbidities were investigated.
Through analysis of an extensive set of variables this study has revealed important differences
between people diagnosed with hypersexual disorder and healthy controls.
In summary, men with HD seem to have experienced more difficulties during childhood than
healthy controls, being more likely to have had a mother with psychiatric problems, to have experienced
various forms of adverse experiences during childhood and to have displayed symptoms of childhood
ADHD. Moreover, attachment difficulties with pronounced avoidance in close relationships were
higher in men with HD. Onset of masturbation was at an earlier age in men with HD and they
experienced higher sexual excitation and less sexual inhibition due to concern about negative
consequences, but higher sexual inhibition due to threat of performance failure. Furthermore, men with
HD were characterized by problems arising through subjective complaints through their high use of
online sexual activities and reported more deviant sexual behaviors, namely higher rates of paraphilia,
sexually coercive behavior, and consumption of images of child abuse. Diagnoses of affective disorders
and symptoms of a large set of psychiatric comorbidities such as impulsivity, symptoms of adult
ADHD, alexithymia, and maladaptive emotion regulation strategies were increased in men with HD.
There were indicators of differences in the childhood of men with HD compared to healthy
controls. In our sample, dysfunctional emotion regulation strategies such as a lowered reappraisal and
increased maladaptive strategies can be seen in men with HD, as well as increased alexithymia. Men
with HD reported a higher rate of adverse childhood experiences; especially the rates of emotional
abuse and neglect, as well as sexual abuse were increased, which have been shown to be associated
to emotion regulation difficulties [57]. Moreover, maladaptive emotion regulation strategies in men
with HD may be fostered by the psychiatric difficulties experienced by the child’s mother [58] which
were increased in men with HD. We argue that a possible path to HD is via a series of aversive states
and experiences in childhood and adolescence which facilitates the development of maladaptive
emotion regulation strategies [34]. Moreover, dysfunctional emotion regulation strategies may be
associated to the attachment difficulties we observed in men with HD, as children show dysfunctional
emotion regulation strategies when they are in a non-secure attachment to their mothers [59]. In a
representative survey of the German population, use of online sexual activities was significantly
associated to anxiously attached individuals [60]. Our regression analysis showed that avoidance
in close relationships differentiated between men with HD and healthy controls, which is in line
with Katehakis’s [34] suggestion that some HD patients may have disengaged emotionally during
childhood. This may lead to impaired development of the limbic system and parts of the prefrontal
cortex, due to an adverse interaction involving the central nervous system, autonomic central nervous
system, and hypothalamic–pituitary–adrenal axis [34].
Our findings are in line with findings suggesting that men with HD experience deficits in
affect regulation and negative affect and may use hypersexual behavior as a maladaptive coping
strategy [61]. These neurobiological deficits may develop in early childhood and may impair emotional
and intellectual abilities [34]. However, we found only emotional disabilities and no differences in
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intelligence as measured by WAIS-IV subtests [39] were observed in this study and in a study with a
smaller sample [62].
A disposition to hypersexual behavior may manifest early in sexual development, our HD group
was characterized by an early onset of masturbation which differentiated significantly between men
with HD and healthy controls in logistic regression analysis. Moreover, hypersexual behavior has been
associated to early onset of sexual interest [35], and early onset of sexual behavior has been linked to
sensation-seeking behavior, depression, and anxiety [63]. Frequency and duration of pornography
consumption were higher in men with HD. However, it is important to note that not only the quantity
of pornography consumption results in problems but that the relationship between frequency and
duration of pornography use and treatment-seeking is not linear, but mediated by the severity of
perceived negative symptoms associated with use of pornography [64]. The incentive salience theory
of addiction [65,66], which has been applied to HD [26,62], posits that in addiction “wanting” stimuli
becomes dissociated from “liking” stimuli. This could explain why men with HD continue with
problematic behavior despite the perceived negative consequences. In fact, the men with HD in our
sample report more problems due to their increased pornography consumption.
The important role of sexual excitation and inhibition in hypersexual behavior has been shown
in large surveys [35,67]. The HD group in our sample reported higher sexual excitation and less
sexual inhibition due to perceived threat of performance consequences, and thus higher sexual arousal.
We argue that this specific pattern of sexual arousal is a vulnerability factor which, in combination
with using sexual behavior as a dysfunctional emotion regulation strategy, increases the likelihood of
developing hypersexual disorder. A study of a large online sample that used total number of sexual
outlets as an indicator of sex drive found that high sexual interest was associated with self-reported
consumption of images of child abuse [68]. In fact, in our sample no healthy control reported to
have ever consumed child pornography as opposed to 80% of men with HD. Rates of sexual coercive
behavior were increased in men with HD, showing highly increased rates of consumption of child
abusive images in men with HD. Based on these results combined with meta-analyses that found
hypersexuality to be an empirically supported risk factor in sexual recidivism [69], we encourage
clinicians to assess criminal history and potential sexual coercive behavior in patients with HD.
Furthermore, we found increased rates of paraphilic interest in men with HD. To date, there
are inconsistent findings on the association of paraphilic interests and HD. Some studies suggest
increased rates of paraphilic interests [14], whereas in a field trial for the proposed criteria of HD [9]
no connection was found. A possible explanation for divergent rates would be openness to report
paraphilic interests, because in Germany information and data gathered in the course of research and
treatment situations are protected by confidentiality, even when they include reports on paraphilic
interest, child pornography consumption, and sexual coercive behavior. Paraphilic interest by itself
(if no others are harmed) does not require or justify clinical intervention [4]; however, paraphilic
interests are often associated with relationship difficulties [70]. Generally, the psychological burden
represented by HD is one of the main findings to emerge from this study. Our data underline increased
symptoms of some psychiatric comorbidities in HD. Especially, the diagnoses of both current and
lifetime symptoms of affective disorders are increased in HD group. In our study, the score for
symptoms of depression as measured by BDI-II was almost three times as high in men with HD as in
healthy controls. In line with our findings, Weiss [71] found that the prevalence of depression was
almost 2.5 times higher in men with HD than in the general population. Together the results of a range
of studies investigating comorbid affective disorders in hypersexual disorder suggest the prevalence is
between 28% and 42% [20,70,71]. Moreover, we suspect that impulsivity, particularly context-specific
sexual impulsivity [25] is a characteristic of hypersexual disorder, based on our observation of increased
impulsivity in men with HD and future studies should attempt to investigate this. Substance abuse is
often connected to increased impulsivity. In our sample we found only increased impulsivity with a
large effect size, but the rates of substance abuse did not differ between groups. There are theoretical
and empirical studies suggesting that substance abuse plays a role in hypersexual behavior [22,72,73],
172
J. Clin. Med. 2019, 8, 157
but the picture remains unclear, since different studies have used different measures and sample sizes.
Furthermore, future studies should investigate potential risky sexual behaviors in men with HD, which
have been shown to be associated to a large variety of mental disorders [74].
Based on theoretical assumptions and our results, we created a working model for the etiology of
hypersexual behavior (Figure 3). While there is no evidence of a monocausal etiology of hypersexual
disorder, the model points out multiple components that may increase the possibility of developing
hypersexual disorder. This working model may be useful for generating new research questions and
adaptions of treatment programs.
 
Figure 3. Working model of hypersexual disorder. We assume an underlying combination of genetic
and environmental factors that may increase the likelihood of developing hypersexual disorder.
A combination of biopsychosocial factors, e.g., genetic and epigenetic factors and adverse childhood
events shape individual characteristics and increase the likelihood of developing comorbid psychiatric
disorders. A high sexual arousal may be connected to genetic factors and may be both influenced
by and influence early onset of sexual experiences. Dysfunctional characteristics of the individual,
comorbid disorders, and high sexual arousal may lead to the development of hypersexual disorder.
The factors marked with an asterisk were derived a posteriori from our results.
Our data have several implications for treatment. We suggest that clinicians assess possible
emotional abuse and neglect, as well as sexual abuse in men with HD. Moreover, our data show
that symptoms of comorbid adult ADHD were increased in men with HD and it has been suggested
that these patients are likely to benefit from pharmacotherapy and behavioral therapy combined [75].
As a reduction of the use of dysfunctional emotion regulation strategies was seen in our sample, a
cognitive-behavioral therapy should also focus on dysphoric mood states and impulsivity in men
with HD [76]. A non-judgmental therapeutic approach is needed to tackle paraphilia, which is more
frequent in men with HD. We found increased rates of sexual coercive behavior and consumption of
child abusive images in men with HD, and if not restricted by limits of confidentiality, we suggest that
an assessment by clinicians is strongly advised to prevent possible harmful behavior.
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5. Limitation
It is important to note that that this sample consisted of individuals who volunteered to take part
in a clinical study and agreed to report intimate details of life events, inner experiences, and sexual
behavior. Thus, the characteristics of this sample may not be comparable to those of people with
hypersexual disorder who are reluctant to share private information.
Causal explanations about the etiology of HD are difficult to draw, because—with the exception
of 2D:4D ratio—we relied on self-report data and clinical interviews in a cross-sectional study and
responses may have been affected by social desirability bias.
It is difficult to transfer the conclusions of this study to other cultures. Furthermore, this Western
European sample was not representative of the Western European population in terms of, for example,
age and educational level.
6. Conclusions
Men with HD appear to have the same neurodevelopment, intelligence levels, sociodemographic
background, and family factors compared to healthy controls. However, men with HD report
differences in important areas of life, such as adverse experiences in childhood, problematic sexual
behavior, and increased psychological difficulties.
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Abstract: Antidepressant-related sexual dysfunction is a frequent adverse event caused by
serotonergic activation that intensely affects quality of life and adherence in depressed patients.
The dopamine system has multiple effects promoting sexual behavior, but no studies have been
carried out to confirm dopaminergic changes involved in animal models after antidepressant use.
Methods: The sexual behavior-related dopaminergic system in the rat was studied by comparing
two different antidepressants and placebo for 28 days. The antidepressants used were paroxetine
(a serotonergic antidepressant that causes highly frequent sexual dysfunction in humans) and
agomelatine (a non-serotonergic antidepressant without associated sexual dysfunction). The tyrosine
hydroxylase immunoreactivity (THI) in the substantia nigra pars compacta, the ventral tegmental
area, the zona incerta, and the hypothalamic arcuate nucleus, as well as the dopaminergic projections
to the striatum, hippocampus, cortex, and median eminence were analyzed. Results: The THI
decreased significantly in the substantia nigra and ventral tegmental area after treatment with
paroxetine, and the labeling was reduced drastically in the zona incerta and mediobasal hypothalamus.
The immunoreactive axons in the target regions (striatum, cortex, hippocampus, and median
eminence) almost disappeared only in the paroxetine-treated rats. Conversely, after treatment with
agomelatine, a moderate reduction in immunoreactivity in the substantia nigra was found without
appreciable modifications in the ventral tegmental area, zona incerta, and mediobasal hypothalamus.
Nevertheless, no sexual or copulatory behavior was observed in any of the experimental or control
groups. Conclusion: Paroxetine but not agomelatine was associated with important decreased
activity in dopaminergic areas such as the substantia nigra and ventral tegmental areas that could be
associated with sexual performance impairment in humans after antidepressant treatment.
Keywords: dopaminergic system; paroxetine; agomelatine; immunohistochemical study; sexual
dysfunction; male rats
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1. Introduction
The dopaminergic (DA) and serotonergic (5-HT) modulatory systems are involved in regulating
multiple functions through their abundant projections throughout the Central Nervous System (CNS).
These systems are closely related and interact to control motor, cognitive, and affective functions.
Dysfunction of these systems results in pathologies as marked as Parkinson’s disease, schizophrenia,
depressive disorders, and Attention Deficit Hyperactivity Disorder (ADHD) AHDH syndrome.
The dopaminergic neurons are an anatomically and functionally heterogeneous group of cells,
located in particular in the diencephalon and mesencephalon. In the murine brain, DA neurons are
identified mainly in three structures. The first structure comprises the meso-diencephalic tegmental
cell groups (A8–A10). Because these neurons originate from the substantia nigra (SN) and the ventral
tegmental area (VTA) of the mesencephalon and diencephalon, we will refer to these neurons as
meso-diencephalic dopaminergic (mdDA) neurons. They constitute the largest group of neurons and
project to the striatum (nigrostriatal pathway), the limbic system (meso-limbic pathway), and the
cerebral cortex (mesocortical pathway). The second structure is the zona incerta cell group (A13)
in the ventral thalamus. The third structure comprises the hypothalamic (A12, A14, and A15) cell
groups. The A12 group is the largest and provides the tuberoinfundibular and the tuberohypophysial
projections involved in neuroendocrine regulation [1,2].
The interaction between DA and 5-HT systems is complex because it involves many types of
membrane receptors that have mixed effects. The 5-HT neurons from the raphe nuclei send projections
to dopaminergic cells in both the VTA and the SN, and to their terminals in the nucleus accumbens,
prefrontal cortex, and striatum [3]. Some experimental data demonstrates that several 5-HT receptors
subtypes (1a, 1b, 2a, 3, and 4) act to facilitate neuronal DA function and release, while the 5-HT2c
receptor mediates an inhibitory effect on DA neuron activity and on DA release [4–6].
In recent years, antidepressant use has increased rapidly in Western countries because it is widely
prescribed by psychiatrists and general practitioners. The introduction of selective serotonin reuptake
inhibitors (SSRIs) in the late 1980s facilitated this process because of the alleged safety of these drugs
compared with more dangerous drugs that were used previously [7,8]. However, some adverse effects
of SSRIs are frequent and underestimated. One example is sexual dysfunction, which affects patients’
quality of life and continuity of treatment [9–13]. The incidence of sexual dysfunction is high (50–70%)
when the mechanism of action is blocking serotonin reuptake, whereas drugs that act preferably on
noradrenaline or dopamine reuptake have a less negative impact on the sexual function [14–16].
A high frequency of treatment discontinuation, close to 40%, has been notified in patients with
major depression due to poor tolerance to antidepressant-related sexual dysfunction [15]. Several
methods have been described for the therapeutic approach of this adverse event, including dose
reduction, change to another antidepressant, or the use of corrective medication; unfortunately,
none of these methods is completely effective deteriorating the quality of life of the patient in the long
term [16,17].
Although mechanisms that cause sexual dysfunction still are not well understood, a recent study
in rats suggests that the inhibitory effects of serotonergic antidepressants are related to the inhibitory
effect of serotonin on dopamine release in hypothalamic and mesolimbic areas [18,19].
The inhibitory effect of serotonin on dopaminergic transmission was first shown by a reduction
in nigral neuronal activity in response to electrical stimulation of the medial and dorsal raphe
nucleus [20,21]. The increase in synaptic serotonin in response to SSRIs could then conceivably result
in an amplification of the tonic inhibitory effects of serotonin, thereby leading to a reduction in
DA transmission in the striatum [22]. This is supported by recent studies that have demonstrated
a reduction in the substantia nigra tyrosine hydroxylase (TH) immunoreactive cell counts in response
to SSRI administration [23].
SSRIs can also inhibit the basal activity of DA neurons in the VTA, which is strongly implicated
in sexual desire and motivation. Thus, fluoxetine causes a dose-dependent inhibition of the VTA
dopaminergic neuron firing rate, but it does not affect the activity of DA cells in other regions [24].
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Acute injection of fluvoxamine, paroxetine, and sertraline produces a dose-dependent inhibition of
some VTA DA neurons, but it does not affect the basal firing rate of other DA cells.
Agomelatine is a novel antidepressant drug that works on melatonergic (MT1 and MT2),
and serotonergic (5-HT 2B and 5-HT2C) receptors [25]. Agomelatine has been used in two randomized
studies in healthy male volunteers. These studies showed that agomelatine 25–50 mg/day is similar to
placebo in sexual response, showing a lack of sexual dysfunction, whereas paroxetine 20 mg/day is
related to a high sexual dysfunction frequency (>80% of patients showed decreased libido and orgasm
delay) [26,27].
Our aim in this research is to study the dopaminergic system in male Wistar rats, especially
the nuclei where neurons are located in the brainstem (substantia nigra pars compacta (SNc) and
VTA), diencephalon (zona incerta (ZI) and hypothalamic arcuate nucleus (Arc)), and their most
relevant axonal projections (striatum, hippocampus, hypothalamus, and cortex) in animals treated
with paroxetine or agomelatine, which represents two different mechanisms of antidepressant action
related to sexual adverse events. We will compare their effects on immunoreactivity to tyrosine
hydroxylase, the rate-limiting enzyme of dopamine synthesis. The presence of this enzyme is
considered a good marker of dopaminergic neurons in the central nervous system. We hypothesize that
if the dopaminergic system is involved in sexual dysfunction caused by SSRIs, different antidepressant
treatments will differentially modify TH immunoreactivity.
2. Material and Methods
Male Wistar rats, aged approximately 3 months old, were used. Rats were maintained under a 12 h
light/dark cycle and at a constant temperature (20 ◦C) with free access to food and water. All animals
were handled and cared for in accordance with the recommendations of European Commission
and Spanish laws (2007/526/EC and RD 1201/2005). Authorization was requested to the Bioethics
Committee of the University of Salamanca.
Twenty animals were distributed into the following groups: (1) four normal rats; (2) four rats treated
orally with 10% hydroxyl-methyl-cellulose (the vehicle in which agomelatine was dissolved); (3) six rats
treated orally with 10 mg/kg/day of paroxetine diluted in aqueous solution; and (4) six rats treated orally
with 10 mg/kg/day of agomelatine diluted in 10% hydroxyl-methyl-cellulose. Because agomelatine
needs to be dissolved in 10% hydroxyl-methyl-cellulose for absorption, an agomelatine control group
was created with four rats that received only 10% hydroxyl-methyl-cellulose to observe its effects on
the dopaminergic system. Since no differences were observed with the normal group, both finally
were grouped as an only control group with eight rats.
Agomelatine solution was kindly provided by the manufacturer (Servier Lab) and paroxetine was
obtained from the pharmacy. All treatments were performed for 28 days at 18:00 h each day. The size
of the sample was empirically chosen due to the lack of previous evidence in the scientific literature on
this topic.
Twenty-four hours after the end of treatment, rats were euthanized between 10:00 and 13:00 h.
The brain was quickly extracted, the front and rear ends of the brain, the brainstem (pons and medulla
oblongata), and the cerebellum were removed, and the remaining block was divided into two halves
and fixed by immersion in Bouin’s fluid. Tissue was embedded in paraffin. The brain block was
oriented to obtain coronal sections (8 μm thick). The whole block of tissue from each animal was serially
cut and mounted (two sections per slide). Every tenth slide was stained with hematoxylin–eosin
for orientation.
In order to observe the copulatory behavior and the possible differences between the experimental
and control groups, two Wistar female rats were used. After 28 days, when the period of administration
of paroxetine, agomelatine or placebo ended, one of the females was coupled in a new cage with one
male from each group successively. Any sexual or approaching behavior was observed for a maximum
of 5 min at 18:00 h, once for each male.
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2.1. Immunohistochemistry
Selected sections were processed for tyrosine hydroxylase immunohistochemistry using the
streptavidin–biotin method (EnVision, Dako, Denmark) with diaminobenzidine (DAB) as the electron
donor. The antiserum (anti-tyrosine hydroxylase, GeneTex) was diluted in Tris buffer, pH 7.6,
containing 0.7% non-gelling seaweed lambda carrageenan (Sigma) and 0.5% Triton X-100 (Sigma).
The antiserum was used at a dilution of 1:300. The conditions and duration of incubation with the
various reagents, especially with DAB and H2O2, was the same in all cases. Use of preimmune serum
and omission of incubation in the primary antiserum during the immunostaining procedure were used
as test controls and resulted in no immunostaining.
2.2. Quantification of Immunohistochemical Staining Intensity
Quantification of immunohistochemical staining intensity was performed using the open source
software ImageJ (National Institutes of Health). We determined the pixel intensity of 60 immunoreactive
neurons in the normal/control and experimental groups (we selected 15 neurons from the VTA nucleus
and 15 from the SNc nucleus in four rats from each groups). To avoid possible differences in the pixel
intensity resulting from the presence or absence of a cell nucleus, all measured cells had a visible cell
nucleus. To determine the intensity of pixels, ImageJ assigns a value of 0 to the color black and a value
of 255 to the color white. Thus, a greater staining intensity corresponds to a lower pixel intensity value.
2.3. Statistical Analysis
A two-factor ANOVA was used to analyze the differences in pixel intensity between groups and
nuclei (SNc and VTA) and interaction between both factors. If the interaction between factors was
statistically significant, one-way ANOVA was used to detect the differences between experimental
groups for each level of area followed by Tukey’s multiple comparison tests where appropriate.
Statistical significance was defined as p < 0.05. The mean and 95% confidence intervals (CIs) for
each outcome are presented. Statistical analysis was conducted using the IBM SPSS 23 package
(IBM, Armonk, NY, USA).
3. Results
In this study, images of the caudate-putamen, nucleus accumbens, and cortex were obtained from
sections that correspond approximately with the coronal sections marked as Bregma 1.68–0.72 mm
in the Paxinos and Watson atlas of the rat brain. Images of the zona incerta, arcuate nucleus and
hippocampus correspond approximately with the coronal planes marked as Bregma −2.04 to −3.24 mm
in the same atlas, and images of the VTA and SNc were obtained from sections that correspond
approximately with the coronal sections marked as Bregma −4.80 to −5.28 mm in the rat brain atlas.
The cortex images refer to the areas S1 (primary somatosensory cortex) and M1 (primary motor cortex)
in the same atlas [27,28].
We found no differences in the staining intensity between normal and control rats treated with
hydroxy-methyl-cellulose. Therefore, the findings in animals treated with paroxetine and agomelatine
were analyzed in relation to the normal/control group of rats.
3.1. Substantia Nigra Compacta and the Ventral Tegmental Area
To identify the nuclei in DA neurons, we used the usual anatomical terms, and also referred to its
name in the aminergic classification system by Dahlström and Fuxe (1964), in which the DA system is
distributed into the groups A8–A14.
In the substantia nigra (A9) and ventral tegmental area (A10) of control rats, TH neurons and
neuronal processes are strongly reactive. Neuron labeling is intense throughout the cytoplasm, so that
when the section affects the neuronal nucleus, it appears as a negative zone. TH axons surrounding
the A9 and A10 nuclei also show a strong reaction, both penetrating the reticular substantia nigra
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(SNR) as located dorsally (Figure 1A). Conversely, in animals treated with paroxetine, the labeling is
weak in both neurons and neuronal processes of the SNc and VTA nuclei. In the areas surrounding
the nuclei, cited axons are barely visible (Figure 1B). In the SNc and VTA of agomelatine-treated rats,
TH reactivity is similar to that described in the control rats, although labeling seems somewhat less
intense (Figure 1C).
A












Figure 1. (A–C). Tyrosine hydroxylase immunoreactivity in the meso-diencephalic dopaminergic
system of rats from the control (A), paroxetine (B), and agomelatine (C) groups. Bars, 100 m. SNc,
substantia nigra pars compacta; SNr, substantia nigra pars reticulate; VTA, ventral tegmental area; MT,
mammilothalamic tract.
3.2. Striatum and Nucleus Accumbens
In the striatum (CPu) of the control animals, the labeling is intense and uniform throughout the
matrix, but striosomes are negative (Figure 2A). In the nucleus accumbens, dopaminergic fibers are
preferentially located in the lateral region. At higher magnifications, labeling is shown as dense dots,
corresponding to the axons of the nigrostriatal pathway. We have not seen cell bodies of dopaminergic
neurons in this region (Figure 2D).
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The dopaminergic projections to the striatum are significantly affected after treatment with
paroxetine, with the absence of immunoreactivity throughout the dorsal and medial CPu and
significantly reduced immunoreactivity in the remaining area (Figure 2B). At higher magnifications,
dopaminergic fibers have mostly disappeared (Figure 2E). In the striatum of animals treated with
agomelatine, TH reactivity is reduced compared to the control group, but is more intense than in rats
treated with paroxetine (Figure 2C,F). In the nucleus accumbens, the pattern of labeling is uniform
throughout the CPu matrix (Figure 2C).
( g )
 
Figure 2. (A–F). Tyrosine hydroxylase immunoreactivity in the striatum of control rats (A,D), and rats
treated with paroxetine (B,E) and agomelatine (C,F). Bars 1000 m (A–C) and 100 m (D–F). The reactivity
is visible as dotted labeling that is evenly distributed by the matrix of the caudate-putamen (CPu),
except in paroxetine-treated rats. CC, corpus callosum; latV, lateral ventriculum; AC, anterior
commissure; Acc, nucleus accumbens; Estr, striatum; Sept, septum.
3.3. Hippocampus
In the hippocampus of control animals, there was a strong reaction in the A3 region of the cornu
ammonis (CA3; Figure 3A), which was shown by discrete labeling throughout the hippocampal
region (Figure 3A lacks a bar, but the magnification is the same as in Figure 3B,C). After treatment
with paroxetine, labeling of TH axons was strongly reduced, especially in CA3 (Figure 3B).
Immunoreactivity slightly decreased in the agomelatine-treated group, even though reactive axons
are observed (Figure 3C). We also detected TH-positive axons in the septum of rats in the control and
agomelatine-treated groups, while labeling had also disappeared in paroxetine-treated animals.
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Figure 3. (A–C). Tyrosine hydroxylase immunoreactivity in the hippocampus of rats from the control
(A), paroxetine (B), and agomelatine (C) groups. Bars, 1000 m. (Figure 3A is presented at the same
magnification as that of Figure 3B,C). The immunoreactivity is limited to the CA3 area and is greatly
reduced following treatment with paroxetine. DG, dentate gyrus; CA, cornu ammonis.
3.4. Cerebral Cortex
Figure 4 summarizes our observations on the dopaminergic innervation of the rat primary
motor/somatosensory cortex (CM/S). This represents the mesocortical pathway. The reactivity in
control rats is limited to axons and is located preferably in layers II/III, and it decreases both beneath
and towards the surface (Figure 4A). Similar to other locations in rats treated with paroxetine,
the labeling almost completely disappears (Figure 4B), but it is reduced in animals treated with
agomelatine (Figure 4C).
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Figure 4. (A–C). Tyrosine hydroxylase immunoreactivity in the cerebral cortex layers I-VI of rats from
the control (A), paroxetine (B), and agomelatine (C) groups. Bars, 1000 m. (Figure 4A is presented at
the same magnification as that of Figure 4B,C). CM/S, motor/somatosensory cortex.
3.5. Zona Incerta and Hypothalamus
In the control rats, TH-positive neurons in the zona incerta (A13) and fibers in and around
the nucleus show intense labeling (Figure 5A). In rats treated with agomelatine, the appearance
and reactivity of dopaminergic neurons is similar to that observed in the control group (Figure 5C).
Conversely, in the animals treated with paroxetine, TH immunostaining is low in the neuronal cell
bodies and it disappears in the nerve fibers (Figure 5B).
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Figure 5. (A–C). Tyrosine hydroxylase immunoreactivity in the zona incerta of rats from the control
(A), paroxetine (B), and agomelatine (C) groups. Bars, 100 m. In the rats treated with paroxetine,
the labeling is weak whereas in animals treated with agomelatine, labeling is similar to that shown the
control rats. IIIV, third ventricle; ZI, zona incerta.
In the dopaminergic A12 group in the arcuate nucleus, the hypothalamic neurons behave similarly
to those of the zona incerta (Figure 6). In the control group, the neurons show a more intense staining
in the cell bodies of the arcuate nucleus (NARC) and in axons in the tuberoinfundibular tract that
reach the outer zone of the median eminence (EM) (Figure 6A). Conversely, in the paroxetine-treated
group, the arcuate neurons exhibit weak immunoreactivity, and the fibers of the median eminence are
nonreactive (Figure 6B). In animals treated with agomelatine, the immunostaining is intense both in
the neuronal bodies and in the median eminence, but it is somewhat reduced compared to control rats
(Figure 6C).
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Figure 6. (A–C). Tyrosine hydroxylase immunoreactivity in the mediobasal hypothalamus of rats
from the control (A), paroxetine (B), and agomelatine (C) groups. Bars, 1000 m. After treatment with
paroxetine, TH immunoreactivity is absent from the median eminence. ARCN, arcuate nucleus; ME,
median eminence; IIIV, third ventricle; VMN, ventromedial nucleus.
3.6. Quantification of TH Immunoreactivity in the SNc and VTA
As noted in the Materials and methods section, we used the open source software ImageJ to
determine the pixel intensity in SNc and VTA neurons. This software assigns a value of 0 to the
color black and a value of 255 to the color white. Thus, a greater staining intensity corresponds to
a lower pixel value intensity. However, interaction between the experimental group and the area was
detected (p-value < 0.0001, Figure 7). To analyze the interacction, we compared the differences between
experimental groups by each area. There were statistical differences between the three experimental
groups (p < 0.0001) in SNc, and between control and paroxetine groups in the VTA (p = 0.001).
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Figure 7. Pixel intensity was determined using open source software ImageJ. There are significant
differences between all groups in the SNc, but no statistical difference between the control group and
rats treated with agomelatine in the VTA.
3.7. Observation of Sexual and Mating Behaviour
The possible sexual or approaching behavior was observed for a maximum of 5 min, at 18:00 h.
just once for each male and female couple. It was observed that the female rats were receptive for
riding when meeting the male. However, the males in both experimental and control groups behaved
sexually indifferent, showing stereotyped behaviors such as running around the cage and raising
on their hind legs. No animals performed coitus with the female; therefore, we cannot draw any
conclusions from this observation.
4. Discussion
To explain sexual dysfunction caused by treatment with SSRIs, various mechanisms have been
proposed, among which is the inhibition of the dopaminergic system [18].
Given that the antidepressant-induced effects on sexual parameters in Wistar rats correspond
well with their known effects in humans [14,15,29], we conducted a comparative experimental study
on the dopaminergic system in male rats treated with paroxetine and agomelatine. This research
improves our understanding of the mechanisms that explain sexual dysfunction, focusing on the
meso-diencephalic dopaminergic system.
Recently, MacGillivray et al. (2011) examined the effects of two different SSRIs, citalopram and
fluoxetine, on cells containing tyrosine hydroxylase (TH) in nigrostriatal dopamine neurons and
showed that both antidepressants induced a significant reduction in the number of TH cells in the
Substantia Nigra. Our experimental model includes DA neurons from the substantia nigra and the
VTA, and DA neurons of the zona incerta (ZI) and the tuberoinfundibular system. In this research,
we did not count the immunoreactive TH cells, but we determined the intensity of staining in SNc and
VTA TH cells.
TH is the rate-limiting enzyme of dopamine synthesis, and it is considered one of the major agents
in determining dopamine levels. When need for neurotransmitter increases at a DA synapse, TH is
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activated to make more DOPA. TH activity must be sustained until the need reduces and its activity
must be turned off when the need for neurotransmitters has passed [30].
We believe it is relevant to clarify the meaning of changes in TH immunoreactivity regarding
the available dopamine and dopaminergic system activity. What we show by immunohistochemical
staining is the approximate number of immunoreactive TH molecules (the rate-limiting enzymes of
catecholamine synthesis) in the areas studied, which is a good marker of dopamine neurons and fibers.
Thus, under controlled staining conditions such as those in this study, more intense labeling means
more TH molecules, which leads to an increased dopamine synthesis rate. Conversely, a reduction in
the intensity of the labeling means generally fewer TH molecules and a decrease in DA synthesis.
If we consider the large number of known 5-HT and DA receptors and the many factors that can
influence regulation of sexual behavior, it is almost impossible to draw accurate conclusions. However,
our data can complement those obtained using other methodologies and from human clinical studies.
To our knowledge, paroxetine and agomelatine have not been explored in this field until now.
DA has multiple effects that promote sexual behavior by stimulating the copulatory capacity and
genital reflexes. In the nigrostriatal pathway, DA influences motor activity; in the mesolimbic pathway,
DA activates motivated behavior, including copulation; and in the medial preoptic area, DA controls
genital reflexes, copulation patterns, and sexual motivation [31].
4.1. Paroxetine Reduces TH Immunoreactivity in All Meso-Diencephalic Dopaminergic Systems
Treatment with paroxetine frequently causes sexual dysfunction in humans for short, medium,
and long durations [32], and this adverse effect is related to the hypofunction of the dopaminergic system
in nigrostriatal and mesolimbic/mesocortical pathways, as reported in various publications [18,31,33,34].
Similar results have been observed after the administration of fluoxetine or escitalopram, which induce
a decrease in DA neuron firing rate in the VTA [35]. It is suggested that this class of antidepressant
acts through 5-HT2C receptors [17]. Recently, Demireva et al. (2018) [36] have demonstrated that
SSRI-induced motor deficits in mice can be reversed by systemic or SNr-localized 5-HT2C receptor
antagonism. SSRIs induce SNr hyperactivity and SNc (dopaminergic) hypoactivity that can also be
reversed by systemic 5-HT2C receptor antagonism. Considering the critical role of DA in hedonic
processes, the decrease in firing activity by SSRIs might contribute to the resistance to antidepressants
in some patients.
Our results additionally show a general decrease in TH immunoreactivity in these dopaminergic
systems after treatment with paroxetine, which is consistent with the results of the authors cited
above, and which could result in a reduction in motivated behavior, including copulation (mesolimbic
pathway) and overall sexual dysfunction.
We also showed a previously unreported reduction of TH reactivity in DA neurons of the ZI.
These neurons originate the incerto-hypothalamic tract, which innervates the anterior hypothalamus
and the dorsomedial and paraventricular nuclei, and which is thought to have a stimulatory role in the
release of LH [37]. More recently, other authors have proposed that ZI dopamine stimulates the release
of LH and prolactin acting through glutamatergic NMDA receptors [38]. The incerto-hypothalamic
pathway is involved in coordination of genital reflexes necessary for erection [39]. Therefore,
the important decrease in the intensity of TH staining in ZI neurons of paroxetine-treated rats,
must correspond to a decrease in the available DA and its stimulatory effect on the release of LH and
sexual behavior.
Our study also shows that TH immunoreactivity is weak in the tuberoinfundibular dopaminergic
neurons, and that labeling disappears from the median eminence dopaminergic axons after treatment
with paroxetine. These observations are consistent with data from Lyons et al. (2016) [40], which showed
that fluoxetine and sertraline, directly suppress tuberoinfundibular dopamine (TIDA) neuron activity.
The hypo-function of this dopaminergic inhibitory system will be accompanied by hyperprolactinemia, as in
treatment with other antidepressants or antipsychotics. Among the consequences of hyperprolactinemia
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in men are erectile dysfunction, with reduced sexual desire, and sometimes ejaculatory and orgasmic
disorder [41–43].
Our findings of decreased immunoreactivity to TH after treatment with paroxetine are consistent
with other published data reporting a reduction of TH gene expression in VTA and SN areas after
fluoxetine administration for 16 and 31 days [44], or a decrease in TH mRNA in the locus ceruleus
after chronic paroxetine administration [45].
The sexual dysfunction linked to antidepressant treatment has also been studied in humans via
neuroimaging, showing that paroxetine and other SSRIs reduce the activity of brain networks involved
in processing the motivational and emotional aspects of sexual function [46,47].
To summarize, many clinical and experimental studies show that SSRI antidepressants (including
paroxetine) can alter all phases of sexual activity, from desire to arousal, orgasm, and ejaculation.
Sexual dysfunction in males results in the inability to achieve erection or reach orgasm, while in
women the problem is usually a decrease in sexual desire and delay or difficulty in reaching orgasm.
In addition, there is growing experimental evidence that inhibition of meso-diencephalic dopaminergic
systems is a determining factor in the aforementioned effects [18].
Our research shows that treatment with paroxetine reduces TH labeling in the incerto-hypothalamic
and tuberoinfundibular dopaminergic systems. Hypo-function in these systems probably leads to
a decrease in hypothalamic-pituitary-gonadal axis activity, which has been shown in clinical studies
after treatment with antidepressants [48,49].
4.2. Agomelatine Treatment Also Slightly Reduces Dopaminergic Activity but Less Than Paroxetine
This study also shows that treatment with agomelatine for 28 days reduces immunoreactivity
to TH in the SNc, although the effect is less intense than after treatment with paroxetine. Moreover,
our data show no difference in immunoreactivity for TH in the VTA between control rats and those
treated with agomelatine, which suggests that agomelatine does not affect the activity of the SNc and
VTA dopaminergic neurons in the same way.
Agomelatine has an antidopaminergic action similar to melatonin [50], although the decrease in
immunoreactivity to TH produced by agomelatine is not as intense as that produced by paroxetine.
However, agomelatine increases levels of DA and NA in the frontal cortex (via mesocortical) by 5HT2C
receptor blockade, but it does not affect the DA in the striatum and accumbens (nigrostriatal and
mesolimbic pathways) [4,51]. Our data shows moderate reactivity of dopaminergic axons in the
striatum as well as an intense TH labeling in the mesocortical fibers (not shown), which is consistent
with previously published results.
It has also been reported that agomelatine stimulates tuberoinfundibular dopaminergic neurons,
thereby inhibiting the lactotrope cell activity [52]. We found no difference in TH staining intensity in
the ZI and in the tuberoinfundibular dopaminergic system between the control rats and those treated
with agomelatine. Thus, we cannot confirm or reject this assertion.
In summary, treatment with agomelatine has a moderate inhibitory effect on the dopaminergic
nigrostriatal system, but its action on the meso-limbic and meso-cortical pathways is barely noticeable
and is much lower than that produced by paroxetine administration. Additionally, agomelatine does
not seem to inhibit the incerto-hypothalamic and tuberoinfundibular dopaminergic systems.
These data are consistent with previous observations that show notable differences in the impact
of various antidepressants on the dopaminergic system. The differential effects of paroxetine and
agomelatine on the TH immunoreactivity and dopaminergic systems may partly explain the impact
that the tested treatments have on sexual function, including the high frequency of sexual dysfunction
in paroxetine-treated patients.
The observations on sexual behavior were negative and no mating behavior was observed.
These negative results could be due to some limitations in the experimental design, even though the
rat was ovulating and sexually receptive during the contact with the male. The lack of mating behavior
could be due to the sexual encounter that took place in a new cage and not in the female’s usual cage.
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On the other hand, the observation took place at 18:00 h, which was the same time of usual contact
with the observer who had previously administered the drugs. Additionally, the observation period of
5 min was perhaps scarce, and the observation method could have been different, for example using
a recording without the presence of the observer.
5. Limitations.
The ImageJ data could only be used for statistical analysis on the substantia nigra and the
VTA since these areas are nuclei in which many neurons are observed in each microscopic cut.
However, this method could not be applied to the other brain territories analyzed because the neuronal
population is much smaller and the representativeness of the statistical analysis in the cuttings could
not be guaranteed.
The presence of negative results in the observation of sexual behavior could be due to some
methodological limitations of the design that should be taken into account for future studies in order
to reproduce suitable results in this field.
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Abstract: This paper reviews the associations between pornography use and sexual dysfunction
based on evidence from observational studies. The existing data in this regard mostly derive from
cross-sectional investigations and case reports. There is little if no evidence that pornography use
may induce delayed ejaculation and erectile dysfunction, although longitudinal studies that control
for confounding variables are required for a full assessment. The associations between pornography
use and sexual desire may differ between women and men although the existing data is contradictory
and causal relationships cannot be established. The strongest evidence is available for the relation of
pornography use with decreased sexual satisfaction, although the results of prospective studies are
inconsistent. The paper outlines future research prospects beneficial in understanding the nature of
associations between pornography use and sexual dysfunctions in men and women.
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1. Introduction
The existing literature provides a number of varying descriptions of the term pornography.
According to the Final Report of the Attorney General’s Commission on Pornography, it can be defined
as any material that is predominantly sexually explicit and intended primarily for the purpose of
sexual arousal [1]. Currently, pornography represents an important economic venture [2,3]. Its greatest
development has occurred along with the emergence of computer technologies and the expansion
of the Internet [4,5]. Due to a high sense of anonymity and almost unrestricted access, the Internet
has become the most important medium of dissemination of pornographic content (known as online
pornography), particularly in the form of images and videos [6,7]. The ease, arousal strength, and
diversity with which pornography can be reached online indicates that it may operate as a supernormal
stimulus [8].
According to various epidemiological studies, a relatively large number of adults have been
exposed to pornography [9–12]. Recent representative surveys demonstrate that in developed countries
with unrestricted Internet access, such as the United States and Australia, the majority of men (64–70%)
and approx. one quarter/third (23–33%) of women are using pornography [13,14]. However, the
number of pornography users is also relatively high in developing countries—recent surveys have
shown that over half of students in Ethiopia and Bangladesh have been exposed to it [11,15]. The
extensive use of pornography is also supported by data provided by Pornhub, one of the largest online
pornographic websites, which clearly indicate that it is primarily men that are associated with content
of this type (74%), and that the number of visitors to pornographic sites is growing from year to year
(Figure 1). Some men deal with pornography on a regular, daily basis [16]. At the same time, the
percentage of women interested in using this type of content is growing [17]. The Pornhub service is
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usually visited by young people under the age 34 from the United States, the United Kingdom and
India. An emerging and as yet not fully assessed issue is the unintentional contact from advertising or
spam e-mail messages both of which may sometimes be difficult to avoid [18].
Figure 1. Statistics of pornography use in the period of 2013–2018 according to data shared by Pornhub:
(a) annual number of visitors to Pornhub, (b) visitors to Pornhub by age.
Although interest in pornographic content can be partially considered as a natural element in
the development of sexual experience in young people, the multiplicity and diversity of available
online pornographic materials as well as the difficulty of restricting access to them lead to a question
on the potential effects of pornography consumption. There is a steady increase in number of studies
addressing the prevalence, patterns, outcomes, and various other aspects related to pornography use
as clearly indicated by a systematic search of English language papers indexed in the PubMed/Medline
database—a key term “pornography” yields 142 papers published in the period 1980–1989, 238
papers in 1990–1999, 524 papers in 2000–2009, and as many as 949 papers in 2010–2018. However,
despite a continuous interest in the study of various aspects of pornography use, there are number
of unresolved issues regarding the nature and magnitude of these effects. For example, some
investigations demonstrate that pornography may fit into the addiction framework via mechanisms
similar to chemical compounds [19,20] although controversies in this regard exist [21–24]. An addiction
to pornography is not recognized in the DSM-5 and ICD-11 classifications (although the latter specifies
a diagnostic category of Compulsive Sexual Behavior Disorder under impulse control disorders
that may be used to diagnose problematic pornography use), various studies refer to it rather as
“self-perceived pornography addiction” [12,16,25–27], and some alternative models based on moral
incongruence, compulsivity, or impulsivity were also proposed to describe problematic pornography
use [21,28,29]. Whether pornography may be associated with changes in sexual function is also a
subject open to wide discussion. However, there are number of recognized risk factors for sexual
dysfunction encompassing medical conditions, substance abuse, medication use, as well as cultural and
social factors [30] which are difficult to address in studies focusing solely on pornography use. In the
general population, the most frequently identified sexual dysfunctions include premature ejaculation
and erectile dysfunction in men and desire and arousal dysfunction in women [31], and a number
of studies have aimed to evaluate the potential associations between the occurrence of these effects
and pornography use. At the same time, the potential effects of pornography use are the subject of a
number of nonacademic discussions, and some publicly expressed opinions in this regard appear to
be politically and ideologically driven. All in all, this creates a need to critically assess the existing
evidence, outline study limitations and shortcomings, and highlight the future research prospects in
the field of pornography use and its associations with sexual function.
The aim of this paper was to review the cross-sectional and longitudinal studies as well as case
reports on potential associations between the use of pornography and sexual dysfunctions, namely
erectile dysfunction, delayed ejaculation, and decrease in sexual desire and sexual satisfaction. These
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conditions are among the most often identified sexual dysfunctions in men and women [30–32]. Both
quantitative (addressing the frequency of use) and qualitative (addressing the patterns of use) research
was taken into account as these two approaches complement each other in understanding the complex
nature of factors associated with pornography [33,34]. For this purpose, a systematic search for original
research published since 2000 in peer-reviewed journals was performed using the PubMed/Medline
and Scopus database, and by hand-searching reference lists from identified papers. The limitations of
the conducted studies and future research prospects are also outlined.
2. Delayed Ejaculation
Delayed ejaculation describes a sexual dysfunction occurring in men, manifested by prolonged
time required to ejaculate or complete inability to achieve it. Due to the complexity of psychosexual and
psychosocial factors that contribute to its pathogenesis, there are no universal methods of treatment [35].
Its potential causes include, among many, frequent masturbation and the occurrence of significant
discrepancies between real sexual intercourse with a partner and sexual fantasy preferred during
masturbation [35,36]. Both masturbation and sexual fantasy are often associated with pornography
use thus its potential relationship with the onset of delayed ejaculation is hypothetically plausible.
A systematic search with key terms “pornography and ejaculation” and “pornography and delayed
ejaculation” identified five original papers, including three cross-sectional studies and two case studies.
The first study to address the potential impact of pornography use on ejaculatory dysfunction
was conducted on a group of 115 hypersexual, predominantly heterosexual men (mean age 41 years,
range 19–76 years) [37]. As reported, a relatively significant percentage of subjects (23.5%; n = 27)
masturbated chronically (at least 1 h/day or >7 h/week), usually while viewing pornography. In
comparison with other subjects, this particular group was characterized by a higher anxiety level and
was less likely to establish partner relationships or to persevere in them, even if they were established.
These subjects frequently (19/27; 71%) reported some sexual dysfunctions with delayed ejaculation
being reported the most often (in over 30% of cases). There are, however, a number of limitations to this
study in the context of understanding the potential role of pornography in the occurrence of delayed
ejaculation: (1) it only included hypersexual male subjects who represent a group that generally
often masturbates and views pornography [38], and it remains unknown how these findings may be
representative of the general population; (2) the onset of delayed ejaculation may result exclusively
from the frequent masturbation or subjects with delayed ejaculation may tend to masturbate more
often—in both cases, pornography use may remain unrelated; (3) it was unestablished whether the
pornography use in hypersexual subjects facing delayed ejaculation preceded problems with this
sexual dysfunction, therefore its role as a causative factor in delayed ejaculation cannot be established.
Two other cross-sectional studies involving young subjects do not support the potential existence
of a relationship between pornography use and delayed ejaculation. The first of them surveyed Italian
students attending their final year of high school (n = 1492; aged 18–19 years) who frequently admitted
to using pornography (78%, including 8% using it on daily basis) and observed that ejaculatory issues
were reported in 1% of surveyed, regardless of the frequency of pornography consumption [39].
In the second study, two large-scale samples of heterosexual men (aged 18–40 years) from three
European countries, Croatia, Norway, and Portugal (n = 3948), were analyzed and, as demonstrated
using multivariate logistic regression, no significant association between delayed ejaculation and
pornography was detected [40].
In addition to cross-sectional studies, Park et al. [41] and Blair [36] reported cases in which delayed
ejaculation appeared in some way to be related to pornography use. The former report described a case
of a 20-year-old man with no chronic or mental disorder who used pornography for a long duration at
a high frequency (1–2 times/day), gradually reaching for content that deviated progressively further
from the standard. He also admitted to using an artificial vagina that supposedly allowed him to reach
orgasm much faster. He self-reported the difficulty in maintaining an erection and ejaculating during
masturbation and sexual intercourse, which contributed to disturbances in partner relations with his
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fiancée. As the authors emphasize, despite the fact that the man felt a physical and mental attraction to
his partner, he preferred to use a more stimulating erotic toy (artificial vagina). The authors suggest
that excessive pornography use could trigger changes in the nervous pathways responsible for sexual
desire and erection, as well as changes in the functioning of the reward system, and subsequently
caused delayed ejaculation [41]. These suggestions, however, remain purely speculative as no evidence
to justify them was provided. As found, the delayed ejaculation was fully resolved after cessation of
online pornography use and the quality of partner relationship was improved. However, the use of
the artificial vagina was simultaneously discontinued. It therefore remains unestablished whether the
delayed ejaculation was in any way related to the use of pornography, the artificial vagina, or both.
The case reported by Blair [36] included a 19-year-old male who could not achieve ejaculation
during sexual penetration. The man started using pornographic content at the age of 12; a year later, he
used it regularly, and at the age of 15 he began to reach for more and more thematic content (depicting
the so-called bondage and acts of domination). Cessation of pornography and advice to avoid
masturbation using a firm grip and switch to a more gentle style of penile stimulation were reported to
be an effective therapy enabling the subject to achieve orgasm during an intercourse [36]. Therefore,
this case also cannot be used as sole evidence for pornography-induced ejaculation impairment as it
could just as well result from penile desensitization, a consequence of frequent masturbation. Some
studies have reported that masturbation frequency and style, particularly the so-called “idiosyncratic”
pattern that due to speed, pressure, and duration is difficult to be replicated by a partner, may be a
predisposition for retarded ejaculation [42–44]. Therefore, the extent to which pornography use may
contribute to such phenomenon remains unclear.
In summary, there is currently little evidence that an association between pornography use
and delayed ejaculation exists and no indication that pornography use can be a cause of this sexual
dysfunction. However, the assessment in this regard is only based on cross-sectional studies and case
reports. Future research, particularly more extensive cohort studies and case-control observations, is
therefore required.
3. Erectile Dysfunction
Erectile dysfunction is defined as a chronic inability to maintain an erection which prevents the
introduction of the penis into the vagina. Its most common causes include age, diabetes, depression,
cardiovascular and neurological diseases, selected psychogenic factors (including stress and abuse of
psychoactive substances), and using selected pharmaceuticals [45]. Considering that some studies
indicated a significant correlation between hypersexuality and problems with erectile function [46], it
is plausible that some association in this respect may also exist for pornography use. A systematic
search with key terms “pornography and erectile dysfunction”, “pornography and erectile function”,
and “pornography and erection” identified a total of seven papers overall encompassing two case
reports [41], six cross-sectional studies [28,39,40,47–49] and one longitudinal study [28].
Two interesting cases were presented by Park et al. [41]. In the first, a 40-year-old man with
difficulty in maintaining an erection and achieving orgasm was described. During the period preceding
the study he had intensively undertaken masturbation associated with the frequent use of online
pornography, which was reported to be associated with an increasing amount of time required to
achieve orgasm. He had also begun to view his wife as becoming gradually less sexually attractive.
His physical parameters (including state of genitals) were in good condition. The patient was advised
that his dysfunctions could have arisen from increased sexual stimulation, frequent masturbation,
and change in the stimulation threshold due to exposure to strong pornographic content. The man,
however, was unable to refrain from masturbation and watching pornography and did not initiate
the treatment [41]. Another case described by the same authors concerns a 24-year-old man who was
abusing alcohol and antidepressants, and had attempted suicide. He also reported to using online
pornography at a frequency estimated at 5 h daily during the 6 months preceding the treatment. He
experienced a weakened sexual interest in his wife, which was manifested by his inability to maintain an
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erection and preference to watching pornography, during which he experienced no erection problems.
After discontinuing the use of pornography, according to the therapist’s recommendation, his erectile
dysfunction disappeared [41]. Both of these cases are complicated with confounding variables and
no casual relation between pornography use and erectile dysfunction can be seen. In the first, it is
not possible to separate the potential effects of frequent pornography use and excessive masturbation,
although one should note that these two phenomena can often be highly correlated in men [50]. The
second case is complicated by psychiatric history (use of antidepressants and suicide attempt) as well
as by the reported alcohol abuse which itself is a common cause of sexual dysfunctions such as erectile
retardation [51].
As found in a pilot observational study conducted in 2006 on a small group of young adult
men (n = 25; mean age 29 years), nearly half of them (n = 12) showed no signs of sexual arousal,
including erections while watching an erotic film (penile rigidity < 5%; and 0% in eight subjects) [47].
These observations were initially associated with a potentially high level of exposure to pornographic
content, lowering the responsiveness to sexual stimuli associated with the presentation of sex in a
more standard edition (vanilla sex). In the second stage of the study, a larger number of men were
recruited (n = 80) and exposed to longer and more diverse erotic films. Nineteen percent of them
(n = 15) failed to respond sexually. It appeared that the risk of sexual dysfunction increased along
with the number of pornographic films that had been viewed by the respondents during the previous
year [47]. Another study of a larger range was conducted in 2016 on a group of 434 men (mean age
29.5 years, range 18–72). Using the International Index of Erectile Function questionnaire, the ability
to achieve an erection and orgasm, the degree of sexual desire, satisfaction with sexual intercourse,
and general sexual satisfaction were evaluated in 276 subjects who had had sexual intercourse during
the last month. The study concluded that problematic online sexual behavior (defined as compulsive,
persistent, uncontrolled use of pornographic content) was a significant predictor of a low level of
erection [49].
In turn, the study surveying Italian high school students (n = 1429; age 18–19 years) did not
show that erection problems were more frequently admitted by teenagers watching pornography,
regardless of the self-reported frequency of its use [39]. A cross-sectional study conducted in two-large
scale samples on heterosexual men (aged 18–40 years): the first in 2011 on Croatian, Norwegian,
and Portuguese heterosexual men (n = 2727) and the second in 2014 on another sample of Croatian
men (n = 1211) identified a positive relationship between pornography use and erectile dysfunction
in the first subset of individuals from Croatia although the effect was small and not confirmed in
other groups [40]. Another study reported that instead of erectile dysfunction, pornography use in
280 heterosexual men (mean age 23 years) was positively correlated with sexual arousal which was
self-reported when watching visual stimuli in the laboratory [48]. Furthermore, subjects indicating
higher pornography consumption also reported a greater desire for solo and partnered sexual behaviors.
However, this study had a number of limitations: a high number of monogamous individuals (which
may be more sexually exploratory, particularly if young), a rather limited frequency of pornography use
in the studied group (individuals were divided into three groups using pornography 0, 1–2, and >2 h
per week but the maximum frequency remained unreported), and an unknown period of pornography
use in the investigated individuals prior to the study.
The most recent study performed by Grubbs and Gola [28] reported a positive association
between self-reported erectile dysfunction and self-reported problematic pornography use but not mere
pornography use in a cross-sectional sample of 147 undergraduate men (mean age 20 years) in the United
States as well as in a sample of 433 men (mean age 33 years) matched to the demographic norms of this
country. The one-year, four-wave longitudinal study that was based on these two samples, completed
across all four time points by 117 participants, and with two point-data collected for 278 subjects, also
found that baseline pornography use and problematic pornography use was positively associated
with prospective erectile dysfunction. However, latent growth modelling indicated that no baseline
variables served as predictors of the trajectory of erectile functioning over time. Although these results
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support the existence of an association between erectile dysfunction and problematic pornography use,
they fail to show a causal relationship. It is thus plausible that men with erectile dysfunction may tend
to use more pornography, including patterns they self-perceive as problematic [28].
As yet, there is little or no evidence on a causal relationship between erectile dysfunction and
frequency of pornography use. It cannot be ruled out that subjects with erectile dysfunction may
be more prone to using pornography more frequently. One should note that cross-sectional and
longitudinal studies performed so far are solely based on self-reported data introducing a significant
limitation. Some research clearly indicates that the prevalence of self-reporting of erectile dysfunction
may vary considerably from the prevalence identified by objective methods such as the International
Index of Erectile Function to the extent that the former might be unreliable in assessing the real presence
of this sexual dysfunction [52]. There is a need for further longitudinal exploration of associations
between erectile dysfunction and pornography use that would include individuals of different age and
with various baseline pornography use and employ a diverse methodology encompassing physiological
measures and partner reports.
4. Changes in Sexual Desire
From the perspective of biological sciences, the term libido is used to describe sexual desire, a trait
controlled by central nervous system associated with the sexual drive and wish to engage in sexual
activities [53]. As highlighted, it should not be mistaken for sexual arousal which manifests itself
physiologically and may not always be positively correlated with sexual desire [54]. This said, it can be
hypothesized whether pornography use increases or decreases libido, and if frequency and duration of
pornography consumption may modify such responses. One can also consider different responses
in males and females due to varying sex roles and sexually differentiated neural activity in response
to sexual stimuli [55]. To explore it, a systematic search for original studies was performed with the
key terms “pornography and libido” and “pornography and sexual desire”. A total of five papers
associated with this subject were identified and included cross-sectional studies [39,40,50,56,57].
Carvalheira, Træen, & Stulhofer [50] analyzed the relationship between masturbation and the
use of pornography and sexual desire in a group of European heterosexual men (mean age 40 years,
range 21–73) who had reported a problem of reduced sexual desire (n = 596). As found, more than
half of the studied subjects who had experienced a significant decrease in libido within six months
before the examination were involved with pornographic materials at least once a week. The study
further found that frequency of masturbation and pornography use are strongly correlated in men
with decreased sexual desire. One should note that the cross-sectional nature of this study does not
allow any causation between pornography consumption and decreased libido to be established, and
that interpretation of the obtained data is also limited by the lack of a control group constituted by
men with no sexual dysfunctions. Although it is generally an interesting or even counterintuitive
observation that men with an impaired libido may watch more pornography and masturbate often, it
is important to highlight that men with lower sexual desire (contrary to women with lower libido) tend
to increase the frequency of masturbation in a manner unrelated to pornography consumption [58,59].
Considering the high accessibility of online pornography, it is no surprise that men who tend to
masturbate often will also constitute a group using it as sexual stimuli.
Cross-sectional observations in Italian students attending the last year of high school (n = 1492,
aged 18–19 years) indicated that as many as 78% of them admitted to using pornographic content,
with 8% indicating doing so on a daily basis. A decrease in sexual desire was reported by 10% of
pornography users, and appeared to increase with the frequency of consumption: among students
exposed at least once a week, it accounted for 16%, while in the case of those exposed less often it was
6%; the nonusers did not report it at all [39].
The findings of Carvalheira, Træen, & Stulhofer [50] and Pizzol, Beroldo, & Foresta [39] were not
confirmed in a large study encompassing large-scale samples of heterosexual men (aged 18–40 years)
from Croatia, Norway, and Portugal (n = 3948) and applying multivariate logistic regression [40]. In
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turn, a study on women (n = 754; aged 18 = 76 years) reported that those involved in a long-term
relationship that use pornography more frequently may reveal increased sexual desire towards their
partners and report a higher desire for sexual variety [56]. This is a relatively important finding
indicating the potential difference in patterns of pornography use between men and women, although
one should note that the cross-sectional nature of the study does not imply causation. It remains
to be explored whether a pornography-induced increase in libido exists in women or women with
higher sexual desire are also more open to watching pornography more frequently. Moreover, the
potential role of sexual partner (in terms of sexual desire and satisfaction) and satisfaction from a
relationship may represent important factors for inclusion in multivariate analyses conducted in the
future. Interestingly, a recent cross-sectional survey of 240 committed heterosexual couples (mean age
of males and females 35 and 33 years, respectively) confirmed the positive correlation of pornography
use by women with their sexual desire but also found a similar but weaker relation in men [57].
Neurobiological research indicates that the potentially negative effect of long-term pornography
use on sexual desire may result from changes in the responsiveness of the reward system to sexual
stimuli, preferentially more active as a result of stimuli associated with pornography than with real
sexual intercourse [60,61]. However, observational studies do not provide consistent data to support
the hypothesis that use of pornography is a causative factor for a decrease in sexual desire and rather
provide a contradictory observation as regards the existence and direction of correlations between
pornography use and libido. These contradictions may potentially arise from the complex nature of
sexual desire in both men and women, which is influenced by a number of biological, psychological,
relational, sexual and cultural factors [62,63]. Considering that some studies have reported that subjects
with higher sexual boredom and lower libido may tend to masturbate more frequently [50], it is
important to elucidate the role the pornography use and pornography-associated masturbation may
play in fulfilling the need for sexual gratification. Further cross-sectional studies as well as prospective
investigations that control for these factors are greatly required to draw some final conclusions on the
relation of pornography use and level of sexual desire.
5. Changes in Sexual Satisfaction
It could be hypothesized that the frequent exposure to pornography can potentially impact sexual
satisfaction. The potential reasons for its decrease may include: (1) a comparison of real partners to
idealized acting roles in pornographic films [64,65], (2) disappointment when the actual partner is
not interested in recreating the scenes observed in pornographic material, (3) disappointment due to
the inability to obtain such a broad spectrum of sexual novelties, with a real partner as presented in
pornographic material [66,67] and (4) contact with pornography chosen instead of sexual intercourse
with a real partner [68,69].
On the other hand, one could also hypothesize that in some cases, use of pornography may
increase sexual satisfaction by providing inspiration for real sex. However, the magnitude of these
effects may differ between men and women, and may also be potentially modified by frequency
and time of pornography use, as well as type of pornography consumed. Moreover, it may also be
hypothesized that shared pornography use in couples may have a positive impact on sexual satisfaction
as it could stimulate partners for more sexual exploration during real intercourse [70].
A systematic search with the key term “pornography and sexual satisfaction” identified a total of
23 papers reporting observational studies among which 20 cross-sectional surveys (Table 1) and four
prospective investigations were reported [65,71–73].
As found, the associations of pornography use on sexual satisfaction may differ across gender
(Table 1). In general, its decrease was more often observed in men than women. Moreover, the
frequency of pornography use may also be differentially associated with sexual satisfaction in both
genders—in men, its decrease was already reported at a rate of use estimated at a few times per year
while in women at a frequency of once a month [74]. As demonstrated in both women and men, age of
first exposure may also be associated with decrease in sexual satisfaction, with a two-fold increase in the
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odds if such exposure occurred≤ 12 years in reference to individuals exposed for the first time>16 years.
Nonreligious individuals and those in a relationship were also found to reveal weaker associations
between pornography use and sexual satisfaction [74,75]. Interestingly, one study reported that, in men,
the negative association between pornography use and sexual satisfaction appeared to diminish once
masturbation frequency was controlled [76]. However, one should note that pornography consumption
and masturbation are usually highly associated in men [50]. Altogether, it highlights that the context
of pornography use may highly moderate the nature of associated effects and should be taken into
account in further assessments. As recently indicated, length of relationship was negatively associated
with pornography use in women, thus mitigating its effects on sexual satisfaction [77]. In turn, in
newly married couples, pornography use was demonstrated to be negatively correlated with sexual
satisfaction [73]. One study demonstrated that the association between pornography use and sexual
satisfaction may be differentiated according to the attachment styles of the studied subjects: with no
association found in secure individuals (neither anxious nor avoidant), a negative association among
preoccupied (high anxiety but low avoidance) and dismissing (low avoidance and high anxiety) subjects
and a positive one among fearful persons (simultaneously highly anxious and avoiding) [78]. This puts
an association between pornography use and sexual satisfaction in a wider psychological context in
which it may arise from early interactions with caregivers that, via internalization of operative cognitive
models, guide behavior and cognition, in relation with sexuality in adulthood. This is particularly
interesting in the light of the research of Szymanski and Stewart-Richardson [79] who demonstrated
that frequency of pornography use as well as problematic pornography use in heterosexual men is
related to more avoidant and more anxious attachment styles. The authors hypothesize that these men
use pornography as it allows them to experience emotional and/or sexual gratification without having
to risk interpersonal rejection or intimacy [79]. Altogether, these findings suggest that the nature
of associations between pornography use and sexual satisfaction may depend on various variables
encompassing gender, relationship status, cultural/religious factors, and psychological background,
and this, in addition to quantitative data, should be taken into account in future studies.
Overall, it appears that individuals, particularly men, who use pornography more often also
tend to report lower satisfaction with their sex life. The limitations of cross-sectional studies do not
allow us to distinguish whether pornography induces a decrease in sexual satisfaction or whether low
sexual satisfaction predicts more frequent pornography consumption, or both. The first longitudinal,
three-wave (six months between waves) panel study in this regard conducted on a population of Dutch
adolescents (n = 1052; aged 13–20 years) revealed that pornography use consistently reduced sexual
satisfaction but also that low sexual satisfaction led to increase in pornography use [65]. This highlights
that these bidirectional relationships must be taken into account, and that other factors contributing to
lower sexual satisfaction (that may potentially include sexual or psychosocial dysfunctions) should be
addressed to fully elucidate the reasons for pornography use. Gender was not demonstrated to be
a moderator of observed effects in this study. However, another four-wave panel study (six months
between waves) which was also conducted on a sample of Dutch adolescents (n = 1132; aged 11–18
years) indicated that more frequent pornography use at baseline predicted less sexual satisfaction at
the last study point in males, while in females, sexual satisfaction was negatively associated with an
increase in pornography use [71]. The findings by Peter & Valkenburg [65] and Doornwaard et al. [71]
were not replicated in the other, three-wave longitudinal study (one year between waves) that surveyed
190 newly married heterosexual couples [73]. As demonstrated, the frequency of pornography use in
women and men failed to predict changes in sexual satisfaction and pre-existing sexual satisfaction
did not predict changes in pornography consumption. More recently, a longitudinal six-wave study
(six months between waves) of females (n = 775) and males (n = 514) aged 15–18 years, also found
no significant association between frequency of pornography use and sexual satisfaction, regardless
of gender [72]. Further prospective studies will be necessary before any definite conclusions can
be drawn.
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Online survey 373 heterosexual men 19 ± 2 (18–29) MultidimensionalSexuality Questionnaire
Frequency of PU and PPU
correlated with ↓ sexual
satisfaction
[79]
Online survey 217 heterosexualcouples 37 ± 11 ♂; 35 ± 10 ♀ Index of SexualSatisfaction
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only in male
[80]
Online survey 650 men (18–25) Snell’s Index of SexualSatisfaction
Earlier exposure to P
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Frequency of PU correlated
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only in male
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[83]
Online survey 1513 heterosexualadults 23 ± 8 Two-item question
Frequency of PU correlated
with ↓ sexual satisfaction [74]
Online survey 240 heterosexualcouples
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adults 50 ± 18 (17–98) One-item question
Frequency of PU correlated
with ↓ sexual satisfaction
only in male
[75]
Online survey 565 women; 471 men (18–55) One-item question
Frequency of PU correlated
with ↓ sexual satisfaction
only in male
[77]
Online survey 894 heterosexual adults 30 ± 9 Two-item question
Frequency of PU correlated
with ↓ sexual satisfaction
with no gender differences
[84]
Online survey 596 women; 234 men 25 ± 8 (18–78) Global Measure ofSexual Satisfaction
Frequency of PU correlated
with ↓ sexual satisfaction,
particularly lower scores
were seen in compulsive
users.
[85]
Online survey 587 women; 232 men 25 ± 8 (18–78) Global Measure ofSexual Satisfaction
Frequency of PU correlated
with ↓ sexual satisfaction in
both gender
[86]
Online survey 1471 women; 1109 men (18–60) New Scale of SexualSatisfaction
Frequency of PU correlated










Frequency of PU correlated




interviews 2610 married adults 53 ± 14 (25–80) One-item question
Frequency of PU correlated
with ↓ sexual satisfaction in
studied group
[88]
Online survey 433 heterosexualmarried couples 38 (22–59) ♂; 35 (20–44) ♀ One-item question
No correlation between
frequency of PU and sexual










Frequency of PU correlated




survey 460 women; 130 men 24 ± 7 (18–64)
One-item question with
Likert scale








Online survey 3004 women; 2079 men 22 ± 1 (18–26) One-item question
Earlier age of exposure to P
increased odds for ↓sexual
satisfaction
[12]
Online survey 470 men 27 ± 11 Global Measure ofSexual Satisfaction
Frequency of PU correlated
with ↓ sexual satisfaction [76]
Online survey 378 men 47 ± 14 Global Measure ofSexual Satisfaction
Frequency of PU correlated
with ↓ sexual satisfaction [76]
P—pornography PU—pornography use; PPU—problematic pornography use; SD—standard deviation.
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Importantly, the majority of cross-sectional studies summarized in Table 1 only assessed individual
pornography use. As shown by Willoughby & Leonhardt [57], shared viewing of pornography in
heterosexual couples is correlated with higher sexual satisfaction. As demonstrated, women using
pornography may more often experience guilt, disgust, and embarrassment [90], which are rather not
experienced when this use is shared with their partners—such a scenario may promote positive sexual
interactions in couples. One should note, however, that the findings of Willoughby & Leonhardt [57]
are derived from a cross-sectional study and no causality can be established. It can be hypothesized
that shared pornography use increases sexual satisfaction in partners or that partners experiencing
higher sexual satisfaction may tend to view pornography together more often.
Additionally, interesting associations between pornography use and a partner’s sexual satisfaction
have been reported. For example, Yucel and Gassanov [91] who surveyed 433 heterosexual married
couples observed that a husband’s pornography consumption was negatively correlated with his
wife’s sexual satisfaction while a wife’s pornography use was not associated with her husband’s
satisfaction. In turn, the longitudinal observations made in 190 newlywed couples found that increased
sexual satisfaction in men was a predictor of a decline in pornography viewing by their wives [73].
These bivariate associations suggest that gender patterns in pornography consumption in couple
relationships may mutually affect sexual satisfaction and may be important to consider in future works
on the effects of pornography use on the quality of sex life.
In conclusion, the accumulating evidence from cross-sectional studies supports the hypothesis
that pornography use is associated with lower sexual satisfaction. However, the magnitude of this
association appears to depend on a number of factors, including gender, relationship status, frequency,
duration, and pattern of pornography use, and the age at which pornography use was initiated. One
should also note that although much attention is paid to associations with lower sexual satisfaction,
some studies not only report no associations of pornography consumption in this regard in large
number of surveyed subjects but also indicate that some individuals experience an increase in sexual
satisfaction. For example, in a recent cross-sectional study of Polish students who admit to current
pornography use, respectively 68% and 7% associated its consumption with no effect and a beneficial
effect on sexual satisfaction [12]. Moreover, studies in couples demonstrate that use of pornography may
not necessarily be associated with less sexual satisfaction, and that in some cases, a positive correlation
can be observed [57]. As already shown in relation to relationship quality, it is highly plausible
that the nature of the association between pornography use and sexual satisfaction in individuals
in romantic relationships may not only depend solely on the frequency of use but the context in
which it is consumed, such as concordance or discrepancy in partners’ use, levels of acceptance of
pornography use from both partners, known or hidden use, and individual or shared use [70,92].
Moreover, the longitudinal studies conducted so far have failed to fully confirm that pornography use
is a causative factor in impaired sexual satisfaction. It remains to be explored whether the potential
effect of pornography in this regard can be influenced by: (i) sexual orientation: the majority of studies
have focused on heterosexual individuals while homo- and bisexual individuals may even be more
frequent pornography users as preliminarily found in men [93], (ii) physical disabilities as they may
also influence a baseline sexual satisfaction [94], and (iii) co-occurrence of other sexual dysfunctions, as
some authors have indicated that pornography use may be a continuation of pre-existing compulsive
sexual behaviors [64,95].
6. Future Research Prospects and Conclusions
Increasing access to the Internet has opened a completely new chapter for the pornographic
industry, simultaneously increasing both the time and strength of exposure to pornographic content,
and its potential effects on health. The studies conducted so far indicate a correlational relationship
between pornography consumption and selected sexual dysfunctions with the strongest evidence for a
decrease in sexual satisfaction. It should be noted that the vast majority of observations are based on
cross-sectional studies or case reports and without future research based on extensive case-control
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and/or prospective cohort studies, causality cannot be comprehensively assessed. One should also
note that assessment of pornography use in studies is mostly based on self-reporting and that objective
confirmation of exposure is not possible. Moreover, the presence of sexual dysfunctions such as
erectile dysfunction is also often self-reported and creates the risk of their being underestimated;
thus, when possible, the use of validated tools is advised. There are number of recognized risk
factors for sexual dysfunctions which need to be considered when evaluating the potential effects of
pornography use in future studies. The frequency of pornography use may in turn be potentially
modulated by various parameters such as gender, cultural/religious factors, relationship status, and
psychological background. Further research on associations between pornography consumption and
sexual dysfunction should also take these into account. Unlike the effect of psychoactive substances or
binge eating, the potential effects of pornography use cannot be recreated using experimental animal
models, while the scope of experimental research involving human volunteers is rather limited and
can often only be used to assess short-term outcomes. This in turn highlights the need for more,
well-designed observational, particularly prospective studies. To provide a broad insight into the
potential associations of pornography use with sexual dysfunctions, it would be best for future studies
to provide a definition of pornography, specify the type of pornographic content consumed by the
studied subjects (e.g., violent, nonviolent, mainstream, and paraphilic), control for the frequency of
masturbation, consider the sexual orientation of participants, whether they are in a relationship or
not, and if they are what is their relationship satisfaction and whether they consume pornography
individually or in a shared manner. The context in which pornography is consumed rather than the
mere use may moderate the associated effects, and such context must be taken into account in further
assessments. The complexity of factors influencing pornography use and modulating its associated
effects, as well as the susceptibility of research models to methodological biases and difficulties in
overcoming the limitations of studies strongly justify a need for further investigation on the associations
between sexual functionality and pornography consumption, which is particularly important given
the high rates of the latter.
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Abstract: In recent decades, hormonal contraceptives (HC) has made a difference in the control of
female fertility, taking an unequivocal role in improving contraceptive efficacy. Some side effects of
hormonal treatments have been carefully studied. However, the influence of these drugs on female
sexual functioning is not so clear, although variations in the plasma levels of sexual hormones could
be associated with sexual dysfunction. Permanent hormonal modifications, during menopause or
caused by some endocrine pathologies, could be directly related to sexual dysfunction in some cases
but not in all of them. HC use seems to be responsible for a decrease of circulating androgen, estradiol,
and progesterone levels, as well as for the inhibition of oxytocin functioning. Hormonal contraceptive
use could alter women’s pair-bonding behavior, reduce neural response to the expectation of erotic
stimuli, and increase sexual jealousy. There are contradictory results from different studies regarding
the association between sexual dysfunction and hormonal contraceptives, so it could be firmly
said that additional research is needed. When contraceptive-related female sexual dysfunction is
suspected, the recommended therapy is the discontinuation of contraceptives with consideration
of an alternative method, such as levonorgestrel-releasing intrauterine systems, copper intrauterine
contraceptives, etonogestrel implants, the permanent sterilization of either partner (when future
fertility is not desired), or a contraceptive ring.
Keywords: female sexual dysfunction; hormonal contraceptive; libido; desire; sex life; orgasm;
vaginal ring; depot medroxyprogesterone acetate
1. Introduction
In recent decades, hormonal contraception (HC) has made a difference in the control of female
fertility, taking an unequivocal role in improving contraceptive efficacy. Moreover, there are numerous
studies that state that the use of hormonal contraceptives is very prevalent in the female population
of childbearing age [1–8]. In a study carried out by Hall et al. in 2012, it was estimated that 63% of
women of reproductive age worldwide who were married or in a relationship were using some type of
contraception, with the contraceptive pill as the third most commonly used method (9% of women
aged 15–19 years) [3,9]. Combined oral contraception seems to be the most popular form of reversible
contraception in Europe and the United States [7,8].
The popularity and widespread use of hormonal contraceptives is partly due to their benefits,
such as: (1) Being a highly effective and reversible form of contraception; (2) the woman has control over
this method of contraception; (3) the failure rate is less than 1%; and (4) they have a well-established
safety profile [1].
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However, the use of hormonal contraceptives is relatively recent: In 1956, an oral contraceptive
pill (mestranol in combination with norethynodrel) was used for the first time in a clinical trial; a year
later, in 1957, the formulation of 150 μg mestranol and 10 mg norethynodrel received approval for the
treatment of “female disorders” (menstrual irregularities, etc.) [1]. It was three years later, in 1960, when
the Food and Drug Administration (FDA) approved the use of the pill as a contraceptive, containing
75 mestranol and 5 mg norethynodrel [1,10]. At the beginning, oral contraceptives were available only
to married women, and, in 1972, the pill also began to be available for single women in all states [1].
Since the approval of the use of the pill in 1960, it has undergone many evolutions in dosage, hormone
type, and regimen. It has been used by more than 100 million women worldwide and has the widest
geographic distribution of any method of contraception [10].
The use of hormonal contraceptives is widespread, with a significant percentage of healthy
population among its users. Some of its side effects are well known, such as the increased prothrombotic
and cardiovascular risk (estrogen dependent) [10]. On the other hand, non-contraceptive benefits of
hormonal contraceptives, such as as cycle regulation with predictable withdrawal bleeds, decreased
menstrual flow, and decreased anemia, have been widely documented [10]. However, the influence of
these drugs on female sexual function is not as clear, although it is mentioned in the technical prospects
of the contraceptive pills. Additionally, there are very few controlled studies in this field.
Conversely, despite the widespread use of contraceptives in the general population, there are many
other drugs that have been widely studied and associated with frequent iatrogenic sexual dysfunction.
Antihypertensive drugs, diuretics, and beta-blockers seem to exert a detrimental impact on sexual
function [11], as do antipsychotics [12–14], antidepressants [12,13,15], and others. In addition, there are
endocrine disorders that are also associated with alterations in sexual function, such as diabetes [16],
obesity, and metabolic syndrome [17]. On top of this, sexual dysfunction is a possible symptom
associated with other hormonal alterations such as those that take place during menopause [18] or
postpartum [19]. There are differences regarding which aspects of sexual function were most affected
by menopause. The Massachusetts Women’s Health Study, the Melbourne Women’s Midlife Health
project, the Penn Ovarian Aging Study and the Study of Women’s Health Across the Nation (SWAN)
are some of the pieces of research that were carried out in this regard. Notably, three out of four of
these studies noted declines in sexual desire during the menopause transition [18].
In this review, first of all, detailed information has been included about the hormonal contraceptive
methods, focusing on the type of administration, hormonal composition, mechanism of action, and
expected effects on hormonal function in women. Second, an approximation is given to the concept
and significance of sexual dysfunction, in addition to its prevalence in the female population. These
first sections have the objective of contextualizing and favoring the understanding of the next ones;
the main aim of this study is to clarify whether there is evidence of the effect of hormonal contraceptives
on female sexual function. In this review, we attempt to provide a summary of the existing data
about the impact of hormonal contraceptives on sexuality. We differentiate between studies that claim
that there are no effects of hormonal contraceptives on sexual function and others that defend that
there are. Within the latter, we differentiate between those that show positive and negative effects on
female sexual function. Likewise, in this review, some treatment options are proposed according to the
studies reviewed.
This review provides a compilation of the existing evidence about the relationship between female
sexual function and hormonal contraceptives, in addition to the existing therapeutic management
strategies. This is the first review that includes a summary table, which allows the clinician to access to
the most relevant information at a glance. Likewise, it is the only study that proposes a therapeutic
algorithm for the management of hormonal contraceptives-related sexual dysfunction.
2. Materials and Methods
The aim of this review is developing, assimilating, and synthesizing the existing evidence about
the influence of hormonal contraception on female sexual function. In addition, we intended to
214
J. Clin. Med. 2019, 8, 908
identify gaps in knowledge in this field in order to design new studies that may fill those gaps in the
future. Our review focuses on the use of hormonal contraceptives in women of childbearing age and
on the influence of these drugs on female sexual function [1,2]. In addition, the study reviews the
differences in the influence of the HCs on female sexual function (FSF) according to the hormonal
composition and the mechanism of action of the different HCs in order to determine which one has
the lowest profile of secondary effects in the sexual area. On the other hand, to our knowledge, this
is the latest effort to offer an overview of the recommended strategies in cases in which the use of
HCs is associated with sexual dysfunction.To achieve this purpose, we performed a scoping review
following PRISMA guidelines (Preferred Reporting Items for Systematic Reviews and Meta-Analyses)
(Figure 1). In this review, we selected key articles based on hormonal contraception and female sexual
function. PubMed and Cochrane were chosen as the main databases used due to the extensive contents
of biomedical research they offer, their free access, and their ease of use. Our search term combinations
were: “Hormonal contraception” AND “female sexual function” OR “female sexual dysfunction.”
The filters “publication date: From 2000/01/01 to 2019/01/31” and “review” were applied in the search
in order to limit the amount of material available. No language restrictions were applied. Similar and
related articles that were considered of special interest for our review were also included, and they were
compiled though cross-referencing. Similarly, some relevant clinical practice guidelines were included.
The 64 papers that were included were chosen because they fit the topic of the review (presenting
information about female sexual dysfunction, hormonal contraception, hormonal variations, and their
relationship with female sexual function; directly treating the impact of hormonal contraceptives in
female sexual function; or providing relevant information about the management strategies of female
sexual dysfunction associated with the use of HCs). We reviewed six prospective observational studies,
eight clinical trials, 19 cross-sectional studies, 22 reviews, and nine other works that include consensus
and clinical practice guidelines. Most of the studies were carried out in European countries, although
there were also studies carried out in the US, Asia, Australia, and South America. The population of
the studies reviewed varied between 40 and 18,787, although in the case of clinical trials, the largest
population analyzed was 600 subjects.
Figure 1. PRISMA flow diagram. (Preferred Reporting Items for Systematic Reviews and Meta-Analyses).
We summarized the findings and best practice recommendations for addressing a woman’s
contraception and its potential association with sexual function. We excluded those articles that
focused on male sexual dysfunction, menopause, and sexual dysfunction related to medical disease,
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such as oncological pathology. Every attempt was made to combine as much similar data as possible.
Institutional review board approval was not needed for this review.
3. Results
3.1. Hormonal Contraceptives
The combined oral contraceptive (COC) was first approved in 1960. Since then, it has undergone
many evolutions in dosage, hormone type, and regimen. It has been used by more than 100 million
women worldwide and has the widest geographic distribution of any method of contraception [10].
In this section, we will provide detailed information about hormonal contraceptives in terms of the
existing types, their hormonal composition, their mechanism of action, and the alterations in hormonal
function that derive from them.
3.1.1. Types
At present, there are twenty different contraceptive methods approved by the FDA [20], ten of
which are female hormonal contraceptive methods: Eight are reversible contraceptive methods, and
two are emergency contraceptive methods. In Table 1, we can see the different categories of hormonal
contraceptives mentioned.
Table 1. Hormonal contraceptives. Route of administration, dosing frequency, mechanism of action,
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Levonorgestrel 1.5 mg Oral Swallow the pills as soon as possible within 3 days after having unprotected sex.
Ulipristal Acetate Oral Swallow the pills within 5 days after having unprotected sex.
Reversible contraceptive methods include: Combined hormonal contraceptives (CHCs),
progestin-only contraceptives, and intrauterine contraceptives (IUCs). COCs include the “pill”
or combined oral contraceptives (COCs), the contraceptive patch, and the vaginal ring. When talking
about progestin-only contraceptives, we can differentiate between progestin-only-pills (POPs), depot
medroxyprogesterone acetate (DMPA), and the “implant” or single rod etonogestrel subdermal implant.
IUCs include copper intrauterine devices (Cu-IUDs) and levonorgestrel-releasing intrauterine systems
(LNG-IUS) [10,21,22]. Emergency hormonal contraceptives (ECs) are: Levonorgestrel of 1.5 mg (1 pill)
or 0.75 mg (2 pills) and ulipristal acetate [20]. Permanent contraceptive methods that are approved
by the FDA are: Sterilization surgery for women, a sterilization implant for women, and sterilization
surgery for men [20].
3.1.2. Hormones
The hormonal composition of hormonal contraceptives is based on progestins alone or on a
combination of progestogens and estrogens [10,20–24]. Several different progestins are used in combined
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oral contraceptives (COCs). These progestins may also have estrogenic, antiestrogenic, androgenic,
antiandrogenic, or antimineralocorticoid activity [10]. Most progestins are 19-nortestosterone
derivatives. Progestins may be classified according to their chemical structure as an estrane
(norethindrone, norethindrone acetate, ethynodiol diacetate) or as a gonane (LNG, desogestrel,
norgestimate). In general, gonane progestins appear to be more potent than the estrane derivatives
(smaller doses can be used), but other differences between the estrane and gonane compounds are
difficult to characterize [10]. Table 2 shows the classification of progestogens used in hormonal
contraception according to their androgenic potency. Among the contraceptive progestins available
in the United States, norgestrel and levonorgestrel are the most androgenic; norethindrone and
norethindrone acetate are less androgenic; and desogestrel, etonogestrel, norgestimate, dienogest, and
drospirenone are the least androgenic [2]. Newer progestins (norgestimate and desogestrel) have little
or no androgenic activity, whereas other progestins (cyproterone acetate, drospirenone, and dienogest)
have antiandrogenic activity [10]. The varying progestational “potencies” attributed to different COC
preparations are based on pharmacological experimental models. Many variables affect the potency of
COCs (including dosage, bioavailability, protein binding, receptor binding affinity, and interindividual
variability), making it difficult to extrapolate the results of isolated experiments to provide clinically
relevant information in humans. There is no clear clinical or epidemiological evidence that compares
the relative potencies of currently available COCs [10]. Systemic progestins may be associated with a
loss of sexual desire due to the suppression of ovarian function and endogenous estrogen production [6].
Along the same line of reasoning, in their study about women’s self-reported sexual desire across
natural cycles, Roney and Simmons observed that levels of salivary progesterone negatively predicted
women’s sexual desire [25,26]. Furthermore, based on the findings by Grebe et al., effective dosages of
progestin should be associated with a stronger positive linkage between women’s loyalty/faithfulness
to their relationship partners and the frequency with which they engaged in sexual intercourse with
their partners [26,27]. However, contraceptive pills with progestogens with antiandrogenic effect
do not affect sexual desire, according to some reports [28,29]. In recent studies, drospirenone and
dienogest have reported a positive effect on sexual response as well as attraction, desire, satisfaction,
and coital frequency [28,30], perhaps due to the ability to reduce the activity of 5-alpha reductase [31].
Table 2. Classification of progestogens used in contraception according to their androgenic potency.












With regard to estrogens as hormonal components of hormonal contraceptive methods, three
types of estrogens are used in COCs (as it can be seen in Figure 2): Ethinylestradiol (EE), estradiol
valerate (E2V), and 17 beta-estradiol (E2). E2V is rapidly metabolized to E2 [10]. Due to its biochemical
structure, estradiol has less impact on the synthesis of hepatic proteins than ethinyl estradiol, which is
likely to result in a better metabolic and vascular profile [3]. The new formulations of launched COCs
have lower doses of estrogen, and EE has been replaced by more “physiological” forms of estrogen,
such as 17β-estradiol (E2) or E2-Valerate (E2 V) [32]. There is some evidence to suggest that estrogens
play an essential role in female sexuality, and prior research has found that declining sexual functioning
in women is most closely related to declining estrogen levels [6,33] Similarly, levels of salivary estradiol
positively predicted women’s sexual desire, conversely to progesterone [25,26]. Regarding loyalty
and faithfulness, dosages of estradiol should predict a weaker positive linkage between women’s
loyalty/faithfulness to their relationship partners and frequency of sexual intercourse (not including
masturbation and sexual fantasies; independently of androgenicity of sexual hormones) [26,27].
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Figure 2. Types of estrogens used in combined oral contraceptives (COCs).
3.1.3. Mechanism of Action of Hormonal Contraceptives
In Table 1, we can see a summary of the different categories of hormonal contraceptives mentioned
with their respective mechanism of action of hormonal contraceptives. The mechanism of action of
hormonal contraceptives depends on their hormonal composition and the route of administration.
Combined hormonal contraceptives (CHCs) encompass oral contraceptives (pill), patch, and the
vaginal ring. Their mechanism of action is similar.
With regard to combined oral contraceptives (COCs), they have multiple mechanisms of action
due to both their estrogenic and progestational components: The suppression of pituitary gonadotropin
secretion (inhibiting ovulation), the increase of cervical mucus viscosity (impairing sperm transport),
the suppression of the luteinizing hormone (LH), and the impairment of ovulation [10].
The patch is a 20 cm2 square matrix system that delivers 200 mg of norelgestromin (the primary
active metabolite of norgestimate) and 35 mg of ethinylestradiol (EE) daily to the systemic circulation.
Following the first application of the patch, serum hormone levels increase gradually over the first
48–72 h, reach a plateau, and then remain constant during the remainder of the 21-day period. Compared
with COC, plasma hormone levels remain constant, and the peak levels are lower because first-pass
hepatic metabolism and gastrointestinal enzyme degradation are avoided. Curiously, although peak
levels are lower, the area under the curve, which represents overall EE exposure, is larger. One patch is
applied weekly for three consecutive weeks, followed by a one patch-free week. The patch can be
placed on one of four sites: The buttocks, upper outer arm, lower abdomen, or upper torso, excluding
the breast [10].
The ring releases 15 mg of EE and 120 mg of the progestin etonogestrel (ENG) (the active metabolite
of desogestrel) per day, which is absorbed through the vaginal epithelium. Serum hormone levels
increase immediately after ring insertion and then decrease slowly over the cycle [10]. The vaginal
route is an ideal method of drug administration, and the advantages of this method are well established.
By avoiding gastrointestinal absorption and the hepatic first-pass effect, the vaginal administration
of contraceptives enables the use of lower hormonal doses and the achievement of steady drug
concentrations [34].
There is another group of hormonal contraceptives only composed of progesterone. This group
can include the progestin-only pill, depot medroxyprogesterone acetate (DMPA), and the etonogestrel
implant. Progestin-only pills (POPs, the “mini-pill”) provide reliable, reversible contraception and
have very few contraindications. The main mechanism of action is the alteration of the cervical mucus
(more viscid, less copious) and the inhibition of sperm penetration. Negative luteinizing hormone (LH)
feedback leads to the suppression of ovulation in up to 50% of users. POPs containing desogestrel may
inhibit ovulation more consistently [21].
DMPA is administered intramuscularly at three-month intervals (every 12–13 weeks) and is
thus considered a long-acting reversible contraceptive (LARC) by some and a short-acting reversible
contraceptive (SARC) by others. DMPA works primarily by inhibiting the secretion of pituitary
gonadotropins, thereby suppressing ovulation. Women enter a hypoestrogenic state, and their
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progesterone is low due to anovulation. DMPA also increases the viscosity of cervical mucus (minor
mechanism of action) and induces endometrial atrophy [21].
The single-rod etonogestrel subdermal implant (Implanon/Implanon NXT/Nexplanon) is a LARC.
The single-rod implant contains 68 mg of the progestin etonogestrel (ENG) and provides contraception
for three years. The ENG implant works primarily by inhibiting ovulation and consistently does so
until the beginning of the third year of use. Ovarian activity, including estradiol synthesis, is still
present. The ENG implant causes a thickening of the cervical mucus and changes in the endometrial
lining [21].
The last group is formed by intrauterine contraceptives (IUCs). This group includes copper
intrauterine devices (Cu-IUDs) and levonorgestrel-releasing intrauterine systems (LNG-IUS). Only
LNG-IUS are explained in this section, because Cu-IUDs do not have a hormonal component. The chief
mechanism of action of all IUCs is the prevention of fertilization; they may also have post-fertilization
effects, including the potential inhibition of implantation. The LNG-IUS produce a weak foreign body
reaction and endometrial changes that include endometrial decidualization and glandular atrophy.
The primary mechanism of action is via changes in the amount and the viscosity of cervical mucus,
which acts as a barrier to sperm penetration. Ovulation is likely inhibited in some women, but it is
preserved in most study subjects. Endometrial estrogen and progesterone receptors are suppressed,
which results in changes in bleeding patterns and may contribute to its contraceptive effect [22].
3.1.4. Hormonal Alterations of Hormonal Contraceptives and Their Influence on Female
Sexual Function
In contrast to animal species in which linear relationships exist between hormonal status and
sexual behavior, sexuality in the human population is remarkably complex and is not determined so
simply by the level of sexual steroids [29].
Hormonal contraceptives (HCs) are responsible for a decrease of circulating androgen
levels [1,2,29,35], as well as a decrease of the baseline serum levels of estradiol [6,29,35] and
progesterone [35] and the inhibition of oxytocin functioning [35]. However, the concentrations
of the follicle-stimulating and luteinizing hormones are similar in freely cycling women and in women
using HCs [35]. Decreased circulating androgen levels with oral combined hormonal contraceptive
(CHC) use, and its negative effects on sexual life, occur by two mechanisms, as follows: (1) An oral CHC
increases sex hormone-binding globulin (SHBG) and decreases free testosterone, and (2) androgen
production from the ovary is suppressed with an oral CHC. This antiandrogenic effect may be magnified
with an oral CHC containing an antiandrogenic progestin [2]. Thus, all CHCs are antiandrogenic,
although some formulations, depending on the specific progestin, are more so than others. The patch
and the vaginal ring are more antiandrogenic than the pill [1]. As expected, the baseline serum levels
of estradiol and progesterone are significantly higher in freely cycling women than in women using an
HC. Nevertheless, the concentrations of the follicle-stimulating and luteinizing hormones are similar
in both groups [35]. In respect of oxytocin, its functioning is likely to be altered by this variation in the
peripheral estradiol and progesterone levels that were found to be altered in women using HCs, and,
therefore, a potential mechanism could be related to the direct binding of progesterone to oxytocin
receptors (OXTRs), thereby inhibiting OXTR functioning.
The association between hormones and sexuality is multidimensional, as several hormones are
important in the regulation of sexual behavior [29].
Though some evidence shows that testosterone has a role in sexual function for women, these
conclusions are derived primarily from studies involving postmenopausal women reporting sexual
dysfunction [2]. It has been established that sexual desire, autoeroticism, and sexual fantasies in
women depend on androgen levels [29]. However, the relevance of changes in androgen levels for an
individual woman is unclear, and some women may be more sensitive to androgen level alteration
than others [2]. The review by Casey et al. mentioned that most of the studies showed alterations
in SHBG and testosterone levels; however, an overall lack of association was found between CHCs
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and sexual desire [2]. In other studies, decreased levels of estrogen and testosterone in older women
have been associated with decreased libido, sensitivity, and erotic stimuli [29]. In addition, it has been
found that patients using birth control pills may present with decreased libido. On the other hand,
there are reports that suggest that progestogens with antiandrogenic effects in contraceptive pills do
not affect sexual desire [29]. While there is conflicting evidence concerning a link between progestins
and libido, there is some evidence to suggest that estrogens play an essential role in female sexuality.
In this respect, prior research has found that declining sexual functioning in women is most closely
related to declining estrogen levels [6].
Finally, with regard to oxytocin, Scheele et al. [35] describe in their work the possible functional
implications of oxytocin in female sexuality and the alterations that occur in women who take hormonal
contraceptives. Multiple lines of evidence suggest that the hypothalamic peptide oxytocin (OXT) is a
key factor modulating pair-bonding behaviors, which means a strong affinity that develops in humans
and some species between a mating couple.
In humans, peripheral OXT concentrations are significantly higher in new lovers compared with
singles. Likewise, OXT reduces jealousy ratings and neural responses in an imagery task of sexual
partner infidelity. OXT also increases the arousal induced by infant photos in nulliparous women
and promotes responsiveness to infant crying and laughter by reducing activation in anxiety-related
neural circuits. Moreover, OXT has been found to increase the intensity of orgasm and contentment
after copulation. Nevertheless, OXT seems to not have an effect on vital signs. The results of the
research by Scheele et al. [35] indicate that endogenous OXT concentrations at baseline positively
predicted striatal responses to the romantic partners’ faces in all female participants. This mechanism
was disturbed in those women using an HC, indicating that the partner-specific modulatory effects of
OXT are antagonized by gonadal steroids. HC use alters women’s pair-bonding behavior (evident in
decreased attractiveness ratings of masculine faces), reduced neural response to the expectation of
erotic stimuli (a preference shift towards olfactory cues of genetic similarity), and increased sexual
jealousy. Furthermore, women who use an HC while choosing partners are more likely to initiate an
eventual separation, and wives who discontinue HC use tend to be less satisfied with marriage if they
perceive their husband’s face to be less attractive. On the other hand, women prefer masculine faces
and exhibit higher levels of intersexual competition related to attractiveness at peak fertility in the
menstrual cycle; however, these cyclical shifts were found to be diminished in women using an HC.
In conclusion, OXT interacts with the brain reward system to reinforce partner value representations in
both sexes, a mechanism which may significantly contribute to stable pair-bonding in humans and
appears to be altered in women using an HC.
3.2. Sexual Dysfunction
To talk about the effects on sexual function, it is first convenient to define the concept of sexual
dysfunction, as well as the types of female sexual dysfunction that are currently described. In this
section, the methods used and validated to quantify the degree of sexual dysfunction are also briefly
discussed. In addition, an estimate of the prevalence of sexual dysfunction in the female population of
childbearing age is shown.
According to the DSM-5 (Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition),
sexual dysfunctions are a heterogeneous group of disorders that are typically characterized by a
clinically significant disturbance in a person’s ability to respond sexually or to experience sexual
pleasure [18,36]. On the contrary, we would define “sexual health” as a state of physical, emotional,
mental, and social well-being related to sexuality; it is not merely the absence of disease, dysfunction,
or infirmary. Sexual health requires a positive and respectful approach to sexuality and sexual
relationships, as well as the possibility of having pleasurable and safe sexual experiences, free of
coercion, discrimination, and violence [37].
Therefore, optimal sexual function transcends the simple absence of dysfunction [18]. In this
regard too, multiple studies have shown a strong positive association between sexual function and
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the health-related quality of life [18]. Having said that, it can be gathered that the female sexual
function is complex and multifactorial, and it is influenced by many biological, psychological, and
environmental factors [2,5,18,29]. Therefore, a complete understanding of women’s sexual function
requires the individual assessment of these factors. The biopsychosocial approach recognizes that
biological, psychological, interpersonal, and sociocultural factors can all affect female sexual function,
and these factors interact with each other in a dynamic system over time. Biological factors may
include hormonal changes that affect the libido or medical/anatomical problems that affect genital
sexual response. Psychological factors include mood symptoms, like depression or anxiety, or negative
behaviors such as critical self-monitoring during sexual activity. Some examples of interpersonal
factors include general satisfaction in the woman’s relationship with her partner, which is closely tied
to overall sexual satisfaction, as well as quality of communication in the relationship. Finally, some
sociocultural factors to consider include the woman’s attitudes about menopause and aging, as well as
religious, cultural, and other social values regarding sex [18].
When assessing alterations of sexual function possibly related to hormonal contraceptives, other
factors that may also affect it should be taken into account. For example, sex hormones (mainly low
levels of estradiol), physical and mental well-being, availability of a partner, feeling for her partner,
illness and its treatments, changes in social circumstances, and low socioeconomic status could have
an impact on women’s desire and sexual responsiveness [5,18]. Therefore, there are several factors
that can affect female sexual function which should be explored by health providers for an adequate
diagnostic and therapeutic approach to sexual dysfunction. However, there are studies that show in
their results that sexual health is not a widely explored area for health providers in general. Mercer et al.
showed that only 21% of women with persistent sexual problems discuss it with their healthcare
provider [18,38]. Furthermore, a recent survey in the USA reported that the majority of gynecologists
routinely ask patients about their sexual activities, but most other areas of patients’ sexuality, such as
sexual problems, including pleasure and satisfaction, are not routinely discussed [34,39].
Theoretical models of women’s sexual response can provide a framework for a better understanding
female sexual dysfunction. Three of these models are briefly explained here. First, according to
the Masters–Johnson model, sexual response progresses predictably and linearly from excitement
to plateau, orgasm, and resolution. The main focus of this model is on the physical response of the
genitals. Secondly, Helen Singer Kaplan noted that many individuals had problems with sexual desire,
denoting the importance of desire to sexual response. In the 1970s, she modified the Masters–Johnson
model to a three-phase model of desire, excitement, and orgasm. Thirdly, in 2000, Rosemary Basson
and colleagues proposed an alternative circular model of female sexual response. This model has
several distinguishing features. On the one hand, spontaneous desire (or “sexual drive”) on the part
of the woman is not always the starting point for sexual activity. On the other hand, this model
emphasizes that sexual stimuli often precede physical arousal and desire, and sexual arousal and desire
often co-occur. Finally, the Basson model acknowledges that both physical and emotional satisfaction
are important outcomes of engaging in sexual activity. This physical and emotional satisfaction can
lead to higher emotional intimacy, which, in turn, can lead to greater receptivity and seeking out of
sexual stimuli—hence, the circular model [18].
There has been debate regarding which model best reflects the experiences of women. In a study
of 133 women, most of whom were in their 40s and 50s, women who had Female Sexual Function
Index (FSFI) scores falling into the “dysfunctional” range and postmenopausal women were more
likely to endorse the Basson model [18,40].
With the concept of sexual dysfunction now developed, we may now discuss the types of
sexual dysfunction that are described. Four types of female sexual dysfunction are currently
recognized: (1) Female orgasmic disorder, (2) female sexual interest/arousal disorder, (3) genito-pelvic
pain/penetration disorder, and (4) substance/medication-induced sexual dysfunction. In order to
quantify sexual dysfunction in a fairly objective way, there are two commonly used instruments in
sexual function studies: The Female Sexual Function Index (FSFI) and the Female Sexual Distress
222
J. Clin. Med. 2019, 8, 908
Scale-Revised (FSDS-R) [18]. The Female Sexual Function Index (FSFI) is a 19 item scale with six
domains: Desire, arousal, lubrication, orgasm, pain, and satisfaction. In this scale, questions are graded
on a Likert scale, and domains are weighted and summed to give a total score ranging from 2–36, with
a cutoff of less than 26.55 suggesting sexual dysfunction. The FSFI has been validated in multiple
languages, across age groups, and for multiple sexual disorders [18,41].
Why is it important to read up on sexual dysfunction? Sexual problems are common, estimated
to affect 22–43% of women worldwide [18]. Overall, 27% of all reproductive-age US women (aged
18–44 years) report sexual dysfunction, with low sexual desire being the most common, and 10.8% of
these women also experience related distress [2]. The prevalence of sexual dysfunction peaks at midlife,
with 14% of women aged 45–64 reporting at least one sexual problem associated with significant
distress [18]. The proportion with a notable or severe problem in desire, arousal, activity, or satisfaction
ranges from 19–25% [5].
3.3. The Effects of Hormonal Contraceptives on Sexuality
This section presents different results found in the literature about the effects of hormonal
contraceptives (HCs) on female sexuality (including results that advocate for positive or negative
effects or the absence of sexual effects). It also discusses the peculiarities of the different types of HCs
on sexuality.
3.3.1. Hormonal Contraceptives Do Not Have Sexual Effects
Some studies have found no change in sexual function with some hormonal contraceptives
(HC) [2,3,6,10,42–46]. A recent systematic review of 36 studies involving more than 13,000 women
reported no significant changes in sexual desire with the use of oral combined hormonal contraception
(CHC) [43]. Another study [47] also reported high satisfaction rates with both LNG-IUS and copper
IUC but no difference in sexual function overall or within psychological domains. In another recent
study, no association was found between any LARC method and sexual satisfaction scores [48].
On the other hand, Reed et al. explored the relationship between oral contraceptive (OC) use and
the risk of developing vulvodynia [49]. Further analysis showed no association between vulvodynia
and previous OC use (HR 1.08, 95% CI 0.81–1.43, p = 0.60). In a study by Iliadou et al. [50], patients
reporting mixed urinary incontinence (MUI) were divided into three groups according to contraceptive
use. Of 196 women with MUI, 16 were currently using OC, and 178 reported no current use. Among
the 8493 controls, 6321 were not using OC, and 2056 were (p < 0.0001). A systematic review of the
literature found that sex drive is unaffected in most women taking OC, 3.5% of women taking OC
reported a decrease in sexual desire, 12.0% reported an increase, and most of them (84.6%) reported no
change [43]. However, the effects of other forms of hormonal contraception on sex drive have not been
studied as comprehensively as OC [1].
3.3.2. Hormonal Contraceptives Have Sexual Effects
Positive Effects
According to the studies reviewed, hormonal contraceptives have a series of non-contraceptive
effects which can influence and improve different areas of female sexual function. Some of these
non-contraceptive effects are: Relief of gynecologic pain [1]; improved appearance, self-confidence, and
self-esteem [2]; decrease of anxiety and discomfort [2]; loss of fear of having an unwanted pregnancy [6];
more stable levels of hormones throughout the cycle [51]; and less bleeding with the consequent lower
risk of anemia [51]. All these effects contribute to the well-being of women and, consequently, to a
possible improvement in the female sexual function. Similarly, hormonal contraceptives have described
positive effects on some areas of female sexuality. The most frequently affected areas are: Sexual desire,
orgasm number and intensity, satisfaction, and arousal. As mentioned, HCs may help to eliminate the
fear of pregnancy, presumably providing a more relaxed and enjoyable sexual experience [1]. Similarly,
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it is reasonable to consider that an improved appearance would promote self-confidence and increase
self-esteem, thereby having a positive effect on sexual function [2]. In a comparison between the vaginal
ring, an oral CHC containing a third-generation progestin, subdermal contraception, and no hormonal
contraception (control group), the three groups using an HC had increased positive indicators of sexual
function (sexual interest and fantasies, orgasm number and intensity, and satisfaction) and decreased
negative indicators (anxiety and discomfort). The same results were obtained in a comparison between
etonogestrel implant and no contraception [2,52]. LNG-IUS have also been positively associated with
sexual desire, arousal, orgasm, and overall sexual function compared with no contraception [2,53].
Furthermore, it may be advantageous for women to have more stable levels of hormones
throughout the cycle. Because of the monthly fluctuations in estrogens, progesterone and androgens
are associated with a range of symptoms, both genital (i.e., vaginal bleeding, heavy menstrual bleeding
(HMB), dysmenorrhea, and pelvic pain) and systemic (i.e., depression, fatigue, headache, irritable
bowel symptoms (IBS), asthma, and allergy), triggered by a local and systemic rise in inflammatory
molecules released by mast cells when estrogen levels drop [51].
Negative Effects
To begin with, diminished sexual pleasure experienced by some women who use hormonal
contraceptive methods may also be a barrier for their use [54], and this could imply an increase in the
woman’s vulnerability to unintended pregnancy [54]. Consequently, it is important to keep in mind
that hormonal contraceptives could have associated side effects that have an influence on female sexual
function. Some of these effects could be: Vaginal dryness [2,10,51], a decrease of lubrication [2,51], and
pelvic floor symptoms such as dyspareunia [3,51], urinary incontinence, vestibulodynia, and interstitial
cystitis [3]. COCs have been also associated with long- and short-term anatomical changes, such as
atrophic vulvovaginitis and a decrease of thickness of the labia minora and vaginal introitus area [1].
Negative effects on some areas of female sexuality have been described with HCs, such as: Decreased
sexual desire [2,6,10,54], frequency of intercourse [2,54], arousal [2,54], pleasure [2,54], orgasm [2,54],
sexual thoughts [54], interest, and enjoyment [6,54].
In contrast to the above section, Elaut et al. [46] and Li et al. [55] defend in their studies that desire
and coital frequency naturally increase around ovulation and premenstrually, and COC-associated
ovulation inhibition and cycle regulation may blunt this effect, with the corresponding negative impact
on libido [10]. Furthermore, longer durations of oral CHC use and younger ages at initiation have
been associated with a higher relative risk of vestibulodynia [2], with the resulting negative impact on
female sexual function.
3.3.3. Effects on Sexual Function According to the Type of Hormonal Contraceptive
Combined oral contraceptives are widely studied. Nevertheless, other hormonal contraception
methods have fewer studies about their influence on sexual function. In this section, the results
obtained from the studies reviewed for each type of hormonal contraceptive will be presented. Table 1
shows a summary of this information.
Contraceptive Patch
Concerning patch-related sexual effects, this could be considered the most innocuous CHC.
Gracia et al. [56] found that among recent COC users, slight increases in sexual function scores were
noted with patch use. However, they concluded that for both products, these changes are not likely to
be clinically significant [1,34]. Therefore, it would be advisable to expand the research in this regard.
Contraceptive Ring
With regard to ring-related sexual effects, there are mixed results. On the one hand, two studies
showed a decrease in sexual function with vaginal ring compared with COCs [56,57], and one study
showed similar results but compared with the patch [58]. However, an improvement in sexual function
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including sexual desire, fantasies, and satisfaction, accompanied by a reduction of sexual distress,
has been described with the vaginal ring [1,2,10,34]. In another study [34], compared with nonusers
of hormonal contraception, both vaginal ring and COC users reported significant improvements for
anxiousness, sexual pleasure, frequency and intensity of orgasm, satisfaction (all p < 0.001), sexual
interest, and complicity (p < 0.01). However, only women in the vaginal ring group reported a
significant increase in sexual fantasies (p < 0.001 versus nonusers), while ratings for sexual interest
and complicity were significantly higher in ring users versus COC users [34]. As suggested by the
researchers, these data indicate that both oral and vaginal contraception seem to improve to some
extent the sexual life of women and their partners, whereas the vaginal ring seems to exert a further
beneficial effect on the psychological aspects of sexual functioning [59].
Vaginal contraception offers many benefits, including high efficacy, good tolerability, ease of use,
once-a-month dosing, and a favorable pharmacokinetic profile, with the added benefits of positive
effects on the vaginal microbiome and on sexual parameters [34]. In addition, good cycle control and
less fluctuating serum hormonal levels could contribute to the high degree of users’ acceptability and
satisfaction. Most importantly, a discussion about the vaginal delivery of contraceptive hormones offers
the opportunity to stimulate an open dialogue about vaginal functions, thus ultimately contributing to
enhancing women’s sexual well-being and reproductive health [34]. Consequently, it could be a good
hormonal contraceptive option.
Depot Medroxyprogesterone Acetate (DMPA)
DMPA is a highly effective method of contraception. It has been used as a contraceptive agent
since 1967 by millions of women worldwide, particularly in less developed regions [21]. In respect
of DMPA-related sexual effects, there are mixed results. Despite decreased libido being a common
complaint among DMPA users and the fact that progestins have been observed to decrease interest in
sex [6], positive sexual effects are also described with this method [6,60]—some reviews even reveal
that DMPA is unlikely to be associated with sexual function in women [1,2,6]. However, further
research would be needed to support these claims.
Etonogestrel Implant
Etonogestrel implant-related sexual effects are described as negative effects. It has been associated
with a lack of interest in sex, a decreased libido, and a reduced sex drive. In addition, a decreased
libido has been observed as a significant cause for implant discontinuation [1,6].
Levonorgestrel-Releasing Intrauterine Systems (LNG-IUS)
Intrauterine contraceptives (IUCs) are long-acting reversible contraceptive (LARC) methods that
are used by over 150 million women worldwide. IUCs are highly effective methods of contraception
that can be used by women of all ages. Rates of IUC use vary throughout the world, from a maximum
of 41% in China to a minimum of 0.8% in sub-Saharan Africa [22]. They have generally been
associated with positive sexual effects. They have been reported to improve desire, sexual function,
and arousal [1,2,60]. Moreover, they seem to improve the health-related quality of life through the
improvement of dysmenorrhea and symptoms in patients with endometriosis and adenomyosis,
among other things [22].
3.3.4. Other Non-Hormonal Methods of Contraception and Their Effect on Sexual Function
Copper Intrauterine Devices (Cu-IUDs)
There has been no evidence to suggest that the copper IUD is associated with an altered libido [6].
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Vasectomy/Tubal Ligation
As a non-hormonal contraceptive method, the effect of sterilization on sexual function extends
beyond a simple hormonal effect into the psychological aspects of permanent pregnancy prevention,
whether positive (i.e., relief and comfort in the knowledge that sexual activity will not result in
pregnancy) or negative (i.e., regret that pregnancy is no longer possible) [2].
Nonuse of Contraception
Female sexual function is complex and multifactorial and is influenced by many biological,
psychological, and environmental factors [2,5,18,29]. Therefore, a complete understanding of women’s
sexual function requires the individual assessment of these factors. Consequently, sexual dysfunction
does not have to be associated with hormonal contraception. The use of no contraception was associated
with a higher rate of the FSD than the use of either CHCs or nonhormonal methods. Furthermore,
lower rates of sexual dysfunction were noted among women using either copper IUC (21%) or a
levonorgestrel intrauterine systems (LNG-IUS) (10%) than among women using no contraception
(35%). Among other reasons, diminished sexual function perceived to be related to contraception may
lead to the nonuse of effective contraception, and, conversely, the nonuse of contraception may in itself
be a factor in sexual dysfunction, perhaps owing to concerns about unintended pregnancy [2].
3.3.5. The Sexual Side Effects of Hormonal Contraceptives are not Well Studied
Existing evidence for an association between sexual dysfunction and contraception is inconsistent,
and additional research is needed [2]. Findings from studies comparing women using non hormonal
contraception with those using hormonal methods have shown mixed results [2]. The sexual side
effects of hormonal contraceptives are not well studied, particularly with regard to their impact on
libido [1]. Similarly, there is no clear information about the effect of HCs on pelvic symptoms and
sexual function, nor on how they affect a woman’s quality of life in relation to bowel and bladder
symptoms, regardless of period control and menstrual bleeding. Moreover, the association between
COC use and the presence of any type of urinary incontinence (UI) is unclear, and results suggest that
the effect of current COC use on dyspareunia per se is inconsistent [3].
Healthcare care providers must be aware that hormonal contraceptives can have negative effects
on female sexuality so they can counsel and care for their patients appropriately [1]. In order to
better evaluate any possible effect on mood or libido, practitioners should assess patients prior to
initiation of hormonal contraception to establish their baseline [60]. The lack of consistency in findings
highlights the complex and multifactorial nature of female sexual function and focuses on the need for
a comprehensive approach to management [2].
3.4. Management Strategies for Sexual Dysfunction Secondary to Hormonal Contraceptives
This section approaches the therapeutic possibilities for female sexual dysfunction described in
the literature. In addition, some keys are given for the management of sexual dysfunction secondary
to hormonal contraceptives (Figure 3).
First, when addressing a new sexual complaint, a thorough history using a biopsychosocial
approach should be undertaken (Table 3) [18], including an assessment of any current or past
psychiatric disorders; medication use and health problems; a history of emotional, physical, or sexual
abuse; beliefs and attitudes regarding sex, menopause, and aging; and body image concerns. Particular
attention should be paid to symptoms of depression, anxiety, and sleep problems, all of which are
common during the menopause transition. Providers should inquire about alcohol or drug use,
as substance use disorders are also associated with sexual dysfunction. Any health or sexual problems
affecting the woman’s sexual partner(s) should also be explored. Providers should inquire about
relationship discord or communication issues, and if present, recommend therapy with a certified
and specialized therapist [18]. A multidisciplinary approach to the management of female sexual
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dysfunction (FSD) is suggested, particularly when multiple contributing or complicating factors are
identified, and this may consist of consultations with other professionals, such as a sex therapist,
a pelvic floor physical therapist, and a sexual health specialist [2].
 
Figure 3. Management strategies for hormonal contraceptive (HC)-related sexual dysfunction.
Table 3. Main data to be collected in the clinical history in case of symptoms of sexual dysfunction.
Information that should be collected in the medical record by health providers in response to a
complaint of sexual dysfunction:
1. Current or past psychiatric disorders.
2. Medication use and health problems.
3. History of emotional, physical, or sexual abuse.
4. Beliefs and attitudes regarding sex, menopause, and aging.
5. Body image concerns.
6. Symptoms of depression, anxiety, and sleep problems.
7. Alcohol or drug use and substance use disorders.
8. Health or sexual problems affecting the woman’s sexual partner(s).
9. Relationship discord or communication issues.
Second, lifestyle counselling should be given by the health providers. General lifestyle counselling
that may be useful for all types of female sexual dysfunction include recommending setting aside
time for connecting with one’s partner, increasing the woman’s exposure to sexual stimuli such as
erotic literature or films, encouraging the maintenance of a healthy weight, ensuring adequate physical
activity and sleep, enhancing skills for coping with stress, and recommending books women can use
for self-education (Table 4) [18].
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Table 4. General lifestyle counselling.
1. Setting aside time to connect with one’s partner
2. Increasing the woman’s exposure to sexual stimuli: erotic literature or films
3. Encouraging maintenance of a healthy weight
4. Ensuring adequate physical activity and sleep
5. Enhancing skills to cope with stress
6. Recommending books women can use for self-education.
When choosing a new hormonal contraception method, health care providers (HCPs) should give
information about all available methods in order to make a shared decision [34]. In the Contraceptive
CHOICE Project, a prospective cohort study of 10,000 women 14–45 years who want to avoid pregnancy
for at least one year and are initiating a new form of reversible contraception, 47% of women who had
an interest in a CHC method selected a different method than the one they originally intended to use
after receiving counselling about several CHC methods, including the pill, patch, and ring. Awareness
of the decision-making factors that affect women’s choices regarding methods of contraception may
enable HCPs to make more informed recommendations that are targeted to the needs of each of their
female patients [4]. The prescription of a contraceptive method is a great opportunity to clarify the
multidimensional components of sexual health, including elements of anatomy and physiology of the
sexual response [34].
Few clinical remedies or recommendations exist for women experiencing HC-related sexual side
effects [54]. Unfortunately, no guidelines exist for the management of sexual dysfunction potentially
associated with CHCs in reproductive-age women [2]. As such, when CHC-related female sexual
dysfunction is suspected, the recommended therapy is discontinuation of a combined hormonal
contraceptive, with consideration of an alternative method of contraception, such as LNG-IUS, a copper
IUC, a etonogestrel implant, the permanent sterilization of either partner when future fertility is not
desired, or a contraceptive ring (for women who prefer a CHC for cycle control and no contraceptive
benefits) [2]. The ring appears to be a reasonable alternative to an oral CHC for women with sexual
function concerns. Likewise, LARC methods also appear to be a reasonable alternative [2]. Nevertheless,
switching to another combined oral contraceptive may provide some benefit, but there is no clear
difference between androgenic or non-androgenic progestins [10]. In addition, the combination of
dehydroepiandrosterone (DHEA) and an OC was not associated with improvements in sexual function,
and it further negated the benefit of OCs on acne [2]. When COC-related female sexual dysfunction
is suspected, another possible option could be to consider formulations with a shorter hormonal
free interval (HFI). Formulations with a shorter HFI (24/4 and 26/2) have recently been developed
with the aim of offering a reduction in hormone withdrawal-associated symptoms together with a
more powerful ovarian suppression. Estradiol valerate/dienogest (E2V/DNG) is administered on a
26/2 regimen and has been shown to offer a high contraceptive efficacy, an improvement in hormone
withdrawal-associated symptoms (including but not limited to headache and pelvic pain), and an
improvement in sexual function [51,61]. In conclusion, the best contraceptive is one that fulfills
women’s needs with acceptable side effects and at an affordable price in different settings [32].
Other options to improve HC-related sexual dysfunction could be vaginal lubricants and
moisturizers. They are the first-line treatment for vaginal dryness and consequent dyspareunia [2],
side effects that are frequently associated with hormonal contraceptives, mainly with combined oral
contraceptives. The majority of women participating in a daily study reported positive perceptions
of lubricant use, including increased pleasure and comfort [62]. Sharing information on the high
frequency of use and positive results experienced across age-groups may be helpful in counseling
reproductive-age women about using lubricants [62].
Furthermore, concerning other possible strategies against sexual dysfunction, some studies
show positive results on female sexual function with exogenous testosterone [2,18,29], exogenous
estrogens [2,6], dehydroepiandrosterone (DHEA) [10,29], tibolone [29], bupropion, and sildenafil [18].
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It appears that supraphysiological serum testosterone levels may be necessary to yield any benefit
on sexual desire and arousal [18]. The use of compounded testosterone products for transdermal
use is on the rise, but these products are not FDA-approved [18], and they can be associated with
several side effects. Meanwhile, testosterone therapy in postmenopausal women has been associated
with improvements in multiple dimensions of sexual function, including sexual desire, subjective
arousal, vaginal blood flow, and frequency of orgasm [2]. Testosterone released from patches has also
been described to produce positive effects on mood and sexual behavior and to increase bone mass
significantly [63].
With regard to hormonal therapy with exogenous estrogens, results are controversial. On the
one hand, exogenous estrogens have been shown to be an effective treatment for low libido and
hypoactive sexual desire disorder [6], and, on the other hand, hormone therapy (estrogen with or
without progesterone) does not appear to have a significant impact on sexual function, with the
exception of vaginal estrogen in women with the genitourinary syndrome of menopause [18]; that is to
say, hormonal therapy with estrogen is efficient with regard to genital atrophy, but it is not efficient in
regard to sexual desire [29].
Furthermore, although dehydroepiandrosterone (DHEA) supplementation could have positive
effects on the female libido [29] by restoring androgen levels in COC users, there is minimal evidence
that this correlates with improved sexual functioning [10]. There is also evidence that bupropion and,
to a lesser extent, sildenafil, are effective for treating antidepressant-induced sexual dysfunction in
women, although some conflicting evidence exists [18].
To conclude, even today, most of the contraceptives available on the market and those currently
undergoing research and development interfere with ovulation or follicular development and also
affect women’s steroid production [32]. This mechanism of action is associated with several side effects,
negative sexual effects included, that could be avoided by new contraceptives strategies. For that
purpose, research conducted over the past few decades has provided more information on gamete
physiology and interaction, offering new opportunities for the development of novel contraceptives
that could act by interfering with the process of gamete interaction or with the chemo-attraction or
chemo-repulsion of spermatozoa to the fertilization site without affecting the hormonal system [32].
4. Discussion
As discussed in the review above, hormonal contraception (HC) has made a difference in the
control of female fertility since its approval by the FDA almost 60 years ago, and it is also widely used
in the female population of child bearing age. Side effects, such as sexual dysfunction, may be sufficient
reasons for the discontinuation of this contraceptive method. This represents an increase of the risk of
unwanted pregnancy, with the possible worsening of women’s wellbeing. However, female sexual
function is complex and multifactorial and, despite an association between hormonal contraception
and sexual dysfunction having been described in the past, the evidence on that topic is inconsistent.
Sexual problems are common, estimated to affect 22–43% of women worldwide [18], and
influencing some types of female sexual dysfunction such as orgasm, sexual interest/arousal,
and genito-pelvic pain. As a consequence of the multiple medications on sexual functioning,
a specific category has been included in the new American DSM-5 classification system: Substance/
medication-induced sexual dysfunction) [18]. As said above, female sexual function is complex and
multifactorial, and a biopsychosocial approach to sexual problems is recommended. It could be said
that an HC can influence female sexual function in two different ways. On the one hand, an HC
could have a negative influence on sexual function as a biologic factor, because HC use has been
associated to hormonal changes. On the other hand, an HC could have a positive influence on sexual
function, in psychological terms, since HC use has been associated with an improvement in mood
symptoms and self-perception. Different options for hormonal contraception exist. There are three main
groups: Combined hormonal contraception (pill, patch and vaginal ring); progestin-only contraceptives
(POPs, DMPA, and implant); and intrauterine devices (LNG-IUDs). The hormonal composition of
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hormonal contraceptives is based on progestins alone or on a combination of progestogens and
estrogens. Apparently, norgestimate and desogestrel, among progestogens, and 17B-estradiol (E2) and
E2-valerate (E2V), among estrogens, have a profile less associated with side effects than the others in
their respective groups.
The association between hormones and sexuality is multidimensional, as several hormones
are important in the regulation of sexual behavior [29]. Hormonal contraceptives (HCs) seem to
be responsible for a decrease of circulating androgen levels [1,2,29,35], baseline serum levels of
estradiol [6,29,35], and baseline serum levels of progesterone [35], as well as the inhibition of oxytocin
functioning [35]. However, the concentrations of the FSH and LH were similar in freely cycling women
and in women using an HC [35]. These hormonal alterations can be translated into negative effects
on the female sexual function, with reports of a decrease of the libido, increased sexual jealousy, and
alterations on women pair-bonding behavior. It has been established that sexual desire, autoeroticism,
and sexual fantasies of women depend on androgen levels [29]. However, the relevance of changes
in androgen levels for an individual woman is unclear, and some women may be more sensitive
to androgen level alteration than others [2]. Furthermore, while there is conflicting information
concerning a link between progestins and libido, there is some evidence to suggest that estrogens play
an essential role in female sexuality [6]. On the other hand, multiple lines of evidence suggest that the
hypothalamic peptide oxytocin (OXT) is a key factor modulating pair-bonding behaviors, and it has
been found to increase the intensity of orgasm and satisfaction after copulation. This mechanism was
disturbed in those women using an HC, indicating that the partner-specific modulatory effects of OXT
are antagonized by gonadal steroids. So, it could be said that HC use alters women’s pair-bonding
behavior, reduces neural response to the expectation of erotic stimuli, and increases sexual jealousy.
Despite an association between hormonal contraception and sexual function having been described,
there are contradictory results between different studies in this respect. Some studies have found no
change in sexual function with hormonal contraceptives (HCs) [2,3,6,10,42–46].
According to the studies reviewed, hormonal contraceptives have a series of non-contraceptive
effects, which can be related to an improvement on different areas of female sexual function such as
sexual desire, orgasm number and intensity, satisfaction, and arousal. All these effects contribute to the
well-being of women and, consequently, to a possible improvement in the female sexual function.
By contrast, HCs could be associated with side effects that have an influence on female sexual
function. Negative effects on some areas of female sexuality have been described with hormonal
contraceptives, such as sexual desire [2,6,10,54], frequency of intercourse [2,54], arousal [2,54],
pleasure [2,54], orgasm [2,54], sexual thoughts [54], interest, and enjoyment [6,54].
Combined oral contraceptives are widely studied, and most studies are based on COCs or used
them as a comparative method of contraception. Nevertheless, other hormonal contraception methods
have fewer studies about their influence on sexual function. There are mixed results with ring- and
DMPA-related sexual side effects. The patch could be considered the most innocuous CHC regarding
sexual side effects. The implant has been associated with negative sexual effects, such as a lack of
interest in sex, a decreased libido, and a reduced sex drive. LNG-IUS have generally been associated
with positive sexual effects, so it could be considered the most innocuous HC regarding sexual side
effects. However, more studies are needed because of the inconsistency of current available data.
Finally, with regard to treatment options for sexual dysfunction, few clinical remedies or
recommendations exist for women experiencing these sexual side effects [54]. Moreover, no clear
guidelines exist for the management of sexual dysfunction potentially associated with CHCs in
reproductive-age women [2]. First, when addressing a new sexual complaint, a thorough history
using a biopsychosocial approach should be undertaken [18]. A multidisciplinary approach to the
management of female sexual dysfunction (FSD) is suggested, particularly when multiple contributing
or complicating factors are identified, and this may consist of consultations with other professionals,
such as a sex therapist, a pelvic floor physical therapist, and a sexual health specialist [2]. Second,
lifestyle counselling should be given by the health providers (Figure 3) [18]. When choosing a
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new hormonal contraception method, health care providers (HCPs) should give information about
all available methods in order to make a shared decision [34]. When CHC-related female sexual
dysfunction is suspected, the recommended therapy is the discontinuation of combined hormonal
contraceptives with consideration of an alternative method of contraception, such as LNG-IUS, a copper
IUC, an etonogestrel implant, the permanent sterilization of either partner when future fertility is not
desired, or a contraceptive ring (for women who prefer CHCs for cycle control and non-contraceptive
benefits) [2]. The ring appears to be a reasonable alternative to oral CHCs for women with sexual
function concerns. Likewise, LARC methods appear to be a reasonable alternative too [2]. Other
alternatives could be switching to another combined oral contraceptive [10] or formulations with a
shorter hormonal free interval (HFI) [51,61]. Furthermore, with regard to other possible strategies
against sexual dysfunction, some studies show positive results on female sexual function with
exogenous testosterone [2,18,29], exogenous estrogens [2,6], dehydroepiandrosterone (DHEA) [10,29],
tibolone [29], bupropion, and sildenafil [18]. Some alternative options to improve HC-related sexual
dysfunction could be vaginal lubricants and moisturizers.
5. Conclusions
The results of the studies reviewed seem to indicate that hormonal contraception could influence
different aspects of female sexual function. However, there are contradictory results between the
different studies regarding the association between sexual dysfunction and hormonal contraceptives,
so it could be firmly said that additional research is needed.
Meanwhile, it could be said that hormonal contraception has been associated with different
alterations in sexual functioning. So, when addressing a new sexual complaint that is time-related
with the beginning of hormonal contraception, health care providers should give information about
other methods and try to switch them to a method less associated with sexual dysfunction. Vaginal
rings and patches are possible options in case of women preferring combined hormonal contraception
who report side effects with the pill.
To conclude, a multidisciplinary approach to the management of female sexual dysfunction is
mandatory, and health care providers should give lifestyle counselling apart from proposing different
treatment options. An adequate relationship with the patient, as well as the routine monitoring
of possible sexual dysfunction, are essential in addressing these difficulties. Undoubtedly, the best
contraceptive is one that fulfills the women’s needs with acceptable side effects and agreed with
the prescriber.
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Abstract: This article provides a short literature overview on female child sexual offenders (FCSO)
focusing on the discrepancy between prevalence rates from different sources, characteristics of FCSO
and their victims, as well as the societal “culture of denial” surrounding these women. FCSO are
a powerful social taboo. Even professionals in the healthcare or justice system were shown to respond
inappropriately in cases of child sexual abuse committed by women. As a result, offences of FCSO
may be underreported and therefore difficult to research. The lack of scientific data on FSCO lowers
the quality of child protection and treatment services. We therefore deem it particularly necessary for
professionals in health care to break the social taboo that is FCSO and to further stimulate research on
the topic of FCSO. We provide some general implications for professionals in health care systems as
well as specific recommendations for researchers. We end with an overall conclusion.




Stereotypically, child sexual abuse implies the image of a male perpetrator sexually abusing
a female child. However, due to an expanding research field since the 1980s [1], it is well established
scientific knowledge today, that part of all child sexual offences are committed by women [2–6].
Although research data on female child sexual offenders (abbreviated female child sexual
offenders (FCSO) in the following References [1,2,5,7–14]) is available and can be used for reviews and
meta-analyses, there is still a noticeable gap of information on what is known about FCSO as opposed
to male child sexual offenders [15]. Additionally, most of what is known resulted from studies with
only small clinical samples of female offenders registered by the criminal system [16]. Consequently,
the assessment and treatment of FCSO is insufficient [2].
Irrespective of the perpetrator’s gender, child sexual abuse is an underreported crime [17]. One
reason for the low level of knowledge about FCSO could be that FCSO are rarely registered in official
statistics and are therefore difficult to reach for clinicians and researchers. One possible explanation
for this phenomenon is that child sexual abuse committed by women seems to be a powerful social
taboo [18]. Therefore, there is a marked resistance against the disclosure of FCSO [19] even among
professionals in the health care and justice system [20]. In order to encourage the disclosure of FCSO,
enhance the thematic research, and improve the quality of child protection and prevention, we deem it
particularly necessary for clinicians and researchers in the field of sexual health to overcome this taboo.
J. Clin. Med. 2019, 8, 401; doi:10.3390/jcm8030401 www.mdpi.com/journal/jcm235
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1.2. Aim
This article is not a systematic review but is intended to provide a short narrative literature
overview on the discrepancy between prevalence rates based on different sources (official reports vs.
victimization surveys) and on the adult FCSO’s characteristics (e.g., average age, socioeconomic status,
mental health issues, victims). Secondly, we focus on FCSO as a social taboo that even percolates
the health care and justice system. In order to overcome this social taboo, we provide some general
implications for professionals in health care systems. In order to foster research activities on FCSO,
we give specific recommendations for researchers in the field of sexual medicine.
2. Method
We explored the current literature on FCSO and mainly included reviews and studies on FCSO
from 2000–2019 examining large and/or representative samples. We focused on data from countries
sharing similar cultural and societal backgrounds. We included some additional studies that were
published before the year 2000, but had an important impact on this research field and are still
frequently cited. We excluded articles in which only juvenile FCSO or general female sexual offenders
(with adult victims) were analyzed. Search terms included “female”, “woman”, or “mother” with
“sexual child abuse”, “child sexual offending”, or “incest” as well as “social taboo” or “gender
stereotypes”. Searches were performed in PsychInfo, PubMed, KrimDok, and socINDEX. When
necessary, additional references were used (e.g., Google).
3. Female Sexual Child Offenders
3.1. Prevalence of Female Child Sexual Offenders
Due to different methodologies and samples, prevalence reports of sexual child abuse committed
by women vary within the literature. There are two main sources of information for estimating the
prevalence of FCSO: Firstly, official reports (i.e., from police or court offices); secondly, victim reports.
An overview of the results of different studies and reviews is shown in Tables 1 and 2.
Table 1. Prevalence rates (PR) for female child sexual offenders (FCSO) based on official reports.
Reference Country Year Source of Information Sample Size (Offenders)
PR for FCSO
(%)
[21] Australia 2005 Incidents reported in officialstatistics 1,294,000 1.7
a




reported to law enforcement)
8539 (victims younger age 6) 12
12,260 (victims aged 6–12) 6
20,005 (victims aged 12–17) 3
[24] Germany 2007–2014 Convictions reported inofficial crime statistics 14,069 1.4
[24] Germany 2016
Inmates remanded in
custody reported in official
crime statistics
402 1.7
Studies included all met the definition of child sexual abuse as experiencing vaginal/anal penetration or attempted
penetration with fingers, penis, objects and/or oral sex, attempted oral sex, unwanted sexual touching or fondling
or any other kind of sexual interaction before the age of 17. a Only includes female relatives, no female strangers.
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Table 2. Prevalence rates (PR) for female child sexual offenders (FCSO) based on victimization surveys.
Reference Country Year Source of Information Sample Size (Victims) PR for FCSO (%)
[25] USA 1996 National Incidence Study by the National Center onChild Abuse and Neglect (NCCAN) 300,200 12
[26] USA 2009/10 Child protective system reports from the NationalChild Abuse and Neglect Data System (NCANDS) 66,765 20
[27] UK 2008/09 Analyses of call records from ChildLine (free hotlinefor children in need) 12,268 17
[28] UK 2005/06 Analyses of call records from ChildLine 6763 a
44 b (male victims)
5 (female victims)
[29] USA 1995–1997
Cohort study among adult members of the Kaiser
Permanent’s Health Appraisal Centre in San Diego
1276 (male victims) 20.8
2310 (female victims) 2.1
[30] UK 2007/08 Analyses of call records from ChildLine 1803 (male victims) 26c
[15] Ireland 2001
Retrospective data on adult accounts of childhood
abuse from SAVI (population-based interview survey)
270 (male victims) 14.8
407 (female victims) 1.7
[31] Germany 2011
Retrospective data from a population-based survey on
child sexual abuse among 16–40 year olds
83 (male victims) 15.3
404 (female victims) 1.5
Studies included all met the definition of child sexual abuse as experiencing vaginal/anal penetration or attempted
penetration with fingers, penis, objects and/or oral sex, attempted oral sex, unwanted sexually touching or foundling
or any other. a To our knowledge, the data on ChildLine cited by Roberts [28] have not been published entirely
elsewhere. Due to this, it was not possible to specify the sample size by gender. b PR specified by gender indicates
the proportion of female perpetrators within gender groups. For instance, a PR of 44 for male victims indicates that
44% of all male victims reported a female perpetrator. c Only includes female relatives, no female strangers.
The comparison of prevalence rates based on official reports (Table 1) and those based on
victimization surveys (Table 2) clearly demonstrate a great gap. Sexual offences against children
committed by women appear to be underreported and not prosecuted adequately. Table 2 only
includes studies with large sample sizes and/or those examined representative samples published
from 2000 and onwards. Taking into account earlier studies on smaller and/or clinical samples,
even higher prevalence rates for FCSO with male victims are reported. For instance, Fromuth and
Buckhart [32] investigated male students from a midwestern (n = 253) and a southwestern (n = 329)
American university. Thirty-eight males from the midwestern university reported that they were
sexually abused as a child and 78% furthermore specified a female perpetrator. Forty-three males from
the southwestern university had been sexually abused as children, of whom 78% reported a female
perpetrator [32].
3.2. Characteristics of Female Child Sexual Offenders and Their Victims
Research so far indicates that FCSO are a rather heterogeneous population with different
features [5,33–35]. However, some common characteristics of FCSO and their victims were found.
The average age of FCSO seems to range from 26–36 [5]. For instance, Faller [3,36] reported on
a sample of 40 FCSO with a mean age of 26.1 years [36] and on another sample of 72 FCSO with a mean
age of 28 years [3]; and Nathan and Ward [37] reported on 12 FCSO with a mean age of 30 years. The
majority of FCSO in empirical research showed a rather low socioeconomic status [5,12,38] with little
vocational qualifications [12,39,40]. According to Berner, Briken, and Hill [41], more than 50% of FCSO
had experienced sexual and/or physical abuse themselves [41]. Indeed, many studies demonstrated
FCSO as being mentally, sexually, and/or physically abused during childhood [12,38,42–45]. They often
show mental health problems, particularly substance abuse [45], personality disorders (passive and/or
dependent) with rather low self-esteem [46], and are frequently involved in abusive relationships
during adulthood [38,47] or have an absence of intimate relationships [45]. FCSO further appear to be
impulsive with low levels of emotional self-regulation [48].
Typically, FSCOs find their victims in their closer social circle [3,16,35,42,49,50]. Often they
are their victims’ caregivers, i.e., mothers, other relatives, or babysitters [3,16,38]. The prevalence
rates shown in Table 2 indicate that FCSO appear to sexual abuse male victims more often than
female victims. However, research results so far are not sufficiently reliably to predict who may be
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at higher risk to be abused by an adult woman: boys or girls [5]. Victims’ age ranges from infants to
adolescents [51,52].
3.3. Perception and Handling of Female Child Sexual Offenders
The discrepancy between official reports and victimization surveys on the prevalence of FCSO
clearly demonstrates the under-recognition of women who behave in a sexually abusive manner.
Official statistics only reflect those women who have had contact with the criminal justice or social
service system. This indicates that reporting FCSO to the police or child welfare agencies seems to be
a great obstacle. In fact, from the very beginning of scientific confrontation with FCSO in the 1930 [53],
women who sexually abuse children have been a powerful social taboo [18]. Women are usually
portrayed as victims and as being passive, innocent, and sexually submissive. Moreover, they are
primarily normalized as the gatekeepers of sexuality [18]. In terms of anatomy, some have argued
that women are receivers of sexuality which might make it difficult to imagine a woman as someone
who sexually abuses others [54]. Instead, women are frequently seen as nurturers and protectors in
positions of trust. They are thought of as mothers and those who provide care for others. Women who
sexually abuse children undermine such normative labels and challenge traditional gender stereotypes
that are firmly established in society [18].
3.3.1. Society
The way in which members of a society perceive and respond to certain events is significantly
shaped by medial reports [55]. Research so far has shown that media’s representation of sexual
offenders is biased [56]. In an analysis of 29 newspaper articles published in Australian dailies,
Landor and Eisenchlas [56] showed that male sexual offenders are strongly criticized in media reports,
whereas female sexual offenders are usually described in a more sympathetic way. Furthermore, the
articles on FCSO usually contain excuses to justify or lessen the seriousness of the women’s abusive
behavior [56]. Hayes and Baker [18] also analyzed the way in which the media reports on women
who sexually abused children. The authors theorized that media reports tend to reinforce traditional
gender stereotypes and therefore suppress the development of a public awareness of sexual offences
committed by women. Examining 487 media reports from Australia and the United Kingdom, they
found that the media mainly presents FCSO as aberrations and pariahs (in terms of outcasts), and thus
do not contribute to an atmosphere supporting the safe and timely reporting of offences by victims [18].
Mackelprang and Becker [57] demonstrated that this unequal perception of men and women
who sexually offend against children is in fact reflected in societal judgements. The authors asked
432 undergraduate students to judge teacher sexual offence vignettes (e.g., amount of time the offender
should be incarcerated) that varied by offender’s gender and attractiveness. For all outcome measures
reflecting punitive judgements and attitudes towards the offender, female teachers who had had
a sexual relationship with a student were evaluated more leniently and judged less punitively than
male teachers who did the same. In addition, there has been an even greater tolerance for FCSO when
they were described as attractive instead of unattractive. This effect was not observed for the vignettes
on male child sexual offenders [57].
3.3.2. Professionals
Professionals in healthcare, criminal justice, and child protection systems were also shown to
respond inappropriately in cases of child sexual abuse committed by women [58–62]. For instance,
children’s disclosure was brushed aside as fantasies [63] or abusive women gained further access to
potential victims [64]. In 2010, Mellor and Deering [20] examined professional responses and attitudes
toward FCSO. A total of 231 Australian psychiatrists, psychologists, probationary psychologists, and
child protection workers were presented with a variation of vignettes describing women and men
who had sexually offended against children. Afterwards they completed a questionnaire on their
attitudes to women’s offending behavior toward children. Compared to male-perpetrated child sexual
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abuse, female-perpetrated child sexual abuse was more likely to be rated leniently. This “indicates
that a level of professional minimization towards female-perpetrated child sexual abuse exists” [20]
(p. 433). Psychotherapists who treat young patients experiencing mother-incest-abuse initially often
struggle with the idea of reporting these cases [65]. As Haliburn concluded, the frequency of mental
health patients reporting histories of child sexual abuse does not surprise clinicians anymore. However,
when the perpetrator is a woman, clinicians’ reaction often is “shock and disbelief and a tendency to
be dismissive” [65] (p. 423).
3.3.3. Victims and Offenders
As a consequence of FCSO being a social taboo, their victims often have difficulties in recognizing
their experiences as sexually abusive [66] and feel intensly confused [67]. It is not unusual that FCSO
disguise their abusive behavior as part of childlare activities [67]. This might in part be the reason
why in fact even the offenders themselves have difficulties in recognizing their behavior as sexually
abusive [68]. FCSO’ victims are faced with serious issues regarding the disclosure of their abuse [69],
thus hesitating more often to disclose the abuse than victims of male offenders [70]. It is particularly
worth mentioning that victims of FCSO in early treatment stages even appear to lie to their therapists
about their abuser’s sex, claiming that they were perpetrated by a man [71]. These difficulties might
be even worse when the female perpetrator is the own mother [72]. Usually shrouded in secrecy,
Haliburn [65] called mother–child incest a “double betrayal”, since both, the violation of trust as well
as the exploitation of the child’s affection and dependency needs to take place. Individuals who were
sexually abused by their own mother were described as feeling additional shame and stigma [73].
4. Implications
Based on the outlined research, we propose some general implications for professionals in health
care followed by more specific recommendations for researchers in the field of sexual health. As there
are many possible clinical and research implications, we do not make any claim to comprehensiveness.
4.1. General Implications
Offences of FCSO are underreported and therefore FCSO are difficult to study. The resulting
knowledge gap about FSCOs reduces the quality of child protection and treatment services.
We therefore deem it particularly necessary for health care professionals to overcome the social
taboo that is FCSO.
As mentioned, there seems to be a marked resistance in the general public and the health care
system to detect FCSO [19]. Historically, the same kind of resistance was documented for the acceptance
and awareness of men who sexually abuse children [74]. Thus, in accordance with Mellor and
Deering [20], we state that the overall awareness and appropriate attitude towards FCSO have to be
improved in health care, criminal justice, and child protection systems. Since a structured training
as proposed by Mellor and Deering [20] may strain the organizational capacities of most institutions,
we recommend an increased engagement of the issues concerning FCSO in internal conferences and
discussions. This may lead to a more open discussion of FCSO among colleagues and therefore to
a stronger representation of the issue in the professional’s mind. Consequently, this should help to
uncover the abusive behavior for both victims and offenders.
As media portrayals of FCSO and their victims are generally inadequate [18], instructions for
journalists concerning the appropriate attitude towards FCSO are also deemed necessary.
The tendency to deny and minimize, leads to FCSO being a hidden phenomenon, undeniably
difficult to uncover (cf. References [18,75–80]). We therefore advise professionals in both clinical
practice and scientific research to consciously challenge and control their own underlying mechanisms
of denial when confronted with cases of FCSO.
Since it is assumed that victims of FCSO and even FCSO themselves have difficulties to recognize
the women’s behavior as sexually abusive [18], we deem an active approach towards FCSO in order
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to meet their needs is most appropriate. Therefore, we propose education and information within
health care, justice, and other systems. For instance, wherever undetected FCSO and/or their victims
might occur (e.g., pediatrician practices, youth welfare offices, kindergarten, schools, counselling for
victims of sexual offending, women’s house), an educational brochure could be distributed to adults.
It might briefly and simply inform the reader about the fact that women are also capable of sexually
abusing children including contact details for both FCSO and victims. By this, a network including
members of different professions within health care, justice, and other systems might be built so that
regular communication and information between different systems regarding the issues of FCSO can
be established.
Furthermore, we find it important that FCSO are also recognized by the general public, making
public outreach necessary. Where great campaigns and activities for public outreach are difficult to
implement, we suggest rather simple ways to contribute to public awareness of FCSO. Media reports
can be considered to have an impact on social discourses [81] and to play a crucial role in the way society
perceives and responds to women who sexually abuse children and therefore undermine traditional
gender stereotypes [55]. Professionals in the health care system are sometimes being consulted as
experts for child sexual abuse, child sexual offenders, or any other related topic for newspaper articles
or television reports. In these situations, we believe in the professional’s responsibility to address child
sexual abuse by women as an existing problem which can be just as harmful for the victims as child
sexual abuse by men can be. In time, the topic may affect and receive more attention in broader circles
of the general public and be discussed beyond the professional fields.
4.2. Implications for Researchers
FCSO are usually only investigated when they are registered in the judicial system (i.e., when they
were reported to the police by victims or others). As described earlier, women who sexually offended
against children remain undetected very often due to several reasons [70]. We therefore encourage
researchers to attempt additional and more active approaches to recruit FCSO for their examinations.
For instance, as research results indicate that FCSO are young women between mid-twenties and
mid-thirties, online surveys may be an appropriate tool to investigate this population. Online surveys
are a highly economic way to reach out for participants who are inhibited due to several barriers such
as women who sexually abuse children and furthermore provide a high level of identity protection.
Both of which should be helpful when trying to recruit FCSO. Additionally, online surveys are highly
suitable to reach women who are at risk to sexually abuse children but did not yet offend against
a child. Besides, researchers already investigated female sexual offenders on the internet concluding
that they use the internet to connect with like-minded women [82,83].
When creating the survey, we recommend simple language due to the relatively low socioeconomic
status of FCSO [5]. As many FCSO reported on being abused in their childhood [41] and having mental
health problems, such as depression [84] and alcohol abuse [45], researchers are advised to distribute
their study link in internet forums and self-help groups on the internet for victims of child abuse,
depressive patients and alcohol abusers.
Additionally, we suggest that researchers should not only include FCSO in their online surveys
but also those women who are solely at risk to offend against children and did not yet offend against
children. Differentiation between women who have a sexual interest in children can be made, e.g.,
those who have a pedophilic interest as motive vs. those who have other motives for offending against
children or those who are willing to be in treatment vs. those who do not want to be in treatment.
These differentiations may lead to different subgroups with varying characteristics implying different
research questions and assumptions. This would be in alignment with research on men who are
sexually interested in children [85–87].
Finally, if the conditions regarding institutional capacity and financial management are met,
qualitative interviews with FCSO or those women who are at risk to sexually offend against children
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would be valuable to ascertain more details of FCSO’ characteristics, their offence behavior, and their
specific underlying mechanisms of denial and minimization.
5. Conclusions
General public and professionals both reinforce and maintain traditional gender stereotypes
which appear to be barriers to the detection of FCSO [80]. The “culture of denial” surrounding women
who are sexually offensive [67] conceals their acts as “silent crimes” [88]. It is likely that the diverting
prevalence rates based on different sources (official reports vs. victimization surveys) are related to
this biased perception and inappropriate handling of FCSO. As a result, FCSO are underreported and
difficult to study which leads to insufficient scientific knowledge. The lack of research data on FSCOs
lowers the quality of child protection and treatment services. The fact that even professionals in the
judicial and health system appear to be part of this collective repression clearly demonstrates that
there is a particular responsibility for researchers and clinicians in the field of sexual health to be aware
of their own underlying mechanisms and inner processes of denial. It is important to pursue an active
approach towards FCSO. Overcoming the social taboo of FCSO is obligatory, especially in the light
of the harsh consequences for victims of FCSO [89]. Moving beyond traditional gender stereotypes
seems to be necessary to get over the confusion that women considered so far as caregivers, guardians,
and defenders (cf. Reference [90]) are able to be just as sexually abusive to children as men.
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Abstract: Human sexual behavior is mediated by a complex interplay of cerebral and spinal
centers, as well as hormonal, peripheral, and autonomic functions. Neuroimaging studies identified
central neural signatures of human sexual responses comprising neural emotional, motivational,
autonomic, and cognitive components. However, empirical evidence regarding the neuromodulation
of these neural signatures of human sexual responses was scarce for decades. Pharmacological
functional magnetic resonance imaging (fMRI) provides a valuable tool to examine the interaction
between neuromodulator systems and functional network anatomy relevant for human sexual
behavior. In addition, this approach enables the examination of potential neural mechanisms
regarding treatment-related sexual dysfunction under psychopharmacological agents. In this
article, we introduce common neurobiological concepts regarding cerebral sexual responses based
on neuroimaging findings and we discuss challenges and findings regarding investigating the
neuromodulation of neural sexual stimulus processing. In particular, we summarize findings from
our research program investigating how neural correlates of sexual stimulus processing are modulated
by serotonergic, dopaminergic, and noradrenergic antidepressant medication in healthy males.
Keywords: erotic stimulus processing; serotonin; noradrenaline; dopamine; fMRI; healthy; human
1. Introduction
Human sexual behavior is mediated by the integration of endocrine, vascular, peripheral, and
central nervous mechanisms. The brain is considered as the “master organ” of sexual functioning [1]
and is involved in all successive steps of human sexual behavior [2]. Electrophysiological and
behavioral studies provided considerable insights into human sexual function, but underlying neural
substrates were largely unknown until functional neuroimaging methods were widely introduced into
neuroscientific research. Since then, the basic principles of neural processing of sexual stimulation
were described in several studies [2–4]. However, empirical evidence regarding the effects of
neuromodulators on these neural mediators was scarce.
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Pharmacological functional magnetic resonance imaging (pharmaco-fMRI) provides a valuable
tool to examine modulatory effects of different neurotransmitter systems on neural signatures
of sexual function. Apart from clarifying these basic principles and the complex interaction
between neuromodulators and functional network anatomy of sexual behavior, investigations
with pharmaco-fMRI also have the potential to elucidate the neural correlates of treatment-related
sexual dysfunction.
Various psychiatric disorders are commonly accompanied by sexual dysfunction, and have an
immediate impact on subjective well-being and quality of life [5,6]. Of note, sexual dysfunction also
occurs as a frequent side effect of psychopharmacological treatment and considerably compromises
adherence to therapy. Clinical observational studies suggest that about 40% of patients with
psychopharmacological antidepressant treatment discontinue their medication due to treatment-related
sexual dysfunction [7]. Thus, the crucial implication of sexual dysfunction as a disease- and treatment-
related symptom motivated the investigation of the underlying neural mechanisms.
In this review, we introduce common concepts of sexual behavior and evidence regarding neural
substrates of sexual responses. We shortly discuss the challenges investigating the neuromodulation
of neural sexual stimulus processing by pharmaco-fMRI. In particular, we summarize our research
program that focused on how these neural correlates were modulated by serotonergic, dopaminergic,
and noradrenergic antidepressant medication in healthy male subjects.
2. Conceptualizing Sexual Behavior and Neural Responses
Despite its debut already in the 1960s, the most commonly used model to conceptualize sexual
activity is still the sexual response cycle by Masters and Johnson [8]. The term “sexual response”
denotes the set of behaviors and functions related to sexual stimulation and the pursuit of a sexual goal.
Based on their observations, Masters and Johnson [8] defined four different phases of sexual responses
that refer to the sequence of physical and emotional changes during sexual arousal and activity. They
distinguished a period of sexual desire and arousal, followed by a plateau, culminating in orgasm and
ending in a refraction period. Kaplan proposed a slightly modified triphasic model comprising sexual
desire, excitement, and orgasm [9]. However, these models were criticized for the linear sequence of
the phases that may, for example, not be entirely transferable to female sexual responses.
Neuroimaging techniques such as positron emission tomography (PET) or functional magnetic
resonance imaging (fMRI) made valuable contributions to identify underlying neural correlates of sexual
responses. As outlined and summarized by Reference [10], the behavioral and neurofunctional principles
underlying the sexual response cycle largely overlap with those related to other primary rewards
such as food [10]. Analogous to concepts related to other rewards, Georgiadis and Kringelbach [10]
suggested that sexual responses may be characterized by terms of motivation–consummation–satiety
or wanting–liking–inhibition. Linking psychological with physiological and neurofunctional processes
in more detail, a meta-analysis of functional imaging studies on sexual arousal conceptualized the
neurophenomenological model of sexual arousal [2]. The model suggests a cognitive component,
comprising the appraisal of and the attention to a subsequent sexual stimulus, which is represented
by neural reactivity within the orbitofrontal cortex (OFC), the inferior temporal cortices, the inferior
and superior parietal lobules, premotor and supplementary motor areas, and within the cerebellum.
An emotional component representing sexual pleasure and hedonic qualities of sexual arousal as
a primary reward is suggested to be mediated by neural activations of the amygdala, the insula, and
primary and secondary somatosensory cortices. Neural processes comprising goal-directed behavior and
the perceived urge to express overt sexual behavior are represented by activations within the anterior
cingulate cortex (ACC), the claustrum, the posterior parietal cortex, the hypothalamus, the substantia
nigra, and the ventral striatum. The autonomic/neuroendocrine component is thought to be mediated
by activations within the ACC, the anterior insula, the putamen, and hypothalamus, and is supposed to
lead subjects to a state of physiological readiness for sexual behavior [2,3,11].
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A more recent meta-analysis [12] distinguished brain networks underlying psychosexual and
physiosexual arousal. Hereby, the psychosexual network was suggested to include the lateral prefrontal
cortex and the hippocampus (cognitive and memory-guided evaluations), the occipitotemporal cortex,
superior parietal lobules (sensory processing), the amygdala and the thalamus (relevance detection
and affective evaluation), the hypothalamus (autonomic responses), basal ganglia (sexual urge), and
the anterior insula (awareness of sexual arousal). Physiosexual processes were conceptualized within
a network comprising the subgenual anterior cingulate cortex (sgACC; autonomic and corresponding
emotion regulation), the anterior midcingulate cortex (aMCC; initiation of copulatory behavior), the
putamen and claustrum (sexual urge), the anterior insula (awareness of rising sexual desire and
engendered bodily reactions), the insular cortex (somatosensory information), and the operculum
(monitoring bodily changes during sexual arousal). Of note, the putamen and the claustrum were
identified as brain regions that connect both psychosexual und physiosexual networks, with potentially
dissociable functions. While the putamen is thought to orchestrate the integration of sensorimotor
information in the context of sexual desire, the putamen might be responsible for cross-modal
processing between and within the networks of sexual arousal.
Most of these studies summarized neural sexual responses that were investigated using visual
stimuli. However, slightly divergent patterns of brain activations were reported due to different
stimulus content (e.g., sexual intensity), presentation mode (visual static images versus dynamic video
sequences), or design type (block versus event-related design) [13]. While sexual motivation and
wanting is reliably induced by visual sexual stimulation, genital stimulation is usually required to
enter the consummatory plateau [4] of the sexual response cycle. Indeed, the use of other types of
stimulus material (e.g., haptic or acoustic) is limited by the circumstances of neuroimaging methods,
like noise and motion sensitivity. A few studies simultaneously recorded fMRI blood oxygenation
level dependent (BOLD) signals elicited by visual stimuli and the corresponding time course of penile
tumescence to investigate neural substrates of orgasm and erection. Neural activations within the
ACC, the insula, amygdala, hypothalamus, and secondary somatosensory cortices were considered to
be associated with penile erection [14,15]. Neural activations in mid-anterior and medial subregions
of the OFC were suggested to relate specifically to orgasm [16]. Only few neuroimaging studies
investigated sexual inhibition/refraction; however, these were mainly in subjects with low sexual
desire. These studies indicate that sexual inhibition is mediated by prefrontal hyperactivity [17,18].
Accordingly, volitional inhibition of sexual arousal in healthy subjects was indeed accompanied by
increased activations within the superior parietal, the ventrolateral prefrontal [19], and the inferior
frontal cortex [20]. Moreover, it was suggested that both intended and unintended sexual inhibition
are related to an exaggerated activity within the neural network of sexual interest that may, however,
prevent a shift to the neural sexual consummation network [4]. Investigating neural responses a few
minutes after ejaculation, one fMRI study linked activation of the amygdala, the temporal lobes, and
the septal area specifically to sexual satiety [21].
3. Neuromodulation of Sexual Responses
Despite these valuable insights arising from neuroimaging studies into potentially underlying
neural correlates of sexual responses, modulatory effects of neurotransmitter systems or
monoaminergic drugs like antidepressants on these neural substrates are largely unknown. Most
of the evidence regarding the neuromodulation of sexual functions stems from animal studies (e.g.,
References [22,23]) or clinical observations in patients during the treatment with psychoactive drugs
(e.g., References [7,24–26]). Understanding the underlying mechanisms is indeed of great relevance
considering the high prevalence of psychopharmacologically related sexual dysfunction, quite likely
arising from central nervous rather than peripheral mechanisms [27].
Apart from sexual hormones and neuropeptides, central monoamines and catecholamines
that are commonly modulated by psychopharmacological agents exert a pivotal role in the
neuromodulation of sexual behavior. Here, we concentrate on dopamine, serotonin, and noradrenaline
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as the most commonly altered neuromodulator systems in psychopharmacotherapy. While an
elevated central dopaminergic neurotransmission was observed to be accompanied by increased
sexual interest, serotonergic agents are associated with an opposite pattern of behavior [27–29].
Considering the overlap of behavioral and neurofunctional principles of sexual functioning with
other primary rewards [10], the favorable effects of dopamine on sexual behavior seem plausible.
Accordingly, the antidepressant and selective noradrenaline and dopamine reuptake inhibitor
(SSNDRI) bupropion is associated with subjectively improved sexual functioning, such as the ability
to achieve and maintain an erection and orgasm, along with increased sexual satisfaction [30].
Moreover, dopamine-agonist treatment in Parkinson’s disease is frequently accompanied by the
clinical observation of hypersexuality [31]. In contrast, up to 70% of patients with schizophrenia
report sexual dysfunction under treatment with antidopaminergic antipsychotics like haloperidol [32].
Apart from hyperprolactinemia due to dopamine D2-receptor blockage in the tuberoinfundibular
pathway [33], the inhibitory effects of dopamine antagonists on the mesolimbic/mesocortical reward
system are considered as a crucial mechanism underlying antipsychotic related sexual dysfunction [34].
The considerable impact of the neuromodulator serotonin in mediating sexual activity was
recognized by the rising prevalence of sexual dysfunction during antidepressant medication, in particular
with selective serotonin reuptake inhibitors (SSRIs) [35]. Although the stimulation of some specific
serotonin receptor subtypes, e.g., 5-HT2c- or 5-HT1A-receptors, may facilitate erection or ejaculation,
primary central serotonergic effects are thought to be inhibitory. These effects are presumably mediated
via decreased dopamine release in mesolimbic regions [28,36] and by suppressing spinal ejaculatory
centers [37]. Accordingly, up to 80% of patients treated with the SSRI sertraline report sexual dysfunction
and, in particular in young patients, antidepressant-related decrease in sexual function is one of the most
relevant side effects [24,38]. Apart from the immediate negative impact on the quality of life [39,40],
antidepressant-related sexual dysfunction is also one of the major reasons that lead to non-adherence to
treatment [41], especially after remission of depressive symptoms. Since early discontinuation compared
to the recommended maintenance therapy over several months is related to increased rates of relapse [42],
the side effect compromises the overall success of antidepressant treatment.
Compared to serotonin, the contribution of the neuromodulator noradrenaline in mediating
sexual responses is less well understood. Clinical observations assume a favorable effect of selective
noradrenaline reuptake inhibitors (SNRIs) on sexual functions compared to SSRIs based on lower rates
of sexual dysfunction under SNRIs [24,43,44]. In line with this, actual sexual activity is related with an
increase in plasma noradrenaline levels during orgasm with a subsequent rapid decline [45]. However,
the limited available data regarding the effects of SNRIs on sexual functioning compromise definite
conclusions [24].
4. Challenges
The conclusions regarding the effects of monoaminergic psychopharmaceuticals on sexual
functions are mainly based on clinical observations and may be confounded by the disease itself.
Most studies did not assess baseline sexual function before the initiation of medication. However, up to
75% of patients with major depression report sexual dysfunction prior to antidepressant treatment,
in particular decreased sexual interest [46,47]. Thus, the mechanisms related to sexual dysfunction
under monoaminergic agents have also to be investigated in healthy subjects to exclude confounds
by the disease itself. Moreover, to meet clinical conditions as much as possible, but also to reach
steady-state conditions, multi-dose trials over several days rather than single-dose applications
are required to investigate neural correlates of sexual responses under antidepressants. Another
limitation often arises from the study design, especially when two agents are compared with each
other or relative to placebo in two different study groups. These study designs limit the capability
to differentiate effects of group from those of medication, even when randomization was applied to
minimize between-group effects. Also, between-group designs usually require larger sample sizes to
reduce putative and systematic effects of group. Thus, apart from placebo-controlled investigations in
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healthy subjects under subchronic administration of study medication, repeated measures within one
group (within-subject and cross-over) may represent the most desirable study design to investigate
psychopharmacological effects on neural responses of sexual behavior.
5. Serotonergic, Dopaminergic, and Noradrenergic Neuromodulation of Sexual Responses
One of the first studies investigating sexual dysfunction under monoaminergic agents and
underlying neural correlates was conducted in 2009 [48] in male patients with major depression.
Neural activations under visual erotic stimulation in nine patients taking SSRIs (six took paroxetine
and three fluoxetine) and in 10 patients taking mirtazapine, which blocks central adrenergic and
serotonin receptors, were compared to 10 healthy controls. This study demonstrated decreased neural
activation within the ACC, the OFC, the insula, and the caudate nucleus in the SSRI-group compared
to controls. These brain regions with attenuated responses were related to attentional and motivational
components of the sexual response cycle. Neural activations in the group treated with mirtazapine
were relatively lower than in controls but still elevated compared to those treated with SSRIs. Sexual
dysfunction as assessed by questionnaires was significantly more frequent in depressed patients
compared to controls, but did not differ between the two treatment groups. This study provided
first evidence for the potential underlying neural correlates of sexual dysfunction in depression while
under antidepressant treatment. However, the study design was not in the position to distinguish
effects of disease from treatment-related effects on sexual functions.
We, therefore, investigated a sample of 18 healthy heterosexual males using fMRI and a randomized
placebo-controlled within-subject cross-over study design. Participants were investigated after
subchronic administration of the SSRI paroxetine, the SSNDRI bupropion, and placebo. Each treatment
was applied for seven days separated by a wash-out time of at least 14 days [49]. During fMRI, we used
a dynamic visual erotic stimulus paradigm consisting of erotic and non-erotic video clips. Erotic video
clips depicted sexual interactions between one man or two women (petting, oral sex, and vaginal
intercourse) extracted from commercial adult films. Non-erotic video clips showed men and women in
emotionally neutral interactions. Subjective behavioral changes in sexual interest, sexual arousal, the
ability to achieve orgasm, the ability to achieve and maintain an erection, and overall sexual satisfaction
during drug administration were assessed by the Massachusetts General Hospital Sexual Functioning
Questionnaire (MGH-SFQ) [50]. We demonstrated significantly attenuated neural activations within
the sgACC, the pgACC, the aMCC, the pMCC, the nucleus accumbens, the midbrain, and the amygdala
under the SSRI during visual erotic stimulation. In line with these neural alterations under the SSRI,
we found a decrease in subjective sexual functions under paroxetine compared to placebo. In particular,
we observed a significant decrease in subjective sexual arousal and the ability to achieve an orgasm
under the SSRI compared to placebo.
Neural activations within the anterior but also rather rostral subdivisions of the ACC were
previously found to be modulated by SSRIs during emotional aversive stimuli [51]. Within the context
of sexual behaviour, neural activations within the ACC are associated with autonomic components
of sexual responses [2,3]. Moreover, neural activity within the pgACC is related to the interaction of
subjective sexual intensity and its hedonic and emotional value [52]. The results, therefore, suggested
an altered neural reactivity within brain regions linked to autonomic and emotional components of
sexual responses under SSRIs. In particular, attenuated neural activations within the pMCC under
the SSRI were correlated with paroxetine blood-serum levels and with detrimental overall subjective
functions under this antidepressant. In addition, by demonstrating attenuated neural activations
within the nucleus accumbens under the SSRI, we found evidence for a diminished neural motivational
component of sexual responses. This attenuation may relate to the close interaction and opposing
effects between dopaminergic and serotonergic systems [53–55]. Increasing levels of serotonin as seen
under SSRIs seem to dampen the functioning of the dopaminergic reward system [54,56]. To further
examine whether the SSRI-related attenuation of the dopaminergic reward system and, in particular,
within the nucleus accumbens might be mediated by other brain regions as observed in secondary
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rewards [57], we applied a psychophysiological interaction approach [58]. Indeed, we observed
a significantly elevated negative reciprocal interaction between the anteroventral prefrontal cortex
(avPFC) and the nucleus accumbens under the SSRI that was also associated with impulsivity as
a personality trait. Thus, an increase in PFC activation may mediate the dampening effects of SSRIs on
the human reward system and associated functions, e.g., sexual satisfaction.
In line with the opposing effects of serotonin and dopamine on reward-related functions and
neural activity, we observed slightly enhanced and prolonged neural activations within the pMCC and
within subcortical regions such as the midbrain, the amygdala, and the thalamus under the SSNDRI
bupropion compared to placebo. Subjective sexual functions were indeed unimpaired under this
agent in accordance to clinical studies, suggesting bupropion as a treatment alternative in patients
with SSRI-related sexual dysfunction [59]. The dopaminergic agents also reveal favourable effects on
sexual functions as compared to SSRIs [59–62]. The elevated neural activation pattern as found in our
study and, in particular, within the ventral striatum and the midbrain as dopaminergic reward-related
brain regions may represent a neural correlate of increased responsiveness to sexual stimuli arising
from the dopaminergic properties of bupropion. Moreover, with concomitant activations within the
amygdala that were previously related to perceived sexual arousal and to orgasmic pleasure [63], and
neural activations within the thalamus and cortical regions such as the MCC, we observed activations
within a neural network referred to as the salience network, which integrates homeostatic autonomic
functions, emotion, and reward processing [64] (see Figure 1).
Figure 1. Implications of subchronic steady state serotonergic, noradrenergic, and dopaminergic
stimulation on subjective sexual functions and neural responses to erotic stimulation in healthy
subjects. For further information on the neurophenomenological model of sexual arousal, see Stoléru
et al. [2]. SgACC = subgenual anterior cingulate cortex, pgACC = pregenual anterior cingulate cortex,
amy = amygdala.
Apart from these diverging effects of the neuromodulators serotonin and dopamine,
a unidirectional neural activation was found under both the SSRI and the SSNDRI within the aMCC
and, thus, in a brain region associated with attentional top-down control [65]. However, the video-clip
task limited the specific investigation of attentional components of sexual responses. We, therefore,
investigated the same sample of 18 healthy male subjects with fMRI under the two antidepressants
paroxetine and bupropion compared to placebo. During fMRI, we now used an established visual
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erotic picture task [52,66] consisting of erotic and non-erotic pictures of positive emotional content
taken from the International Affective Picture System (IAPS) [67]. Of note, half of the stimuli of each
condition (erotic, non-erotic) were announced. The implementation of these anticipatory periods
allowed the reliable investigation of attentional processes [68]. In general, anticipation is regarded
as preceding attention to an upcoming predicted stimulus [69,70] and numerous studies showed
neural parallels between anticipatory and attentional processes [68,71]. Under both serotonergic and
dopaminergic antidepressants, we revealed attenuated neural activations within the fronto-parietal
and cingulo-opercular neural network, essential for task initiation and adjustment, as well as for
the maintenance of attention [65]. Accordingly, these network alterations were accompanied by
unidirectional detrimental effects on the behavioral level under both agents in terms of prolonged
reactions in a divided attention task.
Beneficial effects of increasing dopaminergic neurotransmission on attention and prefrontal cortical
functions were conceptualized as an inverted u-shaped curve [72], whereby either too low or too high
levels of dopamine [73] led to a worsening of prefrontal cortex functioning. Thus, one may argue
that an increase in dopaminergic neurotransmission in healthy subjects as induced by the SSNDRI
bupropion may have increased the responsivity of the neural attention network beyond the optimum
and led to detrimental attentional functioning on a behavioral level. A similar response pattern
was shown for increases in noradrenergic neurotransmission and other cognitive functions such as
error monitoring [74]. In addition, it is of note that an increase in dopaminergic neurotransmission
in prefrontal regions is not only described for bupropion but also for paroxetine via indirect
pathways [75,76], supporting our observation regarding similar attention network alterations. In line
with this, detrimental sustained attention was also found in other studies under SSRI administration in
healthy subjects [77,78].
Apart from the serotonergic and dopaminergic antidepressants, we further investigated neural
effects of noradrenergic antidepressants. Within a randomized placebo-controlled within-subject cross-
over design, 19 healthy heterosexual male subjects were investigated after subchronic administration of
the selective noradrenaline reuptake inhibitor (SNRI) reboxetine and the second-generation antipsychotic
amisulpride. During fMRI, we again used the dynamic erotic video-clip task. Noradrenergic agents and,
in particular, reboxetine were thought to exert less detrimental effects on sexual functioning compared
to serotonergic agents [24,79]. However, this assumption was mainly derived from investigations in
depressive patients that demonstrated greater improvement in sexual satisfaction, in the ability to become
sexually excited [80], and in achieving orgasm [43] under reboxetine. In contrast to these beneficial effects
on sexual functions, we observed a significant decrease in overall subjective sexual function under the
noradrenergic agent reboxetine compared to placebo and amisulpride in healthy subjects. In particular
sexual arousal, the ability to achieve orgasm and penile erection [81] decreased. These results were,
however, in line with other previous clinical reports of prolonged orgasm [82], erectile dysfunction [83],
and anorgasmia [43] under this drug. On the neural level, we revealed diminished neural activations
within the caudate nucleus under reboxetine compared to placebo that were significantly associated
with the decreased sexual interest under this agent. With regard to erotic stimulation, caudate nucleus
activation was linked to goal-directed behavior and reward [84]. Whereas ventral parts of the striatum are
commonly associated with the expectation and the receipt of incentives, dorsal striatal/caudate nucleus
activation was associated with motivational rather than reward processing [85]. Thus, our findings may
support the notion that an increase in noradrenergic neurotransmission might have detrimental effects
on motivational components of sexual responses along with diminished subjective sexual functioning.
It is of note that we did not find significant neural alterations during visual erotic stimulation
and in subjective sexual functions under the antipsychotic drug amisulpride compared to placebo.
The antipsychotic drug amisulpride has high and selective affinity to postsynaptic D2- und
D3-receptors [86–88] and it is known for its capacity to induce sexual dysfunction mainly due to
the blockage of dopamine D2-receptors [33] with secondary increases of prolactin levels [34]. The lack
of significant alterations in neural visual erotic stimulus processing along with unchanged subjective
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sexual functions in our study was most likely due to the low dosage of 200 mg/day amisulpride for
seven days. Antipsychotic effects of amisulpride were reported for high dosages from about 400 to 600
mg/day due to reliable D2-receptor occupancy [86]. In contrast, lower dosages (50 to 200 mg/day)
as used in our study are thought to primarily block presynaptic dopamine autoreceptors with the
consequence of mild pro-dopaminergic effects [86,89,90] that may have left sexual functions and
corresponding neural correlates unimpaired in our sample of healthy male subjects.
To further investigate neural responses to visual erotic stimulus processing including preceding
attention and their modulation by noradrenergic agents, we also applied the abovementioned erotic
picture paradigm with anticipatory periods [91]. Notably, upon static rather than previously applied
dynamic visual erotic stimulation, we observed additional treatment effects of the noradrenergic agent
reboxetine compared to placebo during visual erotic stimulation by diminished neural activations not
only within the caudate nucleus, but also within the ventral striatum/nucleus accumbens, the pgACC,
the aMCC, and the OFC. In addition, decreases in subjective sexual arousal correlated with attenuated
neural activations within the posterior insula, a region that is repeatedly associated with sexual arousal
and penile response [14,84]. Thus, our results support the notion of detrimental effects of noradrenergic
agents on emotional, motivational, and autonomic neural components of sexual responses, along with
decreased subjective sexual function (see Figure 1). In addition, they also underpin the implication
regarding stimulus presentation mode in investigating neural substrates of erotic stimulus processing
considering that treatment effects of noradrenergic agents were found within a broader neural network
during static rather than dynamic visual erotic stimulation.
Similar to the investigation by erotic video stimulation, we also found no significant neural
alteration under amisulpride compared to placebo. Moreover, in contrast to serotonergic and
predominantly dopaminergic antidepressants, neither the noradrenergic agent reboxetine nor the
antipsychotic amisulpride led to neural alterations during the anticipation of erotic stimuli, in line with
unimpaired attentional functions on a behavioral level in this study. However, it is of note that major
nodes of the neural network altered by the noradrenergic agent reboxetine compared to placebo such
as the ventral striatum, the pgACC, aMCC, and the OFC highly resemble those brain regions that were
also modulated by serotonergic agents upon erotic video stimulation in our previous investigation.
While it remains speculative, one may argue that either monoaminergic modulation ends up
via similar neural pathways and presumably also on a molecular level. Interactions of both the
serotonergic and noradrenergic system with dopaminergic projections were extensively studied [54,92],
and a modulation of one system will invariably influence the transmission of the other. Here, the
human reward system may represent a major or common final pathway. The specific increase in
serotonergic and noradrenergic turnover under paroxetine and reboxetine, respectively, dampened
the neural activity within the dopaminergic human reward system and, in particular, within the
nucleus accumbens. However, this attenuation is potentially restricted to the processing of specific
rewards or reinforcers such as sexual stimuli or primary rewards, considering that the serotonergic
and noradrenergic attenuation of neural activity within the nucleus accumbens was not evident when
processing monetary rewards as secondary reinforcers [93,94].
6. Perspectives
Our project using pharmacological and task-based fMRI identified neuromodulatory effects
of monoamines and catecholamines on neural sexual responses and potential neural proxies for
the development of sexual dysfunction under antidepressants. Insights from this methodological
approach mainly concern basic research; however, some aspects might be transferred to clinical
practices. Considering that task-based fMRI may not be easily implemented in clinical routines due
to its complexity and dependency on a subject’s motivation and performance, resting-state fMRI
may provide a valuable alternative. Accordingly, we investigated healthy subjects using resting-state
fMRI [95] and demonstrated that more impaired subjective sexual function under serotonergic agents
was predicted by low baseline functional connectivities under placebo. In particular, functional
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connectivities of the sublenticular extended amygdala with midbrain, pgACC, and the insula revealed
a predictive potential for the development of SSRI-related decreases in sexual functioning. Although
these results await empirical replication in larger samples, they may support the idea of a potentially
valuable contribution of imaging techniques in the prediction of pharmaco-related sexual dysfunction
within the context of personalized medicine.
It is of note that the investigations presented were exclusively conducted in healthy male
subjects and the conclusions drawn may not be transferable to females. Within the past years,
gender and sex aspects were widely recognized in scientific research and, with regard to sexual
responses, sex differences are proposed to not only occur on behavioral and downstream peripheral,
but also on the neural level. Relative to men, meta-analyses suggest a less consistent and decreased
neurofunctional activation in subcortical regions in women during sexual arousal [96,97]. In addition,
female sex hormones appear to play a crucial role in mediating particularly cortical activations
in response to sexual stimulation [97–99]. Moreover, there is evidence for an interaction between
sex hormones and the dominant neurotransmitters such as serotonin and dopamine [100]. These
observations suggest a divergent monoaminergic neuromodulation of erotic stimulus processing
in females. Consequently, the investigation of females under different levels of monoaminergic or
catecholaminergic neurotransmitter levels in combination with different hormonal states is highly
encouraged as a future research topic.
7. Conclusions
Within a broader research program, we investigated healthy male subjects under visual erotic
stimulation by fMRI and different antidepressant medication to disentangle effects of monoaminergic
and catecholaminergic neuromodulatory substances on neural substrates of sexual responses. After
increasing serotonergic neurotransmission, we observed attenuated neural activations within cerebral
networks previously related to motivational, emotional, and autonomic components of sexual behavior
along with diminished subjective sexual functions. Psychophysiological interaction analyses revealed
that the dampening of the motivational component and, in particular, human reward system activation
was presumably mediated by an increase in prefrontal cortex activation as a potential correlate of
increased cognitive control under serotonergic agents. Of note, neural motivational and emotional
components, as well as subjective sexual functions, were either unaffected or even increased under
dopaminergic stimulation. Apart from these divergent effects on erotic stimulus processing, both
serotonergic and dopaminergic stimulation diminished neural attention network activation during
the anticipation of visual sexual stimuli, along with a decrease in behavioral measures of attention.
Investigating the noradrenergic neuromodulation of neural substrates of erotic stimulus processing
revealed similar neural alterations as serotonergic agents, and showed again attenuation of neural
emotional and motivation components along with a decrease in subjective sexual functions. However,
neural activations during the anticipation of sexual stimuli and behavioral attentional functioning were
not altered by a noradrenergic agent. Thus, our results provided evidence for the neuromodulatory
effects of serotonergic, noradrenergic, and dopaminergic agents on neural substrates of erotic stimulus
processing. Considering the overlay of neuromodulatory effects of serotonergic and noradrenergic
neurotransmission, this may suggest that both monoaminergic modulations end up via similar neural
pathways and presumably affect dopaminergic projections within the human reward system. Notably,
the dampening of the human reward system by both serotonergic and noradrenergic agents was,
however, restricted to the processing of visual sexual stimuli as primary reinforcers and was not
evident during processing of monetary rewards as secondary reinforcers.
From a basic research perspective, we demonstrate that modulations in sexual functioning on the
subjective behavioral level are indeed closely linked to cerebral networks that mediate motivational,
emotional, autonomic, and attentional components of the sexual response. Our data emphasize the
hypothesis that altered cerebral reactivity rather than peripheral effects might be the key to explain
side effects of monoaminergic substances on sexual functioning.
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Abstract: In the last few years, there has been a wave of articles related to behavioral addictions;
some of them have a focus on online pornography addiction. However, despite all efforts, we are still
unable to profile when engaging in this behavior becomes pathological. Common problems include:
sample bias, the search for diagnostic instrumentals, opposing approximations to the matter, and the
fact that this entity may be encompassed inside a greater pathology (i.e., sex addiction) that may
present itself with very diverse symptomatology. Behavioral addictions form a largely unexplored
field of study, and usually exhibit a problematic consumption model: loss of control, impairment,
and risky use. Hypersexual disorder fits this model and may be composed of several sexual behaviors,
like problematic use of online pornography (POPU). Online pornography use is on the rise, with a
potential for addiction considering the “triple A” influence (accessibility, affordability, anonymity).
This problematic use might have adverse effects in sexual development and sexual functioning,
especially among the young population. We aim to gather existing knowledge on problematic online
pornography use as a pathological entity. Here we try to summarize what we know about this entity
and outline some areas worthy of further research.
Keywords: online pornography; addiction; cybersex; internet; compulsive sexual behavior;
hypersexuality
1. Introduction
With the inclusion of “Gambling Disorder” in the “Substance Use and Addictive Disorders”
chapter of the DSM-5 [1], the APA publicly acknowledged the phenomenon of behavioral addiction.
Furthermore, “Internet Gaming Disorder” was placed in Section 3—conditions for further study.
This represents the ongoing paradigm shift in the field of addictions that relates to addictive
behavior, and paves the way for new research in the light of cultural changes caused by the
new technologies.
There is apparently an existing common neurobiological [2] and environmental [3] ground
between the varying addictive disorders, including both substance abuse and addictive behavior;
this can manifest as an overlapping of both entities [4].
Phenomenologically, behaviorally addicted individuals frequently exhibit a problematic
consumption model: impaired control (e.g., craving, unsuccessful attempts to reduce the behavior),
impairment (e.g., narrowing of interests, neglect of other areas of life), and risky use (persisting
intake despite awareness of damaging psychological effects). Whether these behaviors also meet
physiological criteria relating to addiction (tolerance, withdrawal) is more debatable [4–6].
Hypersexual disorder is sometimes considered one of those behavioral addictions. It is used as an
umbrella construct that encompasses various problematic behaviors (excessive masturbation, cybersex,
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pornography use, telephone sex, sexual behavior with consenting adults, strip club visitations, etc.) [7].
Its prevalence rates range from 3% to 6%, though it is difficult to determine since there is not a formal
definition of the disorder [8,9].
The lack of robust scientific data makes its research, conceptualization, and assessment difficult,
leading to a variety of proposals to explain it, but is usually associated with significant distress, feelings
of shame and psychosocial dysfunction [8], as well as other addictive behaviors [10] and it warrants
direct examination.
Concurrently, the rise of the new technologies has also opened up a pool of problematic addictive
behavior, mainly Internet Addiction. This addiction may focus on a specific application on the internet
(gaming, shopping, betting, cybersex . . . ) [11] with potential for risk-addictive behavior; in this case,
it would act as a channel for concrete manifestations of said behavior [4,12]. This means inevitable
escalation, providing new outlets for established addicts as well as tempting people (due to increased
privacy, or opportunity) who would not have previously engaged in these behaviors.
Online pornography use, also known as Internet pornography use or cybersex, may be one of
those Internet-specific behaviors with a risk for addiction. It corresponds to the use of Internet to engage
in various gratifying sexual activities [13], among which stands the use of pornography [13,14] which
is the most popular activity [15–17] with an infinite number of sexual scenarios accessible [13,18–20].
Continued use in this fashion sometimes derives in financial, legal, occupational, and relationship
trouble [6,21] or personal problems, with diverse negative consequences. Feelings of loss of control and
persistent use despite these adverse results constitute “online sexual compulsivity” [22] or Problematic
Online Pornography Use (POPU). This problematic consumption model benefits from the “Triple A”
factors [23].
Due to this model, pornography-related masturbation may be more frequent nowadays, but this
is not necessarily a sign of pathology [21]. We know that a considerable proportion of young male
population access Internet for pornography consumption [24,25]; in fact, it is one of their key sources
for sexual health [26]. Some have expressed concern about this, addressing the time gap between when
porn material is consumed for the first time ever, and an actual first sexual experience; specifically,
how the former can have an impact on sexual development [27] like abnormally low sexual desire
when consuming online pornography [28] and erectile dysfunction, which has spiked dramatically
among young men in the past few years when compared to a couple decades ago [29–33].
We systematically reviewed the existing literature on the subject of POPU to try and summarize
the various recent advances made in terms of epidemiology, clinical manifestations, neurobiological
evidence that supports this model of problematic use, its diagnostic conceptualization in relation to
hypersexual disorder, its proposed assessment instruments and treatment strategies.
2. Methods
We performed the systematic review following PRISMA guidelines (Figure 1). Given the
relatively new body of evidence regarding this subject, we conducted our review with no specific
time-delimitation. Priority was placed upon literature reviews and articles published via a newest to
oldest methodology, preferentially for already published reviews on the subject. PubMed and Cochrane
were the main databases used, though a number of articles were compiled through cross-referencing.
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Figure 1. PRISMA flow diagram.
Since our focus was mainly online pornography and addictive sexual behavior, we excluded those
articles that had only a peripheral association with it in our search: those with a focus on generalized
Internet addiction, those centered on the pornographic equivalent of varying paraphilias, and those
that approached the subject from a social perspective.
The following search terms and their derivatives were used in multiple combinations: cybersex,
porn* (to allow for both “pornography” and “pornographic”), addict* (to allow for both “addiction”
and “addictive”), online, internet, sex, compulsive sex, hypersexuality. The reference management tool
Zotero was used to build a database of all articles considered.
3. Results
3.1. Epidemiology
Pornography consumption in the general population proves difficult to be adequately measured,
especially since the rise of the Internet and the “triple A” factors which have allowed for both privacy
and ease of access. Wright’s study about the use of pornography in U.S. male population using the
General Social Survey (GSS) [34], and Price’s study (which expands upon Wright’s by distinguishing
among age, cohort, and period effects) [35] constitute some of the few, if not the only ones, existing
sources that track pornography use in the general population. They show the overall increasing
consumption of pornography over the years, especially among male population in contrast to females.
This is particularly prevalent among young adults, and it steadily decreases with age.
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Some interesting facts about pornography consumption tendencies stand out. One of them is that
the 1963 and 1972 male cohort showed only a very small decline on their usage from the year 1999
onwards, suggesting that porn consumption among these groups has remained relatively constant
since [35]. The other one is that 1999 is also the year the tendency for women aged 18 to 26 to consume
pornography became three times as likely than the ones aged 45 to 53, instead of just two times as
likely as it used to be up until that point [35]. These two facts could be related to changing tendencies
in pornography consumption motivated by technology (switching from the offline to the online model
of consumption), but it is impossible to know for sure since the original data does not account for
differences in both offline and online variants when tracking pornography usage.
As for POPU, there is no clear and reliable data in the literature reviewed that can offer a solid
estimation of its prevalence. Adding up to the already mentioned motives for lack of data on general
pornography consumption, part of it might stem from the perceived taboo nature of the topic at hand
by possible participants, the wide range of assessment tools used by researchers, and the lack of
consensus on what actually constitutes a pathological usage of pornography, which are all issues also
reviewed further into this paper.
The vast majority of studies pertaining POPU or hypersexual behavior prevalence use convenience
samples to measure it, usually finding, despite population differences, that very few users consider
this habit an addiction, and even when they do, even fewer consider that this could have a negative
effect on them. Some examples:
(1) A study assessing behavioral addictions among substance users, found that only 9.80% out of
51 participants considered they had an addiction to sex or pornography [36].
(2) A Swedish study that recruited a sample of 1913 participants through a web questionnaire, 7.6%
reported some Internet sexual problem and 4.5% indicated feeling ‘addicted’ to Internet for love
and sexual purposes, and that this was a ‘big problem’ [17].
(3) A Spanish study with a sample of 1557 college students found that 8.6% was in a potential risk
of developing a pathological usage of online pornography, but that the actual pathological user
prevalence was 0.7% [37].
The only study with a representative sample to date is an Australian one, with a sample of
20,094 participants; 1.2% of the women surveyed considered themselves addicted, whereas for the
men it was 4.4% [38]. Similar findings also apply to hypersexual behavior outside of pornography [39].
Predictors for problematic sexual behavior and pornography use are, across populations: being a
man, young age, religiousness, frequent Internet use, negative mood states, and being prone to sexual
boredom, and novelty seeking [17,37,40,41]. Some of this risk factors are also shared by hypersexual
behavior patients [39,42].
3.2. Ethiopathogenical and Diagnostic Conceptualization
Conceptualizing pathological behaviors continues to be a challenge today. While several attempts
have been made regarding hypersexual behavior, the lack of robust data as of now explains the fact
that there’s no consensus on this matter [9]. POPU comprises a very specific set of sexual behaviors
that involve technology. Due to problematic technology use (especially online technology) being
relatively recent, we need first to talk about hypersexual behavior not related to technology in order to
understand the place of online pornography in it.
Sexuality as a behavior is vastly heterogeneous, and its potential pathological side has been
studied for centuries [43]. Therefore, it represents a challenge to models trying to adequately define
it, since it can incorporate practices ranging from solitary fantasizing to sexual violence [21]. It is
also difficult to define what constitutes an actual dysfunction and manage to avoid the possible
misuse of that definition to stigmatize and pathologize individuals [44]. For example, some set the
limit between normal and pathological sexual behavior at more than seven orgasms in a week [43]
(p. 381), but this approach focusing on quantity can be dangerous, since what constitutes normal and
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pathological behavior can vastly vary between individuals. This lack of uniformity and consistency in
its classification may hinder future research on investigating hypersexual behavior [45] and ignore
the quality aspects that focus on the negative emotions associated with it [46,47]. There have been
proposals to redeem this issue using certain tools, already developed as part of the hypersexual
disorder proposal used in the DSM-5 field trial [43,47].
Hypersexuality generally acts as an umbrella construct [7]. Its nomenclature is still a matter
of debate to this day, and it is frequent to encounter several terms that refer to the same concept:
compulsive sexual behavior, sex addiction, sexual impulsivity, hypersexual behavior or hypersexual
disorder. Some authors, while recognizing the value of the terms “addiction” and “compulsivity”,
prefer to draw attention to the issue of control and its possible loss or compromise as the primary
concern about this behavior, thus referring to it as “out of control sexual behavior” [45,48,49].
Although definitions are not uniform, they usually focus on the frequency or intensity
of symptoms [46] of otherwise normal urges and fantasies, that would result in dysfunction.
This differentiates it from paraphilic sexual behavior, though the need for a better clarification of
possible differences, similarities, and overlap between the two types still persists [45].
Usually included in hypersexual behavior are excessive masturbation and various sexual
related behaviors, like dependence on anonymous sexual encounters, repetitive promiscuity, internet
pornography, telephone sex, and visiting strip clubs [43,44,49–51]. Bancroft particularly thought that,
in using Internet, both masturbation and these sexual activities could blend themselves, stating that
men “use it as an almost limitless extension of their out of control masturbatory behavior”.
While the possibility to diagnose hypersexual behavior was always available with “sexual disorder
not otherwise specified” in the DSM [1], Kafka [43] tried to propose it as a diagnostic entity for the
DSM-5. He presented a set of criteria for it, as part of the sexual disorders chapter. These proposed
models included hypersexual behavior as: (1) sexually motivated, (2) a behavioral addiction, (3) part of
the obsessive-compulsive spectrum disorder, (4) part of the impulsivity-spectrum disorders, and (5) an
“out of control” excessive sexual behavior. This proposal was ultimately rejected due to several reasons;
the main was said to be absence of consolidated epidemiological and neuroimaging data regarding this
behavior [52,53], but also its potential for forensic abuse, a not specific enough set of diagnostic criteria,
and potential politic and social ramifications of pathologizing an integral area of behavior to human
life [54]. It is interesting to compare it to the other two previous set of criteria present in the reviewed
literature, those of Patrick Carnes and Aviel Goodman [9]. All three share the concepts of loss of control,
excessive time spent on sexual behavior and negative consequences to self/others, but diverge on the
other elements. This reflects in broad strokes the lack of consensus in conceptualizing hypersexual
behavior across the years. Currently, the main options propose hypersexual behavior either as an
impulse control disorder or a behavioral addiction [55].
From an impulse control disorder perspective, hypersexual behavior is generally referred
to as Compulsive Sexual Behavior (CSB). Coleman [56] is a proponent of this theory. While he
includes paraphilic behavior under this term [57], and they may coexist in some cases, he distinctly
differentiates it from nonparaphilic CSB, which is what we want to focus on in this review. Interestingly,
nonparaphilic hypersexual behavior is usually as frequent, if not more, than some paraphilias [43,58].
However, more recent definitions of CSB usually refer to multiple sexual behaviors that can be
compulsive: the most commonly reported being masturbation, being followed by compulsive use of
pornography, and promiscuity, compulsive cruising, and multiple relationships (22–76%) [9,59,60].
While there are definite overlaps between hypersexuality and conditions such as
obsessive-compulsive disorder (OCD) and other impulse control disorders [61], there are also some
notable differences pointed out: for example, OCD behaviors do not involve reward, unlike sexual
behavior. Moreover, while engaging in compulsions might result in temporary relief for OCD
patients [62], hypersexual behavior is usually associated by guilt and regret after committing the act [63].
Also, the impulsivity that can sometimes dominate the patient’s behavior is incompatible with the
careful planning that is sometimes required in CSB (for example, in regards to a sexual encounter) [64].
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Goodman thinks that addiction disorders lie at the intersection of compulsive disorders (which
involve anxiety reduction) and impulsive disorders (which involve gratification), with the symptoms
being underpinned by neurobiological mechanisms (serotoninergic, dopaminergic, noradrenergic,
and opioid systems) [65]. Stein agrees with a model combining several ethiopathogenical mechanisms
and proposes an A-B-C model (affective dysregulation, behavioral addiction, and cognitive dyscontrol)
to study this entity [61].
From an addictive behavior standpoint, hypersexual behavior relies on sharing core aspects of
addiction. These aspects, according to the DSM-5 [1], refer to the mentioned problematic consumption
model applied to hypersexual behavior, both offline and online [6,66,67]. Evidence of tolerance
and withdrawal in these patients might probably be key in characterizing this entity as an addictive
disorder [45]. Problematic use of cybersex is also often conceptualized as a behavioral addiction [13,68].
The term “addiction” applying to this entity is still subject to great debate. Zitzman considers
that the resistance to use the term addiction is “more a reflection of cultural sexual liberality and
permissiveness than any lack of symptomatic and diagnostic correspondence with other forms of
addiction” [69]. However, the term needs to be used with caution, since it can be interpreted as a
justification for an irresponsible search for gratification and hedonist pleasure, and blame the disruptive
consequences on it.
There has long been a debate between Patrick Carnes and Eli Coleman over the diagnostics of
hypersexual behavior. Coleman has considered hypersexuality to be driven by the need to reduce
some type of anxiety, not by sexual desire [56] having classified it in seven subtypes (one of them being
use of online pornography) [57], while Carnes (who defined addiction as “a pathological relationship
with a mood altering experience”) finds similitudes to other behavioral addictions like gambling,
focusing on the loss of control and continued behavior despite negative consequences [70].
A thorough review of the literature by Kraus [71], concluded that despite these similitudes,
significant gaps in the concept’s understanding complicate its classification as an addiction. The main
concerns are aimed towards quantity of large-scale prevalence, longitudinal and clinical data
(defining main symptoms and its diagnostic limits), supported by neuropsychological, neurobiological,
and genetic data, as well as some information regarding possible treatment screening and prevention,
and points to digital technology in hypersexual behavior as a key point for future research.
The rise of the Internet increases the possibilities for sexual interactions, and not just online
pornography (webcamming, casual sex websites). Even whether Internet use represents a conduit for
other types of repetitive behavior (e.g., sexual behavior or gambling) or constitutes a different entity in
its own right is still debated [72]. Nevertheless, if the case is the former, the previous evidence and
considerations could very well apply to its online counterpart.
There is currently a need for empirically derived criteria that takes into account unique factors
characterizing online (versus offline) sexual behaviors, since most of them do not have an offline
version that can be compared to [73]. So far, there have been mentions of new phenomena when
dealing with online sexual behavior, like the presence of online dissociation [74], which causes to “be
mentally and emotionally detached when engaged, with compromised time and depersonalization”.
This dissociation has already been described in relation to other online activities [75], which supports
the notion that cybersex problematic use could be related to both internet and sex addiction [76].
Finally, we have to mention that a diagnostic entity called “compulsive sexual behavior disorder”
is being included in the upcoming definitive edition of ICD-11, in the “impulse control disorders”
chapter [77]. The definition can be consulted at https://icd.who.int/dev11/l-m/en#/http%3a%2f%
2fid.who.int%2ficd%2fentity%2f1630268048.
The inclusion of this category in the ICD-11 may be a response to the relevance of this issue
and attest to its clinical utility, whereas the growing but yet inconclusive data prevents us from
properly categorizing it as a mental health disorder [72]. It is believed to provide a better tool (yet
in refinement process) for addressing the needs of treatment seeking patients and the possible guilt
associated [78], and also may reflect the ongoing debates regarding the most appropriate classification
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of CSB and its limited amount of data in some areas [55,71] (Table 1). This inclusion could be the first
step towards recognizing this issue and expanding on it, one key point being undoubtedly its online
pornography subtype.
Table 1. DSM-5 and ICD-11 approaches to classifying hypersexual behavior.
DSM-5 ICD-11
Goal Provide common research and clinicallanguage for mental health problems
Reflect issues of clinical utility in a
broad range of settings, global
applicability, and scientific validity [79]
Conceptualization of
hypersexual disorder Addiction model Impulse control model
Available diagnosis
No current hypersexual disorder
diagnosis, due to insufficient evidence
to categorize it as addiction
Compulsive sexual behavior disorder
3.3. Clinical Manifestations
Clinical manifestations of POPU can be summed up in three key points:
• Erectile dysfunction: while some studies have found little evidence of the association between
pornography use and sexual dysfunction [33], others propose that the rise in pornography use
may be the key factor explaining the sharp rise in erectile dysfunction among young people [80].
In one study, 60% of patients who suffered sexual dysfunction with a real partner, characteristically
did not have this problem with pornography [8]. Some argue that causation between pornography
use and sexual dysfunction is difficult to establish, since true controls not exposed to pornography
are rare to find [81] and have proposed a possible research design in this regard.
• Psychosexual dissatisfaction: pornography use has been associated with sexual dissatisfaction
and sexual dysfunction, for both males and females [82], being more critical of one’s body or their
partner’s, increased performance pressure and less actual sex [83], having more sexual partners
and engaging in paid sex behavior [34]. This impact is especially noted in relationships when it is
one sided [84], in a very similar way to marijuana use, sharing key factors like higher secrecy [85].
These studies are based on regular non-pathological pornography use, but online pornography
may not have harmful effects by itself, only when it has become an addiction [24]. This can explain
the relationship between the use of female-centric pornography and more positive outcomes for
women [86].
• Comorbidities: hypersexual behavior has been associated with anxiety disorder, followed by
mood disorder, substance use disorder and sexual dysfunction [87]. These findings also apply to
POPU [88], also being associated with smoking, drinking alcohol or coffee, substance abuse [41]
and problematic video-game use [89,90].
Having some very specific pornographic content interests has been associated with an increase
in reported problems [17]. It has been debated if these clinical features are the consequence of direct
cybersex abuse or due to the subjects actually perceiving themselves as addicts [91].
3.4. Neurobiological Evidence Supporting Addiction Model
Collecting evidence about POPU is an arduous process; main data on this subject is still limited
by small sample sizes, solely male heterosexual samples and cross-sectional designs [71], with not
enough neuroimaging and neuropsychological studies [4], probably due to conceptual, financial
and logistic obstacles. In addition, while substance addiction can be observed and modeled in
experimental animals, we cannot do this with a candidate behavioral addiction; this may limit our
study of its neurobiological underpinnings [72]. Current knowledge gaps regarding the research of
hypersexual behavior, as well as possible approaches for addressing them, are expertly covered and
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summarized in Kraus’ article [71]. Most of the studies found in our research pertain hypersexual
behavior, with pornography being only one of its accounted accessories.
This evidence is based on an evolving understanding of the neural process among
addiction-related neuroplasticity changes. Dopamine levels play an important part in this sexual
reward stimuli, as observed already in frontotemporal dementia and pro-dopaminergic medication in
Parkinson’s disease being linked with sexual behavior [92,93].
The addictive process with online pornography may be amplified by the accelerated novelty and
the “supranormal stimulus” (term coined by Nobel prize winner Nikolaas Tinbergen) that constitutes
Internet pornography [94]. This phenomenon would supposedly make artificial stimuli (in this case,
pornography in the way it is mostly consumed today, its online form) override an evolutionarily
developed genetic response. The theory is that they potentially activate our natural reward system
at higher levels than what ancestors typically encountered as our brains evolved, making it liable to
switch into an addictive mode [2]. If we consider online porn from this perspective, we can start seeing
similarities to regular substance addicts.
Major brain changes observed across substance addicts lay the groundwork for the future research
of addictive behaviors [95], including:
1. Sensitization [96]
2. Desensitization [97]
3. Dysfunctional prefrontal circuits (hypofrontality) [98]
4. Malfunctioning stress system [99]
These brain changes observed in addicts have been linked with patients with hypersexual behavior
or pornography users through approximately 40 studies of different types: magnetic resonance
imaging, electroencephalography (EEG), neuroendocrine, and neuropsychological.
For example, there are clear differences in brain activity between patients who have compulsive
sexual behavior and controls, which mirror those of drug addicts. When exposed to sexual images,
hypersexual subjects have shown differences between liking (in line with controls) and wanting (sexual
desire), which was greater [8,100]. In other words, in these subjects there is more desire only for the
specific sexual cue, but not generalized sexual desire. This points us to the sexual cue itself being then
perceived as a reward [46].
Evidence of this neural activity signalizing desire is particularly prominent in the prefrontal
cortex [101] and the amygdala [102,103], being evidence of sensitization. Activation in these brain
regions is reminiscent of financial reward [104] and it may carry a similar impact. Moreover, there are
higher EEG readings in these users, as well as the diminished desire for sex with a partner, but not
for masturbation to pornography [105], something that reflects also on the difference in erection
quality [8]. This can be considered a sign of desensitization. However, Steele’s study contains several
methodological flaws to consider (subject heterogeneity, a lack of screening for mental disorders
or addictions, the absence of a control group, and the use of questionnaires not validated for porn
use) [106]. A study by Prause [107], this time with a control group, replicated these very findings.
The role of cue reactivity and craving in the development of cybersex addiction have been corroborated
in heterosexual female [108] and homosexual male samples [109].
This attentional bias to sexual cues is predominant in early hypersexual individuals [110], but a
repeated exposure to them shows in turn desensitization [111,112]. This means a downregulation
of reward systems, possibly mediated by the greater dorsal cingulate [107,113,114]. Since the dorsal
cingulate is involved in anticipating rewards and responding to new events, a decrease in its activity
after repeated exposure points us to the development of habituation to previous stimuli. This results
in a dysfunctional enhanced preference for sexual novelty [115], which may manifest as attempts to
overcome said habituation and desensitization through the search for more (new) pornography as a
means of sexual satisfaction, choosing this behavior instead of actual sex [20].
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These attempts at novelty seeking may be mediated through ventral striatal reactivity [116] and
the amygdala [117]. It is known that the viewing of pornography in frequent users has also been
associated with greater neural activity [99], especially in the ventral striatum [116,118] which plays a
major role in anticipating rewards [119].
However, connectivity between ventral striatum and prefrontal cortex is decreased [103,113];
a decrease in connectivity between prefrontal cortex and the amygdala has also been observed [117].
In addition, hypersexual subjects have shown reduced functional connectivity between caudate and
temporal cortex lobes, as well as gray matter deficit in these areas [120]. All of these alterations could
explain the inability to control sexual behavior impulses.
Moreover, hypersexual subjects showed an increased volume of the amygdala [117], in contrast
to those with a chronic exposure to a substance, which show a decreased amygdala volume [121];
this difference could be explained by the possible neurotoxic effect of the substance. In hypersexual
subjects, increased activity and volume may reflect overlapping with addiction processes (particularly
supporting incentive motivation theories) or be the consequence to chronic social stress mechanisms,
such as the behavioral addiction itself [122].
These users also have shown a dysfunctional stress response, mainly mediated through the
hypothalamus–pituitary–adrenal axis [122] in a way that mirror those alterations seen in substance
addicts. These alterations may be the result of epigenetic changes on classic inflammatory mediators
driving addictions, like corticotropin-releasing-factor (CRF) [123]. This epigenetic regulation
hypothesis considers both hedonic and anhedonic behavioral outcomes are at least partially affected by
dopaminergic genes, and possibly other candidate neurotransmitter-related gene polymorphisms [124].
There is also evidence of higher tumor necrosis factor (TNF) in sex addicts, with a strong correlation
between TNF levels and high scores in hypersexuality rating scales [125].
3.5. Neuropsychological Evidence
In regard to the manifestations of these alterations in sexual behavior, most neuropsychological
studies show some kind of indirect or direct consequence in executive function [126,127], possibly as a
consequence of prefrontal cortex alterations [128]. When applied to online pornography, it contributes
to its development and maintenance [129,130].
The specifics of this poorer executive functioning include: impulsivity [131,132], cognitive
rigidity that impedes learning processes or the ability to shift attention [120,133,134], poor judgment
and decision making [130,135], interference of working memory capacity [130], deficits in
emotion regulation, and excessive preoccupation with sex [136]. These findings are reminiscent
of other behavioral addictions (such as pathological gambling) and the behavior in substance
dependencies [137]. Some studies directly contradict these findings [58], but there may be some
limitations in methodology (for example, small sample size).
Approaching the factors that play a role in the development of hypersexual behavior and cybersex,
there are a number of them. We can think of cue-reactivity, positive reinforcement and associative
learning [104,109,136,138,139] as the core mechanisms of porn addiction development. However,
there may be factors of underlying vulnerability [140], like: (1) the role of sexual gratification and
dysfunctional coping in some predisposed individuals [40,141–143] whether it is a consequence of trait
impulsivity [144,145] or state impulsivity [146], and (2) approach/avoidance tendencies [147–149].
3.6. Prognosis
Most of the studies referenced use subjects with a long-term exposure to online
pornography [34,81,113,114], so its clinical manifestations appear to be a direct and proportional
consequence of engaging in this maladaptive behavior. We mentioned difficulty in obtaining
controls to establish causation, but some case reports suggest that reducing or abandoning this
behavior may cause improvement in pornography-induced sexual dysfunction and psychosexual
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dissatisfaction [79,80] and even full recovery; this would imply that the previously mentioned brain
alterations are somewhat reversible.
3.7. Assessment Tools
Several screening instruments exist for addressing CSB and POPU. They all rely on the responder’s
honesty and integrity; perhaps even more so than regular psychiatry screening tests, since sexual
practices are the most humbling due to their private nature.
For hypersexuality, there are over 20 screening questionnaires and clinical interviews. Some of
the most notable include the Sexual Addiction Screening Test (SAST) proposed by Carnes [150], and its
later revised version SAST-R [151], the Compulsive Sexual Behavior Inventory (CSBI) [152,153] and the
Hypersexual Disorder Screening Inventory (HDSI) [154]. The HDSI was originally used for the clinical
screening of the DSM-5 field proposal of hypersexual disorder. While further explorations of the
empirical implications regarding criteria and the refinements of cutoff scores are needed, it currently
holds the strongest psychometric support and is the best valid instrument in measuring hypersexual
disorder [151].
As for online pornography, the most used screening tool is the Internet Sex-screening
test (ISST) [155]. It assesses five distinct dimensions (online sexual compulsivity, online sexual
behavior-social, online sexual behavior-isolated, online sexual spending and interest in online sexual
behavior) through 25 dichotomic (yes/no) questions. However, its psychometric properties haven only
been mildly analyzed, with a more robust validation in Spanish [156] that has served as a blueprint for
posterior studies [157].
Other notable instruments are the problematic pornography use scale (PPUS) [158] which
measures four facets of POPU (including: distress and functional problems, excessive use, control
difficulties and use for escape/avoidance of negative emotions), the short internet addiction test
adapted to online sexual activities (s-IAT-sex) [159], a 12-item questionnaire measuring two dimensions
of POPU, and the cyber-pornography use inventory (CPUI-9) [160].
The CPUI-9 evaluates three dimensions: (1) access efforts, (2) perceived compulsivity, and
(3) emotional distress. At first considered to have convincing psychometric properties [9], this inventory
has more recently proved to be unreliable: the inclusion of the “emotional distress” dimension address
levels of shame and guilt, which do not belong in an addiction assessment and thus skews the scores
upward [161]. Applying the inventory without this dimension appears to accurately reflect to some
extent compulsive pornography use.
One of the most recent is the pornographic problematic consumption scale (PPCS) [162], based on
Griffith six-component addiction model [163], though it does not measure addiction, only problematic
use of pornography with strong psychometric properties.
Other measures of POPU that are not designed to measure online pornography use but have
been validated using online pornography users [9], include the Pornography Consumption Inventory
(PCI) [164,165], the Compulsive Pornography Consumption Scale (CPCS) [166] and the Pornography
Craving Questionnaire (PCQ) [167] which can assess contextual triggers among different types of
pornography user.
There are also tools for assessing pornography users’ readiness to abandon the behavior
through self-initiated strategies [168] and an assessment of treatment outcome in doing so [169],
identifying in particular three potential relapse motivations: (a) sexual arousal/boredom/opportunity,
(b) intoxication/locations/easy access, and (c) negative emotions.
3.8. Treatment
Given that still many questions remain regarding the conceptualization, assessment, and causes
of hypersexual behavior and POPU, there have been relatively few attempts to research possible
treatment options. In published studies, sample sizes are usually small and too homogeneous, clinical
controls are lacking, and the research methods are scattered, unverifiable, and not replicable [170].
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Usually, combining psychosocial, cognitive–behavioral, psychodynamic, and pharmacologic
methods is considered most efficient in treatment of sexual addiction, but this non-specific approach
reflects the lack of knowledge about the subject [9].
3.8.1. Pharmacological Approaches
The studies have centered on paroxetine and naltrexone thus far. One case series involving
paroxetine on POPU helped to decrease the anxiety levels, but eventually failed to reduce the behavior
by itself [171]. Additionally, using SSRIs to create sexual dysfunction through their side effects is
apparently not effective, and according to clinical experience are useful only in patients with comorbid
psychiatric disorders [172].
Four case reports involving naltrexone to treat POPU have been described. Previous findings have
suggested that naltrexone could be a potential treatment for behavioral addictions and hypersexual
disorder [173,174], theoretically reducing cravings and urges by blocking the euphoria associated with
the behavior. While there is not yet a randomized controlled trial with naltrexone in these subjects,
there are four case reports. Results obtained in reducing pornography use varied from good [175–177]
to moderate [178]; at least in one of them the patient also received sertraline, so it is unclear how much
can be attributed to naltrexone [176].
3.8.2. Psychotherapeutic Approaches
Undoubtedly, psychotherapy can be an important tool in fully comprehending and changing a
behavior. While cognitive-behavioral therapy (CBT) is considered by many clinicians to be useful in
treating hypersexual disorder [179], a study that involved problematic online pornography users failed
to achieve a reduction of the behavior [180], even if the severity of comorbid depressive symptoms
and general quality of life was improved. This brings up the interest notion that merely reducing
pornography use may not represent the most important treatment goal [170]. Other approaches using
CBT to treat POPU have been made, but reoccurring methodological problems in this area prevent us
from extracting reliable conclusions [181,182].
Psychodynamic psychotherapy and others like family therapy, couples’ therapy, and psychosocial
treatments modeled after 12 step programs may prove vital when addressing themes of shame and
guilt and restoring trust among the users’ closest relationships [170,172]. The only randomized
controlled trial that exists with problematic online pornography users focuses on Acceptance and
Commitment Therapy (ACT) [183], an improvement from their 2010 case series [184], which was the
first experimental study to specifically address POPU. The study showed effective results but it is hard
to extrapolate since the sample was again too small and focused on a very specific population.
The reported success with CBT, conjoint therapy and ACT might rely on the fact that are based
on mindfulness and acceptance frameworks; depending on the context, increasing pornography use
acceptance may be equally or more important than reducing its use [170].
4. Discussion
It seems that POPU is not only one subtype of hypersexual disorder, but currently the most
prevalent since it also frequently involves masturbation. Although this is difficult to accurately
determine given the anonymity and accessibility factors that make pornography use today so pervasive,
we can at least confirm that the patron of consumption for pornography has changed for roughly the
last decade. It would not be absurd to assume its online variant has had a significant impact on its
consumers, and that the triple A factors enhance the potential risk for POPU and other sexual behaviors.
As we mentioned, anonymity is a key risk factor for this sexual behavior to develop into a problem.
We need to keep in mind that statistics regarding this problem are obviously limited to people of legal
age to engage in sexual activity, online or otherwise; but it does not escape us that sexual activity
rarely starts after this threshold, and there is a likely chance that minors still in the process of sexual
neurodevelopment are a particularly vulnerable population. The truth is that a stronger consensus
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on what pathological sexual behavior constitutes, both offline and online, is necessary to adequately
measure it in a representative manner and confirm how much of a problem it is in today’s society.
As far as we know, a number of recent studies support this entity as an addiction with important
clinical manifestations such as sexual dysfunction and psychosexual dissatisfaction. Most of the
existing work is based off on similar research done on substance addicts, based on the hypothesis of
online pornography as a ‘supranormal stimulus’ akin to an actual substance that, through continued
consumption, can spark an addictive disorder. However, concepts like tolerance and abstinence are
not yet clearly established enough to merit the labeling of addiction, and thus constitute a crucial part
of future research. For the moment, a diagnostic entity encompassing out of control sexual behavior
has been included in the ICD-11 due to its current clinical relevance, and it will surely be of use to
address patients with these symptoms that ask clinicians for help.
A variety of assessment tools exist to help the average clinician with diagnostic approaches,
but delimiting what is truly pathological and not in accurate manner is still an ongoing problem.
So far, a crucial part of the three sets of criteria proposed by Carnes, Goodman, and Kafka include core
concepts of loss of control, excessive time spent on sexual behavior and negative consequences to self
and others. In some manner or other, they are also present in the majority of screening tools reviewed.
They may be an adequate structure in which to build upon. Other elements, that are considered
with varying degrees of importance, probably signal us to take individual factors into account. Devising
an assessment tool that retains some level of flexibility while also being significant for determining
what is problematic is surely another of the current challenges that we face, and will probably go in
hand with further neurobiological research that help us better understand when a specific dimension
of common human life shifts from normal behavior to a disorder.
As for treatment strategies, the main goal currently focuses on reducing pornography
consumption or abandoning it altogether, since clinical manifestations appear to be reversible. The way
to achieve this varies accordingly to the patient and might also require some individual flexibility in
the strategies utilized, with a mindfulness and acceptance-based psychotherapy being equally or more
important than a pharmacological approach in some cases.
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